activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	1406064	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(-c3ccc(F)cc3)ncnc21		CHEMBL539424	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	Inhibition	%	10.0
	1406064	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(-c3ccc(F)cc3)ncnc21		CHEMBL539424	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	Inhibition	%	10.0
	1406079	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccccc2)nc2c(-c3ccc(F)cc3)ncnc21		CHEMBL368896	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406200	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccccc2)nc2c(Sc3ccccc3)ncnc21		CHEMBL367389	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	1406215	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccccc2)nc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL175541	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	Inhibition	%	9.0
	1406340	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	CSc1ccc(-c2nc3c(Sc4ccccc4)ncnc3n2C)cc1		CHEMBL175868	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406355	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	CSc1ccc(-c2nc3c(Sc4ccc(F)cc4)ncnc3n2C)cc1		CHEMBL175619	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406458	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(Nc2ncnc3[nH]cnc23)cc1		CHEMBL359730	=	Inhibition	%	48.0	CHEMBL3231	Homo sapiens	Inhibition	%	48.0
	1406473	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Nc2[nH]cnc3ncnc2-3)cc1		CHEMBL361227	=	Inhibition	%	52.0	CHEMBL3231	Homo sapiens	Inhibition	%	52.0
	1406487	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccc([S+](C)[O-])cc2)nc2c(Sc3ccccc3)ncnc21		CHEMBL353740	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	1406502	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccc([S+](C)[O-])cc2)nc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL180373	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406517	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccc(S(C)(=O)=O)cc2)nc2c(Sc3ccccc3)ncnc21		CHEMBL177060	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	Inhibition	%	5.0
	1406605	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(Oc2ncnc3[nH]cnc23)cc1		CHEMBL366984	=	Inhibition	%	16.0	CHEMBL3231	Homo sapiens	Inhibition	%	16.0
	1406620	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Oc2[nH]cnc3ncnc2-3)cc1		CHEMBL367695	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	Inhibition	%	9.0
	1406635	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(Nc3ccccc3)ncnc21		CHEMBL321749	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406649	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(-c2ccc(S(C)(=O)=O)cc2)nc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL367018	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406664	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(Br)nc2c(Sc3ccccc3)ncnc21		CHEMBL177289	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1406770	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(Nc3ccc(F)cc3)ncnc21		CHEMBL362629	=	Inhibition	%	7.0	CHEMBL3231	Homo sapiens	Inhibition	%	7.0
	1406785	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(Sc2ncnc3[nH]cnc23)cc1		CHEMBL175600	=	Inhibition	%	33.0	CHEMBL3231	Homo sapiens	Inhibition	%	33.0
	1406903	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Sc2ncnc3[nH]cnc23)cc1		CHEMBL175603	=	Inhibition	%	37.0	CHEMBL3231	Homo sapiens	Inhibition	%	37.0
	1406918	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(Sc2[nH]cnc3nccc2-3)cc1		CHEMBL360302	=	Inhibition	%	36.0	CHEMBL3231	Homo sapiens	Inhibition	%	36.0
	1407029	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Sc2[nH]cnc3nccc2-3)cc1		CHEMBL367533	=	Inhibition	%	42.0	CHEMBL3231	Homo sapiens	Inhibition	%	42.0
	1407044	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(Sc3ccccc3)ncnc21		CHEMBL179751	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	Inhibition	%	6.0
	1407059	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL175622	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	Inhibition	%	6.0
	1407164	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434	=	Inhibition	%	28.0	CHEMBL3231	Homo sapiens	Inhibition	%	28.0
	1407179	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(CSc2[nH]cnc3ncnc2-3)cc1		CHEMBL175451	=	Inhibition	%	18.0	CHEMBL3231	Homo sapiens	Inhibition	%	18.0
	1407290	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(SCc3ccccc3)ncnc21		CHEMBL176384	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	1407305	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(SCc3ccc(F)cc3)ncnc21		CHEMBL175730	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	Inhibition	%	6.0
	1407421	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(-[n+]2c[nH]c3ncncc32)cc1		CHEMBL175816	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1407436	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(-[n+]2c[nH]c3ncncc32)cc1		CHEMBL175817	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	Inhibition	%	2.0
	1407452	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(C[n+]2c[nH]c3ncncc32)cc1		CHEMBL369622	=	Inhibition	%	7.0	CHEMBL3231	Homo sapiens	Inhibition	%	7.0
	1407567	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(C[n+]2c[nH]c3ncncc32)cc1		CHEMBL179515	=	Inhibition	%	4.0	CHEMBL3231	Homo sapiens	Inhibition	%	4.0
	1407582	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Clc1ncnc2c1ncn2Cc1ccccc1		CHEMBL7944	=	Inhibition	%	3.0	CHEMBL3231	Homo sapiens	Inhibition	%	3.0
	1407693	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Clc1ncnc2ncn(Cc3ccccc3)c12		CHEMBL368715	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	Inhibition	%	6.0
	1407708	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Cn2cnc3c(Cl)ncnc32)cc1		CHEMBL369181	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1407816	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Cn2cnc3ncnc(Cl)c32)cc1		CHEMBL175528	=	Inhibition	%	7.0	CHEMBL3231	Homo sapiens	Inhibition	%	7.0
	1407831	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Nc1ncnc2c1ncn2Cc1ccccc1		CHEMBL266094	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	Inhibition	%	5.0
	1407846	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Nc1ncnc2c1ncn2Cc1ccc(F)cc1		CHEMBL426037	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1407959	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Nc1ncnc2ncn(Cc3ccc(F)cc3)c12		CHEMBL180422	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	Inhibition	%	6.0
	1407974	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	COc1ncnc2ncn(Cc3ccc(F)cc3)c12		CHEMBL368714	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	1408089	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(Cc2[nH]cnc3ncnc2-3)cc1		CHEMBL367930	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	1408104	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Cc2[nH]cnc3ncnc2-3)cc1		CHEMBL179158	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	Inhibition	%	2.0
	1408218	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(/C=C/c2[nH]cnc3ncnc2-3)cc1		CHEMBL367470	=	Inhibition	%	22.0	CHEMBL3231	Homo sapiens	Inhibition	%	22.0
	1408233	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(/C=C/c3ccccc3)ncnc21		CHEMBL176186	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1408248	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1cnc2c(-c3ccccc3)ncnc21		CHEMBL179217	=	Inhibition	%	8.0	CHEMBL3231	Homo sapiens	Inhibition	%	8.0
	1408884	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Cn1c(C#CCCO)nc2c(Sc3ccccc3)ncnc21		CHEMBL177784	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1408899	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	c1ccc(Cn2cnc3c(Sc4ccccc4)ncnc32)cc1		CHEMBL180020	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	1409009	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Sc2ncnc3c2ncn3Cc2ccccc2)cc1		CHEMBL179768	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	Inhibition	%	5.0
	1409024	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Cn2cnc3c(Sc4ccccc4)ncnc32)cc1		CHEMBL176245	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	Inhibition	%	2.0
	1409039	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Fc1ccc(Cn2cnc3c(Sc4ccc(F)cc4)ncnc32)cc1		CHEMBL175665	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	1409150	CHEMBL831996	Inhibition of human Rho-dependent protein kinase-II at 30 uM	B	Nc1ncnc2[nH]cnc12		CHEMBL226345	=	Inhibition	%	28.0	CHEMBL3231	Homo sapiens	Inhibition	%	28.0
	1475825	CHEMBL829802	Percent inhibition against ROCK1 at 10 uM using 100 uM ATP	B	CCn1c(-c2nonc2N)nc2cnccc21		CHEMBL189657	=	Inhibition	%	90.0	CHEMBL3231	Homo sapiens	Inhibition	%	90.0
	1475830	CHEMBL828501	Inhibitory concentration against selected kinase ROCK1	B	CCn1c(-c2nonc2N)nc2cnccc21		CHEMBL189657	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	1476646	CHEMBL828501	Inhibitory concentration against selected kinase ROCK1	B	CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21		CHEMBL188434	=	IC50	nM	100.0	CHEMBL3231	Homo sapiens	IC50	nM	100.0
	1723381	CHEMBL862045	Inhibition of ROCK1	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	nM	9100.0
	1723493	CHEMBL862045	Inhibition of ROCK1	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	nM	9100.0
	1723504	CHEMBL862045	Inhibition of ROCK1	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	nM	9100.0
	1723505	CHEMBL862045	Inhibition of ROCK1	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	nM	9100.0
	1723506	CHEMBL862045	Inhibition of ROCK1	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	nM	9100.0
	1723507	CHEMBL862045	Inhibition of ROCK1	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	nM	9100.0
	1744380	CHEMBL866672	Inhibition of Rock1	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	9100.0	CHEMBL3231	Homo sapiens	Ki	uM	9.1
	1776017	CHEMBL908911	Residual activity of ROCK1 at 10 uM in presence of 100 uM ATP relative to control	B	O=C(O)c1cnc2c(Cl)cc(Cl)c(Cl)c2c1O		CHEMBL553336	=	Activity	%	85.0	CHEMBL3231	Homo sapiens	Activity	%	85.0
	1776025	CHEMBL908911	Residual activity of ROCK1 at 10 uM in presence of 100 uM ATP relative to control	B	O=C(O)c1cnc2c(ccc3ccccc32)c1O		CHEMBL216550	=	Activity	%	78.0	CHEMBL3231	Homo sapiens	Activity	%	78.0
	1800578	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnccc21		CHEMBL189657	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	1800579	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(N)c3)cc21		CHEMBL373419	=	IC50	nM	18.0	CHEMBL3231	Homo sapiens	IC50	nM	18.0
	1800580	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(S(C)(=O)=O)c3)cc21		CHEMBL220408	=	IC50	nM	33.0	CHEMBL3231	Homo sapiens	IC50	nM	33.0
	1800581	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(C(C)=O)c3)cc21		CHEMBL387338	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	1800582	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3ccc(NC(C)=O)cc3)cc21		CHEMBL218869	=	IC50	nM	90.0	CHEMBL3231	Homo sapiens	IC50	nM	90.0
	1800583	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(C)=O)c3)cc21		CHEMBL218868	=	IC50	nM	1.8	CHEMBL3231	Homo sapiens	IC50	nM	1.8
	1800584	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3ccccc3)cc21		CHEMBL375877	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
	1800585	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(OC)cc21		CHEMBL218257	=	IC50	nM	4.4	CHEMBL3231	Homo sapiens	IC50	nM	4.4
	1800586	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	IC50	nM	1.8	CHEMBL3231	Homo sapiens	IC50	nM	1.8
	1800587	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN(C)C)cc4)c3)cc21		CHEMBL429700	<=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	1800588	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(CN5CCOCC5)cc4)c3)cc21		CHEMBL376321	<=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	1800589	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(CN(C)C)cc4)c3)cc21		CHEMBL218870	<=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	1800590	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(CN)cc4)c3)cc21		CHEMBL220080	<=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	1800591	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N5CCOCC5)cc4)c3)cc21		CHEMBL216574	<=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	1800592	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	1800593	CHEMBL912268	Inhibition of human ROCK1 in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccccc4)c3)cc21		CHEMBL426526	=	IC50	nM	4.0	CHEMBL3231	Homo sapiens	IC50	nM	4.0
	1800714	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	1800718	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)CC(=O)N1		CHEMBL218654	=	IC50	nM	51.0	CHEMBL3231	Homo sapiens	IC50	nM	51.0
	1800740	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	1800741	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL375312	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	1800742	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2F)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL217910	=	IC50	nM	2500.0	CHEMBL3231	Homo sapiens	IC50	nM	2500.0
	1800743	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	IC50	nM	9.0	CHEMBL3231	Homo sapiens	IC50	nM	9.0
	1800744	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	IC50	nM	9.0	CHEMBL3231	Homo sapiens	IC50	nM	9.0
	1800745	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	1800746	CHEMBL912250	Inhibition of human recombinant ROCK1 expressed in Sf9 cells at 10 mM	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218719	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	nM	5.0
	1824610	CHEMBL915366	Inhibition of Rock1	B	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	>	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	Ki	uM	10.0
	1824674	CHEMBL915366	Inhibition of Rock1	B	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	>	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	Ki	uM	10.0
	1824758	CHEMBL915366	Inhibition of Rock1	B	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	>	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	Ki	uM	10.0
	1989370	CHEMBL899090	Inhibition of ROCK1 activity at 1 uM	B	CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1		CHEMBL398606	=	Inhibition	%	13.5	CHEMBL3231	Homo sapiens	Inhibition	%	13.5
	2051671	CHEMBL941807	Inhibition of ROCK1	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	9105.0	CHEMBL3231	Homo sapiens	Ki	uM	9.105
	2086308	CHEMBL946934	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)c1		CHEMBL271271	<	IC50	nM	16000.0	CHEMBL3231	Homo sapiens	IC50	uM	16.0
	2137198	CHEMBL921079	Inhibition of p160ROCK	B	C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1.Cl.Cl		CHEMBL536267	=	Ki	nM	140.0	CHEMBL3231	Homo sapiens	Ki	nM	140.0
	2147374	CHEMBL922159	Activity of human ROCK1 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	120.0	CHEMBL3231	Homo sapiens	Activity	%	120.0
	2182832	CHEMBL941458	Inhibition of ROCK1 at 5 uM	B	O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12		CHEMBL179242	=	Inhibition	%	13.0	CHEMBL3231	Homo sapiens	INH	%	13.0
	2251073	CHEMBL1011948	Inhibition of ROCK1 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	105.0	CHEMBL3231	Homo sapiens	INH	%	105.0
	2367152	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cncc(OC3CCNCC3)c21		CHEMBL493911	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	uM	0.008
	2367224	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cncc(OCC3CCNCC3)c21		CHEMBL521823	=	IC50	nM	3.0	CHEMBL3231	Homo sapiens	IC50	uM	0.003
	2367225	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NC3CCCNC3)c21		CHEMBL493067	=	IC50	nM	40.0	CHEMBL3231	Homo sapiens	IC50	uM	0.04
	2367226	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21		CHEMBL493066	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	2367227	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@@H](N)C3)c21		CHEMBL523695	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	uM	0.005
	2367228	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	uM	0.005
Not Determined	2367230	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(-c3ccccc3)ncc(OCCCN)c21		CHEMBL493250		IC50			CHEMBL3231	Homo sapiens	IC50		
	2367242	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	IC50	nM	200.0	CHEMBL3231	Homo sapiens	IC50	uM	0.2
	2367243	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CCCO)ncc(OCCCN)c21		CHEMBL493875	=	IC50	nM	126.0	CHEMBL3231	Homo sapiens	IC50	uM	0.126
	2367244	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CCO)ncc(OCCCN)c21		CHEMBL523523	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	2367245	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCN)c21		CHEMBL493874	=	IC50	nM	501.0	CHEMBL3231	Homo sapiens	IC50	uM	0.501
	2367246	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC3CC3)ncc(OCCCN)c21		CHEMBL494882	=	IC50	nM	1995.0	CHEMBL3231	Homo sapiens	IC50	uM	1.995
	2367247	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(-c3cn[nH]c3)ncc(OCCCN)c21		CHEMBL450487	=	IC50	nM	224.0	CHEMBL3231	Homo sapiens	IC50	uM	0.224
	2367248	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(-c3cc[nH]c3)ncc(OCCCN)c21		CHEMBL523057	=	IC50	nM	126.0	CHEMBL3231	Homo sapiens	IC50	uM	0.126
	2367249	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(-c3ccoc3)ncc(OCCCN)c21		CHEMBL445180	=	IC50	nM	562.0	CHEMBL3231	Homo sapiens	IC50	uM	0.562
	2367250	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(-c3ccc[nH]3)ncc(OCCCN)c21		CHEMBL493251	=	IC50	nM	158.0	CHEMBL3231	Homo sapiens	IC50	uM	0.158
	2367269	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642	=	IC50	nM	1580.0	CHEMBL3231	Homo sapiens	IC50	uM	1.58
	2367270	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNC[C@H](O)CO)c21		CHEMBL522351	=	IC50	nM	250.0	CHEMBL3231	Homo sapiens	IC50	uM	0.25
	2367271	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNCCc3ccc(OC)cc3)c21		CHEMBL494060	=	IC50	nM	3980.0	CHEMBL3231	Homo sapiens	IC50	uM	3.98
	2367274	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	IC50	nM	2510.0	CHEMBL3231	Homo sapiens	IC50	uM	2.51
	2367275	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC[C@@H](N)Cc3ccccc3)c21		CHEMBL523859	=	IC50	nM	1260.0	CHEMBL3231	Homo sapiens	IC50	uM	1.26
	2367276	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCN)c21		CHEMBL453510	=	IC50	nM	500.0	CHEMBL3231	Homo sapiens	IC50	uM	0.5
	2367364	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCCN)c21		CHEMBL493269	=	IC50	nM	500.0	CHEMBL3231	Homo sapiens	IC50	uM	0.5
	2367368	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNC3)c21		CHEMBL494088	=	IC50	nM	790.0	CHEMBL3231	Homo sapiens	IC50	uM	0.79
	2367370	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	uM	1.0
	2367373	CHEMBL1028092	Inhibition of human recombinant ROCK1 expressed in Sf9 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	890.0	CHEMBL3231	Homo sapiens	IC50	uM	0.89
	2409516	CHEMBL959251	Inhibition of ROCK1	B	NC[C@H](Cc1cccc(F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL523586	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	2419150	CHEMBL1019638	Inhibition of ROCK1 at 1 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	INH	%	1.0
	2469920	CHEMBL1030556	Inhibition of ROCK1	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	=	IC50	nM	56.0	CHEMBL3231	Homo sapiens	IC50	nM	56.0
	2476003	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccn2)N1		CHEMBL485592	=	IC50	nM	180.0	CHEMBL3231	Homo sapiens	IC50	nM	180.0
	2476004	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	IC50	nM	75.0	CHEMBL3231	Homo sapiens	IC50	nM	75.0
	2476005	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(c3ccc(S(C)(=O)=O)cc3)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1		CHEMBL483394	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	nM	150.0
	2476006	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(C)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1		CHEMBL520640	=	IC50	nM	863.0	CHEMBL3231	Homo sapiens	IC50	nM	863.0
	2476007	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(c3ccc(S(N)(=O)=O)cc3)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1		CHEMBL483575	=	IC50	nM	68.0	CHEMBL3231	Homo sapiens	IC50	nM	68.0
	2476008	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(c3ccc(C(F)(F)F)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1		CHEMBL520808	=	IC50	nM	26.0	CHEMBL3231	Homo sapiens	IC50	nM	26.0
	2476009	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1		CHEMBL485612	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	2476010	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1		CHEMBL485611	=	IC50	nM	15.0	CHEMBL3231	Homo sapiens	IC50	nM	15.0
	2476011	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1		CHEMBL521347	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	2476012	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cn1		CHEMBL483574	=	IC50	nM	3.0	CHEMBL3231	Homo sapiens	IC50	nM	3.0
	2476013	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)ccn1		CHEMBL483402	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	2476014	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1		CHEMBL483401	=	IC50	nM	4.0	CHEMBL3231	Homo sapiens	IC50	nM	4.0
	2476015	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1		CHEMBL520828	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	nM	5.0
	2476016	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	2476017	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(C)c2)N1		CHEMBL485440	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	2476018	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CCOc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1		CHEMBL521144	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
	2476019	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2cccc(C(F)(F)F)c2)N1		CHEMBL483568	=	IC50	nM	288.0	CHEMBL3231	Homo sapiens	IC50	nM	288.0
	2476020	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2cnccn2)N1		CHEMBL483396	=	IC50	nM	105.0	CHEMBL3231	Homo sapiens	IC50	nM	105.0
	2476021	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccncc2)N1		CHEMBL483395	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	2476022	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2cccc(C)c2)N1		CHEMBL483387	=	IC50	nM	129.0	CHEMBL3231	Homo sapiens	IC50	nM	129.0
	2476023	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(Cl)cc2)N1		CHEMBL520848	=	IC50	nM	129.0	CHEMBL3231	Homo sapiens	IC50	nM	129.0
	2476024	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C)c(F)c2)N1		CHEMBL485586	=	IC50	nM	104.0	CHEMBL3231	Homo sapiens	IC50	nM	104.0
	2476025	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C)cc2)N1		CHEMBL485585	=	IC50	nM	101.0	CHEMBL3231	Homo sapiens	IC50	nM	101.0
	2476026	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	COc1ccc(C2=NC(c3ccc(F)cc3)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1		CHEMBL519008	=	IC50	nM	46.0	CHEMBL3231	Homo sapiens	IC50	nM	46.0
	2476027	CHEMBL987092	Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1		CHEMBL519680	=	IC50	nM	105.0	CHEMBL3231	Homo sapiens	IC50	nM	105.0
	2486605	CHEMBL994972	Inhibition of Rock1	B	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	>	Ki	nM	9110.0	CHEMBL3231	Homo sapiens	Ki	uM	9.11
	2511606	CHEMBL973460	Inhibition of ROCK1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.1	CHEMBL3231	Homo sapiens	IC50	uM	0.0011
	2511620	CHEMBL973460	Inhibition of ROCK1	B	COc1ccc(NC(=S)N/N=C2\C(=O)Nc3ccccc32)cc1		CHEMBL504574	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	2511972	CHEMBL973497	Inhibition of ROCK1 at 1 uM	B	CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1		CHEMBL508307	=	Inhibition	%	-8.0	CHEMBL3231	Homo sapiens	INH	%	-8.0
	2525592	CHEMBL983956	Inhibition of human recombinant ROCK1	B	NCCNS(=O)(=O)c1ccc(-c2ccnc3[nH]ccc23)cc1		CHEMBL473080	=	IC50	nM	19.95	CHEMBL3231	Homo sapiens	pIC50		7.7
	2525593	CHEMBL983956	Inhibition of human recombinant ROCK1	B	NCCNS(=O)(=O)c1ccc(-c2ccnc3[nH]c(CC(N)=O)cc23)cc1		CHEMBL519965	=	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	2525594	CHEMBL983956	Inhibition of human recombinant ROCK1	B	Cc1cc2c(-c3ccc(S(=O)(=O)NCCN)cc3)ccnc2[nH]1		CHEMBL482747	=	IC50	nM	316.23	CHEMBL3231	Homo sapiens	pIC50		6.5
	2525608	CHEMBL983956	Inhibition of human recombinant ROCK1	B	Cc1cc2c(-c3ccc(S(=O)(=O)N(C)CCO)cc3)ccnc2[nH]1		CHEMBL520308	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	2528148	CHEMBL985027	Inhibition of Rock1	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1		CHEMBL519693	=	IC50	nM	1258.93	CHEMBL3231	Homo sapiens	pIC50		5.9
	2528149	CHEMBL985027	Inhibition of Rock1	B	c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1		CHEMBL484968	=	IC50	nM	794.33	CHEMBL3231	Homo sapiens	pIC50		6.1
	2528150	CHEMBL985027	Inhibition of Rock1	B	NCc1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1		CHEMBL484967	=	IC50	nM	199.53	CHEMBL3231	Homo sapiens	pIC50		6.7
	2559663	CHEMBL982980	Inhibition of ROCK1	B	Cc1c(Nc2c(C#N)cnc3sc(/C=C/C(=O)N4CCCC4)cc23)ccc2[nH]ccc12		CHEMBL477817	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
	2624361	CHEMBL1007488	Inhibition of ROCK1	B	Cc1c(Nc2c(C#N)cncc2-c2ccc(OCCN3CCN(C)CC3)cc2)ccc2[nH]ccc12		CHEMBL467069	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	2626894	CHEMBL999778	Binding affinity to human ROCK1 at 5 uM	B	Cc1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(Nc3ncnc4ccc(N)cc34)cc2)c1		CHEMBL497033	=	Activity	%	86.0	CHEMBL3231	Homo sapiens	Activity	%	86.0
	2626921	CHEMBL999778	Binding affinity to human ROCK1 at 5 uM	B	Cc1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc(Nc3ncnc4ccc(N)cc34)c2)c1		CHEMBL497615	=	Activity	%	47.0	CHEMBL3231	Homo sapiens	Activity	%	47.0
	2638337	CHEMBL1011436	Inhibition of ROCK1	B	C[C@@H](Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL466496	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	uM	0.06
Not Determined	2638338	CHEMBL1011436	Inhibition of ROCK1	B	NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL467079		IC50			CHEMBL3231	Homo sapiens	IC50		
	2638339	CHEMBL1011436	Inhibition of ROCK1	B	NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1cccc(O)c1		CHEMBL511410	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	uM	0.06
	2638340	CHEMBL1011436	Inhibition of ROCK1	B	C[C@@H](Nc1c(Nc2ccnc(-c3ccccc3F)c2)c(=O)c1=O)c1ccccc1		CHEMBL468125	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	2638341	CHEMBL1011436	Inhibition of ROCK1	B	C[C@@H](Nc1c(Nc2ccnc(-c3ccco3)c2)c(=O)c1=O)c1ccccc1		CHEMBL519113	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	2638342	CHEMBL1011436	Inhibition of ROCK1	B	C[C@@H](Nc1c(Nc2ccnc(-c3ccsc3)c2)c(=O)c1=O)c1ccccc1		CHEMBL481248	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	2661597	CHEMBL1061348	Inhibition of ROCK1 after 1 hr by mobility shift electrophoresis assay	B	COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1		CHEMBL561708	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	2705003	CHEMBL1055625	Inhibition of ROCK-I at 10 uM by HotSpot assay relative to control	B	Cc1cc(O)cc(-c2nn(CC#N)cc2-c2cc(NC[C@H](C)O)nc(-c3cccnc3)n2)c1		CHEMBL560733	=	Inhibition	%	11.72	CHEMBL3231	Homo sapiens	INH	%	11.72
	2721709	CHEMBL1055111	Inhibition of ROCK-1 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	2722274	CHEMBL1063591	Inhibition of ROCK1	B	Cc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O		CHEMBL551140	>	Ki	nM	30000.0	CHEMBL3231	Homo sapiens	Ki	uM	30.0
	2897071	CHEMBL1063782	Inhibitory constant against ROCK1	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	150.0	CHEMBL3231	Homo sapiens	Ki	uM	0.15
	2897072	CHEMBL1063782	Inhibitory constant against ROCK1	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	530.0	CHEMBL3231	Homo sapiens	Ki	uM	0.53
	2897073	CHEMBL1063782	Inhibitory constant against ROCK1	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	Ki	nM	150.0	CHEMBL3231	Homo sapiens	Ki	uM	0.15
	2897074	CHEMBL1063782	Inhibitory constant against ROCK1	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006
	2938421	CHEMBL1038670	Inhibition of ROCK1	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Ki	nM	1400.0	CHEMBL3231	Homo sapiens	Ki	uM	1.4
	2939389	CHEMBL1036968	Inhibition of human ROCK1 expressed in baculovirus system	B	Cc1c[nH]c2ncnc(N3CCN(/C(=N/C#N)Nc4cccc(Br)c4)[C@@H](C)C3)c12		CHEMBL570126	=	IC50	nM	260.0	CHEMBL3231	Homo sapiens	IC50	nM	260.0
	2939390	CHEMBL1036968	Inhibition of human ROCK1 expressed in baculovirus system	B	Cc1c[nH]c2ncnc(N3CCN(/C(=N/C#N)Nc4ccc(F)c(Br)c4)[C@@H](C)C3)c12		CHEMBL565452	=	IC50	nM	310.0	CHEMBL3231	Homo sapiens	IC50	nM	310.0
	2939391	CHEMBL1036968	Inhibition of human ROCK1 expressed in baculovirus system	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)Nc4ccc(F)c(Br)c4)[C@@H](C)C3)c12		CHEMBL570820	=	IC50	nM	51.0	CHEMBL3231	Homo sapiens	IC50	nM	51.0
	2939392	CHEMBL1036968	Inhibition of human ROCK1 expressed in baculovirus system	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)Nc4cccc(OC(=O)N(C)C)c4)[C@@H](C)C3)c12		CHEMBL570116	=	IC50	nM	490.0	CHEMBL3231	Homo sapiens	IC50	nM	490.0
	2945925	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL575741	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	2945926	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL575741	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
	2945927	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1cc(Nc2nc(NC3CCCC3)nc(N3CCNCC3)n2)ccn1		CHEMBL575962	=	IC50	nM	890.0	CHEMBL3231	Homo sapiens	IC50	nM	890.0
Not Determined	2945928	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1cc(Nc2nc(NC3CCCC3)nc(N3CCNCC3)n2)ccn1		CHEMBL575962		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945929	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc(CCNc2nc(Nc3ccncc3)nc(N3CCNCC3)n2)cc1		CHEMBL575798	=	IC50	nM	326.0	CHEMBL3231	Homo sapiens	IC50	nM	326.0
Not Determined	2945930	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc(CCNc2nc(Nc3ccncc3)nc(N3CCNCC3)n2)cc1		CHEMBL575798		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945931	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc(CNc2nc(Nc3ccncc3)nc(N3CCNCC3)n2)cc1		CHEMBL575555	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	nM	400.0
Not Determined	2945932	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc(CNc2nc(Nc3ccncc3)nc(N3CCNCC3)n2)cc1		CHEMBL575555		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945933	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CCC(Nc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL575759	=	IC50	nM	23.0	CHEMBL3231	Homo sapiens	IC50	nM	23.0
Not Determined	2945934	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CCC(Nc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL575759		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945935	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CCC2Nc1nc(Nc2ccncc2)nc(N2CCNCC2)n1		CHEMBL567603	=	IC50	nM	185.0	CHEMBL3231	Homo sapiens	IC50	nM	185.0
Not Determined	2945936	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CCC2Nc1nc(Nc2ccncc2)nc(N2CCNCC2)n1		CHEMBL567603		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945937	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Oc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL584291	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	2945938	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Oc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL584291	=	IC50	nM	57.0	CHEMBL3231	Homo sapiens	IC50	nM	57.0
	2945939	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1cncc(Nc2nc(NC3Cc4ccccc4C3)nc(N3CCNCC3)n2)c1		CHEMBL575761	=	IC50	nM	8400.0	CHEMBL3231	Homo sapiens	IC50	nM	8400.0
Not Determined	2945940	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1cncc(Nc2nc(NC3Cc4ccccc4C3)nc(N3CCNCC3)n2)c1		CHEMBL575761		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945941	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc(Nc2nc(NC3Cc4ccccc4C3)nc(N3CCNCC3)n2)nc1		CHEMBL575973	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	nM	1000.0
Not Determined	2945942	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc(Nc2nc(NC3Cc4ccccc4C3)nc(N3CCNCC3)n2)nc1		CHEMBL575973		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945943	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc(Nc2nc(NC3Cc4ccccc4C3)nc(N3CCNCC3)n2)cc1		CHEMBL575974	=	IC50	nM	7400.0	CHEMBL3231	Homo sapiens	IC50	nM	7400.0
Not Determined	2945944	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc(Nc2nc(NC3Cc4ccccc4C3)nc(N3CCNCC3)n2)cc1		CHEMBL575974		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945945	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCCCC3)n1)C2		CHEMBL573151	=	IC50	nM	8300.0	CHEMBL3231	Homo sapiens	IC50	nM	8300.0
Not Determined	2945946	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCCCC3)n1)C2		CHEMBL573151		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945947	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	CN1CCN(c2nc(Nc3ccncc3)nc(NC3Cc4ccccc4C3)n2)CC1		CHEMBL573152	=	IC50	nM	305.0	CHEMBL3231	Homo sapiens	IC50	nM	305.0
Not Determined	2945948	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	CN1CCN(c2nc(Nc3ccncc3)nc(NC3Cc4ccccc4C3)n2)CC1		CHEMBL573152		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945949	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCCNCC3)n1)C2		CHEMBL566298	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
	2945950	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCCNCC3)n1)C2		CHEMBL566298	=	IC50	nM	17.0	CHEMBL3231	Homo sapiens	IC50	nM	17.0
	2945951	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	CNCCN(C)c1nc(Nc2ccncc2)nc(NC2Cc3ccccc3C2)n1		CHEMBL577177	=	IC50	nM	81.0	CHEMBL3231	Homo sapiens	IC50	nM	81.0
Not Determined	2945952	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	CNCCN(C)c1nc(Nc2ccncc2)nc(NC2Cc3ccccc3C2)n1		CHEMBL577177		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945953	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	C[C@@H]1CN(c2nc(Nc3ccncc3)nc(NC3Cc4ccccc4C3)n2)CCN1		CHEMBL575940	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	2945954	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	C[C@@H]1CN(c2nc(Nc3ccncc3)nc(NC3Cc4ccccc4C3)n2)CCN1		CHEMBL575940	=	IC50	nM	26.0	CHEMBL3231	Homo sapiens	IC50	nM	26.0
	2945955	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	C[C@H]1CN(c2nc(Nc3ccncc3)nc(NC3Cc4ccccc4C3)n2)CCN1		CHEMBL575562	=	IC50	nM	135.0	CHEMBL3231	Homo sapiens	IC50	nM	135.0
Not Determined	2945956	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	C[C@H]1CN(c2nc(Nc3ccncc3)nc(NC3Cc4ccccc4C3)n2)CCN1		CHEMBL575562		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945957	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	C[C@@H]1CNCCN1c1nc(Nc2ccncc2)nc(NC2Cc3ccccc3C2)n1		CHEMBL575765	=	IC50	nM	118.0	CHEMBL3231	Homo sapiens	IC50	nM	118.0
Not Determined	2945958	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	C[C@@H]1CNCCN1c1nc(Nc2ccncc2)nc(NC2Cc3ccccc3C2)n1		CHEMBL575765		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945959	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	C[C@H]1CNCCN1c1nc(Nc2ccncc2)nc(NC2Cc3ccccc3C2)n1		CHEMBL575575	=	IC50	nM	87.0	CHEMBL3231	Homo sapiens	IC50	nM	87.0
Not Determined	2945960	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	C[C@H]1CNCCN1c1nc(Nc2ccncc2)nc(NC2Cc3ccccc3C2)n1		CHEMBL575575		IC50			CHEMBL3231	Homo sapiens	IC50		
	2945961	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Nc1cc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL575340	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	2945962	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Nc1cc(Nc3ccncc3)nc(N3CCNCC3)n1)C2		CHEMBL575340	=	IC50	nM	12.0	CHEMBL3231	Homo sapiens	IC50	nM	12.0
	2945963	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Nc1cc(N3CCNCC3)nc(Nc3ccncc3)n1)C2		CHEMBL578643	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	2945964	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Nc1cc(N3CCNCC3)nc(Nc3ccncc3)n1)C2		CHEMBL578643	=	IC50	nM	154.0	CHEMBL3231	Homo sapiens	IC50	nM	154.0
	2945965	CHEMBL1054435	Inhibition of ROCK1 by IMAP assay	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)cc(N3CCNCC3)n1)C2		CHEMBL572911	=	IC50	nM	1200.0	CHEMBL3231	Homo sapiens	IC50	nM	1200.0
Not Determined	2945966	CHEMBL1054436	Inhibition of ROCK1 in human THP1 cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)cc(N3CCNCC3)n1)C2		CHEMBL572911		IC50			CHEMBL3231	Homo sapiens	IC50		
	2992240	CHEMBL1044543	Inhibition of human ROCK1 at 20 uM by FRET assay	B	C#Cn1c(C#CCCO)nc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL576620	=	Inhibition	%	15.0	CHEMBL3231	Homo sapiens	INH	%	15.0
	2993578	CHEMBL1040953	Inhibition of human recombinant ROCK1	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
	3001937	CHEMBL1047201	Inhibition of ROCK1	B	Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12		CHEMBL571581	>	IC50	nM	9000.0	CHEMBL3231	Homo sapiens	IC50	uM	9.0
	3011622	CHEMBL1037496	Inhibition of ROCK1	B	C#Cc1cccc(-c2ccc(CN3CCN(C)CC3)o2)c1Cc1ccc2c(c1C)C=CC2		CHEMBL570865	>	IC50	nM	5000.0	CHEMBL3231	Homo sapiens	IC50	uM	5.0
	3018994	CHEMBL1039946	Inhibition of ROCK1	B	Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(OCCN3CCN(C)CC3)c2)ccc2[nH]ccc12		CHEMBL567124	>	IC50	nM	8000.0	CHEMBL3231	Homo sapiens	IC50	uM	8.0
	3052467	CHEMBL1072505	Residual activity of ROCK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	101.0	CHEMBL3231	Homo sapiens	Residual activity	%	101.0
	3052719	CHEMBL1043798	Residual activity of ROCK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	105.0	CHEMBL3231	Homo sapiens	Residual activity	%	105.0
	3054028	CHEMBL1071358	Residual activity of ROCK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	73.0	CHEMBL3231	Homo sapiens	Residual activity	%	73.0
	3055315	CHEMBL1072505	Residual activity of ROCK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	98.0	CHEMBL3231	Homo sapiens	Residual activity	%	98.0
	3055567	CHEMBL1043798	Residual activity of ROCK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	102.0	CHEMBL3231	Homo sapiens	Residual activity	%	102.0
	3056872	CHEMBL1071358	Residual activity of ROCK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	68.0	CHEMBL3231	Homo sapiens	Residual activity	%	68.0
	3057124	CHEMBL1072505	Residual activity of ROCK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	96.0	CHEMBL3231	Homo sapiens	Residual activity	%	96.0
	3058444	CHEMBL1043798	Residual activity of ROCK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	93.0	CHEMBL3231	Homo sapiens	Residual activity	%	93.0
	3059728	CHEMBL1071358	Residual activity of ROCK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	81.0	CHEMBL3231	Homo sapiens	Residual activity	%	81.0
	3075703	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3C#CCCO)cc12		CHEMBL592898	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075704	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3C#CC(C)(C)O)cc12		CHEMBL594750	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075705	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccc[nH]3)cc12		CHEMBL594749	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075706	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccsc3)cc12		CHEMBL604060	=	IC50	nM	6000.0	CHEMBL3231	Homo sapiens	IC50	uM	6.0
	3075707	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cccs3)cc12		CHEMBL594748	=	IC50	nM	2500.0	CHEMBL3231	Homo sapiens	IC50	uM	2.5
	3075708	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccoc3)cc12		CHEMBL595709	=	IC50	nM	5200.0	CHEMBL3231	Homo sapiens	IC50	uM	5.2
	3075709	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccco3)cc12		CHEMBL595708	=	IC50	nM	1290.0	CHEMBL3231	Homo sapiens	IC50	uM	1.29
	3075710	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cc(Cl)ccc3O)cc12		CHEMBL605733	=	IC50	nM	7600.0	CHEMBL3231	Homo sapiens	IC50	uM	7.6
	3075711	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cc(F)cc(F)c3O)cc12		CHEMBL596379	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075712	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cc(F)ccc3O)cc12		CHEMBL594517	=	IC50	nM	9800.0	CHEMBL3231	Homo sapiens	IC50	uM	9.8
	3075713	CHEMBL1071954	Inhibition of ROCK1	B	COc1ccccc1-c1ncc(OC[C@@H](N)Cc2ccccc2)cc1-c1ccc2[nH]nc(C)c2c1		CHEMBL604684	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075714	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccc(O)cc3)cc12		CHEMBL595685	=	IC50	nM	1400.0	CHEMBL3231	Homo sapiens	IC50	uM	1.4
	3075715	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cccc(O)c3)cc12		CHEMBL595684	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075716	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccccc3O)cc12		CHEMBL595476	=	IC50	nM	9500.0	CHEMBL3231	Homo sapiens	IC50	uM	9.5
	3075717	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccccc3)cc12		CHEMBL605732	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3075718	CHEMBL1071954	Inhibition of ROCK1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	IC50	nM	79.0	CHEMBL3231	Homo sapiens	IC50	uM	0.079
	3075745	CHEMBL1071954	Inhibition of ROCK1	B	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL593490	=	IC50	nM	1580.0	CHEMBL3231	Homo sapiens	IC50	uM	1.58
	3084387	CHEMBL1072666	Inhibition of ROCK1	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	uM	0.4
	3087017	CHEMBL1071321	Inhibition of ROCK1	B	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL593490	=	IC50	nM	1580.0	CHEMBL3231	Homo sapiens	IC50	uM	1.58
	3089481	CHEMBL1067366	Inhibition of ROCK1	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12		CHEMBL606245	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
	3091849	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	Nc1ncc(-c2ccncc2)nc1N1CCN(CCO)CC1		CHEMBL589655	=	IC50	nM	4600.0	CHEMBL3231	Homo sapiens	IC50	nM	4600.0
	3091851	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N)CC1		CHEMBL602706	=	IC50	nM	4600.0	CHEMBL3231	Homo sapiens	IC50	nM	4600.0
	3091853	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	Cc1cc(-c2cnc(N)c(N3CCCN(C)CC3)n2)ccn1		CHEMBL589656	>	IC50	nM	100000.0	CHEMBL3231	Homo sapiens	IC50	nM	100000.0
	3091855	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	Cc1cnccc1-c1cnc(N)c(N2CCCN(C)CC2)n1	Outside typical range	CHEMBL601935	=	IC50	nM	120000.0	CHEMBL3231	Homo sapiens	IC50	nM	120000.0
	3091857	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccnc(N)c3)cnc2N)CC1		CHEMBL591271	=	IC50	nM	25000.0	CHEMBL3231	Homo sapiens	IC50	nM	25000.0
	3091859	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3cc[nH]n3)cnc2N)CC1		CHEMBL600849	=	IC50	nM	37000.0	CHEMBL3231	Homo sapiens	IC50	nM	37000.0
	3091861	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccnc4[nH]ccc34)cnc2N)CC1		CHEMBL591272	=	IC50	nM	1500.0	CHEMBL3231	Homo sapiens	IC50	nM	1500.0
	3091863	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3cccc4[nH]ncc34)cnc2N)CC1		CHEMBL600236	=	IC50	nM	9600.0	CHEMBL3231	Homo sapiens	IC50	nM	9600.0
	3091865	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccc4[nH]ncc4c3)cnc2N)CC1		CHEMBL590313	=	IC50	nM	2300.0	CHEMBL3231	Homo sapiens	IC50	nM	2300.0
	3091867	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccc4cn[nH]c4c3)cnc2N)CC1		CHEMBL589577	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
	3091869	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CNc1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL589578	=	IC50	nM	6900.0	CHEMBL3231	Homo sapiens	IC50	nM	6900.0
	3091871	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N(C)C)CC1		CHEMBL601834	=	IC50	nM	6500.0	CHEMBL3231	Homo sapiens	IC50	nM	6500.0
	3091873	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CCN(CC)c1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL589336	=	IC50	nM	2600.0	CHEMBL3231	Homo sapiens	IC50	nM	2600.0
	3091875	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccncc3)cnc2NCCO)CC1		CHEMBL589337	=	IC50	nM	42000.0	CHEMBL3231	Homo sapiens	IC50	nM	42000.0
	3091877	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	COCCNc1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL590238	=	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
	3091879	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	COCCN(C)c1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL592701	=	IC50	nM	48000.0	CHEMBL3231	Homo sapiens	IC50	nM	48000.0
	3091881	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL592702	=	IC50	nM	6000.0	CHEMBL3231	Homo sapiens	IC50	nM	6000.0
	3091883	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N2CCCCC2)CC1		CHEMBL602753	=	IC50	nM	18000.0	CHEMBL3231	Homo sapiens	IC50	nM	18000.0
	3091885	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N2CCOCC2)CC1		CHEMBL591754	=	IC50	nM	68000.0	CHEMBL3231	Homo sapiens	IC50	nM	68000.0
	3091887	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	c1cc(-c2cnc(N3CCCC3)c(N3CCCNCC3)n2)ccn1		CHEMBL591986	=	IC50	nM	320.0	CHEMBL3231	Homo sapiens	IC50	nM	320.0
	3091889	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	c1cc(-c2cnc(N3CCCC3)c(N3CCNCC3)n2)ccn1		CHEMBL591287	=	IC50	nM	610.0	CHEMBL3231	Homo sapiens	IC50	nM	610.0
	3091891	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	NC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL602326	=	IC50	nM	290.0	CHEMBL3231	Homo sapiens	IC50	nM	290.0
	3091893	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CNC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL591047	=	IC50	nM	1800.0	CHEMBL3231	Homo sapiens	IC50	nM	1800.0
	3091895	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	NCC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL591285	=	IC50	nM	130.0	CHEMBL3231	Homo sapiens	IC50	nM	130.0
	3091897	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CNCC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL602041	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	nM	150.0
	3091899	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	c1cc(-c2cnc(N3CCCC3)c(N3CCCNCC3)n2)c2cc[nH]c2n1		CHEMBL598963	=	IC50	nM	170.0	CHEMBL3231	Homo sapiens	IC50	nM	170.0
	3091901	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	c1cc(-c2cnc(N3CCCC3)c(N3CCNCC3)n2)c2cc[nH]c2n1		CHEMBL604934	=	IC50	nM	34.0	CHEMBL3231	Homo sapiens	IC50	nM	34.0
	3091903	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	NC1CCN(c2nc(-c3ccnc4[nH]ccc34)cnc2N2CCCC2)CC1		CHEMBL599162	=	IC50	nM	300.0	CHEMBL3231	Homo sapiens	IC50	nM	300.0
	3091905	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	CN(C)c1ncc(-c2ccncc2)nc1N1CCN(CCO)CC1		CHEMBL611386	=	IC50	nM	1400.0	CHEMBL3231	Homo sapiens	IC50	nM	1400.0
	3091907	CHEMBL1074822	Inhibition of human recombinant ROCK1	B	OCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL599163	=	IC50	nM	300.0	CHEMBL3231	Homo sapiens	IC50	nM	300.0
	3131730	CHEMBL1071706	Inhibition of human ROCK1 by homogenous luciferase assay	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	Ki	nM	150.0	CHEMBL3231	Homo sapiens	Ki	nM	150.0
	3131731	CHEMBL1071706	Inhibition of human ROCK1 by homogenous luciferase assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	530.0	CHEMBL3231	Homo sapiens	Ki	nM	530.0
	3131732	CHEMBL1071706	Inhibition of human ROCK1 by homogenous luciferase assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	150.0	CHEMBL3231	Homo sapiens	Ki	nM	150.0
	3131733	CHEMBL1071706	Inhibition of human ROCK1 by homogenous luciferase assay	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	nM	6.0
	3131734	CHEMBL1071706	Inhibition of human ROCK1 by homogenous luciferase assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	4300.0	CHEMBL3231	Homo sapiens	IC50	nM	4300.0
	3131735	CHEMBL1071706	Inhibition of human ROCK1 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC		CHEMBL598336	=	IC50	nM	4300.0	CHEMBL3231	Homo sapiens	IC50	nM	4300.0
	3186224	CHEMBL1111485	Inhibition of ROCK1	B	CCn1c(-c2nonc2N)nc2cncc(OC3CCNCC3)c21		CHEMBL493911	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	3186284	CHEMBL1111485	Inhibition of ROCK1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642	=	IC50	nM	890.0	CHEMBL3231	Homo sapiens	IC50	nM	890.0
	3200313	CHEMBL1102113	Inhibition of ROCK1	B	COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(OC)c2)cc1		CHEMBL1080902	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	nM	4000.0
	3200339	CHEMBL1102113	Inhibition of ROCK1	B	COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1		CHEMBL1076721	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	nM	4000.0
	3200365	CHEMBL1102113	Inhibition of ROCK1	B	COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccccc1		CHEMBL1086736	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	nM	4000.0
	3214035	CHEMBL1103230	Inhibition of ROCK1 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	INH	%	2.0
	3215579	CHEMBL1099847	Inhibition of ROCK1	B	CN(C)CCCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079921	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	3215580	CHEMBL1099847	Inhibition of ROCK1	B	CCN(Cc1cccc(OC)c1)C(=O)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081196	=	IC50	nM	180.0	CHEMBL3231	Homo sapiens	IC50	nM	180.0
	3215581	CHEMBL1099847	Inhibition of ROCK1	B	COc1cccc(CN(CCN(C)C)C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1080279	=	IC50	nM	3.5	CHEMBL3231	Homo sapiens	IC50	nM	3.5
	3219705	CHEMBL1114119	Inhibition of ROCK1 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	106.0	CHEMBL3231	Homo sapiens	INH	%	106.0
	3219866	CHEMBL1113990	Inhibition of ROCK1	B	Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(S(=O)(=O)N3CCN(C)CC3)c2)ccc2[nH]ccc12		CHEMBL1080994	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
	3219867	CHEMBL1113990	Inhibition of ROCK1	B	Cc1ncc(C#N)c(Nc2ccc3[nH]ccc3c2C)c1/C=C/c1cccc(S(=O)(=O)N2CCN(C)CC2)c1		CHEMBL1080995	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
	3220015	CHEMBL1115864	Inhibition of ROCK1	B	CN1C[C@@H]2C[C@H]1CN2c1ccc(-c2ccnc3c(-c4cccc(O)c4)c(-c4ccncc4)nn23)cc1		CHEMBL1087650	=	IC50	nM	17600.0	CHEMBL3231	Homo sapiens	IC50	uM	17.6
	3221887	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Cn1c(-c2nonc2N)nc2ccccc21		CHEMBL1078717	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3221891	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Ki	nM	330.0	CHEMBL3231	Homo sapiens	Ki	uM	0.33
	3221895	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	CC(C)n1c(-c2nonc2N)nc2ccccc21		CHEMBL1079208	=	Ki	nM	1900.0	CHEMBL3231	Homo sapiens	Ki	uM	1.9
	3221899	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1C1CC1		CHEMBL1079293	=	Ki	nM	450.0	CHEMBL3231	Homo sapiens	Ki	uM	0.45
	3221903	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1C1CCC1		CHEMBL1079294	=	Ki	nM	180.0	CHEMBL3231	Homo sapiens	Ki	uM	0.18
	3221907	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1C1CCCC1		CHEMBL1079295	=	Ki	nM	340.0	CHEMBL3231	Homo sapiens	Ki	uM	0.34
	3221911	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1C1CCCCC1		CHEMBL1078929	=	Ki	nM	720.0	CHEMBL3231	Homo sapiens	Ki	uM	0.72
	3221915	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1CC1CC1		CHEMBL1078930	=	Ki	nM	360.0	CHEMBL3231	Homo sapiens	Ki	uM	0.36
	3221919	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1CC1CCC1		CHEMBL1078820	=	Ki	nM	660.0	CHEMBL3231	Homo sapiens	Ki	uM	0.66
	3222997	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	CC(C)Cn1c(-c2nonc2N)nc2ccccc21		CHEMBL1079040	=	Ki	nM	930.0	CHEMBL3231	Homo sapiens	Ki	uM	0.93
	3223001	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2ccccc2n1-c1ccccc1		CHEMBL1078426	=	Ki	nM	590.0	CHEMBL3231	Homo sapiens	Ki	uM	0.59
	3223005	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	N#Cc1ccccc1-n1c(-c2nonc2N)nc2ccccc21		CHEMBL1078427	=	Ki	nM	810.0	CHEMBL3231	Homo sapiens	Ki	uM	0.81
	3223009	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	N#Cc1cccc(-n2c(-c3nonc3N)nc3ccccc32)c1		CHEMBL1078537	>	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	uM	2.5
	3223013	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	N#Cc1ccc(-n2c(-c3nonc3N)nc3ccccc32)cc1		CHEMBL1078538	>	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	uM	2.5
	3223017	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	COc1ccccc1-n1c(-c2nonc2N)nc2ccccc21		CHEMBL1078539	=	Ki	nM	1300.0	CHEMBL3231	Homo sapiens	Ki	uM	1.3
	3223021	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	COc1cccc(-n2c(-c3nonc3N)nc3ccccc32)c1		CHEMBL1078155	>	Ki	nM	5000.0	CHEMBL3231	Homo sapiens	Ki	uM	5.0
	3223025	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	COc1ccc(-n2c(-c3nonc3N)nc3ccccc32)cc1		CHEMBL1078245	=	Ki	nM	2100.0	CHEMBL3231	Homo sapiens	Ki	uM	2.1
	3223029	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2cc(O)ccc2n1C1CCC1		CHEMBL1079032	=	Ki	nM	2200.0	CHEMBL3231	Homo sapiens	Ki	uM	2.2
	3223033	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1		CHEMBL1080071	=	Ki	nM	85.0	CHEMBL3231	Homo sapiens	Ki	uM	0.085
	3223037	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	COc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1		CHEMBL1080072	=	Ki	nM	940.0	CHEMBL3231	Homo sapiens	Ki	uM	0.94
	3223041	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	COC(=O)c1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1		CHEMBL1080073	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3223045	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	CC(=O)Nc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1		CHEMBL1080245	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3223049	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Cc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1		CHEMBL1079135	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3223053	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Nc1nonc1-c1nc2cc(CO)ccc2n1C1CCC1		CHEMBL1080970	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3223057	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	CC(C)Cn1cc(-c2ccccc2)nc1-c1nonc1N		CHEMBL1079243	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3223061	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	Cc1cn(CC(C)C)c(-c2nonc2N)n1		CHEMBL1077670	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3223065	CHEMBL1104159	Inhibition of ROCK1 assessed as decrease in NADH absorbance at 340 nm in the presence of	B	CC(C)Cn1cc(C#N)nc1-c1nonc1N		CHEMBL1082061	>	Ki	nM	3300.0	CHEMBL3231	Homo sapiens	Ki	uM	3.3
	3224949	CHEMBL1101753	Inhibition of ROCK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3226328	CHEMBL1101753	Inhibition of ROCK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3229274	CHEMBL1108494	Inhibition of ROCK1	B	COc1cc2c(cc1Cl)C(c1ccc(Cl)c(Cl)c1)=NCC2		CHEMBL1087421	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	3229287	CHEMBL1108494	Inhibition of ROCK1	B	COc1cc2c(cc1Cl)C(c1cccc(Cl)c1)=NCC2		CHEMBL1088633	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	3240835	CHEMBL1109672	Inhibition of ROCK1	B	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	uM	1.0
	3242228	CHEMBL1111614	Inhibition of ROCK1	B	CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1		CHEMBL1091356	<	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	3251264	CHEMBL1110587	Inhibition of ROCK1	B	Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)NCCO)cc3)ccnc21		CHEMBL1092754	=	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	3260513	CHEMBL1110867	Inhibition of ROCK1	B	O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1		CHEMBL1089082	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	3264381	CHEMBL1104650	Inhibition of ROCK1	B	CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1		CHEMBL1095627	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	3271251	CHEMBL1104650	Inhibition of ROCK1	B	COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1		CHEMBL1095626	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	3294397	CHEMBL1108263	Inhibition of ROCK1	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2ccc(NC(=O)Nc3ccccc3)cc2)n1		CHEMBL1089116	=	IC50	nM	398.0	CHEMBL3231	Homo sapiens	IC50	nM	398.0
	3306868	CHEMBL1117929	Inhibition of ROCK1	B	O=C(Cc1ccccc1)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1084890	=	IC50	nM	180.0	CHEMBL3231	Homo sapiens	IC50	nM	180.0
	3306869	CHEMBL1117929	Inhibition of ROCK1	B	NC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1085141	=	IC50	nM	59.0	CHEMBL3231	Homo sapiens	IC50	nM	59.0
	3306870	CHEMBL1117929	Inhibition of ROCK1	B	CNC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1084892	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	3306871	CHEMBL1117929	Inhibition of ROCK1	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C(NC1CC1)c1ccccc1		CHEMBL1084106	=	IC50	nM	39.0	CHEMBL3231	Homo sapiens	IC50	nM	39.0
	3306872	CHEMBL1117929	Inhibition of ROCK1	B	CN(C)C(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1084107	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	3306873	CHEMBL1117929	Inhibition of ROCK1	B	O=C(CNCc1ccccc1)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1084900	=	IC50	nM	53.0	CHEMBL3231	Homo sapiens	IC50	nM	53.0
	3306874	CHEMBL1117929	Inhibition of ROCK1	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	660.0	CHEMBL3231	Homo sapiens	IC50	nM	660.0
	3306875	CHEMBL1117929	Inhibition of ROCK1	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1.Cl.Cl		CHEMBL1605605	=	IC50	nM	46.0	CHEMBL3231	Homo sapiens	IC50	nM	46.0
	3308553	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cl)cc12		CHEMBL1085214	=	IC50	nM	1500.0	CHEMBL3231	Homo sapiens	IC50	uM	1.5
	3308554	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	CNc1nccc(-c2sc3ccc(Cl)cc3c2C)n1		CHEMBL1086078	=	IC50	nM	1200.0	CHEMBL3231	Homo sapiens	IC50	uM	1.2
	3308555	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N(C)C)n2)sc2ccc(Cl)cc12		CHEMBL1083140	>	IC50	nM	100000.0	CHEMBL3231	Homo sapiens	IC50	uM	100.0
	3308556	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2cc(N)ncn2)sc2ccc(Cl)cc12		CHEMBL1085468	=	IC50	nM	13000.0	CHEMBL3231	Homo sapiens	IC50	uM	13.0
	3308557	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)c2)sc2ccc(Cl)cc12		CHEMBL1083141	=	IC50	nM	8300.0	CHEMBL3231	Homo sapiens	IC50	uM	8.3
	3308558	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccncc2)sc2ccc(Cl)cc12		CHEMBL1083142	=	IC50	nM	28000.0	CHEMBL3231	Homo sapiens	IC50	uM	28.0
	3308559	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc3[nH]ccc23)sc2ccc(Cl)cc12		CHEMBL1083143	=	IC50	nM	7100.0	CHEMBL3231	Homo sapiens	IC50	uM	7.1
	3308560	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2c[nH]c3ncccc23)sc2ccc(Cl)cc12		CHEMBL1086321	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3308561	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccccc12		CHEMBL1086322	=	IC50	nM	2900.0	CHEMBL3231	Homo sapiens	IC50	uM	2.9
	3308562	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(-c3ccccc3)cc12		CHEMBL1085706	=	IC50	nM	4200.0	CHEMBL3231	Homo sapiens	IC50	uM	4.2
	3308563	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3ccccc3)cc12		CHEMBL1083455	=	IC50	nM	580.0	CHEMBL3231	Homo sapiens	IC50	uM	0.58
	3308564	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	COc1ccccc1Cc1ccc2sc(-c3ccnc(N)n3)c(C)c2c1		CHEMBL1086543	=	IC50	nM	9700.0	CHEMBL3231	Homo sapiens	IC50	uM	9.7
	3308565	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	COc1cccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1086544	=	IC50	nM	230.0	CHEMBL3231	Homo sapiens	IC50	uM	0.23
	3308566	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	COc1ccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)cc1		CHEMBL1086545	=	IC50	nM	7200.0	CHEMBL3231	Homo sapiens	IC50	uM	7.2
	3308567	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(C(F)(F)F)c3)cc12		CHEMBL1082757	=	IC50	nM	8600.0	CHEMBL3231	Homo sapiens	IC50	uM	8.6
	3308568	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(O)c3)cc12		CHEMBL1082758	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	3308569	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(C(=O)O)c3)cc12		CHEMBL1084791	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	uM	0.06
	3308570	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	COC(=O)c1cccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1084792	=	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	3308571	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Oc3cccc(O)c3)cc12		CHEMBL1084947	=	IC50	nM	360.0	CHEMBL3231	Homo sapiens	IC50	uM	0.36
	3308572	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Nc3cccc(O)c3)cc12		CHEMBL1083072	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	3308573	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	COc1cccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1083073	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	3308574	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)c3cccc(O)c3)cc12		CHEMBL1083074	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	uM	0.01
	3308575	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	COc1ccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)cc1		CHEMBL1084795	=	IC50	nM	90.0	CHEMBL3231	Homo sapiens	IC50	uM	0.09
	3308576	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)c3cccc(Cl)c3)cc12		CHEMBL1085035	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	3308577	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1cccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1083351	=	IC50	nM	50.0	CHEMBL3231	Homo sapiens	IC50	uM	0.05
	3308578	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)c3ccccc3)cc12		CHEMBL1083352	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	3308579	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(CN)cc12		CHEMBL1085700	=	IC50	nM	2200.0	CHEMBL3231	Homo sapiens	IC50	uM	2.2
	3308580	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(C)N)cc12		CHEMBL1083965	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	uM	0.4
	3308581	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	CCC(N)c1ccc2sc(-c3ccnc(N)n3)c(C)c2c1		CHEMBL1083966	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	uM	0.14
	3308582	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	CCCC(N)c1ccc2sc(-c3ccnc(N)n3)c(C)c2c1		CHEMBL1083967	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	3308583	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)C(C)C)cc12		CHEMBL1085935	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	uM	0.06
	3308584	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)CC(C)C)cc12		CHEMBL1082439	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	3308585	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccccc12		CHEMBL1086322	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308586	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(-c3ccccc3)cc12		CHEMBL1085706	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308587	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3ccccc3)cc12		CHEMBL1083455	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308588	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	COc1ccccc1Cc1ccc2sc(-c3ccnc(N)n3)c(C)c2c1		CHEMBL1086543	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308589	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	COc1cccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1086544	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308590	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	COc1ccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)cc1		CHEMBL1086545	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308591	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(C(F)(F)F)c3)cc12		CHEMBL1082757	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308592	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(O)c3)cc12		CHEMBL1082758	=	EC50	nM	2900.0	CHEMBL3231	Homo sapiens	EC50	uM	2.9
	3308593	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(C(=O)O)c3)cc12		CHEMBL1084791	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308594	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	COC(=O)c1cccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1084792	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308595	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Oc3cccc(O)c3)cc12		CHEMBL1084947	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308596	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Nc3cccc(O)c3)cc12		CHEMBL1083072	=	EC50	nM	1000.0	CHEMBL3231	Homo sapiens	EC50	uM	1.0
	3308597	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	COc1cccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1083073	=	EC50	nM	3600.0	CHEMBL3231	Homo sapiens	EC50	uM	3.6
	3308598	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)c3cccc(O)c3)cc12		CHEMBL1083074	=	EC50	nM	900.0	CHEMBL3231	Homo sapiens	EC50	uM	0.9
	3308599	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	COc1ccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)cc1		CHEMBL1084795	=	EC50	nM	2600.0	CHEMBL3231	Homo sapiens	EC50	uM	2.6
	3308600	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)c3cccc(Cl)c3)cc12		CHEMBL1085035	=	EC50	nM	2700.0	CHEMBL3231	Homo sapiens	EC50	uM	2.7
	3308601	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1cccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1083351	=	EC50	nM	1900.0	CHEMBL3231	Homo sapiens	EC50	uM	1.9
	3308602	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)c3ccccc3)cc12		CHEMBL1083352	=	EC50	nM	1400.0	CHEMBL3231	Homo sapiens	EC50	uM	1.4
	3308603	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(CN)cc12		CHEMBL1085700	>	EC50	nM	10000.0	CHEMBL3231	Homo sapiens	EC50	uM	10.0
	3308604	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(C)N)cc12		CHEMBL1083965	=	EC50	nM	4200.0	CHEMBL3231	Homo sapiens	EC50	uM	4.2
	3308605	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	CCC(N)c1ccc2sc(-c3ccnc(N)n3)c(C)c2c1		CHEMBL1083966	=	EC50	nM	1700.0	CHEMBL3231	Homo sapiens	EC50	uM	1.7
	3308606	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	CCCC(N)c1ccc2sc(-c3ccnc(N)n3)c(C)c2c1		CHEMBL1083967	=	EC50	nM	600.0	CHEMBL3231	Homo sapiens	EC50	uM	0.6
	3308607	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)C(C)C)cc12		CHEMBL1085935	=	EC50	nM	2100.0	CHEMBL3231	Homo sapiens	EC50	uM	2.1
	3308608	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(C(N)CC(C)C)cc12		CHEMBL1082439	=	EC50	nM	1400.0	CHEMBL3231	Homo sapiens	EC50	uM	1.4
	3308615	CHEMBL1117721	Inhibition of ROCK1 assessed as ATP cunsumption relative to control	B	CNc1nccc(-c2sc3ccc(Cl)cc3c2C)n1		CHEMBL1086078	=	Emax	%	17.0	CHEMBL3231	Homo sapiens	Emax	%	17.0
Not Active	3308616	CHEMBL1117722	Inhibition of ROCK1 assessed as ATP cunsumption at 96 uM	B	Cc1c(-c2ccnc(N(C)C)n2)sc2ccc(Cl)cc12		CHEMBL1083140		Activity			CHEMBL3231	Homo sapiens	Activity		
	3308617	CHEMBL1117721	Inhibition of ROCK1 assessed as ATP cunsumption relative to control	B	Cc1c(-c2ccnc(N)c2)sc2ccc(Cl)cc12		CHEMBL1083141	=	Emax	%	44.0	CHEMBL3231	Homo sapiens	Emax	%	44.0
	3308618	CHEMBL1117724	Inhibition of ROCK1 assessed as ATP cunsumption at 96 uM relative to control	B	Cc1c(-c2ccnc(N)n2)sc2ccc(-c3ccccc3)cc12		CHEMBL1085706	=	Emax	%	35.0	CHEMBL3231	Homo sapiens	Emax	%	35.0
	3308619	CHEMBL1117725	Inhibition of ROCK1 assessed as ATP cunsumption at 10 uM relative to control	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3ccccc3)cc12		CHEMBL1083455	=	Emax	%	11.0	CHEMBL3231	Homo sapiens	Emax	%	11.0
	3308620	CHEMBL1117725	Inhibition of ROCK1 assessed as ATP cunsumption at 10 uM relative to control	B	COc1cccc(Cc2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1086544	=	Emax	%	15.0	CHEMBL3231	Homo sapiens	Emax	%	15.0
	3308621	CHEMBL1117725	Inhibition of ROCK1 assessed as ATP cunsumption at 10 uM relative to control	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cc3cccc(O)c3)cc12		CHEMBL1082758	=	Emax	%	50.0	CHEMBL3231	Homo sapiens	Emax	%	50.0
	3308622	CHEMBL1117725	Inhibition of ROCK1 assessed as ATP cunsumption at 10 uM relative to control	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Nc3cccc(O)c3)cc12		CHEMBL1083072	=	Emax	%	35.0	CHEMBL3231	Homo sapiens	Emax	%	35.0
	3308623	CHEMBL1117721	Inhibition of ROCK1 assessed as ATP cunsumption relative to control	B	COc1cccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1083073	=	Emax	%	46.0	CHEMBL3231	Homo sapiens	Emax	%	46.0
	3308624	CHEMBL1117721	Inhibition of ROCK1 assessed as ATP cunsumption relative to control	B	COc1ccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)cc1		CHEMBL1084795	=	Emax	%	56.0	CHEMBL3231	Homo sapiens	Emax	%	56.0
	3308625	CHEMBL1117721	Inhibition of ROCK1 assessed as ATP cunsumption relative to control	B	Cc1cccc(C(N)c2ccc3sc(-c4ccnc(N)n4)c(C)c3c2)c1		CHEMBL1083351	=	Emax	%	67.0	CHEMBL3231	Homo sapiens	Emax	%	67.0
Not Active	3308626	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	CNc1nccc(-c2sc3ccc(Cl)cc3c2C)n1		CHEMBL1086078		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308627	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2ccnc(N)n2)sc2ccc(Cl)cc12		CHEMBL1085214		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308628	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2ccnc(N(C)C)n2)sc2ccc(Cl)cc12		CHEMBL1083140		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308629	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2cc(N)ncn2)sc2ccc(Cl)cc12		CHEMBL1085468		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308630	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2ccnc(N)c2)sc2ccc(Cl)cc12		CHEMBL1083141		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308631	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2ccncc2)sc2ccc(Cl)cc12		CHEMBL1083142		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308632	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2ccnc3[nH]ccc23)sc2ccc(Cl)cc12		CHEMBL1083143		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	3308633	CHEMBL1117729	Inhibition of ROCK1 in human GTM3 cells up to 10 uM by impedance assay	B	Cc1c(-c2c[nH]c3ncccc23)sc2ccc(Cl)cc12		CHEMBL1086321		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	3308641	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	3308642	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	O=S(=O)(c1cccc2c(I)cccc12)N1CCCNCC1		CHEMBL249089	=	IC50	nM	38000.0	CHEMBL3231	Homo sapiens	IC50	uM	38.0
	3309011	CHEMBL1117720	Inhibition of ROCK1 assessed as ATP cunsumption	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	3309012	CHEMBL1117723	Inhibition of ROCK1 in human GTM3 cells by impedance assay	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	EC50	nM	790.0	CHEMBL3231	Homo sapiens	EC50	uM	0.79
	3316807	CHEMBL1120366	Inhibition of ROCK1 at 1 uM	B	O=C(Nc1cccc(-n2ccc3c(NC(=O)c4ccccc4)nccc32)c1)c1ccc(N2CCOCC2)c(C(F)(F)F)c1		CHEMBL1084450	=	Inhibition	%	3.0	CHEMBL3231	Homo sapiens	INH	%	3.0
	3326151	CHEMBL1168778	Inhibition of ROCK1 at 10 uM by HotSpot assay	B	CC(=O)Nc1cccc(-c2ccc(-c3ccnc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cn2)c1.Cl		CHEMBL1164847	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3332135	CHEMBL1166846	Inhibition of ROCK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3333550	CHEMBL1166846	Inhibition of ROCK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3334955	CHEMBL1166846	Inhibition of ROCK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3336375	CHEMBL1166846	Inhibition of ROCK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3341917	CHEMBL1166846	Inhibition of ROCK1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3343364	CHEMBL1166846	Inhibition of ROCK1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	3358791	CHEMBL1175319	Inhibition of ROCK1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	43.0	CHEMBL3231	Homo sapiens	INH	%	43.0
	3359233	CHEMBL1175319	Inhibition of ROCK1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	60.0	CHEMBL3231	Homo sapiens	INH	%	60.0
	3407933	CHEMBL1219255	Inhibition of ROCK1	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215171	=	IC50	nM	48.0	CHEMBL3231	Homo sapiens	IC50	nM	48.0
	3407944	CHEMBL1219255	Inhibition of ROCK1	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1		CHEMBL1215524	=	IC50	nM	33.0	CHEMBL3231	Homo sapiens	IC50	nM	33.0
	3407975	CHEMBL1219255	Inhibition of ROCK1	B	CCN1Cc2ccccc2C[C@@H]1C(=O)Nc1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL1215526	=	IC50	nM	16.0	CHEMBL3231	Homo sapiens	IC50	nM	16.0
	3407989	CHEMBL1219255	Inhibition of ROCK1	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCC1CCN(C)CC1)NC2		CHEMBL1215304	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	3443512	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	3443729	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	28.0	CHEMBL3231	Homo sapiens	INH	%	28.0
	3444884	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	3445287	CHEMBL1244961	Binding affinity to ROCK1	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	56.0	CHEMBL3231	Homo sapiens	Kd	nM	56.0
	3445508	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	INH	%	1.0
	3445725	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	-1.0	CHEMBL3231	Homo sapiens	INH	%	-1.0
	3445918	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	34.0	CHEMBL3231	Homo sapiens	INH	%	34.0
	3446108	CHEMBL1244278	Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	3448608	CHEMBL1244961	Binding affinity to ROCK1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	uM	10.0
	3449038	CHEMBL1244961	Binding affinity to ROCK1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	7800.0	CHEMBL3231	Homo sapiens	Kd	nM	7800.0
	3449331	CHEMBL1244961	Binding affinity to ROCK1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	460.0	CHEMBL3231	Homo sapiens	Kd	nM	460.0
	3449835	CHEMBL1244961	Binding affinity to ROCK1	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	uM	10.0
	3450227	CHEMBL1244961	Binding affinity to ROCK1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	uM	10.0
	3451136	CHEMBL1244961	Binding affinity to ROCK1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	uM	10.0
	3463345	CHEMBL1251678	Inhibition of ROCK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	99.0	CHEMBL3231	Homo sapiens	INH	%	99.0
	3463889	CHEMBL1251678	Inhibition of ROCK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	-2.0	CHEMBL3231	Homo sapiens	INH	%	-2.0
	3464108	CHEMBL1251678	Inhibition of ROCK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	48.0	CHEMBL3231	Homo sapiens	INH	%	48.0
	3502335	CHEMBL1259597	Inhibition of ROCK1 at 1 uM	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c12		CHEMBL1257282	>	Inhibition	%	90.0	CHEMBL3231	Homo sapiens	INH	%	90.0
	3502338	CHEMBL1259597	Inhibition of ROCK1 at 1 uM	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)C4Cc5ccccc5C4)CC3)c12		CHEMBL1257283	>	Inhibition	%	90.0	CHEMBL3231	Homo sapiens	INH	%	90.0
	3556560	CHEMBL1285865	Inhibition of ROCK1 at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	3.0	CHEMBL3231	Homo sapiens	INH	%	3.0
	5120440	CHEMBL1648702	Inhibition of human ROCK-1 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	110.0	CHEMBL3231	Homo sapiens	INH	%	110.0
	5120820	CHEMBL1646804	Inhibition of ROCK1 at 10 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	5122859	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	Cn1nc(C(C)(C)C)cc1N		CHEMBL1643348	=	Activity	%	20.0	CHEMBL3231	Homo sapiens	Activity	%	20.0
	5122860	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	CC1(C)C(=O)Nc2ccccc21		CHEMBL1643349	=	Activity	%	25.0	CHEMBL3231	Homo sapiens	Activity	%	25.0
	5122861	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1ccc(-n2cccc2)nc1		CHEMBL1643350	=	Activity	%	30.0	CHEMBL3231	Homo sapiens	Activity	%	30.0
	5122862	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	NC(=O)c1ccccc1O		CHEMBL27577	=	Activity	%	34.0	CHEMBL3231	Homo sapiens	Activity	%	34.0
	5122863	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1ccn2ccnc2c1		CHEMBL377488	=	Activity	%	38.0	CHEMBL3231	Homo sapiens	Activity	%	38.0
	5122864	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	CC1=NC(C(C)C)CO1		CHEMBL1643351	=	Activity	%	40.0	CHEMBL3231	Homo sapiens	Activity	%	40.0
	5122865	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	CC(=O)c1ccccc1		CHEMBL274467	=	Activity	%	60.0	CHEMBL3231	Homo sapiens	Activity	%	60.0
	5122866	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1ccc2[nH]cnc2c1		CHEMBL306226	=	Activity	%	64.0	CHEMBL3231	Homo sapiens	Activity	%	64.0
	5122867	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	Nc1nc2c(c(=O)[nH]1)CC=N2		CHEMBL219544	=	Activity	%	68.0	CHEMBL3231	Homo sapiens	Activity	%	68.0
	5122868	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1ccc2cnccc2c1		CHEMBL12315	=	Activity	%	70.0	CHEMBL3231	Homo sapiens	Activity	%	70.0
	5122869	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	O=C(Nc1nccs1)c1ccncc1		CHEMBL421744	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	5122870	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1ccc2[nH]ncc2c1		CHEMBL86795	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	5122871	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	Nc1ncnc2ccccc12		CHEMBL266128	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	5122872	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	Nc1ccnc2ccncc12		CHEMBL1643352	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	5122873	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1cc(-c2cnco2)ccn1		CHEMBL1643353	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	5122874	CHEMBL1647663	Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment	B	c1cc(N2CCOCC2)ccn1		CHEMBL1643354	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	5122875	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	NCc1ccc2c(N)nccc2c1		CHEMBL1643355	=	IC50	nM	7762.47	CHEMBL3231	Homo sapiens	pIC50		5.11
	5122876	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	CN(CCc1ccccc1)Cc1ccc2c(N)nccc2c1		CHEMBL1643356	=	IC50	nM	426.58	CHEMBL3231	Homo sapiens	pIC50		6.37
	5122877	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCOc3ccccc3)ccc12		CHEMBL1643357	=	IC50	nM	588.84	CHEMBL3231	Homo sapiens	pIC50		6.23
	5122878	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCc3ccc(Cl)c(Cl)c3)ccc12		CHEMBL1643358	=	IC50	nM	776.25	CHEMBL3231	Homo sapiens	pIC50		6.11
	5122879	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Cc1ccc(CCNCc2ccc3c(N)nccc3c2)cc1		CHEMBL1643359	=	IC50	nM	812.83	CHEMBL3231	Homo sapiens	pIC50		6.09
	5122880	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	COc1ccc(CCNCc2ccc3c(N)nccc3c2)cc1		CHEMBL1643360	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	pIC50		6.0
	5122881	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCc3ccccc3)ccc12		CHEMBL1643361	=	IC50	nM	1288.25	CHEMBL3231	Homo sapiens	pIC50		5.89
	5122882	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCNc3ccccc3)ccc12		CHEMBL1643362	=	IC50	nM	1479.11	CHEMBL3231	Homo sapiens	pIC50		5.83
	5122883	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCc3cccc(C(F)(F)F)c3)ccc12		CHEMBL1643363	=	IC50	nM	1698.24	CHEMBL3231	Homo sapiens	pIC50		5.77
	5122884	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCc3ccncc3)ccc12		CHEMBL1643364	=	IC50	nM	1862.09	CHEMBL3231	Homo sapiens	pIC50		5.73
	5122885	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCc3cccc(Oc4ccccc4)c3)ccc12		CHEMBL1643365	=	IC50	nM	575.44	CHEMBL3231	Homo sapiens	pIC50		6.24
	5122886	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCc3ccc4ccccc4c3)ccc12		CHEMBL1643366	=	IC50	nM	3467.37	CHEMBL3231	Homo sapiens	pIC50		5.46
	5122887	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCc3ccccc3)ccc12		CHEMBL1643367	=	IC50	nM	6760.83	CHEMBL3231	Homo sapiens	pIC50		5.17
	5122889	CHEMBL1647666	Inhibition of ROCK-1	B	Nc1nccc2cc(CNCCc3ccccc3)ccc12		CHEMBL1643361	=	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
	5122893	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	=	IC50	nM	2137.96	CHEMBL3231	Homo sapiens	pIC50		5.67
	5122894	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(O[C@@H]3CCCNC3)ccc12		CHEMBL1643571	=	IC50	nM	1949.84	CHEMBL3231	Homo sapiens	pIC50		5.71
	5122895	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(OC3CCNCC3)ccc12		CHEMBL1643572	=	IC50	nM	3630.78	CHEMBL3231	Homo sapiens	pIC50		5.44
	5122896	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(O[C@@H]3CCCN(Cc4ccccc4)C3)ccc12		CHEMBL1643573	=	IC50	nM	239.88	CHEMBL3231	Homo sapiens	pIC50		6.62
	5122897	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(O[C@H]3CCCN(Cc4ccccc4)C3)ccc12		CHEMBL1643574	=	IC50	nM	239.88	CHEMBL3231	Homo sapiens	pIC50		6.62
	5122898	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(OC3CCN(Cc4ccccc4)CC3)ccc12		CHEMBL1643575	=	IC50	nM	4265.8	CHEMBL3231	Homo sapiens	pIC50		5.37
	5122899	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	CS(=O)(=O)N1CCC[C@H](Oc2ccc3c(N)nccc3c2)C1		CHEMBL1643576	<	IC50	nM	100000.0	CHEMBL3231	Homo sapiens	pIC50		4.0
	5123943	CHEMBL1647704	Inhibition of ROCK1 at 10 uM	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	>	Inhibition	%	80.0	CHEMBL3231	Homo sapiens	INH	%	80.0
	5123976	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	3162.28	CHEMBL3231	Homo sapiens	pIC50		5.5
	5123977	CHEMBL1647666	Inhibition of ROCK-1	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
	5123985	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	870.96	CHEMBL3231	Homo sapiens	pIC50		6.06
	5123986	CHEMBL1647666	Inhibition of ROCK-1	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
	5123994	CHEMBL1647664	Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	IC50	nM	758.58	CHEMBL3231	Homo sapiens	pIC50		6.12
	5123995	CHEMBL1647666	Inhibition of ROCK-1	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
	5140526	CHEMBL1646068	Inhibition of ROCK1 at 1 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	5197176	CHEMBL1670415	Inhibition of ROCK1 in human THP cells assessed as inhibition of MCP1-induced cell migration	B	O=c1[nH]ccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1667967	=	IC50	nM	660.69	CHEMBL3231	Homo sapiens	pIC50		6.18
	5197178	CHEMBL1670412	Binding affinity to ROCK1	B	O=c1[nH]ccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1667967	=	Ki	nM	2.512	CHEMBL3231	Homo sapiens	pKi		8.6
	5197192	CHEMBL1670415	Inhibition of ROCK1 in human THP cells assessed as inhibition of MCP1-induced cell migration	B	c1ccc(CN2CCC[C@H](Oc3ccc4cnccc4c3)C2)cc1		CHEMBL1667965	=	IC50	nM	331.13	CHEMBL3231	Homo sapiens	pIC50		6.48
Not Determined	5197193	CHEMBL1670412	Binding affinity to ROCK1	B	c1ccc(CN2CCC[C@H](Oc3ccc4cnccc4c3)C2)cc1		CHEMBL1667965		pKi			CHEMBL3231	Homo sapiens	pKi		
	5197194	CHEMBL1670500	Inhibition of ROCK1 by RFBA assay	B	O=c1[nH]ccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1667967	=	IC50	nM	251.19	CHEMBL3231	Homo sapiens	pIC50		6.6
	5197200	CHEMBL1670500	Inhibition of ROCK1 by RFBA assay	B	Nc1nccc2c(S(=O)(=O)N3CCCNCC3)cccc12		CHEMBL1667963	=	IC50	nM	3162.28	CHEMBL3231	Homo sapiens	pIC50		5.5
	5197219	CHEMBL1670415	Inhibition of ROCK1 in human THP cells assessed as inhibition of MCP1-induced cell migration	B	Nc1nccc2c(S(=O)(=O)N3CCCNCC3)cccc12		CHEMBL1667963	=	IC50	nM	6918.31	CHEMBL3231	Homo sapiens	pIC50		5.16
	5197221	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	Nc1nccc2c(S(=O)(=O)N3CCCNCC3)cccc12		CHEMBL1667963	=	IC50	nM	758.58	CHEMBL3231	Homo sapiens	pIC50		6.12
	5197222	CHEMBL1670412	Binding affinity to ROCK1	B	Nc1nccc2c(S(=O)(=O)N3CCCNCC3)cccc12		CHEMBL1667963	=	Ki	nM	34.67	CHEMBL3231	Homo sapiens	pKi		7.46
	5197224	CHEMBL1670415	Inhibition of ROCK1 in human THP cells assessed as inhibition of MCP1-induced cell migration	B	Nc1nccc2cc(O[C@H]3CCCN(Cc4ccccc4)C3)ccc12		CHEMBL1643574	=	IC50	nM	776.25	CHEMBL3231	Homo sapiens	pIC50		6.11
	5197226	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	Nc1nccc2cc(O[C@H]3CCCN(Cc4ccccc4)C3)ccc12		CHEMBL1643574	=	IC50	nM	239.88	CHEMBL3231	Homo sapiens	pIC50		6.62
Not Determined	5197228	CHEMBL1670412	Binding affinity to ROCK1	B	Nc1nccc2cc(O[C@H]3CCCN(Cc4ccccc4)C3)ccc12		CHEMBL1643574		pKi			CHEMBL3231	Homo sapiens	pKi		
	5197230	CHEMBL1670415	Inhibition of ROCK1 in human THP cells assessed as inhibition of MCP1-induced cell migration	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	=	IC50	nM	5011.87	CHEMBL3231	Homo sapiens	pIC50		5.3
	5197232	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	=	IC50	nM	2137.96	CHEMBL3231	Homo sapiens	pIC50		5.67
	5197234	CHEMBL1670412	Binding affinity to ROCK1	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	=	Ki	nM	37.15	CHEMBL3231	Homo sapiens	pKi		7.43
	5197247	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	NC[C@H]1CC[C@@H](Oc2ccc3c(=O)[nH]ccc3c2)C1		CHEMBL1667980	=	IC50	nM	165.96	CHEMBL3231	Homo sapiens	pIC50		6.78
	5197248	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	NC[C@@H]1CC[C@H](Oc2ccc3c(=O)[nH]ccc3c2)C1		CHEMBL1667979	=	IC50	nM	81.28	CHEMBL3231	Homo sapiens	pIC50		7.09
	5197249	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	CCN[C@H]1CCC[C@H](Oc2ccc3c(=O)[nH]ccc3c2)C1		CHEMBL1667978	=	IC50	nM	120.23	CHEMBL3231	Homo sapiens	pIC50		6.92
	5197250	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	N[C@H]1CCC[C@H](Oc2ccc3c(=O)[nH]ccc3c2)C1		CHEMBL1667977	=	IC50	nM	31.62	CHEMBL3231	Homo sapiens	pIC50		7.5
	5197251	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	N[C@H]1CC[C@H](Oc2ccc3c(=O)[nH]ccc3c2)C1		CHEMBL1667976	=	IC50	nM	229.09	CHEMBL3231	Homo sapiens	pIC50		6.64
	5197252	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	Cc1cc2c(=O)[nH]ccc2cc1O[C@H]1CCCNC1		CHEMBL1667975	=	IC50	nM	47.86	CHEMBL3231	Homo sapiens	pIC50		7.32
	5197253	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	Cc1c[nH]c(=O)c2ccc(O[C@H]3CCCNC3)cc12		CHEMBL1667974	=	IC50	nM	588.84	CHEMBL3231	Homo sapiens	pIC50		6.23
	5197254	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(O[C@@H]3CCNC3)ccc12		CHEMBL1667973	=	IC50	nM	870.96	CHEMBL3231	Homo sapiens	pIC50		6.06
	5197255	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(O[C@H]3CCNC3)ccc12		CHEMBL1667972	=	IC50	nM	524.81	CHEMBL3231	Homo sapiens	pIC50		6.28
	5197256	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(OC3CCCNCC3)ccc12		CHEMBL1667971	=	IC50	nM	331.13	CHEMBL3231	Homo sapiens	pIC50		6.48
	5198017	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(O[C@H]3CCCNCC3)ccc12		CHEMBL1667970	=	IC50	nM	57.54	CHEMBL3231	Homo sapiens	pIC50		7.24
	5198376	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	=	IC50	nM	186.21	CHEMBL3231	Homo sapiens	pIC50		6.73
	5198377	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(O[C@@H]3CCCNC3)ccc12		CHEMBL1667968	=	IC50	nM	676.08	CHEMBL3231	Homo sapiens	pIC50		6.17
	5198378	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	O=c1[nH]ccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1667967	=	IC50	nM	61.66	CHEMBL3231	Homo sapiens	pIC50		7.21
	5198379	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	c1ccc(CN2CCC[C@@H](Oc3ccc4cnccc4c3)C2)cc1		CHEMBL1667966	=	IC50	nM	72.44	CHEMBL3231	Homo sapiens	pIC50		7.14
	5198380	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	c1ccc(CN2CCC[C@H](Oc3ccc4cnccc4c3)C2)cc1		CHEMBL1667965	=	IC50	nM	169.82	CHEMBL3231	Homo sapiens	pIC50		6.77
	5198381	CHEMBL1670413	Inhibition of ROCK1 by IMAP assay	B	c1cc2cc(OC3CCCNC3)ccc2cn1		CHEMBL1667964	=	IC50	nM	1778.28	CHEMBL3231	Homo sapiens	pIC50		5.75
	5312989	CHEMBL1694384	Inhibition of recombinant human Rock1 kinase assessed as residual activity at 10 uM in presence of 100 uM ATP	B	Cc1ccc(-c2csc3ncnc(SCCC(=O)O)c23)cc1		CHEMBL1689369	=	Activity	%	126.0	CHEMBL3231	Homo sapiens	Activity	%	126.0
	5312997	CHEMBL1694384	Inhibition of recombinant human Rock1 kinase assessed as residual activity at 10 uM in presence of 100 uM ATP	B	CCOc1ccc(-c2csc3ncnc(SCCC(=O)O)c23)cc1		CHEMBL1689372	=	Activity	%	115.0	CHEMBL3231	Homo sapiens	Activity	%	115.0
	6168476	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1COCCN1c1cc(-c2ccc3c(N)[nH]nc3c2)nc(N)n1		CHEMBL1614773	=	IC50	nM	15848.93	CHEMBL3231	Homo sapiens	pIC50		4.8
	6168477	CHEMBL1768782	Inhibition of ROCK1	B	C[C@H]1COCCN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765727	=	IC50	nM	15848.93	CHEMBL3231	Homo sapiens	pIC50		4.8
	6168478	CHEMBL1768782	Inhibition of ROCK1	B	CC[C@@H]1COCCN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765728	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168479	CHEMBL1768782	Inhibition of ROCK1	B	CC(C)[C@@H]1COCCN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765729	=	IC50	nM	15848.93	CHEMBL3231	Homo sapiens	pIC50		4.8
	6168480	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1CCCCN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765730	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168481	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)[nH]nc3c2)cc(N2CCO[C@H](C(=O)Nc3ccccc3)C2)n1		CHEMBL1614774	=	IC50	nM	794.33	CHEMBL3231	Homo sapiens	pIC50		6.1
	6168482	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCO[C@@H](C(=O)Nc3ccccc3)C2)n1		CHEMBL1765731	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168483	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCC[C@H](C(=O)Nc3ccccc3)C2)n1		CHEMBL1765732	=	IC50	nM	1995.26	CHEMBL3231	Homo sapiens	pIC50		5.7
	6168484	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCC[C@@H](C(=O)Nc3ccccc3)C2)n1		CHEMBL1765733	=	IC50	nM	3162.28	CHEMBL3231	Homo sapiens	pIC50		5.5
	6168485	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCC[C@H](C(=O)NC3CCCCC3)C2)n1		CHEMBL1765734	=	IC50	nM	5011.87	CHEMBL3231	Homo sapiens	pIC50		5.3
	6168486	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCC[C@H](C(=O)NC3CCCC3)C2)n1		CHEMBL1765735	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168487	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1CC[C@H](C(=O)Nc2ccccc2)CN1c1cc(-c2ccc3c(N)[nH]nc3c2)nc(N)n1		CHEMBL1614775	=	IC50	nM	199.53	CHEMBL3231	Homo sapiens	pIC50		6.7
	6168488	CHEMBL1768782	Inhibition of ROCK1	B	C[C@H]1CC[C@@H](C(=O)Nc2ccccc2)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765736	=	IC50	nM	3162.28	CHEMBL3231	Homo sapiens	pIC50		5.5
	6168489	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1CC[C@@H](C(=O)Nc2ccccc2)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765737	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168490	CHEMBL1768782	Inhibition of ROCK1	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)Nc3ccccc3)CC[C@H]2C)n1		CHEMBL1765738	=	IC50	nM	3162.28	CHEMBL3231	Homo sapiens	pIC50		5.5
	6168491	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1CC[C@H](C(=O)NC2CCCCC2)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765739	=	IC50	nM	630.96	CHEMBL3231	Homo sapiens	pIC50		6.2
	6168492	CHEMBL1768782	Inhibition of ROCK1	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1		CHEMBL1765740	=	IC50	nM	7943.28	CHEMBL3231	Homo sapiens	pIC50		5.1
	6168493	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1CO[C@H](C(=O)Nc2ccccc2)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765741	=	IC50	nM	158.49	CHEMBL3231	Homo sapiens	pIC50		6.8
	6168494	CHEMBL1768782	Inhibition of ROCK1	B	CC[C@@H]1CO[C@H](C(=O)Nc2ccccc2)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(NC)n1		CHEMBL1765742	=	IC50	nM	3162.28	CHEMBL3231	Homo sapiens	pIC50		5.5
	6168495	CHEMBL1768782	Inhibition of ROCK1	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)OC[C@H]2C)n1		CHEMBL1765743	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168496	CHEMBL1768782	Inhibition of ROCK1	B	CC[C@@H]1CO[C@H](C(=O)NC2CCCCC2)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(NC)n1		CHEMBL1765744	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168497	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCCC(NC(=O)c3ccccc3)C2)n1		CHEMBL1765745	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168498	CHEMBL1768782	Inhibition of ROCK1	B	CC(C)(C)OC(=O)NC1CCCN(c2cc(-c3ccc4c(N)n[nH]c4c3)nc(N)n2)C1		CHEMBL1765746	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168499	CHEMBL1768782	Inhibition of ROCK1	B	CC(C)(C)OC(=O)N[C@H]1CCCN(c2cc(-c3ccc4c(N)n[nH]c4c3)nc(N)n2)C1		CHEMBL1765747	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168500	CHEMBL1768782	Inhibition of ROCK1	B	CC(C)(C)OC(=O)N[C@@H]1CCCN(c2cc(-c3ccc4c(N)n[nH]c4c3)nc(N)n2)C1		CHEMBL1765748	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168501	CHEMBL1768782	Inhibition of ROCK1	B	C[C@H]1CC[C@@H](NC(=O)OC(C)(C)C)CN1c1cc(-c2ccc3c(N)[nH]nc3c2)nc(N)n1		CHEMBL1614776	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168502	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1CC[C@H](NC(=O)OC(C)(C)C)CN1c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765749	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168503	CHEMBL1768782	Inhibition of ROCK1	B	C[C@H]1CC[C@@H](NC(=O)OC(C)(C)C)CN1c1cc(-c2ccc3c(N)[nH]nc3c2)nc(N)n1		CHEMBL1614776	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168504	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1C[C@@H](NC(=O)OC(C)(C)C)CN(c2cc(-c3ccc4c(N)[nH]nc4c3)nc(N)n2)C1		CHEMBL1614777	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168505	CHEMBL1768782	Inhibition of ROCK1	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@H](C)C[C@@H](N(C)C(=O)OC(C)(C)C)C2)n1		CHEMBL1765750	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168506	CHEMBL1768782	Inhibition of ROCK1	B	C[C@@H]1C[C@@H](N(C)C(=O)CC(C)(C)C)CN(c2cc(-c3ccc4c(N)n[nH]c4c3)nc(N)n2)C1		CHEMBL1765751	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168507	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nccc(-c2ccc3c(N)n[nH]c3c2)n1		CHEMBL1688215	=	IC50	nM	1584.89	CHEMBL3231	Homo sapiens	pIC50		5.8
	6168508	CHEMBL1768782	Inhibition of ROCK1	B	Cc1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765756	=	IC50	nM	3981.07	CHEMBL3231	Homo sapiens	pIC50		5.4
	6168509	CHEMBL1768782	Inhibition of ROCK1	B	CC(C)c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765757	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168510	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccccc2)cc(-c2ccc3c(N)n[nH]c3c2)n1		CHEMBL1765758	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168511	CHEMBL1768782	Inhibition of ROCK1	B	COc1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765759	=	IC50	nM	5011.87	CHEMBL3231	Homo sapiens	pIC50		5.3
	6168512	CHEMBL1768782	Inhibition of ROCK1	B	CNc1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765760	=	IC50	nM	7943.28	CHEMBL3231	Homo sapiens	pIC50		5.1
	6168513	CHEMBL1768782	Inhibition of ROCK1	B	CCNc1cc(-c2ccc3c(N)[nH]nc3c2)nc(N)n1		CHEMBL1614771	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168514	CHEMBL1768782	Inhibition of ROCK1	B	CC(C)Nc1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765761	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168515	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(NC2CCCC2)cc(-c2ccc3c(N)n[nH]c3c2)n1		CHEMBL1765762	=	IC50	nM	6309.57	CHEMBL3231	Homo sapiens	pIC50		5.2
	6168516	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(Nc2ccccc2)cc(-c2ccc3c(N)n[nH]c3c2)n1		CHEMBL1765876	=	IC50	nM	2511.89	CHEMBL3231	Homo sapiens	pIC50		5.6
	6168517	CHEMBL1768782	Inhibition of ROCK1	B	CN(C)c1cc(-c2ccc3c(N)n[nH]c3c2)nc(N)n1		CHEMBL1765877	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168518	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)[nH]nc3c2)cc(N2CCOCC2)n1		CHEMBL1614772	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168519	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCCC2)n1		CHEMBL1765878	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6168520	CHEMBL1768782	Inhibition of ROCK1	B	Nc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2CCCCC2)n1		CHEMBL1765879	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	6169242	CHEMBL1768782	Inhibition of ROCK1	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1		CHEMBL1765740	=	IC50	nM	7943.0	CHEMBL3231	Homo sapiens	IC50	nM	7943.0
	6172477	CHEMBL1767757	Inhibition of ROCK1 assessed as residual activity at 25 uM after 20 mins using Long S6 kinase substrate peptide for [gamma-33P]ATP incorporation by liquid scintillation counting	B	CCOC(=O)c1c(O)nc2cccc3c2c1-c1ccccc1C3=O		CHEMBL1345690	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	6173423	CHEMBL1769810	Inhibition of ROCK1 at 25 uM by TR-FRET assay	B	NC(=O)c1ccsc1NC(=O)Cc1csc2ccccc12		CHEMBL1767254	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
Not Active	6230344	CHEMBL1785291	Inhibition of human ROCK1	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	6267537	CHEMBL1799041	Inhibition of ROCK1 at 10 uM	B	O=c1c(Cl)c(OCc2ccc(F)cc2F)cc(CO)n1-c1c(F)cccc1F		CHEMBL1797211	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	6267538	CHEMBL1799041	Inhibition of ROCK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cccc(C(N)=O)c1		CHEMBL1797224	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	6325328	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Nc1ncnc2[nH]cnc12		CHEMBL226345	=	Inhibition	%	80.0	CHEMBL3231	Homo sapiens	INH	%	80.0
	6325358	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	c1ccc(Nc2ncccn2)cc1		CHEMBL1650061	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	6325389	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	76.0	CHEMBL3231	Homo sapiens	INH	%	76.0
	6325422	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	c1ccc2[nH]ncc2c1		CHEMBL86795	=	Inhibition	%	80.0	CHEMBL3231	Homo sapiens	INH	%	80.0
	6325453	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Nc1ncccc1OCc1ccccc1		CHEMBL194009	=	Inhibition	%	64.0	CHEMBL3231	Homo sapiens	INH	%	64.0
	6325483	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Nc1[nH]nc2ccccc12		CHEMBL1331627	=	Inhibition	%	65.0	CHEMBL3231	Homo sapiens	INH	%	65.0
	6325511	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Nc1n[nH]c2ncccc12		CHEMBL1817865	=	Inhibition	%	46.0	CHEMBL3231	Homo sapiens	INH	%	46.0
	6325541	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	c1n[nH]c2c1CCCC2		CHEMBL1817866	=	Inhibition	%	25.0	CHEMBL3231	Homo sapiens	INH	%	25.0
	6325884	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Nc1ccc2ncc(-c3ccccc3)n2n1		CHEMBL1817867	=	Inhibition	%	93.0	CHEMBL3231	Homo sapiens	INH	%	93.0
	6325914	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	c1ccc(-c2cnc3nccnn23)cc1		CHEMBL1817868	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	6325943	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1		CHEMBL1817869	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	6325972	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccccc2)no1		CHEMBL292785	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	6326001	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1		CHEMBL1817870	=	Inhibition	%	7.0	CHEMBL3231	Homo sapiens	INH	%	7.0
	6326030	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	O=C(Nc1ccccc1)Nc1cccc(C(F)(F)F)c1		CHEMBL1605296	=	Inhibition	%	8.0	CHEMBL3231	Homo sapiens	INH	%	8.0
	6326059	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	INH	%	5.0
	6326088	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	Cc1ccc(C(=O)NC2CC2)cc1F		CHEMBL1817871	=	Inhibition	%	3.0	CHEMBL3231	Homo sapiens	INH	%	3.0
	6326118	CHEMBL1820093	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	B	c1ccc(Nc2ccccc2)cc1		CHEMBL38688	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	6339959	CHEMBL1826896	Activity of ROCK1 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	81.0	CHEMBL3231	Homo sapiens	Activity	%	81.0
	6384629	CHEMBL1837774	Inhibition of human ROCK1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	6384630	CHEMBL1837774	Inhibition of human ROCK1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	6384631	CHEMBL1837774	Inhibition of human ROCK1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	6384632	CHEMBL1837774	Inhibition of human ROCK1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	6384633	CHEMBL1837774	Inhibition of human ROCK1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	7567413	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7567901	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7568369	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7568801	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	1200.0	CHEMBL3231	Homo sapiens	Kd	nM	1200.0
	7569386	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7569404	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	470.0	CHEMBL3231	Homo sapiens	Kd	nM	470.0
	7569876	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7570339	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7570766	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	460.0	CHEMBL3231	Homo sapiens	Kd	nM	460.0
	7571377	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	3700.0	CHEMBL3231	Homo sapiens	Kd	nM	3700.0
	7571853	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	60.0	CHEMBL3231	Homo sapiens	Kd	nM	60.0
	7572316	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7572732	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	37.0	CHEMBL3231	Homo sapiens	Kd	nM	37.0
	7572901	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7573358	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7573834	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7574303	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	7800.0	CHEMBL3231	Homo sapiens	Kd	nM	7800.0
	7574711	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7574879	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7575340	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7575811	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7576276	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7576853	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7577312	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7577790	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	300.0	CHEMBL3231	Homo sapiens	Kd	nM	300.0
	7578223	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2100.0	CHEMBL3231	Homo sapiens	Kd	nM	2100.0
	7578861	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	37.0	CHEMBL3231	Homo sapiens	Kd	nM	37.0
	7579235	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7579685	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1200.0	CHEMBL3231	Homo sapiens	Kd	nM	1200.0
	7580186	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7580589	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7581219	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7581604	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7582049	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7582078	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7582542	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7582942	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7583565	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7583962	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7584436	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7584898	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	590.0	CHEMBL3231	Homo sapiens	Kd	nM	590.0
	7585302	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7586307	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7586778	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7587232	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Kd	nM	2100.0	CHEMBL3231	Homo sapiens	Kd	nM	2100.0
	7587414	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7587833	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7588286	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7588757	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7589208	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7589379	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7589803	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	56.0	CHEMBL3231	Homo sapiens	Kd	nM	56.0
	7590270	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7590744	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7591195	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7591352	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7591774	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	760.0	CHEMBL3231	Homo sapiens	Kd	nM	760.0
	7592246	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	=	Kd	nM	4900.0	CHEMBL3231	Homo sapiens	Kd	nM	4900.0
	7592719	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7593319	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	1500.0	CHEMBL3231	Homo sapiens	Kd	nM	1500.0
	7593754	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7594226	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	280.0	CHEMBL3231	Homo sapiens	Kd	nM	280.0
	7594709	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	870.0	CHEMBL3231	Homo sapiens	Kd	nM	870.0
	7595287	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7595731	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7596205	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7596234	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7596681	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7597259	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7597712	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7598213	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3231	Homo sapiens	Kd	nM	10000.0
	7598655	CHEMBL1908712	Binding constant for ROCK1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	0.28	CHEMBL3231	Homo sapiens	Kd	nM	0.28
	7922712	CHEMBL1919207	Inhibition of human recombinant ROCK1 at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	7949120	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922026	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	7949121	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2CCCO)c1		CHEMBL1922027	=	IC50	nM	88.0	CHEMBL3231	Homo sapiens	IC50	nM	88.0
	7949122	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2CCN(C)C)c1		CHEMBL1922028	=	IC50	nM	710.0	CHEMBL3231	Homo sapiens	IC50	nM	710.0
	7949123	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922029	=	IC50	nM	37.0	CHEMBL3231	Homo sapiens	IC50	nM	37.0
	7949124	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2C)c1		CHEMBL1922030	=	IC50	nM	1100.0	CHEMBL3231	Homo sapiens	IC50	nM	1100.0
	7949125	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2CCN(C)C)c1		CHEMBL1922031	=	IC50	nM	6900.0	CHEMBL3231	Homo sapiens	IC50	nM	6900.0
	7949126	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922032	=	IC50	nM	62.0	CHEMBL3231	Homo sapiens	IC50	nM	62.0
	7949127	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCCN(C)C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922033	=	IC50	nM	46.0	CHEMBL3231	Homo sapiens	IC50	nM	46.0
	7949128	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922034	=	IC50	nM	12.0	CHEMBL3231	Homo sapiens	IC50	nM	12.0
	7949129	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1		CHEMBL1922035	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	7949740	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CC2CC2)c1		CHEMBL1922036	=	IC50	nM	280.0	CHEMBL3231	Homo sapiens	IC50	nM	280.0
	7949741	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2Cc2cccc(OC)c2)c1		CHEMBL1922037	>	IC50	nM	20000.0	CHEMBL3231	Homo sapiens	IC50	nM	20000.0
	7949742	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCN(C)C)c1		CHEMBL1922038	=	IC50	nM	243.0	CHEMBL3231	Homo sapiens	IC50	nM	243.0
	7949743	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCCO)c1		CHEMBL1922039	=	IC50	nM	88.0	CHEMBL3231	Homo sapiens	IC50	nM	88.0
	7949744	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CC[N+]2(C)CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1		CHEMBL1922040	=	IC50	nM	6600.0	CHEMBL3231	Homo sapiens	IC50	nM	6600.0
	7949745	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1		CHEMBL1922041	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	nM	1000.0
	7949746	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922042	=	IC50	nM	27.0	CHEMBL3231	Homo sapiens	IC50	nM	27.0
	7949747	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)C2CC2)c1		CHEMBL1922043	=	IC50	nM	33.0	CHEMBL3231	Homo sapiens	IC50	nM	33.0
	7949748	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922044	=	IC50	nM	121.0	CHEMBL3231	Homo sapiens	IC50	nM	121.0
	7949749	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922045	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	7949750	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922046	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	7949751	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922047	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	7949752	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922124	=	IC50	nM	3.0	CHEMBL3231	Homo sapiens	IC50	nM	3.0
	7949753	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cn(-c3ccccc3)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922125	=	IC50	nM	21.0	CHEMBL3231	Homo sapiens	IC50	nM	21.0
	7949754	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCCN(C)C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922126	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	7949755	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCN(C)C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922127	=	IC50	nM	9.0	CHEMBL3231	Homo sapiens	IC50	nM	9.0
	7949756	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cn(CCCO)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922128	=	IC50	nM	3.0	CHEMBL3231	Homo sapiens	IC50	nM	3.0
	7949757	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cn(CCN(C)C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922129	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	nM	5.0
	7949758	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C)C(=O)c2cn(CCN(C)C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922130	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	nM	110.0
	7949759	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCN(C)C)C(=O)c2cn(CCN3CCCC3)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922131	=	IC50	nM	8900.0	CHEMBL3231	Homo sapiens	IC50	nM	8900.0
	7949760	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922132	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
	7949761	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(C(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)C2CC2)c1		CHEMBL1922133	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
	7949762	CHEMBL1924422	Inhibition of ROCK1	B	CCN(Cc1cccc(OC)c1)C(=O)c1c[nH]c2nc(-c3cn[nH]c3)ccc12		CHEMBL1922134	=	IC50	nM	76.0	CHEMBL3231	Homo sapiens	IC50	nM	76.0
	7949763	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CN(CCCN2CCN(C)CC2)C(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922135	=	IC50	nM	260.0	CHEMBL3231	Homo sapiens	IC50	nM	260.0
	7949764	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cn(C)c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922136	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	7949765	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cn(CCN3CCCC3)c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922137	=	IC50	nM	89.0	CHEMBL3231	Homo sapiens	IC50	nM	89.0
	7949766	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN(C)C)c1		CHEMBL1922138	=	IC50	nM	34.0	CHEMBL3231	Homo sapiens	IC50	nM	34.0
	7949767	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCOCC2)c1		CHEMBL1922139	=	IC50	nM	40.0	CHEMBL3231	Homo sapiens	IC50	nM	40.0
	7949768	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCN(C)CC2)c1		CHEMBL1922140	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	7949769	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCCNCC2)c1		CHEMBL1922141	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	7949770	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2[nH]c3nc(-c4cn[nH]c4)ccc3c2CN2CCN(C)CC2)c1		CHEMBL1922142	=	IC50	nM	39.0	CHEMBL3231	Homo sapiens	IC50	nM	39.0
	7949771	CHEMBL1924422	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2[nH]c3nc(-c4cn[nH]c4)ccc3c2CN2CCOCC2)c1		CHEMBL1922143	=	IC50	nM	91.0	CHEMBL3231	Homo sapiens	IC50	nM	91.0
	7956432	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922026	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	7956433	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccncc4)cc3[nH]2)c1		CHEMBL1923052	=	IC50	nM	1900.0	CHEMBL3231	Homo sapiens	IC50	nM	1900.0
	7956434	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccnc(N)n4)cc3[nH]2)c1		CHEMBL1923053	=	IC50	nM	480.0	CHEMBL3231	Homo sapiens	IC50	nM	480.0
	7956435	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccnc(N)c4)cc3[nH]2)c1		CHEMBL1923161	=	IC50	nM	2100.0	CHEMBL3231	Homo sapiens	IC50	nM	2100.0
	7956436	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3cnc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1923162	=	IC50	nM	870.0	CHEMBL3231	Homo sapiens	IC50	nM	870.0
	7956437	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3cnc(-c4cn[nH]c4C)cc3[nH]2)c1		CHEMBL1923163	=	IC50	nM	1200.0	CHEMBL3231	Homo sapiens	IC50	nM	1200.0
	7956438	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3cnc(-c4ccncc4)cc3[nH]2)c1		CHEMBL1923164	=	IC50	nM	1100.0	CHEMBL3231	Homo sapiens	IC50	nM	1100.0
	7956439	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922034	=	IC50	nM	12.0	CHEMBL3231	Homo sapiens	IC50	nM	12.0
	7956440	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4C)nc3[nH]2)c1		CHEMBL1923165	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	7956441	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccncc4)nc3[nH]2)c1		CHEMBL1923166	=	IC50	nM	720.0	CHEMBL3231	Homo sapiens	IC50	nM	720.0
	7956442	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922045	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	7956443	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2c[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL1923167	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
	7956444	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922132	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
	7956445	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2c[nH]c3nc(-c4ccncc4)ccc23)c1		CHEMBL1923168	=	IC50	nM	48.0	CHEMBL3231	Homo sapiens	IC50	nM	48.0
	7956446	CHEMBL1925274	Inhibition of ROCK1	B	COc1ccccc1CNC(=O)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923169	=	IC50	nM	23.0	CHEMBL3231	Homo sapiens	IC50	nM	23.0
	7956447	CHEMBL1925274	Inhibition of ROCK1	B	COc1ccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)cc1		CHEMBL1923170	=	IC50	nM	1900.0	CHEMBL3231	Homo sapiens	IC50	nM	1900.0
	7956448	CHEMBL1925274	Inhibition of ROCK1	B	O=C(NCc1cccc(OC(F)(F)F)c1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923171	=	IC50	nM	760.0	CHEMBL3231	Homo sapiens	IC50	nM	760.0
	7956449	CHEMBL1925274	Inhibition of ROCK1	B	O=C(NCc1ccc(F)c(F)c1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923172	=	IC50	nM	34.0	CHEMBL3231	Homo sapiens	IC50	nM	34.0
	7956450	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc([C@@H](C)NC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923173	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	7956451	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc([C@H](C)NC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923174	=	IC50	nM	500.0	CHEMBL3231	Homo sapiens	IC50	nM	500.0
	7956452	CHEMBL1925274	Inhibition of ROCK1	B	O=C(NCC1CCCCC1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923175	=	IC50	nM	170.0	CHEMBL3231	Homo sapiens	IC50	nM	170.0
	7956453	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CCNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923176	=	IC50	nM	240.0	CHEMBL3231	Homo sapiens	IC50	nM	240.0
	7956454	CHEMBL1925274	Inhibition of ROCK1	B	O=C(NCCc1cccs1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923177	=	IC50	nM	18.0	CHEMBL3231	Homo sapiens	IC50	nM	18.0
	7956455	CHEMBL1925274	Inhibition of ROCK1	B	COc1ccc(OC)c(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923178	=	IC50	nM	1340.0	CHEMBL3231	Homo sapiens	IC50	nM	1340.0
	7956456	CHEMBL1925274	Inhibition of ROCK1	B	COc1ccccc1CNC(=O)c1cc2ccc(-c3cn[nH]c3)nc2[nH]1		CHEMBL1923179	=	IC50	nM	130.0	CHEMBL3231	Homo sapiens	IC50	nM	130.0
	7956457	CHEMBL1925274	Inhibition of ROCK1	B	COc1ccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)cc1		CHEMBL1923180	=	IC50	nM	500.0	CHEMBL3231	Homo sapiens	IC50	nM	500.0
	7956458	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc([C@@H](C)NC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1923181	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	7956459	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc([C@H](C)NC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1923182	=	IC50	nM	560.0	CHEMBL3231	Homo sapiens	IC50	nM	560.0
	7956460	CHEMBL1925274	Inhibition of ROCK1	B	COc1cccc(CNC(=O)c2nc3cc(-c4cc[nH]n4)ccc3s2)c1		CHEMBL1923183	=	IC50	nM	76.0	CHEMBL3231	Homo sapiens	IC50	nM	76.0
	7961147	CHEMBL1931555	Inhibition of ROCK-1	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL3231	Homo sapiens	IC50	uM	30.0
	7961148	CHEMBL1931555	Inhibition of ROCK-1	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL3231	Homo sapiens	IC50	uM	30.0
	7992217	CHEMBL1936089	Inhibition of ROCK1 at 1 uM	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	Inhibition	%	44.0	CHEMBL3231	Homo sapiens	INH	%	44.0
Active	7996852	CHEMBL1941737	Inhibition of ROCK1 at 10 uM by colorimetric analysis	B	Clc1ccc(-n2cc(-c3ccncc3)nn2)cc1		CHEMBL1938953		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Active	7996853	CHEMBL1941737	Inhibition of ROCK1 at 10 uM by colorimetric analysis	B	Clc1cccc(-n2cc(-c3ccncc3)nn2)c1		CHEMBL1938954		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Active	7996854	CHEMBL1941737	Inhibition of ROCK1 at 10 uM by colorimetric analysis	B	Clc1ccc(-n2nncc2-c2ccncc2)cc1		CHEMBL62965		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Active	7996855	CHEMBL1941737	Inhibition of ROCK1 at 10 uM by colorimetric analysis	B	Clc1cccc(-n2nncc2-c2ccncc2)c1		CHEMBL303351		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	8002717	CHEMBL1942290	Inhibition of ROCK1 at 1 uM	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN(C=O)[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940251	=	Inhibition	%	4.0	CHEMBL3231	Homo sapiens	INH	%	4.0
	8002718	CHEMBL1942290	Inhibition of ROCK1 at 1 uM	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccc(F)cc1		CHEMBL1940252	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	INH	%	5.0
	8002719	CHEMBL1942290	Inhibition of ROCK1 at 1 uM	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccccc1		CHEMBL1940253	=	Inhibition	%	-5.0	CHEMBL3231	Homo sapiens	INH	%	-5.0
	8018897	CHEMBL1949061	Inhibition of ROCK1 assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1		CHEMBL1945953	=	Activity	%	96.0	CHEMBL3231	Homo sapiens	Activity	%	96.0
	8018898	CHEMBL1949061	Inhibition of ROCK1 assessed as activity remaining at 10 uM	B	CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1		CHEMBL1945950	=	Activity	%	97.0	CHEMBL3231	Homo sapiens	Activity	%	97.0
	8018899	CHEMBL1949061	Inhibition of ROCK1 assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1		CHEMBL1946262	=	Activity	%	96.0	CHEMBL3231	Homo sapiens	Activity	%	96.0
	8046175	CHEMBL1960389	Inhibition of ROCK1	B	COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1		CHEMBL1957085	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	8047297	CHEMBL1960787	Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	300.0	CHEMBL3231	Homo sapiens	IC50	nM	300.0
	8047298	CHEMBL1960787	Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	IC50	nM	1.6	CHEMBL3231	Homo sapiens	IC50	nM	1.6
	8047299	CHEMBL1960787	Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	5.6	CHEMBL3231	Homo sapiens	IC50	nM	5.6
	8047300	CHEMBL1960787	Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	nM	150.0
	8047362	CHEMBL1960787	Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay	B	CCn1c(-c2nonc2N)nc2cnccc21		CHEMBL189657	<	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	8047363	CHEMBL1960787	Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay	B	CCn1c(-c2nonc2N)nc2cncc(-c3ccc(CN)cc3)c21.Cl		CHEMBL1956072	<	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	8061243	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.61	CHEMBL3231	Homo sapiens	Inhibition	%	-0.61
	8061420	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	5.87	CHEMBL3231	Homo sapiens	Inhibition	%	5.87
	8061644	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	1.25	CHEMBL3231	Homo sapiens	Inhibition	%	1.25
	8061751	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.32	CHEMBL3231	Homo sapiens	Inhibition	%	0.32
	8061942	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.45	CHEMBL3231	Homo sapiens	Inhibition	%	1.45
	8062166	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	5.28	CHEMBL3231	Homo sapiens	Inhibition	%	5.28
	8062282	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	10.83	CHEMBL3231	Homo sapiens	Inhibition	%	10.83
	8062668	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	1.71	CHEMBL3231	Homo sapiens	Inhibition	%	1.71
	8062766	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.28	CHEMBL3231	Homo sapiens	Inhibition	%	1.28
	8062990	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.58	CHEMBL3231	Homo sapiens	Inhibition	%	-0.58
	8063122	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	2.17	CHEMBL3231	Homo sapiens	Inhibition	%	2.17
	8063513	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.16	CHEMBL3231	Homo sapiens	Inhibition	%	0.16
	8063621	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.07	CHEMBL3231	Homo sapiens	Inhibition	%	0.07
	8064027	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	8064142	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	52.44	CHEMBL3231	Homo sapiens	Inhibition	%	52.44
	8064366	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	85.47	CHEMBL3231	Homo sapiens	Inhibition	%	85.47
	8064576	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	1.13	CHEMBL3231	Homo sapiens	Inhibition	%	1.13
	8064714	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.21	CHEMBL3231	Homo sapiens	Inhibition	%	-0.21
	8064938	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	2.03	CHEMBL3231	Homo sapiens	Inhibition	%	2.03
	8065104	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.53	CHEMBL3231	Homo sapiens	Inhibition	%	0.53
	8065220	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.39	CHEMBL3231	Homo sapiens	Inhibition	%	0.39
	8065444	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.54	CHEMBL3231	Homo sapiens	Inhibition	%	2.54
	8065619	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.47	CHEMBL3231	Homo sapiens	Inhibition	%	2.47
	8065958	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	87.14	CHEMBL3231	Homo sapiens	Inhibition	%	87.14
	8066168	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.09	CHEMBL3231	Homo sapiens	Inhibition	%	1.09
	8066528	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.75	CHEMBL3231	Homo sapiens	Inhibition	%	0.75
	8066694	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-0.75	CHEMBL3231	Homo sapiens	Inhibition	%	-0.75
	8067042	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	7.16	CHEMBL3231	Homo sapiens	Inhibition	%	7.16
	8067217	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.44	CHEMBL3231	Homo sapiens	Inhibition	%	0.44
	8067562	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	5.05	CHEMBL3231	Homo sapiens	Inhibition	%	5.05
	8067772	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	11.46	CHEMBL3231	Homo sapiens	Inhibition	%	11.46
	8068131	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	8.16	CHEMBL3231	Homo sapiens	Inhibition	%	8.16
	8068295	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.04	CHEMBL3231	Homo sapiens	Inhibition	%	0.04
	8068644	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.43	CHEMBL3231	Homo sapiens	Inhibition	%	0.43
	8068818	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.05	CHEMBL3231	Homo sapiens	Inhibition	%	2.05
	8069042	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.49	CHEMBL3231	Homo sapiens	Inhibition	%	0.49
	8069167	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	4.95	CHEMBL3231	Homo sapiens	Inhibition	%	4.95
	8069462	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	3.08	CHEMBL3231	Homo sapiens	Inhibition	%	3.08
	8069623	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.71	CHEMBL3231	Homo sapiens	Inhibition	%	0.71
	8069847	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.02	CHEMBL3231	Homo sapiens	Inhibition	%	0.02
	8069973	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.82	CHEMBL3231	Homo sapiens	Inhibition	%	1.82
	8070369	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.63	CHEMBL3231	Homo sapiens	Inhibition	%	0.63
	8070494	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.38	CHEMBL3231	Homo sapiens	Inhibition	%	0.38
	8070718	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.96	CHEMBL3231	Homo sapiens	Inhibition	%	1.96
	8070792	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	25.97	CHEMBL3231	Homo sapiens	Inhibition	%	25.97
	8071173	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.46	CHEMBL3231	Homo sapiens	Inhibition	%	0.46
	8071299	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.48	CHEMBL3231	Homo sapiens	Inhibition	%	0.48
	8071523	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.22	CHEMBL3231	Homo sapiens	Inhibition	%	-0.22
	8071696	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.16	CHEMBL3231	Homo sapiens	Inhibition	%	0.16
	8072045	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	0.74	CHEMBL3231	Homo sapiens	Inhibition	%	0.74
	8072135	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.55	CHEMBL3231	Homo sapiens	Inhibition	%	-0.55
	8072359	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.94	CHEMBL3231	Homo sapiens	Inhibition	%	0.94
	8072516	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	2.24	CHEMBL3231	Homo sapiens	Inhibition	%	2.24
	8072865	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.15	CHEMBL3231	Homo sapiens	Inhibition	%	-0.15
	8073032	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.97	CHEMBL3231	Homo sapiens	Inhibition	%	0.97
	8073381	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.94	CHEMBL3231	Homo sapiens	Inhibition	%	1.94
	8073500	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.97	CHEMBL3231	Homo sapiens	Inhibition	%	0.97
	8073724	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	2.75	CHEMBL3231	Homo sapiens	Inhibition	%	2.75
	8073957	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	0.15	CHEMBL3231	Homo sapiens	Inhibition	%	0.15
	8074109	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	6.47	CHEMBL3231	Homo sapiens	Inhibition	%	6.47
	8074463	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.34	CHEMBL3231	Homo sapiens	Inhibition	%	0.34
	8074620	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.15	CHEMBL3231	Homo sapiens	Inhibition	%	0.15
	8074844	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.73	CHEMBL3231	Homo sapiens	Inhibition	%	1.73
	8074971	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.12	CHEMBL3231	Homo sapiens	Inhibition	%	0.12
	8075306	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	1.06	CHEMBL3231	Homo sapiens	Inhibition	%	1.06
	8075543	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	0.94	CHEMBL3231	Homo sapiens	Inhibition	%	0.94
	8075684	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	-0.01	CHEMBL3231	Homo sapiens	Inhibition	%	-0.01
	8075908	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.78	CHEMBL3231	Homo sapiens	Inhibition	%	0.78
	8076050	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.72	CHEMBL3231	Homo sapiens	Inhibition	%	0.72
	8076422	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.26	CHEMBL3231	Homo sapiens	Inhibition	%	0.26
	8076556	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.37	CHEMBL3231	Homo sapiens	Inhibition	%	0.37
	8076882	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.82	CHEMBL3231	Homo sapiens	Inhibition	%	-0.82
	8077129	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	9.16	CHEMBL3231	Homo sapiens	Inhibition	%	9.16
	8077481	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.21	CHEMBL3231	Homo sapiens	Inhibition	%	-0.21
	8077632	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.18	CHEMBL3231	Homo sapiens	Inhibition	%	0.18
	8077999	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.3	CHEMBL3231	Homo sapiens	Inhibition	%	0.3
	8078138	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-0.2	CHEMBL3231	Homo sapiens	Inhibition	%	-0.2
	8078362	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	1.73	CHEMBL3231	Homo sapiens	Inhibition	%	1.73
	8078464	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.17	CHEMBL3231	Homo sapiens	Inhibition	%	0.17
	8078714	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	51.72	CHEMBL3231	Homo sapiens	Inhibition	%	51.72
	8079054	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.62	CHEMBL3231	Homo sapiens	Inhibition	%	0.62
	8079212	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	0.14	CHEMBL3231	Homo sapiens	Inhibition	%	0.14
	8079436	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	1.42	CHEMBL3231	Homo sapiens	Inhibition	%	1.42
	8079578	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	-0.61	CHEMBL3231	Homo sapiens	Inhibition	%	-0.61
	8079941	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	17.16	CHEMBL3231	Homo sapiens	Inhibition	%	17.16
	8080046	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.82	CHEMBL3231	Homo sapiens	Inhibition	%	0.82
	8080270	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.21	CHEMBL3231	Homo sapiens	Inhibition	%	0.21
	8080298	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	4.52	CHEMBL3231	Homo sapiens	Inhibition	%	4.52
	8080522	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	30.24	CHEMBL3231	Homo sapiens	Inhibition	%	30.24
	8080637	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-0.05	CHEMBL3231	Homo sapiens	Inhibition	%	-0.05
	8081025	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.99	CHEMBL3231	Homo sapiens	Inhibition	%	-0.99
	8081160	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.51	CHEMBL3231	Homo sapiens	Inhibition	%	1.51
	8081528	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	64.64	CHEMBL3231	Homo sapiens	Inhibition	%	64.64
	8081855	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.49	CHEMBL3231	Homo sapiens	Inhibition	%	0.49
	8082107	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	31.01	CHEMBL3231	Homo sapiens	Inhibition	%	31.01
	8082220	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-0.47	CHEMBL3231	Homo sapiens	Inhibition	%	-0.47
	8082444	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	-0.08	CHEMBL3231	Homo sapiens	Inhibition	%	-0.08
	8082617	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.03	CHEMBL3231	Homo sapiens	Inhibition	%	0.03
	8082740	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.21	CHEMBL3231	Homo sapiens	Inhibition	%	1.21
	8082964	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.32	CHEMBL3231	Homo sapiens	Inhibition	%	1.32
	8083120	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	2.63	CHEMBL3231	Homo sapiens	Inhibition	%	2.63
	8083443	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.24	CHEMBL3231	Homo sapiens	Inhibition	%	0.24
	8083697	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	78.44	CHEMBL3231	Homo sapiens	Inhibition	%	78.44
	8084031	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	1.34	CHEMBL3231	Homo sapiens	Inhibition	%	1.34
	8084216	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	7.13	CHEMBL3231	Homo sapiens	Inhibition	%	7.13
	8084558	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.25	CHEMBL3231	Homo sapiens	Inhibition	%	0.25
	8084719	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	8.77	CHEMBL3231	Homo sapiens	Inhibition	%	8.77
	8085041	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.09	CHEMBL3231	Homo sapiens	Inhibition	%	0.09
	8085297	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	1.47	CHEMBL3231	Homo sapiens	Inhibition	%	1.47
	8085629	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	-0.46	CHEMBL3231	Homo sapiens	Inhibition	%	-0.46
	8085818	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	38.42	CHEMBL3231	Homo sapiens	Inhibition	%	38.42
	8086157	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.38	CHEMBL3231	Homo sapiens	Inhibition	%	2.38
	8086319	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	1.28	CHEMBL3231	Homo sapiens	Inhibition	%	1.28
	8086543	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	2.13	CHEMBL3231	Homo sapiens	Inhibition	%	2.13
	8086642	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.94	CHEMBL3231	Homo sapiens	Inhibition	%	1.94
	8087077	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.88	CHEMBL3231	Homo sapiens	Inhibition	%	1.88
	8087235	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.95	CHEMBL3231	Homo sapiens	Inhibition	%	2.95
	8087573	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	2.99	CHEMBL3231	Homo sapiens	Inhibition	%	2.99
	8087711	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	Inhibition	%	2.0
	8087935	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.65	CHEMBL3231	Homo sapiens	Inhibition	%	0.65
	8088077	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.23	CHEMBL3231	Homo sapiens	Inhibition	%	3.23
	8088225	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.5	CHEMBL3231	Homo sapiens	Inhibition	%	1.5
	8088449	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.71	CHEMBL3231	Homo sapiens	Inhibition	%	1.71
	8088577	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	2.15	CHEMBL3231	Homo sapiens	Inhibition	%	2.15
	8088894	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	36.61	CHEMBL3231	Homo sapiens	Inhibition	%	36.61
	8089246	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	8.85	CHEMBL3231	Homo sapiens	Inhibition	%	8.85
	8089394	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	1.3	CHEMBL3231	Homo sapiens	Inhibition	%	1.3
	8089738	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	-0.11	CHEMBL3231	Homo sapiens	Inhibition	%	-0.11
	8089918	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.27	CHEMBL3231	Homo sapiens	Inhibition	%	-0.27
	8090307	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.34	CHEMBL3231	Homo sapiens	Inhibition	%	0.34
	8090474	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.46	CHEMBL3231	Homo sapiens	Inhibition	%	0.46
	8090837	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	-0.35	CHEMBL3231	Homo sapiens	Inhibition	%	-0.35
	8091042	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.22	CHEMBL3231	Homo sapiens	Inhibition	%	1.22
	8091403	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	2.33	CHEMBL3231	Homo sapiens	Inhibition	%	2.33
	8091558	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	4.2	CHEMBL3231	Homo sapiens	Inhibition	%	4.2
	8091782	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.33	CHEMBL3231	Homo sapiens	Inhibition	%	2.33
	8091898	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.7	CHEMBL3231	Homo sapiens	Inhibition	%	3.7
	8092259	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.62	CHEMBL3231	Homo sapiens	Inhibition	%	1.62
	8092410	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	3.25	CHEMBL3231	Homo sapiens	Inhibition	%	3.25
	8092782	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.73	CHEMBL3231	Homo sapiens	Inhibition	%	1.73
	8092911	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	3.27	CHEMBL3231	Homo sapiens	Inhibition	%	3.27
	8093135	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.76	CHEMBL3231	Homo sapiens	Inhibition	%	1.76
	8093223	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.15	CHEMBL3231	Homo sapiens	Inhibition	%	0.15
	8093587	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	5.46	CHEMBL3231	Homo sapiens	Inhibition	%	5.46
	8093726	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	10.07	CHEMBL3231	Homo sapiens	Inhibition	%	10.07
	8093950	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.24	CHEMBL3231	Homo sapiens	Inhibition	%	0.24
	8094070	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	-0.3	CHEMBL3231	Homo sapiens	Inhibition	%	-0.3
	8094250	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.84	CHEMBL3231	Homo sapiens	Inhibition	%	0.84
	8094474	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.58	CHEMBL3231	Homo sapiens	Inhibition	%	1.58
	8094649	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	1.79	CHEMBL3231	Homo sapiens	Inhibition	%	1.79
	8094805	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.26	CHEMBL3231	Homo sapiens	Inhibition	%	0.26
	8095029	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	0.65	CHEMBL3231	Homo sapiens	Inhibition	%	0.65
	8095169	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	1.61	CHEMBL3231	Homo sapiens	Inhibition	%	1.61
	8095372	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.69	CHEMBL3231	Homo sapiens	Inhibition	%	1.69
	8095596	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.62	CHEMBL3231	Homo sapiens	Inhibition	%	0.62
	8095737	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	8.96	CHEMBL3231	Homo sapiens	Inhibition	%	8.96
	8096109	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	6.38	CHEMBL3231	Homo sapiens	Inhibition	%	6.38
	8096226	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.56	CHEMBL3231	Homo sapiens	Inhibition	%	2.56
	8096589	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.9	CHEMBL3231	Homo sapiens	Inhibition	%	0.9
	8096745	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	4.5	CHEMBL3231	Homo sapiens	Inhibition	%	4.5
	8096969	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.65	CHEMBL3231	Homo sapiens	Inhibition	%	2.65
	8097116	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	2.28	CHEMBL3231	Homo sapiens	Inhibition	%	2.28
	8097423	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.58	CHEMBL3231	Homo sapiens	Inhibition	%	2.58
	8097647	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.94	CHEMBL3231	Homo sapiens	Inhibition	%	1.94
	8097797	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	37.02	CHEMBL3231	Homo sapiens	Inhibition	%	37.02
	8098154	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	1.55	CHEMBL3231	Homo sapiens	Inhibition	%	1.55
	8098274	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.06	CHEMBL3231	Homo sapiens	Inhibition	%	-0.06
	8098498	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.3	CHEMBL3231	Homo sapiens	Inhibition	%	-0.3
	8098678	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.21	CHEMBL3231	Homo sapiens	Inhibition	%	0.21
	8098863	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	23.48	CHEMBL3231	Homo sapiens	Inhibition	%	23.48
	8099231	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.33	CHEMBL3231	Homo sapiens	Inhibition	%	1.33
	8099373	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.94	CHEMBL3231	Homo sapiens	Inhibition	%	0.94
	8099791	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.26	CHEMBL3231	Homo sapiens	Inhibition	%	0.26
	8099938	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	3.27	CHEMBL3231	Homo sapiens	Inhibition	%	3.27
	8100308	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	6.06	CHEMBL3231	Homo sapiens	Inhibition	%	6.06
	8100424	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.13	CHEMBL3231	Homo sapiens	Inhibition	%	3.13
	8100648	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.51	CHEMBL3231	Homo sapiens	Inhibition	%	2.51
	8100788	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.73	CHEMBL3231	Homo sapiens	Inhibition	%	1.73
	8101172	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	4.76	CHEMBL3231	Homo sapiens	Inhibition	%	4.76
	8101314	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.49	CHEMBL3231	Homo sapiens	Inhibition	%	0.49
	8101723	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.68	CHEMBL3231	Homo sapiens	Inhibition	%	2.68
	8101976	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	7.68	CHEMBL3231	Homo sapiens	Inhibition	%	7.68
	8102131	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	0.94	CHEMBL3231	Homo sapiens	Inhibition	%	0.94
	8102486	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.86	CHEMBL3231	Homo sapiens	Inhibition	%	0.86
	8102830	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-1.8	CHEMBL3231	Homo sapiens	Inhibition	%	-1.8
	8103008	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-0.24	CHEMBL3231	Homo sapiens	Inhibition	%	-0.24
	8103204	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	2.85	CHEMBL3231	Homo sapiens	Inhibition	%	2.85
	8103428	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	24.74	CHEMBL3231	Homo sapiens	Inhibition	%	24.74
	8103566	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.28	CHEMBL3231	Homo sapiens	Inhibition	%	0.28
	8103716	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.18	CHEMBL3231	Homo sapiens	Inhibition	%	2.18
	8103940	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.61	CHEMBL3231	Homo sapiens	Inhibition	%	0.61
	8104125	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.69	CHEMBL3231	Homo sapiens	Inhibition	%	0.69
	8104273	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	4.15	CHEMBL3231	Homo sapiens	Inhibition	%	4.15
	8104497	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	2.64	CHEMBL3231	Homo sapiens	Inhibition	%	2.64
	8104643	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	37.6	CHEMBL3231	Homo sapiens	Inhibition	%	37.6
	8104981	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	4.31	CHEMBL3231	Homo sapiens	Inhibition	%	4.31
	8105121	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.45	CHEMBL3231	Homo sapiens	Inhibition	%	1.45
	8105345	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	2.5	CHEMBL3231	Homo sapiens	Inhibition	%	2.5
	8105511	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	1.76	CHEMBL3231	Homo sapiens	Inhibition	%	1.76
	8105649	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	1.85	CHEMBL3231	Homo sapiens	Inhibition	%	1.85
	8105873	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.5	CHEMBL3231	Homo sapiens	Inhibition	%	2.5
	8105929	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.07	CHEMBL3231	Homo sapiens	Inhibition	%	1.07
	8106153	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.67	CHEMBL3231	Homo sapiens	Inhibition	%	0.67
	8106318	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.76	CHEMBL3231	Homo sapiens	Inhibition	%	0.76
	8106474	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	7.57	CHEMBL3231	Homo sapiens	Inhibition	%	7.57
	8106698	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	7.73	CHEMBL3231	Homo sapiens	Inhibition	%	7.73
	8106827	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.02	CHEMBL3231	Homo sapiens	Inhibition	%	2.02
	8107172	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-1.44	CHEMBL3231	Homo sapiens	Inhibition	%	-1.44
	8107344	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.41	CHEMBL3231	Homo sapiens	Inhibition	%	0.41
	8107769	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	1.64	CHEMBL3231	Homo sapiens	Inhibition	%	1.64
	8107904	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.46	CHEMBL3231	Homo sapiens	Inhibition	%	0.46
	8108286	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.26	CHEMBL3231	Homo sapiens	Inhibition	%	0.26
	8108461	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	6.4	CHEMBL3231	Homo sapiens	Inhibition	%	6.4
	8108832	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	7.23	CHEMBL3231	Homo sapiens	Inhibition	%	7.23
	8108974	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.34	CHEMBL3231	Homo sapiens	Inhibition	%	1.34
	8109312	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.8	CHEMBL3231	Homo sapiens	Inhibition	%	1.8
	8109666	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	0.32	CHEMBL3231	Homo sapiens	Inhibition	%	0.32
	8109837	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	5.39	CHEMBL3231	Homo sapiens	Inhibition	%	5.39
	8110193	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.6	CHEMBL3231	Homo sapiens	Inhibition	%	2.6
	8110472	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.64	CHEMBL3231	Homo sapiens	Inhibition	%	1.64
	8110638	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.8	CHEMBL3231	Homo sapiens	Inhibition	%	1.8
	8111020	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	48.73	CHEMBL3231	Homo sapiens	Inhibition	%	48.73
	8111143	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	12.11	CHEMBL3231	Homo sapiens	Inhibition	%	12.11
	8111367	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	18.3	CHEMBL3231	Homo sapiens	Inhibition	%	18.3
	8111494	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	1.1	CHEMBL3231	Homo sapiens	Inhibition	%	1.1
	8111660	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.79	CHEMBL3231	Homo sapiens	Inhibition	%	0.79
	8111884	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.33	CHEMBL3231	Homo sapiens	Inhibition	%	0.33
	8112089	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	4.38	CHEMBL3231	Homo sapiens	Inhibition	%	4.38
	8112226	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-1.53	CHEMBL3231	Homo sapiens	Inhibition	%	-1.53
	8112450	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-1.87	CHEMBL3231	Homo sapiens	Inhibition	%	-1.87
	8112618	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.03	CHEMBL3231	Homo sapiens	Inhibition	%	1.03
	8112790	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-1.21	CHEMBL3231	Homo sapiens	Inhibition	%	-1.21
	8113014	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.69	CHEMBL3231	Homo sapiens	Inhibition	%	-0.69
	8113166	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.08	CHEMBL3231	Homo sapiens	Inhibition	%	3.08
	8113302	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	3.68	CHEMBL3231	Homo sapiens	Inhibition	%	3.68
	8113526	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.32	CHEMBL3231	Homo sapiens	Inhibition	%	1.32
	8113650	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.68	CHEMBL3231	Homo sapiens	Inhibition	%	4.68
	8113990	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	0.72	CHEMBL3231	Homo sapiens	Inhibition	%	0.72
	8114166	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	2.09	CHEMBL3231	Homo sapiens	Inhibition	%	2.09
	8114522	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.54	CHEMBL3231	Homo sapiens	Inhibition	%	2.54
	8114798	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.55	CHEMBL3231	Homo sapiens	Inhibition	%	1.55
	8114964	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.07	CHEMBL3231	Homo sapiens	Inhibition	%	1.07
	8115188	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	10.2	CHEMBL3231	Homo sapiens	Inhibition	%	10.2
	8115353	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	1.28	CHEMBL3231	Homo sapiens	Inhibition	%	1.28
	8115697	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.23	CHEMBL3231	Homo sapiens	Inhibition	%	1.23
	8115830	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	12.39	CHEMBL3231	Homo sapiens	Inhibition	%	12.39
	8116213	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	5.01	CHEMBL3231	Homo sapiens	Inhibition	%	5.01
	8116416	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	3.14	CHEMBL3231	Homo sapiens	Inhibition	%	3.14
	8116774	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.01	CHEMBL3231	Homo sapiens	Inhibition	%	-1.01
	8116946	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.47	CHEMBL3231	Homo sapiens	Inhibition	%	1.47
	8117341	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.65	CHEMBL3231	Homo sapiens	Inhibition	%	0.65
	8117499	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	4.86	CHEMBL3231	Homo sapiens	Inhibition	%	4.86
	8117853	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	3.86	CHEMBL3231	Homo sapiens	Inhibition	%	3.86
	8117991	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	1.38	CHEMBL3231	Homo sapiens	Inhibition	%	1.38
	8118215	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	6.19	CHEMBL3231	Homo sapiens	Inhibition	%	6.19
	8118331	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.98	CHEMBL3231	Homo sapiens	Inhibition	%	2.98
	8118503	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.01	CHEMBL3231	Homo sapiens	Inhibition	%	3.01
	8118727	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	3.18	CHEMBL3231	Homo sapiens	Inhibition	%	3.18
	8118863	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.72	CHEMBL3231	Homo sapiens	Inhibition	%	2.72
	8119134	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.5	CHEMBL3231	Homo sapiens	Inhibition	%	0.5
	8119517	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	0.41	CHEMBL3231	Homo sapiens	Inhibition	%	0.41
	8119684	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	1.22	CHEMBL3231	Homo sapiens	Inhibition	%	1.22
	8120027	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.92	CHEMBL3231	Homo sapiens	Inhibition	%	2.92
	8120166	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.76	CHEMBL3231	Homo sapiens	Inhibition	%	0.76
	8120390	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.22	CHEMBL3231	Homo sapiens	Inhibition	%	1.22
	8120550	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-2.14	CHEMBL3231	Homo sapiens	Inhibition	%	-2.14
	8120751	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	24.31	CHEMBL3231	Homo sapiens	Inhibition	%	24.31
	8121103	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.28	CHEMBL3231	Homo sapiens	Inhibition	%	-1.28
	8121275	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	2.02	CHEMBL3231	Homo sapiens	Inhibition	%	2.02
	8121666	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	1.51	CHEMBL3231	Homo sapiens	Inhibition	%	1.51
	8121829	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	2.06	CHEMBL3231	Homo sapiens	Inhibition	%	2.06
	8122174	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.31	CHEMBL3231	Homo sapiens	Inhibition	%	0.31
	8122536	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	6.26	CHEMBL3231	Homo sapiens	Inhibition	%	6.26
	8122656	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.19	CHEMBL3231	Homo sapiens	Inhibition	%	3.19
	8123047	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	4.1	CHEMBL3231	Homo sapiens	Inhibition	%	4.1
	8123189	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	1.68	CHEMBL3231	Homo sapiens	Inhibition	%	1.68
	8123413	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	4.31	CHEMBL3231	Homo sapiens	Inhibition	%	4.31
	8123467	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	11.41	CHEMBL3231	Homo sapiens	Inhibition	%	11.41
	8123841	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	3.41	CHEMBL3231	Homo sapiens	Inhibition	%	3.41
	8124008	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.59	CHEMBL3231	Homo sapiens	Inhibition	%	0.59
	8124232	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	1.07	CHEMBL3231	Homo sapiens	Inhibition	%	1.07
	8124351	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	-0.95	CHEMBL3231	Homo sapiens	Inhibition	%	-0.95
	8124714	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.34	CHEMBL3231	Homo sapiens	Inhibition	%	0.34
	8124879	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-2.07	CHEMBL3231	Homo sapiens	Inhibition	%	-2.07
	8125080	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	1.24	CHEMBL3231	Homo sapiens	Inhibition	%	1.24
	8125304	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.4	CHEMBL3231	Homo sapiens	Inhibition	%	3.4
	8125434	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.21	CHEMBL3231	Homo sapiens	Inhibition	%	-0.21
	8125602	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.88	CHEMBL3231	Homo sapiens	Inhibition	%	1.88
	8125826	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-0.46	CHEMBL3231	Homo sapiens	Inhibition	%	-0.46
	8125990	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.76	CHEMBL3231	Homo sapiens	Inhibition	%	-0.76
	8126154	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	3.15	CHEMBL3231	Homo sapiens	Inhibition	%	3.15
	8126378	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	2.36	CHEMBL3231	Homo sapiens	Inhibition	%	2.36
	8126493	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	6.77	CHEMBL3231	Homo sapiens	Inhibition	%	6.77
	8126853	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	32.98	CHEMBL3231	Homo sapiens	Inhibition	%	32.98
	8126975	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.39	CHEMBL3231	Homo sapiens	Inhibition	%	2.39
	8127199	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.68	CHEMBL3231	Homo sapiens	Inhibition	%	1.68
	8127366	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.49	CHEMBL3231	Homo sapiens	Inhibition	%	2.49
	8127732	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	4.04	CHEMBL3231	Homo sapiens	Inhibition	%	4.04
	8127796	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.05	CHEMBL3231	Homo sapiens	Inhibition	%	1.05
	8128020	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.17	CHEMBL3231	Homo sapiens	Inhibition	%	1.17
	8128172	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.55	CHEMBL3231	Homo sapiens	Inhibition	%	0.55
	8128563	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.5	CHEMBL3231	Homo sapiens	Inhibition	%	0.5
	8128682	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	6.3	CHEMBL3231	Homo sapiens	Inhibition	%	6.3
	8129043	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-0.21	CHEMBL3231	Homo sapiens	Inhibition	%	-0.21
	8129214	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.57	CHEMBL3231	Homo sapiens	Inhibition	%	-1.57
	8129627	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.82	CHEMBL3231	Homo sapiens	Inhibition	%	2.82
	8129766	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.3	CHEMBL3231	Homo sapiens	Inhibition	%	1.3
	8130151	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-0.11	CHEMBL3231	Homo sapiens	Inhibition	%	-0.11
	8130323	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.9	CHEMBL3231	Homo sapiens	Inhibition	%	-0.9
	8130707	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	9.36	CHEMBL3231	Homo sapiens	Inhibition	%	9.36
	8130823	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.48	CHEMBL3231	Homo sapiens	Inhibition	%	2.48
	8131047	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.26	CHEMBL3231	Homo sapiens	Inhibition	%	3.26
	8131186	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	2.78	CHEMBL3231	Homo sapiens	Inhibition	%	2.78
	8131530	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	1.58	CHEMBL3231	Homo sapiens	Inhibition	%	1.58
	8131697	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.95	CHEMBL3231	Homo sapiens	Inhibition	%	2.95
	8132062	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	18.97	CHEMBL3231	Homo sapiens	Inhibition	%	18.97
	8132348	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.77	CHEMBL3231	Homo sapiens	Inhibition	%	0.77
	8132495	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.38	CHEMBL3231	Homo sapiens	Inhibition	%	1.38
	8132887	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	1.5	CHEMBL3231	Homo sapiens	Inhibition	%	1.5
	8133008	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.21	CHEMBL3231	Homo sapiens	Inhibition	%	0.21
	8133232	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	1.31	CHEMBL3231	Homo sapiens	Inhibition	%	1.31
	8133370	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.26	CHEMBL3231	Homo sapiens	Inhibition	%	0.26
	8133542	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.5	CHEMBL3231	Homo sapiens	Inhibition	%	-1.5
	8133766	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.67	CHEMBL3231	Homo sapiens	Inhibition	%	-0.67
	8133946	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	18.73	CHEMBL3231	Homo sapiens	Inhibition	%	18.73
	8134094	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.42	CHEMBL3231	Homo sapiens	Inhibition	%	-0.42
	8134318	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.74	CHEMBL3231	Homo sapiens	Inhibition	%	1.74
	8134478	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	Inhibition	%	0.0
	8134662	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.53	CHEMBL3231	Homo sapiens	Inhibition	%	-0.53
	8134886	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	1.4	CHEMBL3231	Homo sapiens	Inhibition	%	1.4
	8135046	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.04	CHEMBL3231	Homo sapiens	Inhibition	%	2.04
	8135385	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	10.27	CHEMBL3231	Homo sapiens	Inhibition	%	10.27
	8135526	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	6.23	CHEMBL3231	Homo sapiens	Inhibition	%	6.23
	8135871	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	1.58	CHEMBL3231	Homo sapiens	Inhibition	%	1.58
	8136039	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	2.52	CHEMBL3231	Homo sapiens	Inhibition	%	2.52
	8136263	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.6	CHEMBL3231	Homo sapiens	Inhibition	%	3.6
	8136407	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.94	CHEMBL3231	Homo sapiens	Inhibition	%	2.94
	8136697	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.48	CHEMBL3231	Homo sapiens	Inhibition	%	1.48
	8136832	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	68.56	CHEMBL3231	Homo sapiens	Inhibition	%	68.56
	8137056	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	91.85	CHEMBL3231	Homo sapiens	Inhibition	%	91.85
	8137219	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	2.35	CHEMBL3231	Homo sapiens	Inhibition	%	2.35
	8137563	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-0.35	CHEMBL3231	Homo sapiens	Inhibition	%	-0.35
	8137711	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.43	CHEMBL3231	Homo sapiens	Inhibition	%	0.43
	8138101	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.92	CHEMBL3231	Homo sapiens	Inhibition	%	0.92
	8138280	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.53	CHEMBL3231	Homo sapiens	Inhibition	%	-0.53
	8138652	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.38	CHEMBL3231	Homo sapiens	Inhibition	%	-1.38
	8138810	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-0.4	CHEMBL3231	Homo sapiens	Inhibition	%	-0.4
	8139219	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.76	CHEMBL3231	Homo sapiens	Inhibition	%	2.76
	8139378	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.97	CHEMBL3231	Homo sapiens	Inhibition	%	2.97
	8139716	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.14	CHEMBL3231	Homo sapiens	Inhibition	%	2.14
	8139857	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.1	CHEMBL3231	Homo sapiens	Inhibition	%	2.1
	8140081	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	4.37	CHEMBL3231	Homo sapiens	Inhibition	%	4.37
	8140204	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.05	CHEMBL3231	Homo sapiens	Inhibition	%	2.05
	8140587	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.6	CHEMBL3231	Homo sapiens	Inhibition	%	1.6
	8140730	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	5.2	CHEMBL3231	Homo sapiens	Inhibition	%	5.2
	8141032	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.33	CHEMBL3231	Homo sapiens	Inhibition	%	0.33
	8141386	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.29	CHEMBL3231	Homo sapiens	Inhibition	%	1.29
	8141546	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	13.68	CHEMBL3231	Homo sapiens	Inhibition	%	13.68
	8141889	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.33	CHEMBL3231	Homo sapiens	Inhibition	%	0.33
	8142050	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.43	CHEMBL3231	Homo sapiens	Inhibition	%	0.43
	8142274	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.84	CHEMBL3231	Homo sapiens	Inhibition	%	0.84
	8142442	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	0.29	CHEMBL3231	Homo sapiens	Inhibition	%	0.29
	8142618	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.55	CHEMBL3231	Homo sapiens	Inhibition	%	-0.55
	8142842	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	-0.29	CHEMBL3231	Homo sapiens	Inhibition	%	-0.29
	8142991	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.1	CHEMBL3231	Homo sapiens	Inhibition	%	-0.1
	8143146	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.74	CHEMBL3231	Homo sapiens	Inhibition	%	0.74
	8143370	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.72	CHEMBL3231	Homo sapiens	Inhibition	%	2.72
	8143557	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.32	CHEMBL3231	Homo sapiens	Inhibition	%	2.32
	8143716	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.08	CHEMBL3231	Homo sapiens	Inhibition	%	3.08
	8143940	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.58	CHEMBL3231	Homo sapiens	Inhibition	%	3.58
	8144054	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.36	CHEMBL3231	Homo sapiens	Inhibition	%	1.36
	8144417	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.14	CHEMBL3231	Homo sapiens	Inhibition	%	2.14
	8144547	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.08	CHEMBL3231	Homo sapiens	Inhibition	%	2.08
	8144771	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	2.81	CHEMBL3231	Homo sapiens	Inhibition	%	2.81
	8144924	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.95	CHEMBL3231	Homo sapiens	Inhibition	%	1.95
	8145061	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.37	CHEMBL3231	Homo sapiens	Inhibition	%	2.37
	8145285	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.67	CHEMBL3231	Homo sapiens	Inhibition	%	3.67
	8145374	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.14	CHEMBL3231	Homo sapiens	Inhibition	%	1.14
	8145722	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	3.74	CHEMBL3231	Homo sapiens	Inhibition	%	3.74
	8145883	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	0.85	CHEMBL3231	Homo sapiens	Inhibition	%	0.85
	8146107	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	2.01	CHEMBL3231	Homo sapiens	Inhibition	%	2.01
	8146227	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.63	CHEMBL3231	Homo sapiens	Inhibition	%	-0.63
	8146611	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	5.03	CHEMBL3231	Homo sapiens	Inhibition	%	5.03
	8146778	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	12.0	CHEMBL3231	Homo sapiens	Inhibition	%	12.0
	8147171	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	-0.83	CHEMBL3231	Homo sapiens	Inhibition	%	-0.83
	8147313	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.77	CHEMBL3231	Homo sapiens	Inhibition	%	0.77
	8147690	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.25	CHEMBL3231	Homo sapiens	Inhibition	%	0.25
	8147877	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	2.01	CHEMBL3231	Homo sapiens	Inhibition	%	2.01
	8148259	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	1.88	CHEMBL3231	Homo sapiens	Inhibition	%	1.88
	8148373	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	2.16	CHEMBL3231	Homo sapiens	Inhibition	%	2.16
	8148597	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.77	CHEMBL3231	Homo sapiens	Inhibition	%	1.77
	8148736	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	4.05	CHEMBL3231	Homo sapiens	Inhibition	%	4.05
	8149098	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.99	CHEMBL3231	Homo sapiens	Inhibition	%	3.99
	8149257	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.99	CHEMBL3231	Homo sapiens	Inhibition	%	0.99
	8149615	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	71.8	CHEMBL3231	Homo sapiens	Inhibition	%	71.8
	8149713	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.86	CHEMBL3231	Homo sapiens	Inhibition	%	0.86
	8149937	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	4.25	CHEMBL3231	Homo sapiens	Inhibition	%	4.25
	8150062	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	3.36	CHEMBL3231	Homo sapiens	Inhibition	%	3.36
	8150446	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-1.85	CHEMBL3231	Homo sapiens	Inhibition	%	-1.85
	8150566	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.72	CHEMBL3231	Homo sapiens	Inhibition	%	-0.72
	8150790	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.95	CHEMBL3231	Homo sapiens	Inhibition	%	-0.95
	8150955	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	26.13	CHEMBL3231	Homo sapiens	Inhibition	%	26.13
	8151118	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.64	CHEMBL3231	Homo sapiens	Inhibition	%	-0.64
	8151342	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	6.16	CHEMBL3231	Homo sapiens	Inhibition	%	6.16
	8151519	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.66	CHEMBL3231	Homo sapiens	Inhibition	%	0.66
	8151657	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.48	CHEMBL3231	Homo sapiens	Inhibition	%	0.48
	8151881	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	-1.15	CHEMBL3231	Homo sapiens	Inhibition	%	-1.15
	8152035	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.6	CHEMBL3231	Homo sapiens	Inhibition	%	0.6
	8152223	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.74	CHEMBL3231	Homo sapiens	Inhibition	%	1.74
	8152447	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.46	CHEMBL3231	Homo sapiens	Inhibition	%	1.46
	8152605	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.73	CHEMBL3231	Homo sapiens	Inhibition	%	2.73
	8152943	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.51	CHEMBL3231	Homo sapiens	Inhibition	%	2.51
	8153082	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.65	CHEMBL3231	Homo sapiens	Inhibition	%	1.65
	8153443	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.34	CHEMBL3231	Homo sapiens	Inhibition	%	2.34
	8153600	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.43	CHEMBL3231	Homo sapiens	Inhibition	%	1.43
	8153957	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	91.58	CHEMBL3231	Homo sapiens	Inhibition	%	91.58
	8154278	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	6.65	CHEMBL3231	Homo sapiens	Inhibition	%	6.65
	8154404	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	26.51	CHEMBL3231	Homo sapiens	Inhibition	%	26.51
	8154628	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.94	CHEMBL3231	Homo sapiens	Inhibition	%	0.94
	8154787	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.1	CHEMBL3231	Homo sapiens	Inhibition	%	-0.1
	8155131	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-1.2	CHEMBL3231	Homo sapiens	Inhibition	%	-1.2
	8155307	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.4	CHEMBL3231	Homo sapiens	Inhibition	%	-0.4
	8155692	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.72	CHEMBL3231	Homo sapiens	Inhibition	%	0.72
	8155870	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	1.83	CHEMBL3231	Homo sapiens	Inhibition	%	1.83
	8156232	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	-1.0	CHEMBL3231	Homo sapiens	Inhibition	%	-1.0
	8156444	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.09	CHEMBL3231	Homo sapiens	Inhibition	%	1.09
	8156594	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	2.14	CHEMBL3231	Homo sapiens	Inhibition	%	2.14
	8156818	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.51	CHEMBL3231	Homo sapiens	Inhibition	%	1.51
	8156961	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.68	CHEMBL3231	Homo sapiens	Inhibition	%	2.68
	8157305	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	89.83	CHEMBL3231	Homo sapiens	Inhibition	%	89.83
	8157446	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	-0.86	CHEMBL3231	Homo sapiens	Inhibition	%	-0.86
	8157670	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	2.39	CHEMBL3231	Homo sapiens	Inhibition	%	2.39
	8157800	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	-0.62	CHEMBL3231	Homo sapiens	Inhibition	%	-0.62
	8157961	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.94	CHEMBL3231	Homo sapiens	Inhibition	%	2.94
	8158185	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	1.94	CHEMBL3231	Homo sapiens	Inhibition	%	1.94
	8158435	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	65.27	CHEMBL3231	Homo sapiens	Inhibition	%	65.27
	8158593	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	7.68	CHEMBL3231	Homo sapiens	Inhibition	%	7.68
	8158986	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.49	CHEMBL3231	Homo sapiens	Inhibition	%	2.49
	8159121	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	0.81	CHEMBL3231	Homo sapiens	Inhibition	%	0.81
	8159465	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	8.73	CHEMBL3231	Homo sapiens	Inhibition	%	8.73
	8159820	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	22.49	CHEMBL3231	Homo sapiens	Inhibition	%	22.49
	8159961	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	5.65	CHEMBL3231	Homo sapiens	Inhibition	%	5.65
	8160322	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	0.87	CHEMBL3231	Homo sapiens	Inhibition	%	0.87
	8160472	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.4	CHEMBL3231	Homo sapiens	Inhibition	%	0.4
	8160766	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.27	CHEMBL3231	Homo sapiens	Inhibition	%	2.27
	8161140	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	8.01	CHEMBL3231	Homo sapiens	Inhibition	%	8.01
	8161283	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	1.28	CHEMBL3231	Homo sapiens	Inhibition	%	1.28
	8161632	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	3.29	CHEMBL3231	Homo sapiens	Inhibition	%	3.29
	8161994	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	1.22	CHEMBL3231	Homo sapiens	Inhibition	%	1.22
	8162124	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	0.72	CHEMBL3231	Homo sapiens	Inhibition	%	0.72
	8162508	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	3.23	CHEMBL3231	Homo sapiens	Inhibition	%	3.23
	8162761	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	81.3	CHEMBL3231	Homo sapiens	Inhibition	%	81.3
	8162909	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	15.53	CHEMBL3231	Homo sapiens	Inhibition	%	15.53
	8163133	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	55.07	CHEMBL3231	Homo sapiens	Inhibition	%	55.07
	8163302	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.98	CHEMBL3231	Homo sapiens	Inhibition	%	0.98
	8163436	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.71	CHEMBL3231	Homo sapiens	Inhibition	%	1.71
	8163660	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	2.21	CHEMBL3231	Homo sapiens	Inhibition	%	2.21
	8163783	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	13.81	CHEMBL3231	Homo sapiens	Inhibition	%	13.81
	8164141	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	67.65	CHEMBL3231	Homo sapiens	Inhibition	%	67.65
	8164281	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.34	CHEMBL3231	Homo sapiens	Inhibition	%	1.34
	8164505	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.6	CHEMBL3231	Homo sapiens	Inhibition	%	1.6
	8164660	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	1.39	CHEMBL3231	Homo sapiens	Inhibition	%	1.39
	8164804	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.73	CHEMBL3231	Homo sapiens	Inhibition	%	0.73
	8165028	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.87	CHEMBL3231	Homo sapiens	Inhibition	%	0.87
	8165098	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.58	CHEMBL3231	Homo sapiens	Inhibition	%	1.58
	8165322	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	8.73	CHEMBL3231	Homo sapiens	Inhibition	%	8.73
	8165463	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.56	CHEMBL3231	Homo sapiens	Inhibition	%	0.56
	8165606	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	9.73	CHEMBL3231	Homo sapiens	Inhibition	%	9.73
	8165830	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	6.3	CHEMBL3231	Homo sapiens	Inhibition	%	6.3
	8165956	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	4.61	CHEMBL3231	Homo sapiens	Inhibition	%	4.61
	8166318	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.34	CHEMBL3231	Homo sapiens	Inhibition	%	3.34
	8166448	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	0.52	CHEMBL3231	Homo sapiens	Inhibition	%	0.52
	8166672	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.51	CHEMBL3231	Homo sapiens	Inhibition	%	1.51
	8166773	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	7.47	CHEMBL3231	Homo sapiens	Inhibition	%	7.47
	8167085	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	92.08	CHEMBL3231	Homo sapiens	Inhibition	%	92.08
	8167450	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	25.04	CHEMBL3231	Homo sapiens	Inhibition	%	25.04
	8167614	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.34	CHEMBL3231	Homo sapiens	Inhibition	%	2.34
	8167971	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	9.21	CHEMBL3231	Homo sapiens	Inhibition	%	9.21
	8168095	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	61.6	CHEMBL3231	Homo sapiens	Inhibition	%	61.6
	8168319	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	74.33	CHEMBL3231	Homo sapiens	Inhibition	%	74.33
	8168460	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.85	CHEMBL3231	Homo sapiens	Inhibition	%	1.85
	8168820	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	1.29	CHEMBL3231	Homo sapiens	Inhibition	%	1.29
	8168984	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	5.33	CHEMBL3231	Homo sapiens	Inhibition	%	5.33
	8169350	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.98	CHEMBL3231	Homo sapiens	Inhibition	%	1.98
	8169654	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.37	CHEMBL3231	Homo sapiens	Inhibition	%	1.37
	8169788	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	2.31	CHEMBL3231	Homo sapiens	Inhibition	%	2.31
	8170157	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	41.08	CHEMBL3231	Homo sapiens	Inhibition	%	41.08
	8170282	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.31	CHEMBL3231	Homo sapiens	Inhibition	%	1.31
	8170506	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.1	CHEMBL3231	Homo sapiens	Inhibition	%	2.1
	8170646	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	1.94	CHEMBL3231	Homo sapiens	Inhibition	%	1.94
	8171005	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.36	CHEMBL3231	Homo sapiens	Inhibition	%	0.36
	8171202	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	2.06	CHEMBL3231	Homo sapiens	Inhibition	%	2.06
	8171419	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	93.73	CHEMBL3231	Homo sapiens	Inhibition	%	93.73
	8171784	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	66.55	CHEMBL3231	Homo sapiens	Inhibition	%	66.55
	8171937	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	0.34	CHEMBL3231	Homo sapiens	Inhibition	%	0.34
	8172293	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	0.24	CHEMBL3231	Homo sapiens	Inhibition	%	0.24
	8172645	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	4.13	CHEMBL3231	Homo sapiens	Inhibition	%	4.13
	8172787	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.92	CHEMBL3231	Homo sapiens	Inhibition	%	1.92
	8173147	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	1.53	CHEMBL3231	Homo sapiens	Inhibition	%	1.53
	8173312	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.51	CHEMBL3231	Homo sapiens	Inhibition	%	2.51
	8173677	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.68	CHEMBL3231	Homo sapiens	Inhibition	%	1.68
	8173988	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	7.56	CHEMBL3231	Homo sapiens	Inhibition	%	7.56
	8174120	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.77	CHEMBL3231	Homo sapiens	Inhibition	%	0.77
	8174344	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.27	CHEMBL3231	Homo sapiens	Inhibition	%	1.27
	8174492	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.17	CHEMBL3231	Homo sapiens	Inhibition	%	1.17
	8174838	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.96	CHEMBL3231	Homo sapiens	Inhibition	%	0.96
	8174981	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	13.69	CHEMBL3231	Homo sapiens	Inhibition	%	13.69
	8175341	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	10.92	CHEMBL3231	Homo sapiens	Inhibition	%	10.92
	8175597	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	1.71	CHEMBL3231	Homo sapiens	Inhibition	%	1.71
	8175760	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	1.17	CHEMBL3231	Homo sapiens	Inhibition	%	1.17
	8175984	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.24	CHEMBL3231	Homo sapiens	Inhibition	%	2.24
	8176137	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	80.6	CHEMBL3231	Homo sapiens	Inhibition	%	80.6
	8176286	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	2.09	CHEMBL3231	Homo sapiens	Inhibition	%	2.09
	8176510	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	0.76	CHEMBL3231	Homo sapiens	Inhibition	%	0.76
	8176642	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.42	CHEMBL3231	Homo sapiens	Inhibition	%	4.42
	8176996	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	5.6	CHEMBL3231	Homo sapiens	Inhibition	%	5.6
	8177138	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	1.38	CHEMBL3231	Homo sapiens	Inhibition	%	1.38
	8177362	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	1.86	CHEMBL3231	Homo sapiens	Inhibition	%	1.86
	8177500	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	1.15	CHEMBL3231	Homo sapiens	Inhibition	%	1.15
	8177664	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	9.67	CHEMBL3231	Homo sapiens	Inhibition	%	9.67
	8177888	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	0.86	CHEMBL3231	Homo sapiens	Inhibition	%	0.86
	8178028	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	4.77	CHEMBL3231	Homo sapiens	Inhibition	%	4.77
	8178340	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.82	CHEMBL3231	Homo sapiens	Inhibition	%	1.82
	8178691	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	8178840	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	2.85	CHEMBL3231	Homo sapiens	Inhibition	%	2.85
	8179187	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.95	CHEMBL3231	Homo sapiens	Inhibition	%	1.95
	8179331	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	0.63	CHEMBL3231	Homo sapiens	Inhibition	%	0.63
	8179555	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	5.11	CHEMBL3231	Homo sapiens	Inhibition	%	5.11
	8179692	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.42	CHEMBL3231	Homo sapiens	Inhibition	%	0.42
	8179949	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	7.45	CHEMBL3231	Homo sapiens	Inhibition	%	7.45
	8180327	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.2	CHEMBL3231	Homo sapiens	Inhibition	%	0.2
	8180483	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	90.55	CHEMBL3231	Homo sapiens	Inhibition	%	90.55
	8180855	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	5.77	CHEMBL3231	Homo sapiens	Inhibition	%	5.77
	8180988	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.34	CHEMBL3231	Homo sapiens	Inhibition	%	1.34
	8181212	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.52	CHEMBL3231	Homo sapiens	Inhibition	%	1.52
	8181343	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	2.38	CHEMBL3231	Homo sapiens	Inhibition	%	2.38
	8181707	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.2	CHEMBL3231	Homo sapiens	Inhibition	%	1.2
	8181846	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	7.02	CHEMBL3231	Homo sapiens	Inhibition	%	7.02
	8182233	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	2.11	CHEMBL3231	Homo sapiens	Inhibition	%	2.11
	8182373	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.45	CHEMBL3231	Homo sapiens	Inhibition	%	0.45
	8182597	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.54	CHEMBL3231	Homo sapiens	Inhibition	%	2.54
	8182689	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	4.25	CHEMBL3231	Homo sapiens	Inhibition	%	4.25
	8183035	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.49	CHEMBL3231	Homo sapiens	Inhibition	%	1.49
	8183184	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.26	CHEMBL3231	Homo sapiens	Inhibition	%	0.26
	8183408	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	2.35	CHEMBL3231	Homo sapiens	Inhibition	%	2.35
	8183537	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	1.44	CHEMBL3231	Homo sapiens	Inhibition	%	1.44
	8183903	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	0.31	CHEMBL3231	Homo sapiens	Inhibition	%	0.31
	8184039	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.05	CHEMBL3231	Homo sapiens	Inhibition	%	0.05
	8184305	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.3	CHEMBL3231	Homo sapiens	Inhibition	%	1.3
	8184529	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.83	CHEMBL3231	Homo sapiens	Inhibition	%	1.83
	8184676	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.71	CHEMBL3231	Homo sapiens	Inhibition	%	1.71
	8184833	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	-0.74	CHEMBL3231	Homo sapiens	Inhibition	%	-0.74
	8185057	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.7	CHEMBL3231	Homo sapiens	Inhibition	%	1.7
	8185206	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.02	CHEMBL3231	Homo sapiens	Inhibition	%	0.02
	8185561	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	1.86	CHEMBL3231	Homo sapiens	Inhibition	%	1.86
	8185692	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	5.13	CHEMBL3231	Homo sapiens	Inhibition	%	5.13
	8186055	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.05	CHEMBL3231	Homo sapiens	Inhibition	%	1.05
	8186196	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.21	CHEMBL3231	Homo sapiens	Inhibition	%	1.21
	8186420	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.15	CHEMBL3231	Homo sapiens	Inhibition	%	1.15
	8186584	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.56	CHEMBL3231	Homo sapiens	Inhibition	%	0.56
	8186947	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	3.43	CHEMBL3231	Homo sapiens	Inhibition	%	3.43
	8187045	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.2	CHEMBL3231	Homo sapiens	Inhibition	%	2.2
	8187269	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	3.29	CHEMBL3231	Homo sapiens	Inhibition	%	3.29
	8187393	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.01	CHEMBL3231	Homo sapiens	Inhibition	%	1.01
	8187765	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.87	CHEMBL3231	Homo sapiens	Inhibition	%	0.87
	8187894	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	2.51	CHEMBL3231	Homo sapiens	Inhibition	%	2.51
	8188118	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.49	CHEMBL3231	Homo sapiens	Inhibition	%	2.49
	8188261	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.29	CHEMBL3231	Homo sapiens	Inhibition	%	2.29
	8188396	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	0.21	CHEMBL3231	Homo sapiens	Inhibition	%	0.21
	8188620	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.16	CHEMBL3231	Homo sapiens	Inhibition	%	1.16
	8188894	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.89	CHEMBL3231	Homo sapiens	Inhibition	%	0.89
	8189042	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.31	CHEMBL3231	Homo sapiens	Inhibition	%	0.31
	8189422	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	1.58	CHEMBL3231	Homo sapiens	Inhibition	%	1.58
	8189571	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	2.63	CHEMBL3231	Homo sapiens	Inhibition	%	2.63
	8189927	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	2.52	CHEMBL3231	Homo sapiens	Inhibition	%	2.52
	8190059	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.21	CHEMBL3231	Homo sapiens	Inhibition	%	0.21
	8190283	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.31	CHEMBL3231	Homo sapiens	Inhibition	%	2.31
	8190423	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.71	CHEMBL3231	Homo sapiens	Inhibition	%	1.71
	8190784	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.7	CHEMBL3231	Homo sapiens	Inhibition	%	0.7
	8190948	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.57	CHEMBL3231	Homo sapiens	Inhibition	%	1.57
	8191310	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	19.79	CHEMBL3231	Homo sapiens	Inhibition	%	19.79
	8191630	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	31.34	CHEMBL3231	Homo sapiens	Inhibition	%	31.34
	8191752	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	2.92	CHEMBL3231	Homo sapiens	Inhibition	%	2.92
	8191976	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.25	CHEMBL3231	Homo sapiens	Inhibition	%	0.25
	8192125	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.22	CHEMBL3231	Homo sapiens	Inhibition	%	1.22
	8192478	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.35	CHEMBL3231	Homo sapiens	Inhibition	%	2.35
	8192622	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.2	CHEMBL3231	Homo sapiens	Inhibition	%	1.2
	8192982	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.28	CHEMBL3231	Homo sapiens	Inhibition	%	-0.28
	8193254	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	-0.55	CHEMBL3231	Homo sapiens	Inhibition	%	-0.55
	8193399	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	4.3	CHEMBL3231	Homo sapiens	Inhibition	%	4.3
	8193623	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-0.3	CHEMBL3231	Homo sapiens	Inhibition	%	-0.3
	8193780	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	3.96	CHEMBL3231	Homo sapiens	Inhibition	%	3.96
	8193929	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	3.22	CHEMBL3231	Homo sapiens	Inhibition	%	3.22
	8194153	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	22.2	CHEMBL3231	Homo sapiens	Inhibition	%	22.2
	8194284	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	0.48	CHEMBL3231	Homo sapiens	Inhibition	%	0.48
	8194639	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.88	CHEMBL3231	Homo sapiens	Inhibition	%	1.88
	8194782	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	6.72	CHEMBL3231	Homo sapiens	Inhibition	%	6.72
	8195006	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	5.7	CHEMBL3231	Homo sapiens	Inhibition	%	5.7
	8195139	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	4.39	CHEMBL3231	Homo sapiens	Inhibition	%	4.39
	8195303	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.44	CHEMBL3231	Homo sapiens	Inhibition	%	1.44
	8195527	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	7.03	CHEMBL3231	Homo sapiens	Inhibition	%	7.03
	8195666	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.43	CHEMBL3231	Homo sapiens	Inhibition	%	1.43
	8195988	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	73.21	CHEMBL3231	Homo sapiens	Inhibition	%	73.21
	8196329	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.95	CHEMBL3231	Homo sapiens	Inhibition	%	1.95
	8196479	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.01	CHEMBL3231	Homo sapiens	Inhibition	%	1.01
	8196831	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	2.39	CHEMBL3231	Homo sapiens	Inhibition	%	2.39
	8196972	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.27	CHEMBL3231	Homo sapiens	Inhibition	%	1.27
	8197196	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.19	CHEMBL3231	Homo sapiens	Inhibition	%	0.19
	8197333	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.21	CHEMBL3231	Homo sapiens	Inhibition	%	-0.21
	8197608	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.76	CHEMBL3231	Homo sapiens	Inhibition	%	1.76
	8197972	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.6	CHEMBL3231	Homo sapiens	Inhibition	%	0.6
	8198129	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	1.14	CHEMBL3231	Homo sapiens	Inhibition	%	1.14
	8198491	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	-0.11	CHEMBL3231	Homo sapiens	Inhibition	%	-0.11
	8198621	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	0.99	CHEMBL3231	Homo sapiens	Inhibition	%	0.99
	8198845	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	0.28	CHEMBL3231	Homo sapiens	Inhibition	%	0.28
	8198976	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.06	CHEMBL3231	Homo sapiens	Inhibition	%	2.06
	8199348	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.36	CHEMBL3231	Homo sapiens	Inhibition	%	2.36
	8199482	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.15	CHEMBL3231	Homo sapiens	Inhibition	%	1.15
	8199869	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	2.92	CHEMBL3231	Homo sapiens	Inhibition	%	2.92
	8200007	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.25	CHEMBL3231	Homo sapiens	Inhibition	%	2.25
	8200231	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	0.91	CHEMBL3231	Homo sapiens	Inhibition	%	0.91
	8200335	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	2.28	CHEMBL3231	Homo sapiens	Inhibition	%	2.28
	8200674	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	1.5	CHEMBL3231	Homo sapiens	Inhibition	%	1.5
	8200824	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.37	CHEMBL3231	Homo sapiens	Inhibition	%	1.37
	8201048	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.67	CHEMBL3231	Homo sapiens	Inhibition	%	1.67
	8201178	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	2.63	CHEMBL3231	Homo sapiens	Inhibition	%	2.63
	8201537	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	4.04	CHEMBL3231	Homo sapiens	Inhibition	%	4.04
	8201670	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.64	CHEMBL3231	Homo sapiens	Inhibition	%	-0.64
	8201949	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.46	CHEMBL3231	Homo sapiens	Inhibition	%	1.46
	8202313	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.08	CHEMBL3231	Homo sapiens	Inhibition	%	-0.08
	8202480	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	4.54	CHEMBL3231	Homo sapiens	Inhibition	%	4.54
	8202829	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.54	CHEMBL3231	Homo sapiens	Inhibition	%	1.54
	8203183	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	0.95	CHEMBL3231	Homo sapiens	Inhibition	%	0.95
	8203314	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.12	CHEMBL3231	Homo sapiens	Inhibition	%	1.12
	8203684	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	2.01	CHEMBL3231	Homo sapiens	Inhibition	%	2.01
	8203818	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.47	CHEMBL3231	Homo sapiens	Inhibition	%	1.47
	8204042	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.04	CHEMBL3231	Homo sapiens	Inhibition	%	1.04
	8204208	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	2.78	CHEMBL3231	Homo sapiens	Inhibition	%	2.78
	8204569	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	3.92	CHEMBL3231	Homo sapiens	Inhibition	%	3.92
	8204674	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	4.03	CHEMBL3231	Homo sapiens	Inhibition	%	4.03
	8205013	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	5.67	CHEMBL3231	Homo sapiens	Inhibition	%	5.67
	8205386	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	5.25	CHEMBL3231	Homo sapiens	Inhibition	%	5.25
	8205522	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	2.91	CHEMBL3231	Homo sapiens	Inhibition	%	2.91
	8205885	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	Inhibition	%	1.0
	8206017	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.59	CHEMBL3231	Homo sapiens	Inhibition	%	-0.59
	8206241	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.12	CHEMBL3231	Homo sapiens	Inhibition	%	0.12
	8206293	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.61	CHEMBL3231	Homo sapiens	Inhibition	%	1.61
	8206517	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	1.51	CHEMBL3231	Homo sapiens	Inhibition	%	1.51
	8206660	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.02	CHEMBL3231	Homo sapiens	Inhibition	%	-0.02
	8206840	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	5.96	CHEMBL3231	Homo sapiens	Inhibition	%	5.96
	8207064	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	32.75	CHEMBL3231	Homo sapiens	Inhibition	%	32.75
	8207190	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	1.58	CHEMBL3231	Homo sapiens	Inhibition	%	1.58
	8207544	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	0.72	CHEMBL3231	Homo sapiens	Inhibition	%	0.72
	8207676	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.97	CHEMBL3231	Homo sapiens	Inhibition	%	1.97
	8207900	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	0.94	CHEMBL3231	Homo sapiens	Inhibition	%	0.94
	8208045	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	4.7	CHEMBL3231	Homo sapiens	Inhibition	%	4.7
	8208401	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	4.3	CHEMBL3231	Homo sapiens	Inhibition	%	4.3
	8208567	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	73.92	CHEMBL3231	Homo sapiens	Inhibition	%	73.92
	8208924	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	43.59	CHEMBL3231	Homo sapiens	Inhibition	%	43.59
	8209029	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	-2.02	CHEMBL3231	Homo sapiens	Inhibition	%	-2.02
	8209253	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.4	CHEMBL3231	Homo sapiens	Inhibition	%	1.4
	8209369	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.46	CHEMBL3231	Homo sapiens	Inhibition	%	0.46
	8209743	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.11	CHEMBL3231	Homo sapiens	Inhibition	%	1.11
	8209879	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	10.85	CHEMBL3231	Homo sapiens	Inhibition	%	10.85
	8210103	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	1.18	CHEMBL3231	Homo sapiens	Inhibition	%	1.18
	8210244	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.07	CHEMBL3231	Homo sapiens	Inhibition	%	2.07
	8210604	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-0.45	CHEMBL3231	Homo sapiens	Inhibition	%	-0.45
	8210863	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	2.48	CHEMBL3231	Homo sapiens	Inhibition	%	2.48
	8211007	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.1	CHEMBL3231	Homo sapiens	Inhibition	%	0.1
	8211401	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.77	CHEMBL3231	Homo sapiens	Inhibition	%	0.77
	8211524	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	1.91	CHEMBL3231	Homo sapiens	Inhibition	%	1.91
	8211748	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.24	CHEMBL3231	Homo sapiens	Inhibition	%	1.24
	8211877	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	1.33	CHEMBL3231	Homo sapiens	Inhibition	%	1.33
	8212233	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.75	CHEMBL3231	Homo sapiens	Inhibition	%	2.75
	8212374	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	6.12	CHEMBL3231	Homo sapiens	Inhibition	%	6.12
	8212731	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	0.97	CHEMBL3231	Homo sapiens	Inhibition	%	0.97
	8212901	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	90.09	CHEMBL3231	Homo sapiens	Inhibition	%	90.09
	8213125	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	3.48	CHEMBL3231	Homo sapiens	Inhibition	%	3.48
	8213254	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	79.32	CHEMBL3231	Homo sapiens	Inhibition	%	79.32
	8213582	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.15	CHEMBL3231	Homo sapiens	Inhibition	%	-0.15
	8213695	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.15	CHEMBL3231	Homo sapiens	Inhibition	%	2.15
	8213919	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.51	CHEMBL3231	Homo sapiens	Inhibition	%	0.51
	8214066	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	2.34	CHEMBL3231	Homo sapiens	Inhibition	%	2.34
	8214427	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	3.85	CHEMBL3231	Homo sapiens	Inhibition	%	3.85
	8214561	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	0.56	CHEMBL3231	Homo sapiens	Inhibition	%	0.56
	8214937	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	1.08	CHEMBL3231	Homo sapiens	Inhibition	%	1.08
	8215188	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.49	CHEMBL3231	Homo sapiens	Inhibition	%	2.49
	8215341	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.93	CHEMBL3231	Homo sapiens	Inhibition	%	1.93
	8215565	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	3.01	CHEMBL3231	Homo sapiens	Inhibition	%	3.01
	8215729	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	3.4	CHEMBL3231	Homo sapiens	Inhibition	%	3.4
	8216072	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	2.04	CHEMBL3231	Homo sapiens	Inhibition	%	2.04
	8216191	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.45	CHEMBL3231	Homo sapiens	Inhibition	%	0.45
	8216551	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.2	CHEMBL3231	Homo sapiens	Inhibition	%	1.2
	8216689	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	9.51	CHEMBL3231	Homo sapiens	Inhibition	%	9.51
	8216913	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	46.17	CHEMBL3231	Homo sapiens	Inhibition	%	46.17
	8217047	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.23	CHEMBL3231	Homo sapiens	Inhibition	%	2.23
	8217445	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	4.29	CHEMBL3231	Homo sapiens	Inhibition	%	4.29
	8217576	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	3.62	CHEMBL3231	Homo sapiens	Inhibition	%	3.62
	8217901	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	1.07	CHEMBL3231	Homo sapiens	Inhibition	%	1.07
	8218240	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.11	CHEMBL3231	Homo sapiens	Inhibition	%	1.11
	8218367	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	3.7	CHEMBL3231	Homo sapiens	Inhibition	%	3.7
	8218734	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	2.21	CHEMBL3231	Homo sapiens	Inhibition	%	2.21
	8218865	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	5.78	CHEMBL3231	Homo sapiens	Inhibition	%	5.78
	8219089	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.24	CHEMBL3231	Homo sapiens	Inhibition	%	0.24
	8219249	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	2.14	CHEMBL3231	Homo sapiens	Inhibition	%	2.14
	8219499	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	3.31	CHEMBL3231	Homo sapiens	Inhibition	%	3.31
	8219884	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	3.53	CHEMBL3231	Homo sapiens	Inhibition	%	3.53
	8220053	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.85	CHEMBL3231	Homo sapiens	Inhibition	%	2.85
	8220406	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	1.06	CHEMBL3231	Homo sapiens	Inhibition	%	1.06
	8220520	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.95	CHEMBL3231	Homo sapiens	Inhibition	%	3.95
	8220744	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	70.68	CHEMBL3231	Homo sapiens	Inhibition	%	70.68
	8220882	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	2.49	CHEMBL3231	Homo sapiens	Inhibition	%	2.49
	8221242	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	77.85	CHEMBL3231	Homo sapiens	Inhibition	%	77.85
	8221375	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.41	CHEMBL3231	Homo sapiens	Inhibition	%	0.41
	8221599	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.22	CHEMBL3231	Homo sapiens	Inhibition	%	2.22
	8221764	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.19	CHEMBL3231	Homo sapiens	Inhibition	%	1.19
	8221895	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	6.5	CHEMBL3231	Homo sapiens	Inhibition	%	6.5
	8222119	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	0.91	CHEMBL3231	Homo sapiens	Inhibition	%	0.91
	8222217	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.01	CHEMBL3231	Homo sapiens	Inhibition	%	0.01
	8222575	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	0.63	CHEMBL3231	Homo sapiens	Inhibition	%	0.63
	8222693	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	7.32	CHEMBL3231	Homo sapiens	Inhibition	%	7.32
	8222917	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	67.79	CHEMBL3231	Homo sapiens	Inhibition	%	67.79
	8223061	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	11.54	CHEMBL3231	Homo sapiens	Inhibition	%	11.54
	8223414	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	6.36	CHEMBL3231	Homo sapiens	Inhibition	%	6.36
	8223575	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.35	CHEMBL3231	Homo sapiens	Inhibition	%	2.35
	8223825	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	8.02	CHEMBL3231	Homo sapiens	Inhibition	%	8.02
	8224049	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	10.57	CHEMBL3231	Homo sapiens	Inhibition	%	10.57
	8224211	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	Inhibition	%	10.0
	8224381	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.68	CHEMBL3231	Homo sapiens	Inhibition	%	2.68
	8224605	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-0.49	CHEMBL3231	Homo sapiens	Inhibition	%	-0.49
	8224740	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	0.58	CHEMBL3231	Homo sapiens	Inhibition	%	0.58
	8225078	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	83.98	CHEMBL3231	Homo sapiens	Inhibition	%	83.98
	8225212	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	1.47	CHEMBL3231	Homo sapiens	Inhibition	%	1.47
	8225436	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	2.17	CHEMBL3231	Homo sapiens	Inhibition	%	2.17
	8225574	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	3.64	CHEMBL3231	Homo sapiens	Inhibition	%	3.64
	8225933	CHEMBL1961924	GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	0.84	CHEMBL3231	Homo sapiens	Inhibition	%	0.84
	8226091	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.75	CHEMBL3231	Homo sapiens	Inhibition	%	1.75
	8226440	CHEMBL1961925	GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	3.74	CHEMBL3231	Homo sapiens	Inhibition	%	3.74
active	9648280	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9648281	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)CCOc1cc(-c2ccc(C(N)=O)cc2)cc2[nH]nc(N)c12		CHEMBL2001398	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9648282	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1		CHEMBL2003768	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9648283	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9648284	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9648285	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL1982880	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9648286	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9648287	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9648288	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9648289	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9648290	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9648291	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9648292	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9648293	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9648294	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9648295	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	3.981	CHEMBL3231	Homo sapiens	pKi		8.4
inactive	9648296	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9648297	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9648298	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9648299	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9648300	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	=	Ki	nM	5.012	CHEMBL3231	Homo sapiens	pKi		8.3
active	9648301	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9648302	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9648303	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	15848.93	CHEMBL3231	Homo sapiens	pKi		4.8
inactive	9648304	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9648305	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1(C)CC2=Nc3cc(Cl)ccc3SC2=C(O)C1		CHEMBL1562756	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9648306	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9648307	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9648308	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9648309	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9648310	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9648311	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9648312	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
active	9652324	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	7.943	CHEMBL3231	Homo sapiens	pKi		8.1
active	9652325	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(Nc2ncnc3ccccc23)cc1		CHEMBL289959	=	Ki	nM	31622.78	CHEMBL3231	Homo sapiens	pKi		4.5
inactive	9652326	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652327	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9652328	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9652329	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652330	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652331	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652332	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652333	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652334	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652335	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9652336	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9652337	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9652338	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9652339	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9652340	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652341	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCc2c1cccc2-c1cccs1		CHEMBL1991782	<	Ki	nM	79432.82	CHEMBL3231	Homo sapiens	pKi		4.1
active	9652342	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2ncc(Br)cc12		CHEMBL2002105	=	Ki	nM	63095.73	CHEMBL3231	Homo sapiens	pKi		4.2
active	9652343	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9652344	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9652345	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652346	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
active	9652347	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9652348	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2000934	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652349	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1C(=O)Nc1ccccc1N2		CHEMBL1980671	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
inactive	9652350	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652351	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652352	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1cc2nn[nH]c2cc1Cl		CHEMBL1996923	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652353	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9652354	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652355	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652356	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652357	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9652358	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1983589	=	Ki	nM	6.31	CHEMBL3231	Homo sapiens	pKi		8.2
active	9652359	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc2c(c1)Cc1c[nH]nc1-2		CHEMBL1989423	=	Ki	nM	50118.72	CHEMBL3231	Homo sapiens	pKi		4.3
inactive	9652360	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652361	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652362	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9652363	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9652364	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2005718	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
inactive	9652365	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9652366	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652367	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652368	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9652369	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9652370	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
inactive	9652371	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652372	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9652373	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652374	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652375	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	63095.73	CHEMBL3231	Homo sapiens	pKi		4.2
inactive	9652376	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1OC		CHEMBL1996604	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652377	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9652378	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652379	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9652380	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652381	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652382	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652383	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652384	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
active	9652385	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652386	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652387	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652388	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9652389	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652390	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1966842	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652391	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652392	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652393	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9652394	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12		CHEMBL2001668	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652395	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652396	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9652397	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9652398	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652399	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652400	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	=	Ki	nM	15.85	CHEMBL3231	Homo sapiens	pKi		7.8
inactive	9652401	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652402	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652403	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9652404	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9652405	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9652406	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1		CHEMBL1970369	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652407	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9652408	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652409	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9652410	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9652411	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2cccc(-c3ccc(F)cc3)c12		CHEMBL1971519	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9652412	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)c2c(n1)sc1c(N)ncnc12		CHEMBL504950	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9652413	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9652414	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9652415	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9652416	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652417	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C		CHEMBL1977041	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9652418	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652419	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
active	9652420	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9652421	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652422	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1985723	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
inactive	9652423	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652424	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	7.943	CHEMBL3231	Homo sapiens	pKi		8.1
inactive	9652425	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652426	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652427	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9652428	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9652429	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9652430	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1		CHEMBL1972462	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652431	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1977128	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
inactive	9652432	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1997759	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652433	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652434	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9652435	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O		CHEMBL1974803	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652436	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9652437	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)C1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1965702	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9652438	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652439	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9652440	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCc2c(Br)cccc21		CHEMBL1984500	=	Ki	nM	19952.62	CHEMBL3231	Homo sapiens	pKi		4.7
active	9652441	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
inactive	9652442	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2005112	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652443	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9652444	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652445	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652446	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652447	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652448	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9652449	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652450	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21		CHEMBL207253	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652451	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=NNC(=O)c1nnn(-c2nonc2N)c1-c1ccccc1)c1ccco1		CHEMBL1890036	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9652452	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652453	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9652454	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652455	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(Cl)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)NCCOCCOCCN)[nH]c12		CHEMBL2002682	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9652456	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652457	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652458	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652459	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652460	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccc2cnc(-c3ccccc3)n12		CHEMBL1969156	=	Ki	nM	50118.72	CHEMBL3231	Homo sapiens	pKi		4.3
active	9652461	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9652462	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652463	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9652464	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9652465	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652466	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	=	Ki	nM	0.7943	CHEMBL3231	Homo sapiens	pKi		9.1
inactive	9652467	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652468	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9652469	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9652470	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9652471	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9652472	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCOc1cccc(Nc2ccnc(N)n2)c1		CHEMBL1995448	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9652473	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9652474	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9652475	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652476	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652477	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9652478	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1		CHEMBL2006580	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652479	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9652480	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652481	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1Cl)c1ccccc1F		CHEMBL2001228	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652482	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652483	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1		CHEMBL2006481	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652484	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652485	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9652486	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9652487	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652488	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9652489	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCNc1nc2cc(Cl)c(OC)cc2nc1NCC		CHEMBL1995927	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652490	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
active	9652491	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652492	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652493	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652494	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652495	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9652496	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652497	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	=	Ki	nM	2.512	CHEMBL3231	Homo sapiens	pKi		8.6
active	9652498	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
inactive	9652499	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652500	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1-c1cccc2nccn12		CHEMBL1980003	=	Ki	nM	63095.73	CHEMBL3231	Homo sapiens	pKi		4.2
active	9652501	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9652502	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9652503	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9652504	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(CNc2nc(Nc3cc(C4CC4)[nH]n3)c3sccc3n2)cc1		CHEMBL1997924	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9652505	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9652506	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
active	9652507	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9652508	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1		CHEMBL2002240	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652509	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)c1ccccc1		CHEMBL1978267	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652510	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652511	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1		CHEMBL1991143	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652512	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
active	9652513	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9652514	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652515	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
inactive	9652516	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652517	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652518	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9652519	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652520	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9652521	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652522	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9652523	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	50118.72	CHEMBL3231	Homo sapiens	pKi		4.3
active	9652524	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9652525	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652526	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9652527	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9652528	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9652529	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652530	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9652531	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652532	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652533	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2ccncc2s1		CHEMBL1971534	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9652534	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9652535	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9652536	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652537	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9652538	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
inactive	9652539	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652540	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9652541	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9652542	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652543	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652544	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc(CO)cc1)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1974363	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652545	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	=	Ki	nM	12.59	CHEMBL3231	Homo sapiens	pKi		7.9
inactive	9652546	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652547	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9652548	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9652549	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652550	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9652551	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9652552	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
inactive	9652553	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9652554	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1		CHEMBL513846	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652555	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9652556	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9652557	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9652558	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9652559	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9652560	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652561	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1972290	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9652562	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652563	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9652564	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1		CHEMBL1975208	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9652565	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9656570	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656571	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656572	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656573	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656574	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656575	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656576	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	0.7943	CHEMBL3231	Homo sapiens	pKi		9.1
active	9656577	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9656578	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9656579	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656580	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
inactive	9656581	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656582	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656583	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656584	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(F)cc12		CHEMBL2007603	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656585	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656586	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	=	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9656587	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9656588	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nsc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL2002553	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656589	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656590	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9656591	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656592	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9656593	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9656594	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9656595	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656596	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656597	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9656598	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656599	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656600	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1996543	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656601	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9656602	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9656603	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656604	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1		CHEMBL1983309	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656605	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9656606	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1999126	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656607	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656608	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9656609	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656610	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656611	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656612	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9656613	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656614	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9656615	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656616	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656617	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9656618	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656619	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9656620	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656621	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9656622	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656623	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(Cl)c1		CHEMBL1983595	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9656624	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9656625	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656626	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656627	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9656628	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9656629	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9656630	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9656631	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656632	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9656633	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9656634	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
active	9656635	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9656636	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9656637	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9656638	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9656639	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9656640	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656641	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656642	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9656643	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)c1cccc(-c2ccc3nccn3n2)c1		CHEMBL1994159	=	Ki	nM	50118.72	CHEMBL3231	Homo sapiens	pKi		4.3
inactive	9656644	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)S(=O)(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2006631	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656645	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9656646	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656647	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1		CHEMBL1966087	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9656648	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9656649	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9656650	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9656651	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656652	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
active	9656653	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNCC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1996980	=	Ki	nM	3.981	CHEMBL3231	Homo sapiens	pKi		8.4
active	9656654	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
inactive	9656655	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL1970735	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656656	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9656657	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656658	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9656659	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1		CHEMBL2004365	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656660	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	25118.86	CHEMBL3231	Homo sapiens	pKi		4.6
active	9656661	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9656662	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656663	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656664	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656665	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656666	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656667	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9656668	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	3.162	CHEMBL3231	Homo sapiens	pKi		8.5
active	9656669	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656670	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656671	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9656672	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9656673	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656674	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	=	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656675	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9656676	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656677	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656678	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656679	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9656680	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656681	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9656682	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656683	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656684	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1c(N)nc2sc(C(N)=O)cc21		CHEMBL2002802	=	Ki	nM	39810.72	CHEMBL3231	Homo sapiens	pKi		4.4
inactive	9656685	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656686	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9656687	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9656688	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656689	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656690	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc(F)cc2)n1		CHEMBL1992231	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9656691	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9656692	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656693	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccc(Cl)cc1)Nc1cccc2[nH]ncc12		CHEMBL1977713	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656694	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656695	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656696	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9656697	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656698	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656699	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656700	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc2c(c1)C(=O)Nc1ccccc1N2		CHEMBL1970873	<	Ki	nM	50118.72	CHEMBL3231	Homo sapiens	pKi		4.3
active	9656701	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9656702	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656703	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656704	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9656705	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9656706	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656707	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656708	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2scc(-c3ccccc3)c12		CHEMBL1975212	=	Ki	nM	19952.62	CHEMBL3231	Homo sapiens	pKi		4.7
active	9656709	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9656710	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	15848.93	CHEMBL3231	Homo sapiens	pKi		4.8
inactive	9656711	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656712	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656713	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9656714	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC1CCCCC1Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1994438	=	Ki	nM	12.59	CHEMBL3231	Homo sapiens	pKi		7.9
active	9656715	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(-c2cccc3onc(N)c23)c1		CHEMBL1980376	=	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656716	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656717	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9656718	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656719	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9656720	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656721	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2Br)C1		CHEMBL2004647	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656722	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9656723	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9656724	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9656725	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656726	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9656727	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
active	9656728	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	=	Ki	nM	6.31	CHEMBL3231	Homo sapiens	pKi		8.2
inactive	9656729	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656730	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	=	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
active	9656731	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9656732	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9656733	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9656734	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9656735	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9656736	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656737	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656738	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
inactive	9656739	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656740	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656741	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	<	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9656742	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	12.59	CHEMBL3231	Homo sapiens	pKi		7.9
active	9656743	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	1.259	CHEMBL3231	Homo sapiens	pKi		8.9
inactive	9656744	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656745	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COC(=O)c1c(N)nc2ccccn12		CHEMBL1981492	=	Ki	nM	39810.72	CHEMBL3231	Homo sapiens	pKi		4.4
active	9656746	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9656747	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656748	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	=	Ki	nM	3.162	CHEMBL3231	Homo sapiens	pKi		8.5
active	9656749	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9656750	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656751	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9656752	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656753	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656754	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656755	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656756	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9656757	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656758	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656759	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656760	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656761	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656762	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656763	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOCC(C)Oc1cccc2[nH]nc(N)c12		CHEMBL2002736	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9656764	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9656765	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656766	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1983195	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656767	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9656768	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9656769	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCNc1cc2cc(-c3ccccc3)ccc2cn1		CHEMBL1989957	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656770	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656771	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656772	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656773	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ccc(-c2cccn3c(=O)[nH]nc23)cc1		CHEMBL1975503	=	Ki	nM	12589.25	CHEMBL3231	Homo sapiens	pKi		4.9
active	9656774	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9656775	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656776	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656777	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9656778	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9656779	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4c(F)cccc4F)c3)nc3sccn23)n1		CHEMBL1997051	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9656780	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656781	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9656782	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9656783	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
inactive	9656784	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656785	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	=	Ki	nM	0.7943	CHEMBL3231	Homo sapiens	pKi		9.1
inactive	9656786	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656787	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9656788	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9656789	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656790	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9656791	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(-c2ccnc3[nH]ccc23)cc1		CHEMBL482538	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9656792	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	=	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
inactive	9656793	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656794	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9656795	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nn(C)c2sc(C(N)=O)c(N)c12		CHEMBL1996837	=	Ki	nM	12589.25	CHEMBL3231	Homo sapiens	pKi		4.9
active	9656796	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9656797	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12		CHEMBL1990346	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9656798	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9656799	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9656800	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9656801	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9656802	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9656803	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9656804	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	=	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
inactive	9656805	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656806	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9656807	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12		CHEMBL1994308	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9656808	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
inactive	9656809	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21		CHEMBL1977604	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9656810	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9656811	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9656812	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660821	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
active	9660822	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
active	9660823	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9660824	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660825	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660826	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1		CHEMBL1992555	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9660827	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	6.31	CHEMBL3231	Homo sapiens	pKi		8.2
active	9660828	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9660829	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660830	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660831	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660832	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12		CHEMBL535331	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660833	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660834	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(F)cc1		CHEMBL1966204	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9660835	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9660836	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)=C(C)c1cccc2c(CCCOc3cccc(Cl)c3Cl)c(C(=O)O)[nH]c12		CHEMBL1982980	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660837	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660838	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9660839	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	=	Ki	nM	15.85	CHEMBL3231	Homo sapiens	pKi		7.8
active	9660840	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9660841	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9660842	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660843	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc2cccc(-c3ccccc3)n12		CHEMBL1997119	=	Ki	nM	31622.78	CHEMBL3231	Homo sapiens	pKi		4.5
active	9660844	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9660845	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1		CHEMBL2002323	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660846	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9660847	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(C2CCc3[nH]ncc3C2)cc1		CHEMBL2000879	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
inactive	9660848	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660849	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9660850	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2004513	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9660851	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nonc1-n1cc(CO)nn1		CHEMBL1991251	=	Ki	nM	39810.72	CHEMBL3231	Homo sapiens	pKi		4.4
inactive	9660852	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL1969483	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660853	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660854	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1nc(-c2ccc3c(c2)OCO3)c2cc[nH]c2n1		CHEMBL2004515	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9660855	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9660856	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660857	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9660858	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	=	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660859	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9660860	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9660861	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660862	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	=	Ki	nM	1.259	CHEMBL3231	Homo sapiens	pKi		8.9
active	9660863	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9660864	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660865	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660866	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
active	9660867	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9660868	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660869	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660870	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12		CHEMBL1995736	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660871	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660872	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
active	9660873	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9660874	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9660875	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9660876	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1998551	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660877	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1977374	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660878	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(NC(=O)N2CCC(c3nc4c(C(N)=O)cccc4[nH]3)CC2)c1		CHEMBL1973363	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9660879	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9660880	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9660881	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9660882	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1978656	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660883	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	=	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660884	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(N)c2ccccc12		CHEMBL1998253	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660885	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660886	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9660887	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660888	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660889	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660890	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	=	Ki	nM	3.981	CHEMBL3231	Homo sapiens	pKi		8.4
inactive	9660891	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9660892	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660893	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9660894	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660895	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1		CHEMBL2001149	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9660896	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660897	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(Cl)cc1		CHEMBL1987073	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
inactive	9660898	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL2000078	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660899	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9660900	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660901	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9660902	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1995712	<	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
inactive	9660903	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660904	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660905	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9660906	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(-c2cccc3nccn23)cc1		CHEMBL1992723	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9660907	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccccc1)Nc1cc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)ccc1Cl		CHEMBL2005482	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660908	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9660909	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660910	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1997909	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660911	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660912	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCNc1cc2cc(-c3ccncc3)ccc2cn1		CHEMBL1998435	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9660913	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	=	Ki	nM	15.85	CHEMBL3231	Homo sapiens	pKi		7.8
inactive	9660914	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660915	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
active	9660916	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9660917	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660918	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9660919	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9660920	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
active	9660921	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9660922	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	=	Ki	nM	25118.86	CHEMBL3231	Homo sapiens	pKi		4.6
inactive	9660923	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	FC(F)(F)Oc1ccc(-c2ccc3[nH]cc(C4=CCNCC4)c3c2)cc1		CHEMBL1987982	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660924	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660925	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9660926	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9660927	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9660928	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660929	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660930	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9660931	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660932	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660933	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9660934	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
active	9660935	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9660936	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9660937	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9660938	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9660939	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	=	Ki	nM	3.162	CHEMBL3231	Homo sapiens	pKi		8.5
active	9660940	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9660941	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1980562	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
inactive	9660942	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660943	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9660944	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9660945	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660946	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9660947	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660948	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCNC(=O)c1n[nH]c(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1		CHEMBL365617	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660949	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660950	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660951	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9660952	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	=	Ki	nM	39810.72	CHEMBL3231	Homo sapiens	pKi		4.4
inactive	9660953	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccccc1Nc1ncnc(Nc2cccc(F)c2)n1		CHEMBL1979933	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
inactive	9660954	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1ccc2c(c1)nnc1nnnn12		CHEMBL1986503	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660955	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660956	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660957	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9660958	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660959	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(O)c1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL2001641	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9660960	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OC1CCCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1976936	<	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9660961	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9660962	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660963	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9660964	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
inactive	9660965	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660966	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660967	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9660968	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9660969	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	=	Ki	nM	7.943	CHEMBL3231	Homo sapiens	pKi		8.1
inactive	9660970	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660971	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9660972	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1982167	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660973	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9660974	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660975	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9660976	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9660977	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660978	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL2000104	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660979	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660980	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1987448	=	Ki	nM	5.012	CHEMBL3231	Homo sapiens	pKi		8.3
active	9660981	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9660982	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9660983	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660984	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660985	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9660986	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9660987	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
inactive	9660988	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9660989	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9660990	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660991	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2005216	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
active	9660992	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9660993	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9660994	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9660995	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660996	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9660997	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9660998	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9660999	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9661000	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cncc(C=Cc2ccncc2)c1		CHEMBL1972568	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9661001	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9661002	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661003	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9661004	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCC1COc1cncc(CCc2ccncc2)c1		CHEMBL1996155	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9661005	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9661006	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9661007	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9661008	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	=	Ki	nM	7.943	CHEMBL3231	Homo sapiens	pKi		8.1
active	9661009	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9661010	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9661011	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1.259	CHEMBL3231	Homo sapiens	pKi		8.9
active	9661012	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
inactive	9661013	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1988995	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661014	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL207995	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9661015	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9661016	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661017	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9661018	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	=	Ki	nM	3.981	CHEMBL3231	Homo sapiens	pKi		8.4
inactive	9661019	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9661020	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661021	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9661022	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9661023	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1CN=C(c2cccc(Cl)c2)c2c(sc3c2CCCC3)N1		CHEMBL2002470	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9661024	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9661025	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661026	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661027	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
active	9661028	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9661029	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9661030	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9661031	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661032	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	=	Ki	nM	39.81	CHEMBL3231	Homo sapiens	pKi		7.4
inactive	9661033	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661034	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C		CHEMBL1997611	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9661035	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9661036	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661037	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9661038	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9661039	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661040	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9661041	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL1999774	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661042	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661043	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9661044	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9661045	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
inactive	9661046	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661047	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661048	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661049	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1.259	CHEMBL3231	Homo sapiens	pKi		8.9
inactive	9661050	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9661051	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9661052	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9661053	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661054	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9661055	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661056	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9661057	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9661058	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
inactive	9661059	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9661060	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9661061	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	=	Ki	nM	31.62	CHEMBL3231	Homo sapiens	pKi		7.5
inactive	9661062	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl		CHEMBL1990212	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665029	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665030	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	3.981	CHEMBL3231	Homo sapiens	pKi		8.4
active	9665031	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9665032	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	=	Ki	nM	6.31	CHEMBL3231	Homo sapiens	pKi		8.2
active	9665033	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2sccc12		CHEMBL1972934	=	Ki	nM	31622.78	CHEMBL3231	Homo sapiens	pKi		4.5
inactive	9665034	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665035	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665036	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	=	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
active	9665037	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9665038	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
inactive	9665039	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665040	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665041	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9665042	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL2004072	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665043	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
inactive	9665044	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665045	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9665046	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCNNc1cc(C)c(C#N)c2nc3ccccc3n12		CHEMBL2000433	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665047	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL1974157	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665048	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665049	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9665050	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665051	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4ccccc4)c3)nc3sccn23)n1		CHEMBL1988076	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665052	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665053	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665054	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665055	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665056	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1992363	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9665057	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
inactive	9665058	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9665059	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9665060	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665061	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665062	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9665063	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665064	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1		CHEMBL1173055	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665065	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9665066	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665067	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1982271	=	Ki	nM	5.012	CHEMBL3231	Homo sapiens	pKi		8.3
inactive	9665068	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665069	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
inactive	9665070	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665071	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
active	9665072	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9665073	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9665074	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665075	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665076	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665077	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665078	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665079	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665080	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665081	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665082	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1983006	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665083	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCCC1COc1cncc(CCc2ccccc2)c1		CHEMBL1972183	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665084	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9665085	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9665086	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9665087	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CCCCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2001451	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9665088	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665089	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665090	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	=	Ki	nM	199.53	CHEMBL3231	Homo sapiens	pKi		6.7
active	9665091	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	=	Ki	nM	25.12	CHEMBL3231	Homo sapiens	pKi		7.6
inactive	9665092	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665093	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665094	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665095	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665096	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665097	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1		CHEMBL1973016	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665098	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665099	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
active	9665100	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9665101	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665102	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665103	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
inactive	9665104	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
inactive	9665105	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665106	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
inactive	9665107	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9665108	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL1968245	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9665109	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9665110	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	=	Ki	nM	3.981	CHEMBL3231	Homo sapiens	pKi		8.4
inactive	9665111	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665112	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665113	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665114	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCCC(=O)O)cc2)n1		CHEMBL2003689	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665115	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665116	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9665117	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665118	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9665119	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9665120	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	=	Ki	nM	12.59	CHEMBL3231	Homo sapiens	pKi		7.9
inactive	9665121	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665122	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1		CHEMBL1419458	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665123	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665124	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9665125	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665126	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9665127	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9665128	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665129	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(c1ccccc1CNc1nc(N)nc2[nH]ccc12)S(C)(=O)=O		CHEMBL1970006	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665130	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665131	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665132	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9665133	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9665134	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Ki	nM	125.89	CHEMBL3231	Homo sapiens	pKi		6.9
active	9665135	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9665136	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665137	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9665138	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
inactive	9665139	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665140	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665141	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1990162	<	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9665142	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	7.943	CHEMBL3231	Homo sapiens	pKi		8.1
active	9665143	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
active	9665144	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9665145	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12		CHEMBL1998414	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665146	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665147	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
active	9665148	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9665149	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9665150	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665151	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665152	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665153	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665154	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665155	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9665156	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665157	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9665158	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665159	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	=	Ki	nM	7.943	CHEMBL3231	Homo sapiens	pKi		8.1
active	9665160	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1987948	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
inactive	9665161	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665162	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665163	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	=	Ki	nM	316.23	CHEMBL3231	Homo sapiens	pKi		6.5
inactive	9665164	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665165	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665166	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
inactive	9665167	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665168	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1		CHEMBL336961	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665169	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665170	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	=	Ki	nM	63.1	CHEMBL3231	Homo sapiens	pKi		7.2
active	9665171	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1970083	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9665172	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665173	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9665174	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665175	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665176	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
active	9665177	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	79432.82	CHEMBL3231	Homo sapiens	pKi		4.1
active	9665178	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(-c2ccc3c(c2)CNC3=O)ccc1F		CHEMBL1976290	=	Ki	nM	19952.62	CHEMBL3231	Homo sapiens	pKi		4.7
active	9665179	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
inactive	9665180	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665181	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9665182	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665183	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665184	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	=	Ki	nM	501.19	CHEMBL3231	Homo sapiens	pKi		6.3
inactive	9665185	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665186	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	<	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665187	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9665188	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665189	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665190	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665191	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9665192	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	=	Ki	nM	39810.72	CHEMBL3231	Homo sapiens	pKi		4.4
active	9665193	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CN)CNc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1968930	=	Ki	nM	2.512	CHEMBL3231	Homo sapiens	pKi		8.6
inactive	9665194	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665195	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665196	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665197	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665198	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665199	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665200	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665201	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9665202	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9665203	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	=	Ki	nM	79.43	CHEMBL3231	Homo sapiens	pKi		7.1
active	9665204	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
inactive	9665205	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665206	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
inactive	9665207	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665208	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	=	Ki	nM	630.96	CHEMBL3231	Homo sapiens	pKi		6.2
active	9665209	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CS(=O)(=O)Nc1ccc(Nc2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1988872	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9665210	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665211	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665212	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665213	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9665214	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
active	9665215	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9665216	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N		CHEMBL1980715	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
inactive	9665217	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	<	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9665218	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Ki	nM	1995.26	CHEMBL3231	Homo sapiens	pKi		5.7
inactive	9665219	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665220	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665221	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
inactive	9665222	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1c2c([nH]c3cc(-c4ccco4)nn13)CSC2		CHEMBL1972152	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665223	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665224	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9665225	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665226	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665227	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665228	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(CN2CCCCC2)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL202635	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665229	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
inactive	9665230	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665231	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665232	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665233	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	251.19	CHEMBL3231	Homo sapiens	pKi		6.6
inactive	9665234	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665235	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665236	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1994318	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9665237	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665238	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665239	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(C=Cc1ccc(Br)cc1)Nc1cccc2cnccc12		CHEMBL1967719	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
active	9665240	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9665241	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665242	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9665243	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9665244	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
inactive	9665245	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665246	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	=	Ki	nM	1.995	CHEMBL3231	Homo sapiens	pKi		8.7
inactive	9665247	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9665248	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665249	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665250	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665251	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665252	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9665253	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	=	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9665254	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	=	Ki	nM	19.95	CHEMBL3231	Homo sapiens	pKi		7.7
inactive	9665255	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9665256	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665257	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	=	Ki	nM	3162.28	CHEMBL3231	Homo sapiens	pKi		5.5
inactive	9665258	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
active	9665259	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9665260	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(C)OC(=O)n1cc(-c2cncn2C2CCCCC2)c2ccccc21		CHEMBL1975357	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665261	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	=	Ki	nM	398.11	CHEMBL3231	Homo sapiens	pKi		6.4
active	9665262	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
inactive	9665263	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665264	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9665265	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9665266	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9665267	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	=	Ki	nM	7943.28	CHEMBL3231	Homo sapiens	pKi		5.1
inactive	9665268	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	<	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9665269	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	=	Ki	nM	794.33	CHEMBL3231	Homo sapiens	pKi		6.1
inactive	9665270	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9669233	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	1000.0	CHEMBL3231	Homo sapiens	pKi		6.0
active	9669234	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	pKi		7.0
active	9669235	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	158.49	CHEMBL3231	Homo sapiens	pKi		6.8
active	9669236	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1966069	=	Ki	nM	50.12	CHEMBL3231	Homo sapiens	pKi		7.3
active	9669237	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	=	Ki	nM	1584.89	CHEMBL3231	Homo sapiens	pKi		5.8
inactive	9669238	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
active	9669239	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	=	Ki	nM	1258.93	CHEMBL3231	Homo sapiens	pKi		5.9
active	9669240	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
inactive	9669241	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	5011.87	CHEMBL3231	Homo sapiens	pKi		5.3
active	9669242	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	c1ccc(C2CCc3[nH]ncc32)cc1		CHEMBL1965683	=	Ki	nM	19952.62	CHEMBL3231	Homo sapiens	pKi		4.7
active	9669243	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cccc(Cl)c2)cc1		CHEMBL1968606	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9669244	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	=	Ki	nM	3981.07	CHEMBL3231	Homo sapiens	pKi		5.4
active	9669245	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	12.59	CHEMBL3231	Homo sapiens	pKi		7.9
active	9669246	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	CSc1nn(-c2ccccn2)c(N)c1C(N)=O		CHEMBL2004615	=	Ki	nM	6309.57	CHEMBL3231	Homo sapiens	pKi		5.2
inactive	9669247	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12		CHEMBL1984039	<	Ki	nM	10000.0	CHEMBL3231	Homo sapiens	pKi		5.0
inactive	9669248	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
active	9669249	CHEMBL1963814	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK1	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	=	Ki	nM	2511.89	CHEMBL3231	Homo sapiens	pKi		5.6
	10839476	CHEMBL2015507	Inhibition of ROCK1 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	84.0	CHEMBL3231	Homo sapiens	INH	%	84.0
	10849727	CHEMBL2019686	Inhibition of ROCK1	B	CSc1ccccc1Nc1nc(N2CCNCC2)nc2c(NCC3CC3)ncnc12		CHEMBL2017214	>	IC50	nM	40000.0	CHEMBL3231	Homo sapiens	IC50	uM	40.0
	10862227	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023154	=	IC50	nM	650.0	CHEMBL3231	Homo sapiens	IC50	uM	0.65
	10862232	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023156	=	IC50	nM	1150.0	CHEMBL3231	Homo sapiens	IC50	uM	1.15
	10862233	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)Cc1ccccc1		CHEMBL2023160	=	IC50	nM	1410.0	CHEMBL3231	Homo sapiens	IC50	uM	1.41
	10862235	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)c1ccccc1		CHEMBL2023158	=	IC50	nM	1690.0	CHEMBL3231	Homo sapiens	IC50	uM	1.69
	10862236	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCc1ccc(Cl)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023153	=	IC50	nM	2200.0	CHEMBL3231	Homo sapiens	IC50	uM	2.2
	10862238	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023155	=	IC50	nM	2460.0	CHEMBL3231	Homo sapiens	IC50	uM	2.46
	10862239	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	COc1ccc(CCNC(=O)Nc2ccc3[nH]ncc3c2)cc1		CHEMBL2023152	=	IC50	nM	2600.0	CHEMBL3231	Homo sapiens	IC50	uM	2.6
	10862240	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023159	=	IC50	nM	2610.0	CHEMBL3231	Homo sapiens	IC50	uM	2.61
	10862241	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCC(O)c1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023151	=	IC50	nM	2900.0	CHEMBL3231	Homo sapiens	IC50	uM	2.9
	10862243	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc2[nH]ncc2c1)N[C@H](CO)Cc1ccccc1		CHEMBL2023150	=	IC50	nM	4600.0	CHEMBL3231	Homo sapiens	IC50	uM	4.6
	10862249	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)c1ccccc1		CHEMBL2023157	=	IC50	nM	9070.0	CHEMBL3231	Homo sapiens	IC50	uM	9.07
	10862250	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL225282	=	IC50	nM	13900.0	CHEMBL3231	Homo sapiens	IC50	uM	13.9
	10862252	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	CN(CCc1ccccc1)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023149	=	IC50	nM	21500.0	CHEMBL3231	Homo sapiens	IC50	uM	21.5
	10862253	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)Cc1ccccc1		CHEMBL2023161	=	IC50	nM	31010.0	CHEMBL3231	Homo sapiens	IC50	uM	31.01
	10862255	CHEMBL2025929	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells at 400 uM after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1ccccn1		CHEMBL2022281	=	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	10862260	CHEMBL2025929	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells at 400 uM after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1ccncc1		CHEMBL66221	=	Inhibition	%	44.0	CHEMBL3231	Homo sapiens	INH	%	44.0
	10862262	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	CN(C)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023147	=	IC50	nM	59100.0	CHEMBL3231	Homo sapiens	IC50	uM	59.1
	10862264	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	CC(=O)Nc1ccc2[nH]ncc2c1		CHEMBL503641	=	IC50	nM	65000.0	CHEMBL3231	Homo sapiens	IC50	uM	65.0
	10862265	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cnccc1Cl		CHEMBL2022282	=	IC50	nM	72500.0	CHEMBL3231	Homo sapiens	IC50	uM	72.5
	10862266	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cccnc1		CHEMBL67352	=	IC50	nM	75500.0	CHEMBL3231	Homo sapiens	IC50	uM	75.5
	10862268	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023148	=	IC50	nM	157100.0	CHEMBL3231	Homo sapiens	IC50	uM	157.1
	10862269	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	Nc1ccc2[nH]ncc2c1		CHEMBL17551	=	IC50	nM	181300.0	CHEMBL3231	Homo sapiens	IC50	uM	181.3
	10862271	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cncc(Br)c1		CHEMBL1566648	=	IC50	nM	270000.0	CHEMBL3231	Homo sapiens	IC50	uM	270.0
	10862273	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cnccc1-c1ccc(F)cc1		CHEMBL2023144	>	IC50	nM	400000.0	CHEMBL3231	Homo sapiens	IC50	uM	400.0
	10862274	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cncc(-c2ccc(F)cc2)c1		CHEMBL2023145	>	IC50	nM	400000.0	CHEMBL3231	Homo sapiens	IC50	uM	400.0
Not Determined	10862277	CHEMBL2025930	Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc2[nH]ncc2c1)Oc1ccccc1		CHEMBL2023146		IC50			CHEMBL3231	Homo sapiens	IC50		
Not Determined	10863361	CHEMBL2024942	Binding affinity to His6-tagged recombinant human ROCK1 by fluorescence anisotropy assay	B	CN(C)c1ccc2c(c1)OC1=CC(N(C)C)C=CC1=C2c1ccc(C(=O)O)cc1C(=O)N[C@H](CCCCN)C(=O)NC(=N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023845		Kd			CHEMBL3231	Homo sapiens	Kd		
	10863362	CHEMBL2024942	Binding affinity to His6-tagged recombinant human ROCK1 by fluorescence anisotropy assay	B	C=S(=O)(O)c1ccc2c(c1)C(C)(C)C1=[N+]2CCC2OC3CCN4C(=C3C=C12)C(C)(C)c1cc(CC(=O)NCCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCCCNCCNS(=O)(=O)c2cccc3cnccc23)C(N)=O)ccc14		CHEMBL2023841	=	Kd	nM	1.3	CHEMBL3231	Homo sapiens	Kd	nM	1.3
	10863752	CHEMBL2024907	Inhibition of ROCK1 by TR-FRET assay	B	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	IC50	nM	456.0	CHEMBL3231	Homo sapiens	IC50	nM	456.0
	10867560	CHEMBL2026615	Inhibition of ROCK1 by filter binding assay	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	IC50	nM	5000.0	CHEMBL3231	Homo sapiens	IC50	uM	5.0
	10926142	CHEMBL2046220	Inhibition of human ROCK-I assessed as remaining activity at 0.8 uM after 40 mins by scintillation counting	B	CC(C)Nc1cc(-c2oc3ccccc3c(=O)c2-c2ccc(F)cc2)ccn1		CHEMBL2041958	=	Activity	%	94.0	CHEMBL3231	Homo sapiens	Activity	%	94.0
	10926143	CHEMBL2046220	Inhibition of human ROCK-I assessed as remaining activity at 0.8 uM after 40 mins by scintillation counting	B	O=c1c(-c2ccc(F)cc2)c(-c2ccnc(NC3CCCCC3)c2)oc2ccccc12		CHEMBL2041962	=	Activity	%	106.0	CHEMBL3231	Homo sapiens	Activity	%	106.0
	10941285	CHEMBL2049853	Inhibition of ROCK1	B	CC(C)C[C@H]1CN(c2ccc(C(F)(F)F)c(C(=O)c3cccnc3N)n2)CCN1		CHEMBL2046643	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	uM	4.0
	10978443	CHEMBL2064849	Inhibition of human recombinant ROCK1 using ulight-RRRSLLE as substrate assessed as residual activity at 1 uM after 30 mins by Cerep assay	B	N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1		CHEMBL2064515	>	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	10980284	CHEMBL2065131	Inhibition of ROCK1 at 10 uM by FRET assay	B	CSc1ccccc1Nc1nc(N2CC3(CNC3)C2)nc2c(NCC3CC3)ncnc12		CHEMBL2017253	=	Inhibition	%	25.0	CHEMBL3231	Homo sapiens	INH	%	25.0
	10980285	CHEMBL2065131	Inhibition of ROCK1 at 10 uM by FRET assay	B	CSc1ccccc1Nc1nc(N2CCN(C3CCNCC3)CC2)nc2c(NCC3CC3)ncnc12		CHEMBL2063926	<	Inhibition	%	15.0	CHEMBL3231	Homo sapiens	INH	%	15.0
	10980317	CHEMBL2065161	Inhibition of ROCK1 by FRET assay	B	CSc1ccccc1Nc1nc(N2CCN(C3CCNCC3)CC2)nc2c(NCC3CC3)ncnc12		CHEMBL2063926	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	12035212	CHEMBL2150555	Inhibition of ROCK1 at 1 uM	B	C[C@H](N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147537	>	Inhibition	%	80.0	CHEMBL3231	Homo sapiens	INH	%	80.0
Active	12037015	CHEMBL2149978	Inhibition of ROCK1 at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1c[nH]c3ncccc13)C2=O		CHEMBL2147767		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	12047337	CHEMBL2157614	Inhibition of ROCK1 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	0.7	CHEMBL3231	Homo sapiens	INH	%	0.7
	12112574	CHEMBL2174408	Inhibition of ROCK1 at 1 uM by 33P kinase hotspot assay	B	NC(=O)c1ccc(Nc2ncc(F)c(Nc3ccccc3Cl)n2)cc1		CHEMBL2170414	=	Inhibition	%	-5.0	CHEMBL3231	Homo sapiens	INH	%	-5.0
	12112575	CHEMBL2174408	Inhibition of ROCK1 at 1 uM by 33P kinase hotspot assay	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Inhibition	%	-2.0	CHEMBL3231	Homo sapiens	INH	%	-2.0
	12145293	CHEMBL2186671	Inhibition of ROCK1 using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	Inhibition	%	25.0	CHEMBL3231	Homo sapiens	INH	%	25.0
	12145294	CHEMBL2186671	Inhibition of ROCK1 using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	Inhibition	%	25.0	CHEMBL3231	Homo sapiens	INH	%	25.0
	12172226	CHEMBL2212006	Inhibition of ROCK1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	38.0	CHEMBL3231	Homo sapiens	Activity	%	38.0
	12195421	CHEMBL2209630	Inhibition of recombinant ROCK1 after 1 hr by scintillation counter analysis in presence of gamma-[33P]ATP	B	CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O		CHEMBL2205426	=	Ki	nM	220.0	CHEMBL3231	Homo sapiens	Ki	nM	220.0
	12195587	CHEMBL2212366	Inhibition of human recombinant ROCK1 using Ulight-RRRSLLE as substrate assessed as residual activity at 1 uM after 30 mins relative to staurosporine	B	CCN(CC)CCOc1ccc(/C=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL2206008	=	Activity	%	102.4	CHEMBL3231	Homo sapiens	Activity	%	102.4
	12266833	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12266834	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12266835	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	101.0	CHEMBL3231	Homo sapiens	Residual Activity	%	101.0
	12266836	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12266837	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12266838	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12266839	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	92.0	CHEMBL3231	Homo sapiens	Residual Activity	%	92.0
	12266840	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12266841	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12266842	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	104.0	CHEMBL3231	Homo sapiens	Residual Activity	%	104.0
	12266843	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	99.0	CHEMBL3231	Homo sapiens	Residual Activity	%	99.0
	12266844	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12266845	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12266846	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12266847	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	104.0	CHEMBL3231	Homo sapiens	Residual Activity	%	104.0
	12266848	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12266849	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12266850	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12266851	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	101.0	CHEMBL3231	Homo sapiens	Residual Activity	%	101.0
	12266852	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	91.0	CHEMBL3231	Homo sapiens	Residual Activity	%	91.0
	12266853	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12266854	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	108.0	CHEMBL3231	Homo sapiens	Residual Activity	%	108.0
	12266855	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12266856	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12266857	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12266858	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	94.0	CHEMBL3231	Homo sapiens	Residual Activity	%	94.0
	12266859	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	97.0	CHEMBL3231	Homo sapiens	Residual Activity	%	97.0
	12266860	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12266861	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	124.0	CHEMBL3231	Homo sapiens	Residual Activity	%	124.0
	12266862	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12266863	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12266864	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12266865	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12266866	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12266867	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12266868	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12266869	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12266870	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12266871	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	125.0	CHEMBL3231	Homo sapiens	Residual Activity	%	125.0
	12266872	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12266873	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12266874	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12266875	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	98.0	CHEMBL3231	Homo sapiens	Residual Activity	%	98.0
	12266876	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	86.0	CHEMBL3231	Homo sapiens	Residual Activity	%	86.0
	12266877	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	111.0	CHEMBL3231	Homo sapiens	Residual Activity	%	111.0
	12266878	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12266879	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	125.0	CHEMBL3231	Homo sapiens	Residual Activity	%	125.0
	12266880	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12266881	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12266882	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12266883	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12266884	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12266885	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	59.0	CHEMBL3231	Homo sapiens	Residual Activity	%	59.0
	12266886	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	34.0	CHEMBL3231	Homo sapiens	Residual Activity	%	34.0
	12268529	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268530	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12268531	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268532	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12268533	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12268534	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268535	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	107.0	CHEMBL3231	Homo sapiens	Residual Activity	%	107.0
	12268536	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268537	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12268538	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268539	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	126.0	CHEMBL3231	Homo sapiens	Residual Activity	%	126.0
	12268540	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	132.0	CHEMBL3231	Homo sapiens	Residual Activity	%	132.0
	12268541	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268542	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12268543	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268544	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268545	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268546	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268547	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	83.0	CHEMBL3231	Homo sapiens	Residual Activity	%	83.0
	12268548	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	83.0	CHEMBL3231	Homo sapiens	Residual Activity	%	83.0
	12268549	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12268550	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268551	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12268552	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	101.0	CHEMBL3231	Homo sapiens	Residual Activity	%	101.0
	12268553	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268554	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	5.0	CHEMBL3231	Homo sapiens	Residual Activity	%	5.0
	12268555	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12268556	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	65.0	CHEMBL3231	Homo sapiens	Residual Activity	%	65.0
	12268557	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12268558	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	77.0	CHEMBL3231	Homo sapiens	Residual Activity	%	77.0
	12268559	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	132.0	CHEMBL3231	Homo sapiens	Residual Activity	%	132.0
	12268560	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	107.0	CHEMBL3231	Homo sapiens	Residual Activity	%	107.0
	12268561	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268562	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	70.0	CHEMBL3231	Homo sapiens	Residual Activity	%	70.0
	12268563	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12268564	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	108.0	CHEMBL3231	Homo sapiens	Residual Activity	%	108.0
	12268565	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268566	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268567	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12268568	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268569	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268570	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	98.0	CHEMBL3231	Homo sapiens	Residual Activity	%	98.0
	12268571	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268572	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12268573	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268574	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268575	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268576	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	50.0	CHEMBL3231	Homo sapiens	Residual Activity	%	50.0
	12268577	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268578	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268579	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	107.0	CHEMBL3231	Homo sapiens	Residual Activity	%	107.0
	12268580	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268581	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268582	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	126.0	CHEMBL3231	Homo sapiens	Residual Activity	%	126.0
	12268583	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12268584	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268585	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268586	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	124.0	CHEMBL3231	Homo sapiens	Residual Activity	%	124.0
	12268587	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	52.0	CHEMBL3231	Homo sapiens	Residual Activity	%	52.0
	12268588	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268589	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268590	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	111.0	CHEMBL3231	Homo sapiens	Residual Activity	%	111.0
	12268591	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12268592	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	134.0	CHEMBL3231	Homo sapiens	Residual Activity	%	134.0
	12268593	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	128.0	CHEMBL3231	Homo sapiens	Residual Activity	%	128.0
	12268594	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268595	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12268596	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268597	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268598	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268599	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12268600	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12268601	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268602	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268603	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268604	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	6.0	CHEMBL3231	Homo sapiens	Residual Activity	%	6.0
	12268605	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268606	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	125.0	CHEMBL3231	Homo sapiens	Residual Activity	%	125.0
	12268607	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268608	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268609	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268610	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268611	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268612	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	88.0	CHEMBL3231	Homo sapiens	Residual Activity	%	88.0
	12268613	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268614	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268615	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268616	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	89.0	CHEMBL3231	Homo sapiens	Residual Activity	%	89.0
	12268617	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268618	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268619	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12268620	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	111.0	CHEMBL3231	Homo sapiens	Residual Activity	%	111.0
	12268621	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268622	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268623	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	128.0	CHEMBL3231	Homo sapiens	Residual Activity	%	128.0
	12268624	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268625	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268626	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12268627	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	134.0	CHEMBL3231	Homo sapiens	Residual Activity	%	134.0
	12268628	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12268629	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268630	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268631	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268632	CHEMBL2219151	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	37.0	CHEMBL3231	Homo sapiens	Residual Activity	%	37.0
	12268633	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	82.0	CHEMBL3231	Homo sapiens	Residual Activity	%	82.0
	12268634	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12268635	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	99.0	CHEMBL3231	Homo sapiens	Residual Activity	%	99.0
	12268636	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12268637	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	126.0	CHEMBL3231	Homo sapiens	Residual Activity	%	126.0
	12268638	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268639	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	87.0	CHEMBL3231	Homo sapiens	Residual Activity	%	87.0
	12268640	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	91.0	CHEMBL3231	Homo sapiens	Residual Activity	%	91.0
	12268641	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	107.0	CHEMBL3231	Homo sapiens	Residual Activity	%	107.0
	12268642	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268643	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268644	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268645	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12268646	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	125.0	CHEMBL3231	Homo sapiens	Residual Activity	%	125.0
	12268647	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12268648	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	104.0	CHEMBL3231	Homo sapiens	Residual Activity	%	104.0
	12268649	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12268650	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12268651	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12268652	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	114.0	CHEMBL3231	Homo sapiens	Residual Activity	%	114.0
	12268653	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	128.0	CHEMBL3231	Homo sapiens	Residual Activity	%	128.0
	12268654	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268655	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268656	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	111.0	CHEMBL3231	Homo sapiens	Residual Activity	%	111.0
	12268657	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12268658	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12268659	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	72.0	CHEMBL3231	Homo sapiens	Residual Activity	%	72.0
	12268660	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12268661	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	137.0	CHEMBL3231	Homo sapiens	Residual Activity	%	137.0
	12268662	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268663	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12268664	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12268665	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12268666	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12268667	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	120.0	CHEMBL3231	Homo sapiens	Residual Activity	%	120.0
	12268668	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	133.0	CHEMBL3231	Homo sapiens	Residual Activity	%	133.0
	12268669	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	129.0	CHEMBL3231	Homo sapiens	Residual Activity	%	129.0
	12268670	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	140.0	CHEMBL3231	Homo sapiens	Residual Activity	%	140.0
	12268671	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	124.0	CHEMBL3231	Homo sapiens	Residual Activity	%	124.0
	12268672	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268673	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268674	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268675	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	97.0	CHEMBL3231	Homo sapiens	Residual Activity	%	97.0
	12268676	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	24.0	CHEMBL3231	Homo sapiens	Residual Activity	%	24.0
	12268677	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12268678	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	78.0	CHEMBL3231	Homo sapiens	Residual Activity	%	78.0
	12268679	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268680	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12268681	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	117.0	CHEMBL3231	Homo sapiens	Residual Activity	%	117.0
	12268682	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	125.0	CHEMBL3231	Homo sapiens	Residual Activity	%	125.0
	12268683	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	124.0	CHEMBL3231	Homo sapiens	Residual Activity	%	124.0
	12268684	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268685	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	23.0	CHEMBL3231	Homo sapiens	Residual Activity	%	23.0
	12268686	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	14.0	CHEMBL3231	Homo sapiens	Residual Activity	%	14.0
	12268687	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268688	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268689	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12268690	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12268691	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	126.0	CHEMBL3231	Homo sapiens	Residual Activity	%	126.0
	12268692	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12268693	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268694	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268695	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	113.0	CHEMBL3231	Homo sapiens	Residual Activity	%	113.0
	12268696	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268697	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268698	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268699	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12268700	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	107.0	CHEMBL3231	Homo sapiens	Residual Activity	%	107.0
	12268701	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	107.0	CHEMBL3231	Homo sapiens	Residual Activity	%	107.0
	12268702	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	126.0	CHEMBL3231	Homo sapiens	Residual Activity	%	126.0
	12268703	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	123.0	CHEMBL3231	Homo sapiens	Residual Activity	%	123.0
	12268704	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	127.0	CHEMBL3231	Homo sapiens	Residual Activity	%	127.0
	12268705	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	89.0	CHEMBL3231	Homo sapiens	Residual Activity	%	89.0
	12268706	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	96.0	CHEMBL3231	Homo sapiens	Residual Activity	%	96.0
	12268707	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268708	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	110.0	CHEMBL3231	Homo sapiens	Residual Activity	%	110.0
	12268709	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268710	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	90.0	CHEMBL3231	Homo sapiens	Residual Activity	%	90.0
	12268711	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	116.0	CHEMBL3231	Homo sapiens	Residual Activity	%	116.0
	12268712	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL3231	Homo sapiens	Residual Activity	%	2.0
	12268713	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	88.0	CHEMBL3231	Homo sapiens	Residual Activity	%	88.0
	12268714	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	16.0	CHEMBL3231	Homo sapiens	Residual Activity	%	16.0
	12268715	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	93.0	CHEMBL3231	Homo sapiens	Residual Activity	%	93.0
	12268716	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	31.0	CHEMBL3231	Homo sapiens	Residual Activity	%	31.0
	12268717	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12268718	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12268719	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	96.0	CHEMBL3231	Homo sapiens	Residual Activity	%	96.0
	12268720	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	74.0	CHEMBL3231	Homo sapiens	Residual Activity	%	74.0
	12268721	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	96.0	CHEMBL3231	Homo sapiens	Residual Activity	%	96.0
	12268722	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	92.0	CHEMBL3231	Homo sapiens	Residual Activity	%	92.0
	12268723	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12268724	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12268725	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	94.0	CHEMBL3231	Homo sapiens	Residual Activity	%	94.0
	12268726	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	122.0	CHEMBL3231	Homo sapiens	Residual Activity	%	122.0
	12268727	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12268728	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	36.0	CHEMBL3231	Homo sapiens	Residual Activity	%	36.0
	12268729	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	108.0	CHEMBL3231	Homo sapiens	Residual Activity	%	108.0
	12268730	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12268731	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12268732	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	104.0	CHEMBL3231	Homo sapiens	Residual Activity	%	104.0
	12268733	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	96.0	CHEMBL3231	Homo sapiens	Residual Activity	%	96.0
	12268734	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	12.0	CHEMBL3231	Homo sapiens	Residual Activity	%	12.0
	12268735	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12268736	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12268737	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	89.0	CHEMBL3231	Homo sapiens	Residual Activity	%	89.0
	12268738	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12268739	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	93.0	CHEMBL3231	Homo sapiens	Residual Activity	%	93.0
	12268740	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12268741	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	126.0	CHEMBL3231	Homo sapiens	Residual Activity	%	126.0
	12268742	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	101.0	CHEMBL3231	Homo sapiens	Residual Activity	%	101.0
	12268743	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12268744	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	108.0	CHEMBL3231	Homo sapiens	Residual Activity	%	108.0
	12268745	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	24.0	CHEMBL3231	Homo sapiens	Residual Activity	%	24.0
	12268746	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12268747	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12268748	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	104.0	CHEMBL3231	Homo sapiens	Residual Activity	%	104.0
	12268749	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	101.0	CHEMBL3231	Homo sapiens	Residual Activity	%	101.0
	12268750	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	124.0	CHEMBL3231	Homo sapiens	Residual Activity	%	124.0
	12268751	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268752	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	105.0	CHEMBL3231	Homo sapiens	Residual Activity	%	105.0
	12268753	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12268754	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	84.0	CHEMBL3231	Homo sapiens	Residual Activity	%	84.0
	12268755	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	82.0	CHEMBL3231	Homo sapiens	Residual Activity	%	82.0
	12268756	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	98.0	CHEMBL3231	Homo sapiens	Residual Activity	%	98.0
	12268757	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	98.0	CHEMBL3231	Homo sapiens	Residual Activity	%	98.0
	12268758	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	112.0	CHEMBL3231	Homo sapiens	Residual Activity	%	112.0
	12268759	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	96.0	CHEMBL3231	Homo sapiens	Residual Activity	%	96.0
	12268760	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	121.0	CHEMBL3231	Homo sapiens	Residual Activity	%	121.0
	12268761	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12270402	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	1.0	CHEMBL3231	Homo sapiens	Residual Activity	%	1.0
	12270403	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	109.0	CHEMBL3231	Homo sapiens	Residual Activity	%	109.0
	12270404	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12270405	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	95.0	CHEMBL3231	Homo sapiens	Residual Activity	%	95.0
	12270406	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	88.0	CHEMBL3231	Homo sapiens	Residual Activity	%	88.0
	12270407	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	97.0	CHEMBL3231	Homo sapiens	Residual Activity	%	97.0
	12270408	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	84.0	CHEMBL3231	Homo sapiens	Residual Activity	%	84.0
	12270409	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12270410	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	23.0	CHEMBL3231	Homo sapiens	Residual Activity	%	23.0
	12270411	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	102.0	CHEMBL3231	Homo sapiens	Residual Activity	%	102.0
	12270412	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	97.0	CHEMBL3231	Homo sapiens	Residual Activity	%	97.0
	12270413	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12270414	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	29.0	CHEMBL3231	Homo sapiens	Residual Activity	%	29.0
	12270415	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	80.0	CHEMBL3231	Homo sapiens	Residual Activity	%	80.0
	12270416	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	99.0	CHEMBL3231	Homo sapiens	Residual Activity	%	99.0
	12270417	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	90.0	CHEMBL3231	Homo sapiens	Residual Activity	%	90.0
	12270418	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	108.0	CHEMBL3231	Homo sapiens	Residual Activity	%	108.0
	12270419	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	119.0	CHEMBL3231	Homo sapiens	Residual Activity	%	119.0
	12270420	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	103.0	CHEMBL3231	Homo sapiens	Residual Activity	%	103.0
	12270421	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	101.0	CHEMBL3231	Homo sapiens	Residual Activity	%	101.0
	12270422	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	106.0	CHEMBL3231	Homo sapiens	Residual Activity	%	106.0
	12270423	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	85.0	CHEMBL3231	Homo sapiens	Residual Activity	%	85.0
	12270424	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	98.0	CHEMBL3231	Homo sapiens	Residual Activity	%	98.0
	12270425	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	115.0	CHEMBL3231	Homo sapiens	Residual Activity	%	115.0
	12270426	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	108.0	CHEMBL3231	Homo sapiens	Residual Activity	%	108.0
	12270427	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	118.0	CHEMBL3231	Homo sapiens	Residual Activity	%	118.0
	12270428	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12270429	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	100.0	CHEMBL3231	Homo sapiens	Residual Activity	%	100.0
	12270430	CHEMBL2219152	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	19.0	CHEMBL3231	Homo sapiens	Residual Activity	%	19.0
	12660661	CHEMBL2330651	Inhibition of ROCK1 (unknown origin) using FITC-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	470.0	CHEMBL3231	Homo sapiens	IC50	nM	470.0
	12679730	CHEMBL2345842	Inhibition of ROCK1 (unknown origin) at 1 uM	B	Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1		CHEMBL2331664	=	Inhibition	%	5.25	CHEMBL3231	Homo sapiens	INH	%	5.25
	12693174	CHEMBL2345777	Inhibition of ROCK1 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
	12700144	CHEMBL2342682	Inhibition of recombinant ROCK1 (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	58.0	CHEMBL3231	Homo sapiens	INH	%	58.0
	12705922	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332071	=	IC50	nM	58.0	CHEMBL3231	Homo sapiens	IC50	nM	58.0
	12705945	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N(CCO)Cc1ccccc1		CHEMBL2331562	=	IC50	nM	33.0	CHEMBL3231	Homo sapiens	IC50	nM	33.0
	12705976	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332073	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	12705979	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332069	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	12705986	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(C(CCO)NC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332076	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
	12705991	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cn2)c1		CHEMBL2332063	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	12705992	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1cccc(F)c1		CHEMBL2332056	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	12706003	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	CN(C)CCC(NC(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccccc1		CHEMBL2332059	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	12706004	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332068	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	12706005	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332065	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	12706018	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1O[C@H]1CCN(C)C1		CHEMBL2332060	=	IC50	nM	4.0	CHEMBL3231	Homo sapiens	IC50	nM	4.0
	12706019	CHEMBL2341176	Inhibition of ROCK1 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332097	=	IC50	nM	4.0	CHEMBL3231	Homo sapiens	IC50	nM	4.0
Not Determined	12708354	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	CN(C)c1nc([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333879		IC50			CHEMBL3231	Homo sapiens	IC50		
	12708355	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	COc1ccc([C@@H]2CN(C)C[C@H]2c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333887	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	12708356	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	NCc1ccc(C(=O)NC(c2ccc(Cl)cc2)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333884	=	IC50	nM	22.0	CHEMBL3231	Homo sapiens	IC50	nM	22.0
	12708357	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	CN(C)CC(=O)NC(c1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333882	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	12708358	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccc(Cl)cc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333898	=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	12708359	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C(N)c3cccc(Cl)c3)nc12		CHEMBL2333896	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	12708360	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	NC(c1cccc(Cl)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333894	=	IC50	nM	15.0	CHEMBL3231	Homo sapiens	IC50	nM	15.0
	12708361	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	COc1ccc(C[C@H](N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333909	=	IC50	nM	16.0	CHEMBL3231	Homo sapiens	IC50	nM	16.0
	12708362	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c([C@H](N)Cc3cccc(F)c3)nc12		CHEMBL2333908	=	IC50	nM	7.0	CHEMBL3231	Homo sapiens	IC50	nM	7.0
	12708363	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	N[C@H](Cc1ccc(F)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333906	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	12708364	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	N[C@@H](Cc1ccc(F)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333905	=	IC50	nM	17.0	CHEMBL3231	Homo sapiens	IC50	nM	17.0
Not Determined	12708365	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	N[C@@H](Cc1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2334293		IC50			CHEMBL3231	Homo sapiens	IC50		
	12708366	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2334292	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	12708367	CHEMBL2346264	Inhibition of ROCK1 (unknown origin)	B	COc1ccc(C(N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2334288	=	IC50	nM	48.0	CHEMBL3231	Homo sapiens	IC50	nM	48.0
	12727664	CHEMBL2351128	Inhibition of ROCK1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	87.0	CHEMBL3231	Homo sapiens	Activity	%	87.0
	12728950	CHEMBL2353068	Inhibition of ROCK1 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	96.0	CHEMBL3231	Homo sapiens	Activity	%	96.0
	12729833	CHEMBL2352165	Inhibition of ROCK1 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	94.0	CHEMBL3231	Homo sapiens	Activity	%	94.0
	12730093	CHEMBL2351128	Inhibition of ROCK1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	106.0	CHEMBL3231	Homo sapiens	Activity	%	106.0
Not Active	13328751	CHEMBL2388474	Inhibition of ROCK1 (unknown origin)	B	Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12		CHEMBL2386917		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	13342312	CHEMBL2396458	Competitive binding affinity to ROCK1 (unknown origin) assessed as enzyme remaining bound to anchored active-site ligand at 10 uM relative to control	B	Clc1ccc(CNc2nccc(-c3ccc4[nH]ncc4c3)n2)cc1Cl		CHEMBL1892019	<	Activity	%	30.0	CHEMBL3231	Homo sapiens	Activity	%	30.0
	13374360	CHEMBL2406303	Inhibition of ROCK1 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	4.0	CHEMBL3231	Homo sapiens	INH	%	4.0
	13434510	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434511	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434512	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434513	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434514	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434515	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434516	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434517	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434518	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434519	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434520	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13434521	CHEMBL2424232	Inhibition of ROCK1 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	<	Inhibition	%	35.0	CHEMBL3231	Homo sapiens	INH	%	35.0
	13475357	CHEMBL2439757	Inhibition of wild type human ROCK1 by high throughput ATP-[33P] radiolabeled assay	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978	=	IC50	nM	1030.0	CHEMBL3231	Homo sapiens	IC50	nM	1030.0
	13476400	CHEMBL2439124	Inhibition of human wild type ROCK1 at 1 uM by qPCR analysis relative to control	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978	>	Inhibition	%	90.0	CHEMBL3231	Homo sapiens	INH	%	90.0
	13503618	CHEMBL2447747	Inhibition of ROCK1 (unknown origin) assessed as residual activity at 10 uM relative to control	B	COc1cc(-c2cc(=O)c3cc(Br)cc(Br)c3o2)ccc1O		CHEMBL2442531	=	Activity	%	89.0	CHEMBL3231	Homo sapiens	Activity	%	89.0
	13503619	CHEMBL2447747	Inhibition of ROCK1 (unknown origin) assessed as residual activity at 10 uM relative to control	B	COc1cc(-c2cc(=O)c3cc(Br)cc(Br)c3o2)cc(Cl)c1O		CHEMBL2442530	=	Activity	%	121.0	CHEMBL3231	Homo sapiens	Activity	%	121.0
	13503620	CHEMBL2447747	Inhibition of ROCK1 (unknown origin) assessed as residual activity at 10 uM relative to control	B	COc1cc(-c2cc(=O)c3cc(Cl)cc(C)c3o2)ccc1O		CHEMBL2442529	=	Activity	%	113.0	CHEMBL3231	Homo sapiens	Activity	%	113.0
	13503621	CHEMBL2447747	Inhibition of ROCK1 (unknown origin) assessed as residual activity at 10 uM relative to control	B	COc1cc(-c2cc(=O)c3cc(Cl)cc(Cl)c3o2)ccc1O		CHEMBL2442424	=	Activity	%	120.0	CHEMBL3231	Homo sapiens	Activity	%	120.0
Not Active	13503649	CHEMBL2447756	Inhibition of ROCK1 (unknown origin) at 10 uM	B	COc1cc(-c2cc(=O)c3cc(C)cc(C)c3o2)ccc1O		CHEMBL2442389		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	13508478	CHEMBL2447350	Inhibition of ROCK1 (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	13871758	CHEMBL3100922	Inhibition of human ROCK-1 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	80.0	CHEMBL3231	Homo sapiens	Activity	%	80.0
	13899591	CHEMBL3111856	Inhibition of human recombinant ROCK1 using ATP/Ulight-RRRSLLE as substrate at 1 uM after 30 mins by LANCE assay	B	Cc1nn(-c2ccc(Cl)cc2Cl)c2c1c1c(c3cccn32)C(=O)NC1=O		CHEMBL3110144	<	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	13953215	CHEMBL3132645	Inhibition of human ROCK-1 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	113.0	CHEMBL3231	Homo sapiens	Activity	%	113.0
	13953246	CHEMBL3132645	Inhibition of human ROCK-1 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	104.0	CHEMBL3231	Homo sapiens	Activity	%	104.0
	13954682	CHEMBL3132645	Inhibition of human ROCK-1 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	98.0	CHEMBL3231	Homo sapiens	Activity	%	98.0
	14543536	CHEMBL3224492	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate at 50 uM after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218298	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	14543537	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218299	=	IC50	nM	480.0	CHEMBL3231	Homo sapiens	IC50	nM	480.0
	14543538	CHEMBL3226383	Inhibition of ROCK1 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	220.0	CHEMBL3231	Homo sapiens	Ki	uM	0.22
	14543539	CHEMBL3226383	Inhibition of ROCK1 (unknown origin)	B	C[C@@H](N)c1ccc(C(=O)Nc2ccncc2)cc1.Cl		CHEMBL2419278	=	IC50	nM	570.0	CHEMBL3231	Homo sapiens	IC50	uM	0.57
	14543540	CHEMBL3226383	Inhibition of ROCK1 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	260.0	CHEMBL3231	Homo sapiens	IC50	uM	0.26
	14543541	CHEMBL3226383	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	IC50	nM	0.53	CHEMBL3231	Homo sapiens	IC50	nM	0.53
	14543546	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218005	=	IC50	nM	170.0	CHEMBL3231	Homo sapiens	IC50	uM	0.17
	14543547	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	27.0	CHEMBL3231	Homo sapiens	IC50	uM	0.027
	14543548	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218007	=	IC50	nM	1400.0	CHEMBL3231	Homo sapiens	IC50	uM	1.4
	14543549	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218009	=	IC50	nM	50.0	CHEMBL3231	Homo sapiens	IC50	uM	0.05
	14543550	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc2[nH]ccc12)Nc1nc(-c2ccncc2)cs1		CHEMBL3218010	=	IC50	nM	37800.0	CHEMBL3231	Homo sapiens	IC50	uM	37.8
	14543551	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	uM	0.008
	14545698	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218012	=	IC50	nM	620.0	CHEMBL3231	Homo sapiens	IC50	uM	0.62
	14545699	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccc(O)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218013	=	IC50	nM	380.0	CHEMBL3231	Homo sapiens	IC50	uM	0.38
	14545700	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	NC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218014	=	IC50	nM	1200.0	CHEMBL3231	Homo sapiens	IC50	uM	1.2
	14545701	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CS(=O)(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218015	=	IC50	nM	560.0	CHEMBL3231	Homo sapiens	IC50	uM	0.56
	14545702	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218016	=	IC50	nM	1300.0	CHEMBL3231	Homo sapiens	IC50	uM	1.3
	14545703	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218017	=	IC50	nM	500.0	CHEMBL3231	Homo sapiens	IC50	uM	0.5
	14545704	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218018	=	IC50	nM	2100.0	CHEMBL3231	Homo sapiens	IC50	uM	2.1
	14545705	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218019	=	IC50	nM	3360.0	CHEMBL3231	Homo sapiens	IC50	uM	3.36
	14545706	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC(C)Oc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218020	=	IC50	nM	13000.0	CHEMBL3231	Homo sapiens	IC50	uM	13.0
	14545707	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218021	=	IC50	nM	100.0	CHEMBL3231	Homo sapiens	IC50	uM	0.1
	14545708	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1F)Nc1nc(-c2ccncc2)cs1		CHEMBL3218022	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	uM	0.4
	14545709	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccc(F)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218023	=	IC50	nM	570.0	CHEMBL3231	Homo sapiens	IC50	uM	0.57
	14545710	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc(Cl)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218024	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	uM	0.14
	14545711	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1Cl)Nc1nc(-c2ccncc2)cs1		CHEMBL3217759	=	IC50	nM	340.0	CHEMBL3231	Homo sapiens	IC50	uM	0.34
	14545712	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccc(Cl)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218025	=	IC50	nM	2400.0	CHEMBL3231	Homo sapiens	IC50	uM	2.4
	14545713	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Cc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218026	=	IC50	nM	460.0	CHEMBL3231	Homo sapiens	IC50	uM	0.46
	14545714	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Cc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218027	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	uM	0.15
	14545715	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Cc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218028	=	IC50	nM	5200.0	CHEMBL3231	Homo sapiens	IC50	uM	5.2
	14545716	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CN(Cc1ccccc1)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218274	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	uM	0.11
	14545717	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc(CNC(=O)N(C)c2nc(-c3ccncc3)cs2)c1		CHEMBL3218275	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	14545718	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc(CN(C)C(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218276	=	IC50	nM	40.0	CHEMBL3231	Homo sapiens	IC50	uM	0.04
	14545719	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218277	=	IC50	nM	43.0	CHEMBL3231	Homo sapiens	IC50	uM	0.043
	14545720	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H](CO)c1ccccc1		CHEMBL3218278	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	14545721	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218279	=	IC50	nM	90.0	CHEMBL3231	Homo sapiens	IC50	uM	0.09
	14545722	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	NC(=O)[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218280	=	IC50	nM	80.0	CHEMBL3231	Homo sapiens	IC50	uM	0.08
	14545723	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218281	=	IC50	nM	70.0	CHEMBL3231	Homo sapiens	IC50	uM	0.07
	14545724	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc([C@@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218282	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	uM	0.03
	14545725	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218283	=	IC50	nM	120.0	CHEMBL3231	Homo sapiens	IC50	uM	0.12
	14545726	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218284	=	IC50	nM	640.0	CHEMBL3231	Homo sapiens	IC50	uM	0.64
	14545727	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218285	=	IC50	nM	2900.0	CHEMBL3231	Homo sapiens	IC50	uM	2.9
	14545728	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H](CO)c1ccccc1		CHEMBL3218286	=	IC50	nM	5200.0	CHEMBL3231	Homo sapiens	IC50	uM	5.2
	14545729	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218287	=	IC50	nM	52200.0	CHEMBL3231	Homo sapiens	IC50	uM	52.2
	14545730	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	NC(=O)[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218288	=	IC50	nM	3700.0	CHEMBL3231	Homo sapiens	IC50	uM	3.7
	14545731	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218289	=	IC50	nM	29500.0	CHEMBL3231	Homo sapiens	IC50	uM	29.5
	14545732	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc([C@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218290	=	IC50	nM	18700.0	CHEMBL3231	Homo sapiens	IC50	uM	18.7
	14545733	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218291	=	IC50	nM	30000.0	CHEMBL3231	Homo sapiens	IC50	uM	30.0
	14545734	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218292	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	uM	50.0
	14545735	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218293	=	IC50	nM	120.0	CHEMBL3231	Homo sapiens	IC50	uM	0.12
	14545736	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218294	=	IC50	nM	6400.0	CHEMBL3231	Homo sapiens	IC50	uM	6.4
	14545737	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)NC(CO)c1ccccc1		CHEMBL3218295	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	uM	0.06
	14545738	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC(NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218296	=	IC50	nM	430.0	CHEMBL3231	Homo sapiens	IC50	uM	0.43
	14545787	CHEMBL3224492	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate at 50 uM after 1 hr by Z-Lyte-based FRET assay	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218008	=	Inhibition	%	9.1	CHEMBL3231	Homo sapiens	INH	%	9.1
	14545829	CHEMBL3224493	Inhibition of ROCK1 (unknown origin) at 1 uM	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	Inhibition	%	96.0	CHEMBL3231	Homo sapiens	INH	%	96.0
	14545830	CHEMBL3226385	Inhibition of N-terminal GST-tagged ROCK1 (1 to 535) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1		CHEMBL510515	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	14585318	CHEMBL3241834	Inhibition of human ROCK-1 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	108.0	CHEMBL3231	Homo sapiens	Activity	%	108.0
	14591704	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	IC50	nM	120.0	CHEMBL3231	Homo sapiens	IC50	nM	120.0
	14591705	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	OCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL599163	=	IC50	nM	570.0	CHEMBL3231	Homo sapiens	IC50	nM	570.0
	14591706	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	CN(C)CC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238163	=	IC50	nM	288.0	CHEMBL3231	Homo sapiens	IC50	nM	288.0
	14591707	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	CC(=O)NCC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238164	=	IC50	nM	350.0	CHEMBL3231	Homo sapiens	IC50	nM	350.0
	14591708	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	CC(=O)NCCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238165	=	IC50	nM	346.0	CHEMBL3231	Homo sapiens	IC50	nM	346.0
	14591709	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	c1nc(N2CCCC2)c(N2CCCNCC2)nc1-c1cc2cn[nH]c2cn1		CHEMBL3238166	=	IC50	nM	203.0	CHEMBL3231	Homo sapiens	IC50	nM	203.0
	14591710	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	c1cc2[nH]ncc2cc1-c1cncc(N2CCCNCC2)n1		CHEMBL3238167	=	IC50	nM	105.0	CHEMBL3231	Homo sapiens	IC50	nM	105.0
	14591711	CHEMBL3240143	Inhibition of truncated ROCK-1 (unknown origin)	B	Cc1n[nH]c2ccc(-c3cncc(N4CCCNCC4)n3)cc12		CHEMBL3238168	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
	14982803	CHEMBL3377889	Inhibition of human Rock1 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 2 uM ATP	B	COCCOCC1(C(=O)Nc2cccc(OC(=O)N(C)C)c2)CCN(c2ncnc3[nH]cc(C)c23)CC1		CHEMBL3356430	>	IC50	nM	2800.0	CHEMBL3231	Homo sapiens	IC50	nM	2800.0
	14982853	CHEMBL3377889	Inhibition of human Rock1 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 2 uM ATP	B	Cc1c[nH]c2ncnc(N3CCC(Cc4c[nH]cn4)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356431	=	IC50	nM	514.0	CHEMBL3231	Homo sapiens	IC50	nM	514.0
	14982854	CHEMBL3377889	Inhibition of human Rock1 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 2 uM ATP	B	Cc1c[nH]c2ncnc(N3CCC(CCN(C)C)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356432	=	IC50	nM	139.0	CHEMBL3231	Homo sapiens	IC50	nM	139.0
	14982855	CHEMBL3377889	Inhibition of human Rock1 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 2 uM ATP	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	=	IC50	nM	69.0	CHEMBL3231	Homo sapiens	IC50	nM	69.0
	14982859	CHEMBL3378490	Inhibition of human Rock1 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 200 uM ATP	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	=	IC50	nM	2200.0	CHEMBL3231	Homo sapiens	IC50	nM	2200.0
	14983168	CHEMBL3377040	Inhibition of ROCK1 (unknown origin) at 1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	13.0	CHEMBL3231	Homo sapiens	INH	%	13.0
	14984410	CHEMBL3384381	Inhibition of ROCK1 (unknown origin) at 0.1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	-7.0	CHEMBL3231	Homo sapiens	INH	%	-7.0
	15018685	CHEMBL3361577	Inhibition of ROCK1 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	-1.3	CHEMBL3231	Homo sapiens	INH	%	-1.3
	15019201	CHEMBL3364394	Inhibition of ROCK1 (unknown origin) at 1 uM in presence of 100 uM ATP	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C	Outside typical range	CHEMBL3298512	=	Inhibition	%	-14.0	CHEMBL3231	Homo sapiens	INH	%	-14.0
	15022506	CHEMBL3374444	Inhibition of ROCK1 (unknown origin) at 1 uM	B	COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1		CHEMBL3329684	=	Inhibition	%	55.0	CHEMBL3231	Homo sapiens	INH	%	55.0
	15025417	CHEMBL3365919	Inhibition of ROCK1 (unknown origin) at 1 uM by radioisotope-based P81 filter-binding assay	B	O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2/C1=C/c1ccc[nH]1		CHEMBL3322590	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	15041766	CHEMBL3368578	Inhibition of ROCK1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1OC		CHEMBL3102948	=	Inhibition	%	33.0	CHEMBL3231	Homo sapiens	INH	%	33.0
	15041767	CHEMBL3368578	Inhibition of ROCK1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1cc(-c2c[nH]c3ncc(-c4cccc(N)c4)cc23)cc(OC)c1OC		CHEMBL3319457	=	Inhibition	%	94.0	CHEMBL3231	Homo sapiens	INH	%	94.0
	15041768	CHEMBL3368578	Inhibition of ROCK1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4ccc(C(=O)N5CCOCC5)c(N)c4)cc23)cc1OC		CHEMBL3319467	=	Inhibition	%	16.0	CHEMBL3231	Homo sapiens	INH	%	16.0
	15041769	CHEMBL3368578	Inhibition of ROCK1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4cc(OC)c(OC)c(OC)c4)cc23)cc1OC		CHEMBL3319468	=	Inhibition	%	66.0	CHEMBL3231	Homo sapiens	INH	%	66.0
	15041770	CHEMBL3368578	Inhibition of ROCK1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1N		CHEMBL3319470	=	Inhibition	%	16.0	CHEMBL3231	Homo sapiens	INH	%	16.0
Not Active	15062580	CHEMBL3370293	Inhibition of human ROCK1 by Off-chip mobility shift assay	B	O=C(Cc1c(F)cccc1Cl)Nc1onc(-c2ccc(F)cc2)c1-c1ccncn1		CHEMBL3310142		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	15077389	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	nM	5.0
	15077390	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	93.0	CHEMBL3231	Homo sapiens	IC50	nM	93.0
	15077391	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	15077392	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	NCCNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL1214929	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
	15077393	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	CC(C)(N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147538	=	IC50	nM	21.0	CHEMBL3231	Homo sapiens	IC50	nM	21.0
	15077394	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	CC(C)(N)CNc1nc(-c2ccncc2)nc2cnccc12		CHEMBL3338837	=	IC50	nM	12.0	CHEMBL3231	Homo sapiens	IC50	nM	12.0
	15077395	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	CC(C)(N)CNc1nc(-c2ccc3[nH]ncc3c2)nc2cnccc12		CHEMBL3338838	=	IC50	nM	32.0	CHEMBL3231	Homo sapiens	IC50	nM	32.0
	15077396	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	c1cc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)nc2cn1		CHEMBL3338839	=	IC50	nM	36.0	CHEMBL3231	Homo sapiens	IC50	nM	36.0
	15077397	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	c1ccc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)nc2c1		CHEMBL3338840	=	IC50	nM	39.0	CHEMBL3231	Homo sapiens	IC50	nM	39.0
	15077398	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	c1ccc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)cc2c1		CHEMBL3338841	=	IC50	nM	141.0	CHEMBL3231	Homo sapiens	IC50	nM	141.0
	15077399	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	NCCNc1nc(-c2ccc3[nH]ncc3c2)nc2ccccc12		CHEMBL3338842	=	IC50	nM	52.0	CHEMBL3231	Homo sapiens	IC50	nM	52.0
	15077400	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	NCCCNc1nc(-c2ccc3[nH]ncc3c2)nc2ccccc12		CHEMBL3338843	=	IC50	nM	233.0	CHEMBL3231	Homo sapiens	IC50	nM	233.0
	15077401	CHEMBL3383292	Inhibition of ROCK-1 (unknown origin)	B	CN1CCN(c2nc(-c3ccc4[nH]ncc4c3)nc3ccccc23)CC1		CHEMBL3338844	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	nM	1000.0
	15091069	CHEMBL3382233	Inhibition of human recombinant ROCK1 using Ulight-RRRSLLE substrate assessed as remaining enzyme activity at 1 uM after 30 mins relative to control	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1		CHEMBL2206014	=	Activity	%	92.0	CHEMBL3231	Homo sapiens	Activity	%	92.0
	15112144	CHEMBL3388156	Inhibition of ROCK1 (unknown origin)	B	COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1		CHEMBL3360318	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
	15188576	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12		CHEMBL1951346	=	IC50	nM	1283.0	CHEMBL3231	Homo sapiens	IC50	nM	1283.0
	15188577	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c2c1C		CHEMBL3410025	>	IC50	nM	20000.0	CHEMBL3231	Homo sapiens	IC50	nM	20000.0
	15188578	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)c(F)c3)c12		CHEMBL3407526	=	IC50	nM	2390.0	CHEMBL3231	Homo sapiens	IC50	nM	2390.0
	15188579	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4)cc3)c12		CHEMBL3410036	=	IC50	nM	5536.0	CHEMBL3231	Homo sapiens	IC50	nM	5536.0
	15188580	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(F)cc4)cc3)c12		CHEMBL3410039	=	IC50	nM	3920.0	CHEMBL3231	Homo sapiens	IC50	nM	3920.0
	15188581	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4Cl)cc3)c12		CHEMBL3410040	=	IC50	nM	4390.0	CHEMBL3231	Homo sapiens	IC50	nM	4390.0
	15188582	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4cccc(Cl)c4)cc3)c12		CHEMBL3410041	=	IC50	nM	15050.0	CHEMBL3231	Homo sapiens	IC50	nM	15050.0
	15188583	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(Cl)cc4)cc3)c12		CHEMBL3410042	=	IC50	nM	5915.0	CHEMBL3231	Homo sapiens	IC50	nM	5915.0
	15188584	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1ccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410045	=	IC50	nM	7628.0	CHEMBL3231	Homo sapiens	IC50	nM	7628.0
	15188585	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1cccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)c1		CHEMBL3410047	=	IC50	nM	4317.0	CHEMBL3231	Homo sapiens	IC50	nM	4317.0
	15188586	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410048	>	IC50	nM	20000.0	CHEMBL3231	Homo sapiens	IC50	nM	20000.0
Not Determined	15188587	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(Cl)cc4)c(F)c3)c2c1C		CHEMBL3410053		IC50			CHEMBL3231	Homo sapiens	IC50		
Not Determined	15188588	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCN)c4ccc(Cl)cc4)c(F)c3)c2c1C		CHEMBL3410054		IC50			CHEMBL3231	Homo sapiens	IC50		
Not Determined	15188589	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCN(C)C)c4ccc(Cl)cc4)c(F)c3)c2c1C		CHEMBL3410055		IC50			CHEMBL3231	Homo sapiens	IC50		
Not Determined	15188590	CHEMBL3411301	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COCCN(C(=O)Nc1ccc(-c2ncnc3[nH]c(C)c(C)c23)cc1F)c1ccc(Cl)cc1		CHEMBL3410056		IC50			CHEMBL3231	Homo sapiens	IC50		
	15246149	CHEMBL3429818	Inhibition of human N-terminal GST-tagged ROCK1 expressed in insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426625	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	15246150	CHEMBL3429818	Inhibition of human N-terminal GST-tagged ROCK1 expressed in insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426624	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	15246151	CHEMBL3429818	Inhibition of human N-terminal GST-tagged ROCK1 expressed in insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)Cc1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426623	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	15246152	CHEMBL3429818	Inhibition of human N-terminal GST-tagged ROCK1 expressed in insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426622	<	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	15620160	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1		CHEMBL3581150	=	Ki	nM	30.0	CHEMBL3231	Homo sapiens	Ki	nM	30.0
	15620161	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1		CHEMBL3581149	=	Ki	nM	22.0	CHEMBL3231	Homo sapiens	Ki	nM	22.0
	15620162	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1		CHEMBL3581148	=	Ki	nM	45.0	CHEMBL3231	Homo sapiens	Ki	nM	45.0
	15620163	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1		CHEMBL3581147	=	Ki	nM	44.0	CHEMBL3231	Homo sapiens	Ki	nM	44.0
	15620164	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1		CHEMBL3580669	=	Ki	nM	10.0	CHEMBL3231	Homo sapiens	Ki	nM	10.0
	15620165	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1		CHEMBL3581146	=	Ki	nM	18.0	CHEMBL3231	Homo sapiens	Ki	nM	18.0
	15620166	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(Cl)c3)cs2)c1		CHEMBL3581145	=	Ki	nM	120.0	CHEMBL3231	Homo sapiens	Ki	nM	120.0
	15620167	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1		CHEMBL3581144	=	Ki	nM	110.0	CHEMBL3231	Homo sapiens	Ki	nM	110.0
	15620168	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(OC)c3)cs2)c1		CHEMBL3581143	>	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	nM	2500.0
	15620169	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N(C)C)c3)cs2)c1		CHEMBL3581142	>	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	nM	2500.0
	15620170	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	CNc1cc(-c2csc(NC(=O)Cc3cccc(OC)c3)n2)ccn1		CHEMBL3581141	=	Ki	nM	770.0	CHEMBL3231	Homo sapiens	Ki	nM	770.0
	15620171	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1		CHEMBL3581140	=	Ki	nM	170.0	CHEMBL3231	Homo sapiens	Ki	nM	170.0
	15620172	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(C)c3)cs2)c1		CHEMBL3581139	=	Ki	nM	210.0	CHEMBL3231	Homo sapiens	Ki	nM	210.0
	15620173	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2cc(-c3ccncn3)cs2)c1		CHEMBL3581138	=	Ki	nM	120.0	CHEMBL3231	Homo sapiens	Ki	nM	120.0
	15620174	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccncn3)cs2)c1		CHEMBL3581137	>	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	nM	2500.0
	15620175	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nnc(-c3ccncc3)s2)c1		CHEMBL3581136	=	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	nM	2500.0
	15620176	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccncc3)ns2)c1		CHEMBL3581135	=	Ki	nM	89.0	CHEMBL3231	Homo sapiens	Ki	nM	89.0
	15620177	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2ccc(-c3ccncc3)s2)c1		CHEMBL3581134	=	Ki	nM	140.0	CHEMBL3231	Homo sapiens	Ki	nM	140.0
	15620178	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2csc(-c3ccncc3)c2)c1		CHEMBL3581133	=	Ki	nM	61.0	CHEMBL3231	Homo sapiens	Ki	nM	61.0
	15620179	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2cc(-c3ccncc3)cs2)c1		CHEMBL3581132	=	Ki	nM	10.0	CHEMBL3231	Homo sapiens	Ki	nM	10.0
	15620180	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2cnc(-c3ccncc3)s2)c1		CHEMBL3581131	=	Ki	nM	490.0	CHEMBL3231	Homo sapiens	Ki	nM	490.0
	15620181	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2csc(-c3ccncc3)n2)c1		CHEMBL3581130	=	Ki	nM	530.0	CHEMBL3231	Homo sapiens	Ki	nM	530.0
	15620182	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(C2CCCN(c3nc(-c4ccncc4)cs3)C2=O)c1		CHEMBL3581129	=	Ki	nM	17.0	CHEMBL3231	Homo sapiens	Ki	nM	17.0
	15620183	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3581128	=	Ki	nM	26.0	CHEMBL3231	Homo sapiens	Ki	nM	26.0
	15620184	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	Nc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3581127	=	Ki	nM	350.0	CHEMBL3231	Homo sapiens	Ki	nM	350.0
	15620185	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccc2c(c1Cl)OCO2)Nc1nc(-c2ccncc2)cs1		CHEMBL3581126	=	Ki	nM	7.0	CHEMBL3231	Homo sapiens	Ki	nM	7.0
	15620186	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccc2c(c1)OCO2)Nc1nc(-c2ccncc2)cs1		CHEMBL3581125	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	Ki	nM	100.0
	15620187	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccc(O)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3581124	=	Ki	nM	70.0	CHEMBL3231	Homo sapiens	Ki	nM	70.0
	15620188	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3581123	=	Ki	nM	28.0	CHEMBL3231	Homo sapiens	Ki	nM	28.0
	15620189	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccccc1O)Nc1nc(-c2ccncc2)cs1		CHEMBL3581122	=	Ki	nM	900.0	CHEMBL3231	Homo sapiens	Ki	nM	900.0
	15620190	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1ccc(CC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL1427910	=	Ki	nM	540.0	CHEMBL3231	Homo sapiens	Ki	nM	540.0
	15620191	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3581121	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	Ki	nM	100.0
	15620192	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	COc1ccccc1CC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3581120	>	Ki	nM	2500.0	CHEMBL3231	Homo sapiens	Ki	nM	2500.0
	15620193	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccc(F)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3581119	=	Ki	nM	81.0	CHEMBL3231	Homo sapiens	Ki	nM	81.0
	15620194	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3581118	=	Ki	nM	120.0	CHEMBL3231	Homo sapiens	Ki	nM	120.0
	15620195	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccccc1F)Nc1nc(-c2ccncc2)cs1		CHEMBL3581117	=	Ki	nM	130.0	CHEMBL3231	Homo sapiens	Ki	nM	130.0
	15620196	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3581116	=	Ki	nM	170.0	CHEMBL3231	Homo sapiens	Ki	nM	170.0
	15620197	CHEMBL3585197	Inhibition of ROCK1 (6 to 553 amino acids) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate preincubated for 15 mins followed by ATP addition by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=C(Nc1nc(-c2ccncc2)cs1)c1ccccc1F		CHEMBL3581115	=	Ki	nM	1100.0	CHEMBL3231	Homo sapiens	Ki	uM	1.1
	15620859	CHEMBL3585218	Inhibition of human leukocytic ROCK1 expressed in insect cells using KKRNRTLSV as substrate after 10 mins by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	530.0	CHEMBL3231	Homo sapiens	Ki	nM	530.0
	15620860	CHEMBL3585218	Inhibition of human leukocytic ROCK1 expressed in insect cells using KKRNRTLSV as substrate after 10 mins by pyruvate kinase/lactate dehydrogenase coupled assay	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	Ki	nM	150.0	CHEMBL3231	Homo sapiens	Ki	nM	150.0
	15620861	CHEMBL3585218	Inhibition of human leukocytic ROCK1 expressed in insect cells using KKRNRTLSV as substrate after 10 mins by pyruvate kinase/lactate dehydrogenase coupled assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	150.0	CHEMBL3231	Homo sapiens	Ki	nM	150.0
	15649107	CHEMBL3595092	Inhibition of ROCK1 (unknown origin)	B	N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1		CHEMBL3593777	=	IC50	nM	190.0	CHEMBL3231	Homo sapiens	IC50	nM	190.0
	15747329	CHEMBL3624080	Inhibition of ROCK1 (unknown origin) assessed as residual enzyme activity at 10 uM by kinaseprolier assay	B	NCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21		CHEMBL3622826	>	Activity	%	65.0	CHEMBL3231	Homo sapiens	Activity	%	65.0
	15753779	CHEMBL3630464	Inhibition of human ROCK1 at 10 uM by kinase inhibition assay	B	COc1ccc2c(c1)SCc1cnc(-c3ccccc3)nc1-2		CHEMBL481789	=	Inhibition	%	-6.3	CHEMBL3231	Homo sapiens	INH	%	-6.3
	15753839	CHEMBL3630464	Inhibition of human ROCK1 at 10 uM by kinase inhibition assay	B	Clc1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)cc1		CHEMBL3628818	=	Inhibition	%	-5.6	CHEMBL3231	Homo sapiens	INH	%	-5.6
	15753916	CHEMBL3630464	Inhibition of human ROCK1 at 10 uM by kinase inhibition assay	B	COc1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1		CHEMBL3628537	=	Inhibition	%	-0.4	CHEMBL3231	Homo sapiens	INH	%	-0.4
	15753958	CHEMBL3630474	Inhibition of human ROCK1 by kinase inhibition assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	10'-8M	1.9
	15754266	CHEMBL3631692	Inhibition of ROCK1 (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	-3.0	CHEMBL3231	Homo sapiens	INH	%	-3.0
	15756827	CHEMBL3631323	Inhibition of ROCK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	9.07	CHEMBL3231	Homo sapiens	INH	%	9.07
	15757896	CHEMBL3631323	Inhibition of ROCK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	-6.9	CHEMBL3231	Homo sapiens	INH	%	-6.9
	15758875	CHEMBL3631323	Inhibition of ROCK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC	Outside typical range	CHEMBL3628628	=	Inhibition	%	-11.5	CHEMBL3231	Homo sapiens	INH	%	-11.5
276297	16262622	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCNC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL3666715	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
276301	16283571	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCCN4CCOCC4)c(OC)cc3n2)c1		CHEMBL3666719	>	IC50	nM	3000.0	CHEMBL3231	Homo sapiens	IC50	nM	3000.0
276299	16295818	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL3666717	=	IC50	nM	2600.0	CHEMBL3231	Homo sapiens	IC50	nM	2600.0
276303	16296416	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccc(OCCOC)cc3n2)c1		CHEMBL3666759	>	IC50	nM	3000.0	CHEMBL3231	Homo sapiens	IC50	nM	3000.0
276300	16308850	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COc1cc2nc(-c3cccc(NC(=O)CN4CCOCC4)c3)nc(Nc3ccc4[nH]ncc4c3)c2cc1OCCN1CCCC1		CHEMBL3666720	>	IC50	nM	3000.0	CHEMBL3231	Homo sapiens	IC50	nM	3000.0
276302	16334212	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN(C)C)ccc3n2)c1		CHEMBL3666718	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	nM	1000.0
276298	16338746	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1)Nc1cccnc1		CHEMBL3666716	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
276296	16344714	CHEMBL3708003	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(=O)Oc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL3666762	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
	16379693	CHEMBL3739163	Inhibition of ROCK1 (unknown origin) at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O		CHEMBL3735816	=	Inhibition	%	88.9	CHEMBL3231	Homo sapiens	INH	%	88.9
	16379694	CHEMBL3739163	Inhibition of ROCK1 (unknown origin) at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1C(C)N1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O		CHEMBL3735890	=	Inhibition	%	77.0	CHEMBL3231	Homo sapiens	INH	%	77.0
	16388324	CHEMBL3737499	Inhibition of ROCK1 (unknown origin) at 1 uM by selectscreen kinase profiling assay in presence of ATP	B	COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2		CHEMBL3091673	=	Inhibition	%	8.0	CHEMBL3231	Homo sapiens	INH	%	8.0
	16413511	CHEMBL3743745	Inhibition of ROCK1 (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	16426110	CHEMBL3751281	Inhibition of ROCK1 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	-4.8	CHEMBL3231	Homo sapiens	INH	%	-4.8
	16431991	CHEMBL3750030	Inhibition of human ROCK1 using [KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	16451597	CHEMBL3761178	Inhibition of ROCK1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	0.8	CHEMBL3231	Homo sapiens	INH	%	0.8
	16451749	CHEMBL3761178	Inhibition of ROCK1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	2.3	CHEMBL3231	Homo sapiens	INH	%	2.3
	16474710	CHEMBL3767330	Inhibition of ROCK1 (unknown origin) at 10 uM	B	CN1CCN(CCCOc2ccc(N3C(=O)/C(=C/c4ccc(Oc5ccc(F)cc5)cc4)SC3=S)cc2)CC1		CHEMBL3765499	=	Inhibition	%	61.1	CHEMBL3231	Homo sapiens	INH	%	61.1
	16493392	CHEMBL3772096	Inhibition of ROCK1 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	260.0	CHEMBL3231	Homo sapiens	IC50	nM	260.0
	16493394	CHEMBL3772096	Inhibition of ROCK1 (unknown origin)	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	51.0	CHEMBL3231	Homo sapiens	IC50	nM	51.0
	16493396	CHEMBL3772096	Inhibition of ROCK1 (unknown origin)	B	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	=	IC50	nM	200.0	CHEMBL3231	Homo sapiens	IC50	nM	200.0
	16493398	CHEMBL3772096	Inhibition of ROCK1 (unknown origin)	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	=	IC50	nM	56.0	CHEMBL3231	Homo sapiens	IC50	nM	56.0
	16493400	CHEMBL3772096	Inhibition of ROCK1 (unknown origin)	B	NC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3770730	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	16493402	CHEMBL3772096	Inhibition of ROCK1 (unknown origin)	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3770836	=	IC50	nM	1.2	CHEMBL3231	Homo sapiens	IC50	nM	1.2
	16495210	CHEMBL3777752	Inhibition of N-terminal His6-tagged recombinant human ROCK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	6.0	CHEMBL3231	Homo sapiens	Activity	%	6.0
	16496129	CHEMBL3777752	Inhibition of N-terminal His6-tagged recombinant human ROCK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	3.0	CHEMBL3231	Homo sapiens	Activity	%	3.0
	16508919	CHEMBL3777752	Inhibition of N-terminal His6-tagged recombinant human ROCK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	-1.0	CHEMBL3231	Homo sapiens	Activity	%	-1.0
	16547858	CHEMBL3796433	Inhibition of ROCK-1 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL3793353	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
	16556367	CHEMBL3796372	Inhibition of N-terminal His6-tagged recombinant human ROCK1 (17 to 535 amino acids) assessed as residual activity at 10 uM in presence of [gamma-32P]ATP by radiometric protein kinase assay	B	Cc1sc2ncnc(Nc3cccc(C(=O)O)c3)c2c1-c1ccccc1		CHEMBL3792965	=	Activity	%	101.5	CHEMBL3231	Homo sapiens	Activity	%	101.5
	16556368	CHEMBL3796372	Inhibition of N-terminal His6-tagged recombinant human ROCK1 (17 to 535 amino acids) assessed as residual activity at 10 uM in presence of [gamma-32P]ATP by radiometric protein kinase assay	B	O=C(O)c1cccc(Nc2ncnc3scc(-c4ccccc4)c23)c1		CHEMBL1719248	=	Activity	%	88.6	CHEMBL3231	Homo sapiens	Activity	%	88.6
	16556369	CHEMBL3796372	Inhibition of N-terminal His6-tagged recombinant human ROCK1 (17 to 535 amino acids) assessed as residual activity at 10 uM in presence of [gamma-32P]ATP by radiometric protein kinase assay	B	Cc1ccc(-c2csc3ncnc(Nc4cccc(C(=O)O)c4)c23)cc1		CHEMBL3401764	=	Activity	%	105.8	CHEMBL3231	Homo sapiens	Activity	%	105.8
	16557686	CHEMBL3796591	Inhibition of human ROCK1 at 500 nM	B	Cc1ccc(C(=O)OCc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL3794389	=	Inhibition	%	93.0	CHEMBL3231	Homo sapiens	INH	%	93.0
	16557697	CHEMBL3796591	Inhibition of human ROCK1 at 500 nM	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL3792888	=	Inhibition	%	100.0	CHEMBL3231	Homo sapiens	INH	%	100.0
	16559757	CHEMBL3794950	Inhibition of human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using fluorescence labelled LIMKtide substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccccc1)c1n[nH]c2ccccc12		CHEMBL508964	=	Inhibition	%	3.3	CHEMBL3231	Homo sapiens	INH	%	3.3
	16559758	CHEMBL3794950	Inhibition of human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using fluorescence labelled LIMKtide substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccc(C(=O)N2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12		CHEMBL3793843	=	Inhibition	%	6.9	CHEMBL3231	Homo sapiens	INH	%	6.9
	16559759	CHEMBL3794950	Inhibition of human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using fluorescence labelled LIMKtide substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccc(CN2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12		CHEMBL3792850	=	Inhibition	%	1.9	CHEMBL3231	Homo sapiens	INH	%	1.9
	16565471	CHEMBL3804491	Inhibition of N-terminal GST-tagged human ROCK1 expressed in baculovirus preincubated for 5 mins using long S6 peptide as substrate measured after 10 mins in presence of [gamma-33P]ATP by scintillation counting method	B	C[C@H](c1ccccc1)N1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C		CHEMBL3798011	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	nM	1000.0
	16580654	CHEMBL3803132	Inhibition of N-terminal GST-tagged human ROCK1 expressed in baculovirus preincubated for 5 mins using long S6 peptide as substrate at 1 uM measured after 60 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CCN1c2cc(-c3c[nH]c4ncccc34)ccc2C(=O)NC1(C)C		CHEMBL3798713	=	Inhibition	%	97.0	CHEMBL3231	Homo sapiens	INH	%	97.0
	16580655	CHEMBL3803132	Inhibition of N-terminal GST-tagged human ROCK1 expressed in baculovirus preincubated for 5 mins using long S6 peptide as substrate at 1 uM measured after 60 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CCN1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C		CHEMBL3798933	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	16589169	CHEMBL3807601	Inhibition of ROCK1 (unknown origin) at 0.5 uM by mobility shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)oc1Cl		CHEMBL3805228	=	Inhibition	%	94.4	CHEMBL3231	Homo sapiens	INH	%	94.4
	16589707	CHEMBL3807895	Inhibition of ROCK1 (unknown origin) by mobility shift assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.68	CHEMBL3231	Homo sapiens	IC50	nM	0.68
	16595522	CHEMBL3811148	Inhibition of recombinant human N-terminal His6-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 300 uM in presence of radiolabelled ATP by radiometric assay relative to control	B	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)C(C)C		CHEMBL3809381	=	Activity	%	95.0	CHEMBL3231	Homo sapiens	Activity	%	95.0
	16595528	CHEMBL3811142	Inhibition of recombinant human N-terminal His6-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 30 uM in presence of radiolabelled ATP by radiometric assay relative to control	B	CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)C(C)C)[C@@H](C)CC		CHEMBL3808687	=	Activity	%	0.0	CHEMBL3231	Homo sapiens	Activity	%	0.0
	16603152	CHEMBL3811364	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1		CHEMBL490	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	16603153	CHEMBL3811364	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	CCCn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccncn1		CHEMBL1738878	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	16603154	CHEMBL3811364	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	COc1cccc(OC)c1CNC(=O)c1cc(C2NC(=O)NC(C)=C2C(=O)Nc2ccc3[nH]ncc3c2)ccc1F		CHEMBL3809020	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	16603155	CHEMBL3811364	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3c(C(F)(F)F)cccc3C(F)(F)F)c2)NC(=O)N1		CHEMBL3809788	=	Inhibition	%	22.0	CHEMBL3231	Homo sapiens	INH	%	22.0
	16603156	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	IC50	nM	100.0	CHEMBL3231	Homo sapiens	IC50	uM	0.1
	16603157	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)O)c2)NC(=O)N1		CHEMBL3810250	=	IC50	nM	190.0	CHEMBL3231	Homo sapiens	IC50	uM	0.19
	16603158	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CNC(=O)c1cc(C2NC(=O)NC(C)=C2C(=O)Nc2ccc3[nH]ncc3c2)ccc1F		CHEMBL3810349	=	IC50	nM	560.0	CHEMBL3231	Homo sapiens	IC50	uM	0.56
	16603159	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3ccccc3)c2)NC(=O)N1		CHEMBL3808840	=	IC50	nM	69.0	CHEMBL3231	Homo sapiens	IC50	uM	0.069
	16603160	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3cccc(F)c3)c2)NC(=O)N1		CHEMBL3809100	=	IC50	nM	21.0	CHEMBL3231	Homo sapiens	IC50	uM	0.021
	16603161	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3c(F)cccc3F)c2)NC(=O)N1		CHEMBL3808621	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	uM	0.11
	16603162	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	COc1ccccc1CNC(=O)c1cc(C2NC(=O)NC(C)=C2C(=O)Nc2ccc3[nH]ncc3c2)ccc1F		CHEMBL3809965	=	IC50	nM	57.0	CHEMBL3231	Homo sapiens	IC50	uM	0.057
	16603163	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	COc1cccc(CNC(=O)c2cc(C3NC(=O)NC(C)=C3C(=O)Nc3ccc4[nH]ncc4c3)ccc2F)c1		CHEMBL3810312	=	IC50	nM	97.0	CHEMBL3231	Homo sapiens	IC50	uM	0.097
	16603164	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	COc1ccc(CNC(=O)c2cc(C3NC(=O)NC(C)=C3C(=O)Nc3ccc4[nH]ncc4c3)ccc2F)cc1		CHEMBL3810073	=	IC50	nM	50.0	CHEMBL3231	Homo sapiens	IC50	uM	0.05
	16603165	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3ccccn3)c2)NC(=O)N1		CHEMBL3808660	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	uM	0.011
	16603166	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCCc3ccccn3)c2)NC(=O)N1		CHEMBL3810107	=	IC50	nM	23.0	CHEMBL3231	Homo sapiens	IC50	uM	0.023
	16603167	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCCc3ccncc3)c2)NC(=O)N1		CHEMBL3808565	=	IC50	nM	84.0	CHEMBL3231	Homo sapiens	IC50	uM	0.084
	16603168	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3nccc4ccccc34)c2)NC(=O)N1		CHEMBL3809796	=	IC50	nM	12.0	CHEMBL3231	Homo sapiens	IC50	uM	0.012
	16603169	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3c(Cl)cccc3Cl)c2)NC(=O)N1		CHEMBL3810271	=	IC50	nM	6700.0	CHEMBL3231	Homo sapiens	IC50	uM	6.7
	16603170	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3c(C)cccc3C)c2)NC(=O)N1		CHEMBL3809913	=	IC50	nM	5800.0	CHEMBL3231	Homo sapiens	IC50	uM	5.8
	16603171	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)c2)NC(=O)N1		CHEMBL3808657	=	IC50	nM	1900.0	CHEMBL3231	Homo sapiens	IC50	uM	1.9
	16603172	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3ncccc3C)c2)NC(=O)N1		CHEMBL3809697	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	uM	0.15
	16604905	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCCc3c(C)cccc3C)c2)NC(=O)N1		CHEMBL3808918	=	IC50	nM	290.0	CHEMBL3231	Homo sapiens	IC50	uM	0.29
	16604906	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(CC(=O)NCc3c(C)cccc3C)c2)NC(=O)N1		CHEMBL3808499	=	IC50	nM	450.0	CHEMBL3231	Homo sapiens	IC50	uM	0.45
	16604907	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(CC(=O)NCc3c(C(F)(F)F)cccc3C(F)(F)F)c2)NC(=O)N1		CHEMBL3809604	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	uM	0.4
	16604908	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	COc1cccc(OC)c1CNC(=O)Cc1cc(C2NC(=O)NC(C)=C2C(=O)Nc2ccc3[nH]ncc3c2)ccc1F		CHEMBL3809124	=	IC50	nM	200.0	CHEMBL3231	Homo sapiens	IC50	uM	0.2
	16604909	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)N(C)c2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3c(C)cccc3C)c2)NC(=O)N1		CHEMBL3809584	=	IC50	nM	2100.0	CHEMBL3231	Homo sapiens	IC50	uM	2.1
Not Determined	16604910	CHEMBL3811365	Inhibition of ROCK1 (unknown origin) by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3c(c2)OCO3)C(c2ccc(F)c(C(=O)NCc3ccccn3)c2)NC(=O)N1		CHEMBL3810383		IC50			CHEMBL3231	Homo sapiens	IC50		
	16604922	CHEMBL3811368	Potency index, ratio of GSK180736A IC50 to compound IC50 for ROCK1 (unknown origin)	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(C(=O)NCc3ccccn3)c2)NC(=O)N1		CHEMBL3808660	=	Ratio IC50		10.0	CHEMBL3231	Homo sapiens	Ratio IC50		10.0
	16614618	CHEMBL3816764	Inhibition of human ROCK1 at 1 uM using [KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-9.0	CHEMBL3231	Homo sapiens	INH	%	-9.0
	16618133	CHEMBL3816519	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	16642017	CHEMBL3826428	Inhibition of catalytic GST-tagged human ROCK1 expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	-7.0	CHEMBL3231	Homo sapiens	INH	%	-7.0
	16815467	CHEMBL3871627	Inhibition of human recombinant GST-tagged ROCK1 catalytic domain (1 to 535 residues) expressed in baculovirus expression system at 1 uM	B	O=C(O)/C=C\C(=O)Nc1cccc(-c2n[nH]c3ccc(NS(=O)(=O)c4ccccc4)cc23)c1		CHEMBL3986609	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	16837465	CHEMBL3876127	Inhibition of human recombinant GST-tagged ROCK1 cytoplasmic domain (1 to 535 residues) expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
262157	17644685	CHEMBL3706010	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3cn[nH]c3)cc2)NC(=O)c2cc(Cl)ccc21		CHEMBL3649655	>	IC50	nM	30000.0	CHEMBL3231	Homo sapiens	IC50	nM	30000.0
262158	17644686	CHEMBL3706010	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccnc(N)c3)cc2)NC(=O)c2cc(Cl)ccc21		CHEMBL3649656	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
262159	17644687	CHEMBL3706010	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	COc1ccc2c(c1)C(=O)N[C@@H](Cc1ccc(-c3ccnc(N)c3)cc1)C(=O)N2C		CHEMBL3649657	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
262160	17644688	CHEMBL3706010	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@H](Cc2ccc(-c3ccnc4[nH]ccc34)cc2)NC(=O)c2cc(Cl)ccc21		CHEMBL3649658	=	IC50	nM	5100.0	CHEMBL3231	Homo sapiens	IC50	nM	5100.0
262161	17644689	CHEMBL3706010	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	COc1ccc2c(c1)C(=O)N[C@@H](Cc1ccc(-c3ccnc4[nH]ccc34)cc1)C(=O)N2C		CHEMBL3649659	=	IC50	nM	2800.0	CHEMBL3231	Homo sapiens	IC50	nM	2800.0
326137	17704885	CHEMBL3887235	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](CC2C=CC(c3ccncc3)=CC2)NC(=O)c2cc(Cl)ccc21		CHEMBL4112110	>	IC50	nM	30000.0	CHEMBL3231	Homo sapiens	IC50	nM	30000.0
326138	17704886	CHEMBL3887235	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	C[C@@]1(Cc2ccc(C3C=CN=CC3)cc2)NC(=O)c2cc(Cl)ccc2NC1=O		CHEMBL3934988	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
326139	17704887	CHEMBL3887235	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccncc3)cc2)NC(=O)C2=C(Cl)CCC=C21		CHEMBL4106738	>	IC50	nM	30000.0	CHEMBL3231	Homo sapiens	IC50	nM	30000.0
326140	17704888	CHEMBL3887235	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccncc3)cc2)NC(=O)c2ccc(Cl)cc21		CHEMBL4114625	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
326141	17704889	CHEMBL3887235	Inhibition Assay: In a final reaction volume of 25 L, ROCK-I (h, amino acids 17-535) (5-10 mU) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccncc3)cc2)NC(=O)C2=CCCC(Cl)=C21		CHEMBL4107646	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
326142	17704890	CHEMBL3887236	Inhibition Assay: In a final reaction volume of 25 L, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](CC2C=CC(c3ccncc3)=CC2)NC(=O)c2cc(Cl)ccc21		CHEMBL4112110	=	IC50	nM	1100.0	CHEMBL3231	Homo sapiens	IC50	nM	1100.0
326143	17704891	CHEMBL3887236	Inhibition Assay: In a final reaction volume of 25 L, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	C[C@@]1(Cc2ccc(C3C=CN=CC3)cc2)NC(=O)c2cc(Cl)ccc2NC1=O		CHEMBL3934988	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	nM	10000.0
326144	17704892	CHEMBL3887236	Inhibition Assay: In a final reaction volume of 25 L, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccncc3)cc2)NC(=O)C2=C(Cl)CCC=C21		CHEMBL4106738	=	IC50	nM	860.0	CHEMBL3231	Homo sapiens	IC50	nM	860.0
326145	17704893	CHEMBL3887236	Inhibition Assay: In a final reaction volume of 25 L, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccncc3)cc2)NC(=O)c2ccc(Cl)cc21		CHEMBL4114625	=	IC50	nM	800.0	CHEMBL3231	Homo sapiens	IC50	nM	800.0
326146	17704894	CHEMBL3887236	Inhibition Assay: In a final reaction volume of 25 L, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 M KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and [-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 L of a 3% phosphoric acid solution. 10 L of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccncc3)cc2)NC(=O)C2=CCCC(Cl)=C21		CHEMBL4107646	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	nM	1000.0
351443	17727612	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(F)cc2C1		CHEMBL3938988	=	IC50	nM	679.0	CHEMBL3231	Homo sapiens	IC50	nM	679.0
351444	17727613	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)Nc1nc2ccccc2o1		CHEMBL3968518	=	IC50	nM	729.0	CHEMBL3231	Homo sapiens	IC50	nM	729.0
351445	17727614	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	COC[C@@H]1CCCN1C(=O)Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1		CHEMBL3974064	=	IC50	nM	16200.0	CHEMBL3231	Homo sapiens	IC50	nM	16200.0
351446	17727615	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)NC1CCC1		CHEMBL3944615	=	IC50	nM	6482.0	CHEMBL3231	Homo sapiens	IC50	nM	6482.0
351447	17727616	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	CCOc1ccc2c(c1)N(C(=O)Cc1ccc(-c3n[nH]c(=O)c4ccccc34)cc1)CC2		CHEMBL3953195	=	IC50	nM	23.0	CHEMBL3231	Homo sapiens	IC50	nM	23.0
351448	17727617	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1CCCc2ccccc21		CHEMBL3929004	=	IC50	nM	11940.0	CHEMBL3231	Homo sapiens	IC50	nM	11940.0
351449	17727618	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1csc(-c2ccc(C(F)(F)F)cc2)n1		CHEMBL3957734	=	IC50	nM	670.0	CHEMBL3231	Homo sapiens	IC50	nM	670.0
351450	17727619	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	Cn1ccnc1C(=O)Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1		CHEMBL3930239	=	IC50	nM	544.0	CHEMBL3231	Homo sapiens	IC50	nM	544.0
351451	17727620	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	CN(C)c1ccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)cc1		CHEMBL3968772	=	IC50	nM	35.0	CHEMBL3231	Homo sapiens	IC50	nM	35.0
351452	17727621	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1ccc(N2CCCCC2)cc1		CHEMBL3935660	=	IC50	nM	49.0	CHEMBL3231	Homo sapiens	IC50	nM	49.0
351453	17727622	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1ccccc1		CHEMBL3980970	=	IC50	nM	175.0	CHEMBL3231	Homo sapiens	IC50	nM	175.0
351454	17727623	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Oc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1CCC(c2ccccc2)C1		CHEMBL3952135	=	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
351455	17727624	CHEMBL3887751	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2c[nH]c(=O)c3ccccc23)cc1)N1CCc2ccccc21		CHEMBL3921800	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	nM	20.0
354385	17730216	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218005	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	nM	150.0
354386	17730217	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218005	=	IC50	nM	170.0	CHEMBL3231	Homo sapiens	IC50	nM	170.0
354387	17730218	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218298	=	IC50	nM	10430.0	CHEMBL3231	Homo sapiens	IC50	nM	10430.0
354388	17730219	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NC(=O)c1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3892412	=	IC50	nM	16300.0	CHEMBL3231	Homo sapiens	IC50	nM	16300.0
354389	17730220	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218299	=	IC50	nM	480.0	CHEMBL3231	Homo sapiens	IC50	nM	480.0
354390	17730221	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CN(Cc1ccccc1)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218274	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	nM	110.0
354391	17730222	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	nM	60.0
354392	17730223	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	27.0	CHEMBL3231	Homo sapiens	IC50	nM	27.0
354393	17730224	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
354394	17730225	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	23.0	CHEMBL3231	Homo sapiens	IC50	nM	23.0
354395	17730226	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218007	=	IC50	nM	1400.0	CHEMBL3231	Homo sapiens	IC50	nM	1400.0
354396	17730227	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218008	=	IC50	nM	9120.0	CHEMBL3231	Homo sapiens	IC50	nM	9120.0
354397	17730228	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218008	=	IC50	nM	36190.0	CHEMBL3231	Homo sapiens	IC50	nM	36190.0
354398	17730229	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218008	=	IC50	nM	15260.0	CHEMBL3231	Homo sapiens	IC50	nM	15260.0
354399	17730230	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CNC(=O)N(C)c2nc(-c3ccncc3)cs2)c1		CHEMBL3218275	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	nM	60.0
354400	17730231	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CN(C)C(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218276	=	IC50	nM	40.0	CHEMBL3231	Homo sapiens	IC50	nM	40.0
354401	17730232	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218009	=	IC50	nM	50.0	CHEMBL3231	Homo sapiens	IC50	nM	50.0
354402	17730233	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	Nc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3954084	=	IC50	nM	45850.0	CHEMBL3231	Homo sapiens	IC50	nM	45850.0
354403	17730234	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc2[nH]ccc12)Nc1nc(-c2ccncc2)cs1		CHEMBL3218010	=	IC50	nM	37790.0	CHEMBL3231	Homo sapiens	IC50	nM	37790.0
354404	17730235	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CNc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3923247	=	IC50	nM	470.0	CHEMBL3231	Homo sapiens	IC50	nM	470.0
354405	17730236	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
354406	17730237	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
354407	17730238	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	9.0	CHEMBL3231	Homo sapiens	IC50	nM	9.0
354408	17730239	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	NC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218014	=	IC50	nM	1150.0	CHEMBL3231	Homo sapiens	IC50	nM	1150.0
354409	17730240	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218016	=	IC50	nM	1250.0	CHEMBL3231	Homo sapiens	IC50	nM	1250.0
354410	17730241	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CS(=O)(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218015	=	IC50	nM	560.0	CHEMBL3231	Homo sapiens	IC50	nM	560.0
354411	17730242	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccccc1O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218012	=	IC50	nM	620.0	CHEMBL3231	Homo sapiens	IC50	nM	620.0
354412	17730243	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccc(O)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218013	=	IC50	nM	380.0	CHEMBL3231	Homo sapiens	IC50	nM	380.0
354413	17730244	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218017	=	IC50	nM	500.0	CHEMBL3231	Homo sapiens	IC50	nM	500.0
354414	17730245	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218018	=	IC50	nM	2140.0	CHEMBL3231	Homo sapiens	IC50	nM	2140.0
354415	17730246	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218019	=	IC50	nM	3360.0	CHEMBL3231	Homo sapiens	IC50	nM	3360.0
354416	17730247	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CC(C)Oc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218020	=	IC50	nM	13000.0	CHEMBL3231	Homo sapiens	IC50	nM	13000.0
354417	17730248	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(OC(F)(F)F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3965107	=	IC50	nM	7480.0	CHEMBL3231	Homo sapiens	IC50	nM	7480.0
354418	17730249	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(OC(F)F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3932202	=	IC50	nM	920.0	CHEMBL3231	Homo sapiens	IC50	nM	920.0
354419	17730250	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218021	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
354420	17730251	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218021	=	IC50	nM	100.0	CHEMBL3231	Homo sapiens	IC50	nM	100.0
354421	17730252	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccccc1F)Nc1nc(-c2ccncc2)cs1		CHEMBL3218022	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	nM	400.0
354422	17730253	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccc(F)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218023	=	IC50	nM	570.0	CHEMBL3231	Homo sapiens	IC50	nM	570.0
354423	17730254	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc(Cl)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218024	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
354424	17730255	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccccc1Cl)Nc1nc(-c2ccncc2)cs1		CHEMBL3217759	=	IC50	nM	340.0	CHEMBL3231	Homo sapiens	IC50	nM	340.0
354425	17730256	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccc(Cl)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218025	=	IC50	nM	2390.0	CHEMBL3231	Homo sapiens	IC50	nM	2390.0
354426	17730257	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	Cc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218026	=	IC50	nM	460.0	CHEMBL3231	Homo sapiens	IC50	nM	460.0
354427	17730258	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	Cc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218027	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	nM	150.0
354428	17730259	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	Cc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218028	=	IC50	nM	5160.0	CHEMBL3231	Homo sapiens	IC50	nM	5160.0
354429	17730260	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccc([N+](=O)[O-])cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3913793	=	IC50	nM	34550.0	CHEMBL3231	Homo sapiens	IC50	nM	34550.0
354430	17730261	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc(OC)c1		CHEMBL3931698	=	IC50	nM	9950.0	CHEMBL3231	Homo sapiens	IC50	nM	9950.0
354431	17730262	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1OC		CHEMBL3894166	=	IC50	nM	35420.0	CHEMBL3231	Homo sapiens	IC50	nM	35420.0
354432	17730263	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1OC		CHEMBL3963188	=	IC50	nM	45130.0	CHEMBL3231	Homo sapiens	IC50	nM	45130.0
354433	17730264	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccc(Cl)cc1Cl)Nc1nc(-c2ccncc2)cs1		CHEMBL3935950	=	IC50	nM	1880.0	CHEMBL3231	Homo sapiens	IC50	nM	1880.0
354434	17730265	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cc(Cl)cc(Cl)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3908001	=	IC50	nM	6260.0	CHEMBL3231	Homo sapiens	IC50	nM	6260.0
354435	17730266	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cc(F)cc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3958434	=	IC50	nM	4070.0	CHEMBL3231	Homo sapiens	IC50	nM	4070.0
354436	17730267	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccc2ccccc12)Nc1nc(-c2ccncc2)cs1		CHEMBL3987124	=	IC50	nM	1100.0	CHEMBL3231	Homo sapiens	IC50	nM	1100.0
354437	17730268	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccco1)Nc1nc(-c2ccncc2)cs1		CHEMBL3963845	=	IC50	nM	1170.0	CHEMBL3231	Homo sapiens	IC50	nM	1170.0
354438	17730269	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1cccnc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3926492	=	IC50	nM	910.0	CHEMBL3231	Homo sapiens	IC50	nM	910.0
354439	17730270	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccccn1)Nc1nc(-c2ccncc2)cs1		CHEMBL3944452	=	IC50	nM	1820.0	CHEMBL3231	Homo sapiens	IC50	nM	1820.0
354440	17730271	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1ccncc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3973907	=	IC50	nM	2070.0	CHEMBL3231	Homo sapiens	IC50	nM	2070.0
354441	17730272	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218277	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
354442	17730273	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218277	=	IC50	nM	43.0	CHEMBL3231	Homo sapiens	IC50	nM	43.0
354443	17730274	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218293	=	IC50	nM	120.0	CHEMBL3231	Homo sapiens	IC50	nM	120.0
354444	17730275	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218285	=	IC50	nM	3560.0	CHEMBL3231	Homo sapiens	IC50	nM	3560.0
354445	17730276	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218285	=	IC50	nM	3290.0	CHEMBL3231	Homo sapiens	IC50	nM	3290.0
354446	17730277	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218294	=	IC50	nM	6440.0	CHEMBL3231	Homo sapiens	IC50	nM	6440.0
354447	17730278	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H](CO)c1ccccc1		CHEMBL3218278	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
354448	17730279	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)NC(CO)c1ccccc1		CHEMBL3218295	=	IC50	nM	60.0	CHEMBL3231	Homo sapiens	IC50	nM	60.0
354449	17730280	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H](CO)c1ccccc1		CHEMBL3218286	=	IC50	nM	5200.0	CHEMBL3231	Homo sapiens	IC50	nM	5200.0
354450	17730281	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218279	=	IC50	nM	90.0	CHEMBL3231	Homo sapiens	IC50	nM	90.0
354451	17730282	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218287	=	IC50	nM	52170.0	CHEMBL3231	Homo sapiens	IC50	nM	52170.0
354452	17730283	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	NC(=O)[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218280	=	IC50	nM	80.0	CHEMBL3231	Homo sapiens	IC50	nM	80.0
354453	17730284	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	NC(=O)[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218288	=	IC50	nM	3700.0	CHEMBL3231	Homo sapiens	IC50	nM	3700.0
354454	17730285	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218281	=	IC50	nM	70.0	CHEMBL3231	Homo sapiens	IC50	nM	70.0
354455	17730286	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218289	=	IC50	nM	29480.0	CHEMBL3231	Homo sapiens	IC50	nM	29480.0
354456	17730287	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CC(C)(NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3966306	=	IC50	nM	190.0	CHEMBL3231	Homo sapiens	IC50	nM	190.0
354457	17730288	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)NC(c1ccccc1)c1ccccc1		CHEMBL3914256	=	IC50	nM	1870.0	CHEMBL3231	Homo sapiens	IC50	nM	1870.0
354458	17730289	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc([C@@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218282	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
354459	17730290	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1cccc([C@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218290	=	IC50	nM	18710.0	CHEMBL3231	Homo sapiens	IC50	nM	18710.0
354460	17730291	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccc([C@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3889585	=	IC50	nM	1090.0	CHEMBL3231	Homo sapiens	IC50	nM	1090.0
354461	17730292	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	COc1ccc([C@@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL4107622	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
354462	17730293	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218291	=	IC50	nM	29970.0	CHEMBL3231	Homo sapiens	IC50	nM	29970.0
354463	17730294	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218283	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	nM	110.0
354464	17730295	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	CC(NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218296	=	IC50	nM	430.0	CHEMBL3231	Homo sapiens	IC50	nM	430.0
354465	17730296	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218292	>	IC50	nM	50000.0	CHEMBL3231	Homo sapiens	IC50	nM	50000.0
354466	17730297	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218284	=	IC50	nM	550.0	CHEMBL3231	Homo sapiens	IC50	nM	550.0
354467	17730298	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)Nc1ccc(F)cc1F		CHEMBL3965078	=	IC50	nM	14540.0	CHEMBL3231	Homo sapiens	IC50	nM	14540.0
354468	17730299	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1ccc(F)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3962641	=	IC50	nM	8060.0	CHEMBL3231	Homo sapiens	IC50	nM	8060.0
354469	17730300	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)Nc1ccccc1F		CHEMBL3919067	=	IC50	nM	13330.0	CHEMBL3231	Homo sapiens	IC50	nM	13330.0
354470	17730301	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)Nc1ccccc1Cl		CHEMBL3978510	=	IC50	nM	2490.0	CHEMBL3231	Homo sapiens	IC50	nM	2490.0
354471	17730302	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)NC1Cc2ccccc2C1		CHEMBL3963230	=	IC50	nM	40910.0	CHEMBL3231	Homo sapiens	IC50	nM	40910.0
354472	17730303	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(NCc1nc2ccccc2[nH]1)Nc1nc(-c2ccncc2)cs1		CHEMBL3975425	=	IC50	nM	40910.0	CHEMBL3231	Homo sapiens	IC50	nM	40910.0
354473	17730304	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H]1CCc2ccccc21		CHEMBL4114172	=	IC50	nM	28240.0	CHEMBL3231	Homo sapiens	IC50	nM	28240.0
354474	17730305	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H]1CCc2ccccc21		CHEMBL3916739	=	IC50	nM	3210.0	CHEMBL3231	Homo sapiens	IC50	nM	3210.0
354475	17730306	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H]1CCCc2ccccc21		CHEMBL4112033	=	IC50	nM	6990.0	CHEMBL3231	Homo sapiens	IC50	nM	6990.0
354476	17730307	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H]1CCCc2ccccc21		CHEMBL3903548	=	IC50	nM	6250.0	CHEMBL3231	Homo sapiens	IC50	nM	6250.0
354477	17730308	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCc2ccccc2C1		CHEMBL3915031	=	IC50	nM	3870.0	CHEMBL3231	Homo sapiens	IC50	nM	3870.0
354478	17730309	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(c2ccncc2)CC1		CHEMBL3890560	=	IC50	nM	16890.0	CHEMBL3231	Homo sapiens	IC50	nM	16890.0
354479	17730310	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(Cc2ccccc2)C[C@@H]1Cc1ccccc1		CHEMBL3906049	=	IC50	nM	24270.0	CHEMBL3231	Homo sapiens	IC50	nM	24270.0
354480	17730311	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(C(=O)c2ccco2)CC1		CHEMBL3976768	=	IC50	nM	35050.0	CHEMBL3231	Homo sapiens	IC50	nM	35050.0
354481	17730312	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(c2ccncn2)CC1		CHEMBL3900632	=	IC50	nM	41390.0	CHEMBL3231	Homo sapiens	IC50	nM	41390.0
354482	17730313	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(c2cccnc2)CC1		CHEMBL3968238	=	IC50	nM	14010.0	CHEMBL3231	Homo sapiens	IC50	nM	14010.0
354483	17730314	CHEMBL3887786	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 M.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(CC2CCCO2)CC1		CHEMBL3902671	=	IC50	nM	210.0	CHEMBL3231	Homo sapiens	IC50	nM	210.0
417289	17780752	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cccnc1		CHEMBL67352	=	IC50	nM	75500.0	CHEMBL3231	Homo sapiens	IC50	nM	75500.0
417290	17780753	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cnccc1Cl		CHEMBL2022282	=	IC50	nM	72500.0	CHEMBL3231	Homo sapiens	IC50	nM	72500.0
417291	17780754	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cncc(Br)c1	Outside typical range	CHEMBL1566648	=	IC50	nM	270000.0	CHEMBL3231	Homo sapiens	IC50	nM	270000.0
417292	17780755	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cnccc1-c1ccc(F)cc1	Outside typical range	CHEMBL2023144	>	IC50	nM	4000000.0	CHEMBL3231	Homo sapiens	IC50	nM	4000000.0
417293	17780756	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cncc(-c2ccc(F)cc2)c1	Outside typical range	CHEMBL2023145	>	IC50	nM	4000000.0	CHEMBL3231	Homo sapiens	IC50	nM	4000000.0
417294	17780757	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	Nc1ccc2[nH]ncc2c1	Outside typical range	CHEMBL17551	=	IC50	nM	181300.0	CHEMBL3231	Homo sapiens	IC50	nM	181300.0
417295	17780758	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	CN(C)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023147	=	IC50	nM	59100.0	CHEMBL3231	Homo sapiens	IC50	nM	59100.0
417296	17780759	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccccc1)Nc1ccc2[nH]ncc2c1	Outside typical range	CHEMBL2023148	=	IC50	nM	157100.0	CHEMBL3231	Homo sapiens	IC50	nM	157100.0
417297	17780760	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL225282	=	IC50	nM	13900.0	CHEMBL3231	Homo sapiens	IC50	nM	13900.0
417298	17780761	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	CN(CCc1ccccc1)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023149	=	IC50	nM	21500.0	CHEMBL3231	Homo sapiens	IC50	nM	21500.0
417300	17780762	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCC(O)c1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023151	=	IC50	nM	2900.0	CHEMBL3231	Homo sapiens	IC50	nM	2900.0
417301	17780763	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	COc1ccc(CCNC(=O)Nc2ccc3[nH]ncc3c2)cc1		CHEMBL2023152	=	IC50	nM	2600.0	CHEMBL3231	Homo sapiens	IC50	nM	2600.0
417302	17780764	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCc1ccc(Cl)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023153	=	IC50	nM	2200.0	CHEMBL3231	Homo sapiens	IC50	nM	2200.0
417303	17780765	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023154	=	IC50	nM	650.0	CHEMBL3231	Homo sapiens	IC50	nM	650.0
417304	17780766	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023155	=	IC50	nM	2460.0	CHEMBL3231	Homo sapiens	IC50	nM	2460.0
417305	17780767	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023156	=	IC50	nM	1150.0	CHEMBL3231	Homo sapiens	IC50	nM	1150.0
417306	17780768	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)c1ccccc1		CHEMBL2023157	=	IC50	nM	9070.0	CHEMBL3231	Homo sapiens	IC50	nM	9070.0
417307	17780769	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)c1ccccc1		CHEMBL2023158	=	IC50	nM	1690.0	CHEMBL3231	Homo sapiens	IC50	nM	1690.0
417308	17780770	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023159	=	IC50	nM	2610.0	CHEMBL3231	Homo sapiens	IC50	nM	2610.0
417309	17780771	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)Cc1ccccc1		CHEMBL2023160	=	IC50	nM	1410.0	CHEMBL3231	Homo sapiens	IC50	nM	1410.0
417310	17780772	CHEMBL3888818	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 l of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 M of substrate with 12.5 M of ATP (ROCK1 assay) or 2 M of substrate with 50 M of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)Cc1ccccc1		CHEMBL2023161	=	IC50	nM	31010.0	CHEMBL3231	Homo sapiens	IC50	nM	31010.0
439048	17798792	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3951271	=	IC50	nM	6.69	CHEMBL3231	Homo sapiens	IC50	nM	6.69
439049	17798793	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC2(c3ccccc3Cl)CC2)ccc1-c1cn[nH]c1		CHEMBL3923391	=	IC50	nM	13.9	CHEMBL3231	Homo sapiens	IC50	nM	13.9
439050	17798794	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3960736	=	IC50	nM	4.27	CHEMBL3231	Homo sapiens	IC50	nM	4.27
439051	17798795	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3984075	=	IC50	nM	17.7	CHEMBL3231	Homo sapiens	IC50	nM	17.7
439052	17798796	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3955445	=	IC50	nM	9.61	CHEMBL3231	Homo sapiens	IC50	nM	9.61
439053	17798797	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(O)c2)ccc1-c1cn[nH]c1		CHEMBL3986802	=	IC50	nM	0.85	CHEMBL3231	Homo sapiens	IC50	nM	0.85
439054	17798798	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3913336	=	IC50	nM	1.11	CHEMBL3231	Homo sapiens	IC50	nM	1.11
439055	17798799	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3928809	=	IC50	nM	2.63	CHEMBL3231	Homo sapiens	IC50	nM	2.63
439056	17798800	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2csc(-c3ccccc3)n2)ccc1-c1cn[nH]c1		CHEMBL3900840	=	IC50	nM	155.0	CHEMBL3231	Homo sapiens	IC50	nM	155.0
439057	17798801	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN2CCOCC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3956456	=	IC50	nM	107.0	CHEMBL3231	Homo sapiens	IC50	nM	107.0
439058	17798802	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(COC(=O)NC(C)(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3925445	=	IC50	nM	108.0	CHEMBL3231	Homo sapiens	IC50	nM	108.0
439059	17798803	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3955270	=	IC50	nM	6.39	CHEMBL3231	Homo sapiens	IC50	nM	6.39
439060	17798804	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN2CCN(C)CC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3980726	=	IC50	nM	147.0	CHEMBL3231	Homo sapiens	IC50	nM	147.0
439061	17798805	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN2CCCC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3943121	=	IC50	nM	243.0	CHEMBL3231	Homo sapiens	IC50	nM	243.0
439062	17798806	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccn2)ccc1-c1cn[nH]c1		CHEMBL3972689	=	IC50	nM	184.0	CHEMBL3231	Homo sapiens	IC50	nM	184.0
439063	17798807	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2nc3ccccc3s2)ccc1-c1cn[nH]c1		CHEMBL3906029	=	IC50	nM	556.0	CHEMBL3231	Homo sapiens	IC50	nM	556.0
439064	17798808	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(F)c2)ccc1-c1cn[nH]c1		CHEMBL3967386	=	IC50	nM	8.42	CHEMBL3231	Homo sapiens	IC50	nM	8.42
439065	17798809	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(-c3ccccc3)c2)ccc1-c1cn[nH]c1		CHEMBL3900611	=	IC50	nM	334.0	CHEMBL3231	Homo sapiens	IC50	nM	334.0
439066	17798810	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccnc2)ccc1-c1cn[nH]c1		CHEMBL3928583	=	IC50	nM	104.0	CHEMBL3231	Homo sapiens	IC50	nM	104.0
439067	17798811	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3891623	=	IC50	nM	10.5	CHEMBL3231	Homo sapiens	IC50	nM	10.5
439068	17798812	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccccc1CNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3951573	=	IC50	nM	182.0	CHEMBL3231	Homo sapiens	IC50	nM	182.0
439069	17798813	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2OC(F)(F)F)ccc1-c1cn[nH]c1		CHEMBL3981137	=	IC50	nM	85.8	CHEMBL3231	Homo sapiens	IC50	nM	85.8
439070	17798814	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2C)ccc1-c1cn[nH]c1		CHEMBL3952342	=	IC50	nM	7.36	CHEMBL3231	Homo sapiens	IC50	nM	7.36
439071	17798815	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL3892048	=	IC50	nM	37.4	CHEMBL3231	Homo sapiens	IC50	nM	37.4
439072	17798816	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3966859	=	IC50	nM	7.9	CHEMBL3231	Homo sapiens	IC50	nM	7.9
439073	17798817	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2C(F)(F)F)ccc1-c1cn[nH]c1		CHEMBL3987039	=	IC50	nM	20.4	CHEMBL3231	Homo sapiens	IC50	nM	20.4
439074	17798818	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3910168	=	IC50	nM	12.8	CHEMBL3231	Homo sapiens	IC50	nM	12.8
439075	17798819	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(OC(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3976301	=	IC50	nM	1708.0	CHEMBL3231	Homo sapiens	IC50	nM	1708.0
439076	17798820	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(Cl)c2Cl)ccc1-c1cn[nH]c1		CHEMBL3915532	=	IC50	nM	5.77	CHEMBL3231	Homo sapiens	IC50	nM	5.77
439077	17798821	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)(C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3916624	=	IC50	nM	214.0	CHEMBL3231	Homo sapiens	IC50	nM	214.0
439078	17798822	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2O)ccc1-c1cn[nH]c1		CHEMBL3986384	=	IC50	nM	9.2	CHEMBL3231	Homo sapiens	IC50	nM	9.2
439079	17798823	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3952741	=	IC50	nM	43.3	CHEMBL3231	Homo sapiens	IC50	nM	43.3
439080	17798824	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2)ccc1-c1cn[nH]c1		CHEMBL3965421	=	IC50	nM	26.5	CHEMBL3231	Homo sapiens	IC50	nM	26.5
439081	17798825	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL3987001	=	IC50	nM	124.0	CHEMBL3231	Homo sapiens	IC50	nM	124.0
439082	17798826	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3920786	=	IC50	nM	16.5	CHEMBL3231	Homo sapiens	IC50	nM	16.5
439083	17798827	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3963314	=	IC50	nM	28.1	CHEMBL3231	Homo sapiens	IC50	nM	28.1
439084	17798828	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2S(=O)(=O)CC(C)C)ccc1-c1cn[nH]c1		CHEMBL3926252	=	IC50	nM	2440.0	CHEMBL3231	Homo sapiens	IC50	nM	2440.0
439085	17798829	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc3c(c2)OCO3)ccc1-c1cn[nH]c1		CHEMBL3980727	=	IC50	nM	34.8	CHEMBL3231	Homo sapiens	IC50	nM	34.8
439086	17798830	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)c(C(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3907073	=	IC50	nM	107.0	CHEMBL3231	Homo sapiens	IC50	nM	107.0
439087	17798831	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)[C@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3902021	=	IC50	nM	337.0	CHEMBL3231	Homo sapiens	IC50	nM	337.0
439088	17798832	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3969934	=	IC50	nM	3.37	CHEMBL3231	Homo sapiens	IC50	nM	3.37
439089	17798833	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)[C@@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3915358	=	IC50	nM	26.3	CHEMBL3231	Homo sapiens	IC50	nM	26.3
439090	17798834	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3890863	=	IC50	nM	40.8	CHEMBL3231	Homo sapiens	IC50	nM	40.8
439091	17798835	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3934496	=	IC50	nM	96.1	CHEMBL3231	Homo sapiens	IC50	nM	96.1
439092	17798836	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Br)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3906535	=	IC50	nM	16.9	CHEMBL3231	Homo sapiens	IC50	nM	16.9
439093	17798837	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(OCC(C)C)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3929051	=	IC50	nM	1880.0	CHEMBL3231	Homo sapiens	IC50	nM	1880.0
439094	17798838	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2SCC(C)C)ccc1-c1cn[nH]c1		CHEMBL3894920	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439095	17798839	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Oc3ccccc3)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3920141	=	IC50	nM	663.0	CHEMBL3231	Homo sapiens	IC50	nM	663.0
439096	17798840	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3892122	=	IC50	nM	14.3	CHEMBL3231	Homo sapiens	IC50	nM	14.3
439097	17798841	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)c(OC)c2F)ccc1-c1cn[nH]c1		CHEMBL3951004	=	IC50	nM	64.0	CHEMBL3231	Homo sapiens	IC50	nM	64.0
439098	17798842	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(OC)c2F)ccc1-c1cn[nH]c1		CHEMBL3926788	=	IC50	nM	14.8	CHEMBL3231	Homo sapiens	IC50	nM	14.8
439099	17798843	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)cc(F)c2)ccc1-c1cn[nH]c1		CHEMBL3912625	=	IC50	nM	125.0	CHEMBL3231	Homo sapiens	IC50	nM	125.0
439100	17798844	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1ccccc1Cl		CHEMBL3914530	=	IC50	nM	11.3	CHEMBL3231	Homo sapiens	IC50	nM	11.3
439101	17798845	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3944065	=	IC50	nM	21.3	CHEMBL3231	Homo sapiens	IC50	nM	21.3
439102	17798846	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3907133	=	IC50	nM	5.35	CHEMBL3231	Homo sapiens	IC50	nM	5.35
439103	17798847	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3c[nH]nc3C)c(OC)c2)c1		CHEMBL3942539	=	IC50	nM	461.0	CHEMBL3231	Homo sapiens	IC50	nM	461.0
439104	17798848	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1c[nH]nc1C		CHEMBL3941476	=	IC50	nM	147.0	CHEMBL3231	Homo sapiens	IC50	nM	147.0
439105	17798849	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3967606	=	IC50	nM	16.9	CHEMBL3231	Homo sapiens	IC50	nM	16.9
439106	17798850	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(F)c2)c1		CHEMBL3928973	=	IC50	nM	33.3	CHEMBL3231	Homo sapiens	IC50	nM	33.3
439107	17798851	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2C)c1		CHEMBL4111347	=	IC50	nM	1170.0	CHEMBL3231	Homo sapiens	IC50	nM	1170.0
439108	17798852	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2S(C)(=O)=O)c1		CHEMBL4107460	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439109	17798853	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2F)c1		CHEMBL4110256	=	IC50	nM	43.3	CHEMBL3231	Homo sapiens	IC50	nM	43.3
439110	17798854	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CN(C)CCOc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3949659	=	IC50	nM	1580.0	CHEMBL3231	Homo sapiens	IC50	nM	1580.0
439111	17798855	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)O)c2)ccc1-c1cn[nH]c1		CHEMBL3921882	=	IC50	nM	7.7	CHEMBL3231	Homo sapiens	IC50	nM	7.7
439112	17798856	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3958305	=	IC50	nM	3.05	CHEMBL3231	Homo sapiens	IC50	nM	3.05
439113	17798857	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)N3CCCC3)c2)ccc1-c1cn[nH]c1		CHEMBL3935094	=	IC50	nM	64.3	CHEMBL3231	Homo sapiens	IC50	nM	64.3
439114	17798858	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2cc(F)cc(F)c2)ccc1-c1cn[nH]c1		CHEMBL3934001	=	IC50	nM	26.5	CHEMBL3231	Homo sapiens	IC50	nM	26.5
439115	17798859	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H]2C[C@H]2c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3965294	=	IC50	nM	30.1	CHEMBL3231	Homo sapiens	IC50	nM	30.1
439116	17798860	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)ccc2F)ccc1-c1cn[nH]c1		CHEMBL3921599	=	IC50	nM	18.6	CHEMBL3231	Homo sapiens	IC50	nM	18.6
439117	17798861	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N(C)CCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3956876	=	IC50	nM	379.0	CHEMBL3231	Homo sapiens	IC50	nM	379.0
439118	17798862	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N(C)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3904808	=	IC50	nM	1340.0	CHEMBL3231	Homo sapiens	IC50	nM	1340.0
439119	17798863	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3936323	=	IC50	nM	5.91	CHEMBL3231	Homo sapiens	IC50	nM	5.91
439120	17798864	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL3901566	=	IC50	nM	9.03	CHEMBL3231	Homo sapiens	IC50	nM	9.03
439121	17798865	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccc3ccccc3c2)ccc1-c1cn[nH]c1		CHEMBL3916608	=	IC50	nM	36.3	CHEMBL3231	Homo sapiens	IC50	nM	36.3
439122	17798866	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)c(F)c(F)c2)ccc1-c1cn[nH]c1		CHEMBL3953239	=	IC50	nM	34.1	CHEMBL3231	Homo sapiens	IC50	nM	34.1
439123	17798867	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(Cl)ccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3922088	=	IC50	nM	7.72	CHEMBL3231	Homo sapiens	IC50	nM	7.72
439124	17798868	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc3nc(N)sc3c2)ccc1-c1cn[nH]c1		CHEMBL3911197	=	IC50	nM	1240.0	CHEMBL3231	Homo sapiens	IC50	nM	1240.0
439125	17798869	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(OC(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3943648	=	IC50	nM	21.8	CHEMBL3231	Homo sapiens	IC50	nM	21.8
439126	17798870	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)c(F)c2)ccc1-c1cn[nH]c1		CHEMBL3969590	=	IC50	nM	22.8	CHEMBL3231	Homo sapiens	IC50	nM	22.8
439127	17798871	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(C)c2F)ccc1-c1cn[nH]c1		CHEMBL3943471	=	IC50	nM	13.2	CHEMBL3231	Homo sapiens	IC50	nM	13.2
439128	17798872	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2cccc(CN3CCN(C)CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3936832	=	IC50	nM	156.0	CHEMBL3231	Homo sapiens	IC50	nM	156.0
439129	17798873	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)ccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3908876	=	IC50	nM	9.89	CHEMBL3231	Homo sapiens	IC50	nM	9.89
439130	17798874	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NC3(C)CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3920062	=	IC50	nM	3.16	CHEMBL3231	Homo sapiens	IC50	nM	3.16
439131	17798875	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4111337	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	nM	11.0
439132	17798876	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(CN(C)C)c2)ccc1-c1cn[nH]c1		CHEMBL3947868	=	IC50	nM	2510.0	CHEMBL3231	Homo sapiens	IC50	nM	2510.0
439133	17798877	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc3[nH]ncc23)ccc1-c1cn[nH]c1		CHEMBL3936240	=	IC50	nM	41.8	CHEMBL3231	Homo sapiens	IC50	nM	41.8
439134	17798878	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(N3CCCC3)c2)ccc1-c1cn[nH]c1		CHEMBL3974586	=	IC50	nM	724.0	CHEMBL3231	Homo sapiens	IC50	nM	724.0
439135	17798879	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(F)c2Cl)ccc1-c1cn[nH]c1		CHEMBL3948586	=	IC50	nM	8.46	CHEMBL3231	Homo sapiens	IC50	nM	8.46
439136	17798880	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)cc(F)cc2F)ccc1-c1cn[nH]c1		CHEMBL3985933	=	IC50	nM	21.9	CHEMBL3231	Homo sapiens	IC50	nM	21.9
439137	17798881	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3957255	=	IC50	nM	12.4	CHEMBL3231	Homo sapiens	IC50	nM	12.4
439138	17798882	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)cc(F)c2F)ccc1-c1cn[nH]c1		CHEMBL3973474	=	IC50	nM	38.5	CHEMBL3231	Homo sapiens	IC50	nM	38.5
439139	17798883	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)C[C@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1ccccc1		CHEMBL3902479	=	IC50	nM	53.7	CHEMBL3231	Homo sapiens	IC50	nM	53.7
439140	17798884	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3914458	=	IC50	nM	99.3	CHEMBL3231	Homo sapiens	IC50	nM	99.3
439141	17798885	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(NS(C)(=O)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3965403	=	IC50	nM	24.6	CHEMBL3231	Homo sapiens	IC50	nM	24.6
439142	17798886	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(N(C)C)c2)ccc1-c1cn[nH]c1		CHEMBL3957117	=	IC50	nM	371.0	CHEMBL3231	Homo sapiens	IC50	nM	371.0
439143	17798887	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)ccc1F		CHEMBL3985775	=	IC50	nM	26.0	CHEMBL3231	Homo sapiens	IC50	nM	26.0
439144	17798888	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(F)c2F)ccc1-c1cn[nH]c1		CHEMBL3965554	=	IC50	nM	22.9	CHEMBL3231	Homo sapiens	IC50	nM	22.9
439145	17798889	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3896978	=	IC50	nM	17.8	CHEMBL3231	Homo sapiens	IC50	nM	17.8
439146	17798890	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2F)ccc1-c1cn[nH]c1		CHEMBL3938495	=	IC50	nM	15.8	CHEMBL3231	Homo sapiens	IC50	nM	15.8
439147	17798891	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(N(C)C(C)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3968042	=	IC50	nM	4080.0	CHEMBL3231	Homo sapiens	IC50	nM	4080.0
439148	17798892	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccc3c(c2)OCCO3)ccc1-c1cn[nH]c1		CHEMBL3973591	=	IC50	nM	742.0	CHEMBL3231	Homo sapiens	IC50	nM	742.0
439149	17798893	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC2=CCC3NC(=O)NC3=C2)ccc1-c1cn[nH]c1		CHEMBL3908696	=	IC50	nM	3770.0	CHEMBL3231	Homo sapiens	IC50	nM	3770.0
439150	17798894	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(Cl)c2)c1		CHEMBL4109840	=	IC50	nM	9.86	CHEMBL3231	Homo sapiens	IC50	nM	9.86
439151	17798895	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc3sccc3c2)ccc1-c1cn[nH]c1		CHEMBL3964208	=	IC50	nM	24.9	CHEMBL3231	Homo sapiens	IC50	nM	24.9
439152	17798896	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3960608	=	IC50	nM	11.7	CHEMBL3231	Homo sapiens	IC50	nM	11.7
439153	17798897	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccc3c(c2)CCO3)ccc1-c1cn[nH]c1		CHEMBL4110015	=	IC50	nM	50.1	CHEMBL3231	Homo sapiens	IC50	nM	50.1
439154	17798898	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL4111655	=	IC50	nM	8.06	CHEMBL3231	Homo sapiens	IC50	nM	8.06
439155	17798899	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3934418	=	IC50	nM	13.9	CHEMBL3231	Homo sapiens	IC50	nM	13.9
439156	17798900	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2Cl)c1		CHEMBL4106851	=	IC50	nM	529.0	CHEMBL3231	Homo sapiens	IC50	nM	529.0
439157	17798901	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2F)c1		CHEMBL4111518	=	IC50	nM	5.98	CHEMBL3231	Homo sapiens	IC50	nM	5.98
439158	17798902	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)Cc2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL3969281	=	IC50	nM	35.8	CHEMBL3231	Homo sapiens	IC50	nM	35.8
439159	17798903	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CO)[C@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108938	=	IC50	nM	23.9	CHEMBL3231	Homo sapiens	IC50	nM	23.9
439160	17798904	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)[C@@H](O)c1ccccc1		CHEMBL3893663	=	IC50	nM	602.0	CHEMBL3231	Homo sapiens	IC50	nM	602.0
439161	17798905	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CCNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3965912	=	IC50	nM	92.9	CHEMBL3231	Homo sapiens	IC50	nM	92.9
439162	17798906	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](Cc2ccccc2)C(N)=O)ccc1-c1cn[nH]c1		CHEMBL3918124	=	IC50	nM	37.4	CHEMBL3231	Homo sapiens	IC50	nM	37.4
439163	17798907	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(C2(NC(=O)c3ccc(-c4cn[nH]c4)c(OC)c3)CC2)c1		CHEMBL3978630	=	IC50	nM	55.2	CHEMBL3231	Homo sapiens	IC50	nM	55.2
439164	17798908	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3912670	=	IC50	nM	50.5	CHEMBL3231	Homo sapiens	IC50	nM	50.5
439165	17798909	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(C#N)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3903819	=	IC50	nM	38.7	CHEMBL3231	Homo sapiens	IC50	nM	38.7
439166	17798910	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N(C)C)ccc1-c1cn[nH]c1		CHEMBL3903654	=	IC50	nM	2270.0	CHEMBL3231	Homo sapiens	IC50	nM	2270.0
439167	17798911	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2cccc(C(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3928122	=	IC50	nM	94.6	CHEMBL3231	Homo sapiens	IC50	nM	94.6
439168	17798912	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccc(C(F)(F)F)cc2)ccc1-c1cn[nH]c1		CHEMBL3963293	=	IC50	nM	166.0	CHEMBL3231	Homo sapiens	IC50	nM	166.0
439169	17798913	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(O)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3937215	=	IC50	nM	35.5	CHEMBL3231	Homo sapiens	IC50	nM	35.5
439170	17798914	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4113575	=	IC50	nM	84.1	CHEMBL3231	Homo sapiens	IC50	nM	84.1
439171	17798915	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2cccc(O)c2)ccc1-c1cn[nH]c1		CHEMBL3976118	=	IC50	nM	21.5	CHEMBL3231	Homo sapiens	IC50	nM	21.5
439172	17798916	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(c2ccccc2)N2CCCC2)ccc1-c1cn[nH]c1		CHEMBL3947236	=	IC50	nM	156.0	CHEMBL3231	Homo sapiens	IC50	nM	156.0
439173	17798917	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccccc1CCNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3919941	=	IC50	nM	155.0	CHEMBL3231	Homo sapiens	IC50	nM	155.0
439174	17798918	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@@H](O)c2cccc(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL4109715	=	IC50	nM	23.4	CHEMBL3231	Homo sapiens	IC50	nM	23.4
439175	17798919	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CO)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3896691	=	IC50	nM	12.5	CHEMBL3231	Homo sapiens	IC50	nM	12.5
439176	17798920	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4109752	=	IC50	nM	34.0	CHEMBL3231	Homo sapiens	IC50	nM	34.0
439177	17798921	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3898415	=	IC50	nM	53.7	CHEMBL3231	Homo sapiens	IC50	nM	53.7
439178	17798922	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(O)c2cccc(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL3891207	=	IC50	nM	42.03	CHEMBL3231	Homo sapiens	IC50	nM	42.03
439179	17798923	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(c2ccccc2)N2CCNCC2)ccc1-c1cn[nH]c1		CHEMBL3919291	=	IC50	nM	180.0	CHEMBL3231	Homo sapiens	IC50	nM	180.0
439180	17798924	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](CO)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112104	=	IC50	nM	77.9	CHEMBL3231	Homo sapiens	IC50	nM	77.9
439181	17798925	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)ccc1F		CHEMBL3928198	=	IC50	nM	6.53	CHEMBL3231	Homo sapiens	IC50	nM	6.53
439182	17798926	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)n1		CHEMBL3905628	=	IC50	nM	73.4	CHEMBL3231	Homo sapiens	IC50	nM	73.4
439183	17798927	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C(F)(F)F)c2)c1		CHEMBL4114533	=	IC50	nM	7.09	CHEMBL3231	Homo sapiens	IC50	nM	7.09
439184	17798928	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(Cn2ccnn2)c1)c1ccccc1		CHEMBL4111045	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439185	17798929	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C#N)c2)ccc1-c1cn[nH]c1		CHEMBL3914478	=	IC50	nM	32.6	CHEMBL3231	Homo sapiens	IC50	nM	32.6
439186	17798930	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3898965	=	IC50	nM	172.0	CHEMBL3231	Homo sapiens	IC50	nM	172.0
439187	17798931	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3898965	=	IC50	nM	3.36	CHEMBL3231	Homo sapiens	IC50	nM	3.36
439188	17798932	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3946084	=	IC50	nM	5.5	CHEMBL3231	Homo sapiens	IC50	nM	5.5
439189	17798933	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3946084	=	IC50	nM	143.0	CHEMBL3231	Homo sapiens	IC50	nM	143.0
439190	17798934	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(C#N)cc2)ccc1-c1cn[nH]c1		CHEMBL3953311	=	IC50	nM	365.0	CHEMBL3231	Homo sapiens	IC50	nM	365.0
439191	17798935	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(C#N)c2)c1		CHEMBL3937334	=	IC50	nM	55.6	CHEMBL3231	Homo sapiens	IC50	nM	55.6
439192	17798936	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3957255	=	IC50	nM	301.0	CHEMBL3231	Homo sapiens	IC50	nM	301.0
439193	17798937	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3957255	=	IC50	nM	7.8	CHEMBL3231	Homo sapiens	IC50	nM	7.8
439194	17798938	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL3950642	=	IC50	nM	23.5	CHEMBL3231	Homo sapiens	IC50	nM	23.5
439195	17798939	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3922917	=	IC50	nM	174.0	CHEMBL3231	Homo sapiens	IC50	nM	174.0
439196	17798940	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2ccc(F)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3982461	=	IC50	nM	16.9	CHEMBL3231	Homo sapiens	IC50	nM	16.9
439197	17798941	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4108570	=	IC50	nM	13.1	CHEMBL3231	Homo sapiens	IC50	nM	13.1
439198	17798942	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3921203	=	IC50	nM	19.7	CHEMBL3231	Homo sapiens	IC50	nM	19.7
439199	17798943	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL3950642	=	IC50	nM	1510.0	CHEMBL3231	Homo sapiens	IC50	nM	1510.0
439200	17798944	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c(C)n[nH]c3C)c(C)c2)c1		CHEMBL4110660	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439201	17798945	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OCC(C)(C)O)c1)c1ccccc1		CHEMBL4111265	=	IC50	nM	1790.0	CHEMBL3231	Homo sapiens	IC50	nM	1790.0
439202	17798946	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C)c1)c1ccccc1		CHEMBL4113955	=	IC50	nM	405.0	CHEMBL3231	Homo sapiens	IC50	nM	405.0
439203	17798947	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1)c1ccccc1		CHEMBL4108218	=	IC50	nM	11.4	CHEMBL3231	Homo sapiens	IC50	nM	11.4
439204	17798948	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1ccccc1		CHEMBL4112614	=	IC50	nM	10.3	CHEMBL3231	Homo sapiens	IC50	nM	10.3
439205	17798949	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3965274	=	IC50	nM	3.17	CHEMBL3231	Homo sapiens	IC50	nM	3.17
439206	17798950	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2cccc(O)n2)ccc1-c1cn[nH]c1		CHEMBL3965517	=	IC50	nM	7.39	CHEMBL3231	Homo sapiens	IC50	nM	7.39
439207	17798951	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1ccccc1)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1		CHEMBL4107796	=	IC50	nM	17.1	CHEMBL3231	Homo sapiens	IC50	nM	17.1
439208	17798952	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)cc2CO)c1		CHEMBL3976502	=	IC50	nM	792.0	CHEMBL3231	Homo sapiens	IC50	nM	792.0
439209	17798953	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3947211	=	IC50	nM	11.7	CHEMBL3231	Homo sapiens	IC50	nM	11.7
439210	17798954	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3965274	=	IC50	nM	59.8	CHEMBL3231	Homo sapiens	IC50	nM	59.8
439211	17798955	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1)c1ccc(F)cc1		CHEMBL4114240	=	IC50	nM	22.5	CHEMBL3231	Homo sapiens	IC50	nM	22.5
439212	17798956	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3965274	=	IC50	nM	3.1	CHEMBL3231	Homo sapiens	IC50	nM	3.1
439213	17798957	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3947211	=	IC50	nM	7.22	CHEMBL3231	Homo sapiens	IC50	nM	7.22
439214	17798958	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3947211	=	IC50	nM	56.5	CHEMBL3231	Homo sapiens	IC50	nM	56.5
439215	17798959	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NC(C)c2cccc(O)n2)ccc1-c1cn[nH]c1		CHEMBL3975539	=	IC50	nM	130.0	CHEMBL3231	Homo sapiens	IC50	nM	130.0
439216	17798960	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3901295	=	IC50	nM	4.7	CHEMBL3231	Homo sapiens	IC50	nM	4.7
439217	17798961	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C=CC(NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1c(F)cccc1F		CHEMBL3939661	=	IC50	nM	17.5	CHEMBL3231	Homo sapiens	IC50	nM	17.5
439218	17798962	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3930451	=	IC50	nM	37.3	CHEMBL3231	Homo sapiens	IC50	nM	37.3
439219	17798963	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)c2cccc3ccccc23)ccc1-c1cn[nH]c1		CHEMBL3969951	=	IC50	nM	6.68	CHEMBL3231	Homo sapiens	IC50	nM	6.68
439220	17798964	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)c2ccccc2OC)ccc1-c1cn[nH]c1		CHEMBL3893355	=	IC50	nM	72.4	CHEMBL3231	Homo sapiens	IC50	nM	72.4
439221	17798965	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3962377	=	IC50	nM	33.3	CHEMBL3231	Homo sapiens	IC50	nM	33.3
439222	17798966	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](c2c(F)cccc2F)C(O)CO)ccc1-c1cn[nH]c1		CHEMBL4115278	=	IC50	nM	34.9	CHEMBL3231	Homo sapiens	IC50	nM	34.9
439223	17798967	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3920393	=	IC50	nM	23.8	CHEMBL3231	Homo sapiens	IC50	nM	23.8
439224	17798968	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3920393	=	IC50	nM	38.2	CHEMBL3231	Homo sapiens	IC50	nM	38.2
439225	17798969	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3901295	=	IC50	nM	94.2	CHEMBL3231	Homo sapiens	IC50	nM	94.2
439226	17798970	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3901295	=	IC50	nM	1.53	CHEMBL3231	Homo sapiens	IC50	nM	1.53
439227	17798971	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCc1ccccc1CNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3932451	=	IC50	nM	36.4	CHEMBL3231	Homo sapiens	IC50	nM	36.4
439228	17798972	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3962377	=	IC50	nM	256.0	CHEMBL3231	Homo sapiens	IC50	nM	256.0
439229	17798973	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3962377	=	IC50	nM	16.2	CHEMBL3231	Homo sapiens	IC50	nM	16.2
439230	17798974	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(O)c1)c1ccc(F)cc1		CHEMBL4113669	=	IC50	nM	2.22	CHEMBL3231	Homo sapiens	IC50	nM	2.22
439231	17798975	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2c[nH]nc2C)ccc1C(=O)NCc1c(F)cccc1Cl		CHEMBL3930850	=	IC50	nM	14.2	CHEMBL3231	Homo sapiens	IC50	nM	14.2
439232	17798976	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1c(F)cccc1Cl		CHEMBL3978005	=	IC50	nM	26.3	CHEMBL3231	Homo sapiens	IC50	nM	26.3
439233	17798977	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1cc(F)c(-c2cn[nH]c2)cc1F)c1ccccc1		CHEMBL4113186	=	IC50	nM	472.0	CHEMBL3231	Homo sapiens	IC50	nM	472.0
439234	17798978	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(Cc2ccccc2)C(C)=O)ccc1-c1cn[nH]c1		CHEMBL3982811	=	IC50	nM	23.0	CHEMBL3231	Homo sapiens	IC50	nM	23.0
439235	17798979	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(S(C)(=O)=O)c1)c1ccccc1		CHEMBL4107114	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439236	17798980	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2c[nH]nc2C(F)(F)F)ccc1C(=O)NCc1c(F)cccc1Cl		CHEMBL3957411	=	IC50	nM	39.4	CHEMBL3231	Homo sapiens	IC50	nM	39.4
439237	17798981	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)c(F)cc1C(=O)N[C@H](C)c1ccccc1		CHEMBL4108065	=	IC50	nM	37.1	CHEMBL3231	Homo sapiens	IC50	nM	37.1
439238	17798982	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4112775	=	IC50	nM	205.0	CHEMBL3231	Homo sapiens	IC50	nM	205.0
439239	17798983	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108225	=	IC50	nM	50.8	CHEMBL3231	Homo sapiens	IC50	nM	50.8
439240	17798984	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C#N)c1)c1ccc(F)cc1		CHEMBL4109237	=	IC50	nM	873.0	CHEMBL3231	Homo sapiens	IC50	nM	873.0
439241	17798985	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	N#Cc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4109949	=	IC50	nM	510.0	CHEMBL3231	Homo sapiens	IC50	nM	510.0
439242	17798986	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4106845	=	IC50	nM	82.7	CHEMBL3231	Homo sapiens	IC50	nM	82.7
439243	17798987	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1c(F)cccc1F)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1		CHEMBL4114203	=	IC50	nM	63.7	CHEMBL3231	Homo sapiens	IC50	nM	63.7
439244	17798988	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4110689	=	IC50	nM	52.6	CHEMBL3231	Homo sapiens	IC50	nM	52.6
439245	17798989	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	N#Cc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4107876	=	IC50	nM	397.0	CHEMBL3231	Homo sapiens	IC50	nM	397.0
439246	17798990	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1c(-c2cn[nH]c2)ccc(C(=O)N[C@H](CO)c2c(F)cccc2F)c1F		CHEMBL4114195	=	IC50	nM	219.0	CHEMBL3231	Homo sapiens	IC50	nM	219.0
439247	17798991	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1c(F)cccc1F)c1ccc(-c2cn[nH]c2)c(Cl)c1		CHEMBL4107563	=	IC50	nM	42.3	CHEMBL3231	Homo sapiens	IC50	nM	42.3
439248	17798992	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CO)c1c(F)cccc1F		CHEMBL4109193	=	IC50	nM	362.0	CHEMBL3231	Homo sapiens	IC50	nM	362.0
439249	17798993	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1c(F)cccc1F)c1ccc(-c2cn[nH]c2)c(C(F)(F)F)c1		CHEMBL4107473	=	IC50	nM	193.0	CHEMBL3231	Homo sapiens	IC50	nM	193.0
439250	17798994	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3899661	=	IC50	nM	19.2	CHEMBL3231	Homo sapiens	IC50	nM	19.2
439251	17798995	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CO)Cc1ccccc1		CHEMBL3959761	=	IC50	nM	9.8	CHEMBL3231	Homo sapiens	IC50	nM	9.8
439252	17798996	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(CO)c1ccccc1F		CHEMBL3890689	=	IC50	nM	345.0	CHEMBL3231	Homo sapiens	IC50	nM	345.0
439253	17798997	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](C)c1ccc(F)cc1		CHEMBL4112558	=	IC50	nM	7.0	CHEMBL3231	Homo sapiens	IC50	nM	7.0
439254	17798998	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1c(F)cccc1F		CHEMBL3939886	=	IC50	nM	4.25	CHEMBL3231	Homo sapiens	IC50	nM	4.25
439255	17798999	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(CCN(C)C)c1ccccc1		CHEMBL3975905	=	IC50	nM	174.0	CHEMBL3231	Homo sapiens	IC50	nM	174.0
439256	17799000	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CCO)c1ccccc1		CHEMBL4108559	=	IC50	nM	6.55	CHEMBL3231	Homo sapiens	IC50	nM	6.55
439257	17799001	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1ccc(F)cc1Cl		CHEMBL3904054	=	IC50	nM	3.26	CHEMBL3231	Homo sapiens	IC50	nM	3.26
439258	17799002	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(NCc1ccccc1)c1ccc(-c2cn[nH]c2)cc1CCO		CHEMBL3965615	=	IC50	nM	1880.0	CHEMBL3231	Homo sapiens	IC50	nM	1880.0
439259	17799003	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(c1ccccc1F)C(C)(C)O		CHEMBL3965594	=	IC50	nM	37.3	CHEMBL3231	Homo sapiens	IC50	nM	37.3
439260	17799004	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL3950642	=	IC50	nM	15.6	CHEMBL3231	Homo sapiens	IC50	nM	15.6
439261	17799005	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)cc2N)c1		CHEMBL3960761	=	IC50	nM	131.0	CHEMBL3231	Homo sapiens	IC50	nM	131.0
439262	17799006	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CO)[C@H](O)c1ccccc1		CHEMBL4106810	=	IC50	nM	64.2	CHEMBL3231	Homo sapiens	IC50	nM	64.2
439263	17799007	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CO)ccc1-c1cn[nH]c1		CHEMBL3928475	=	IC50	nM	51.5	CHEMBL3231	Homo sapiens	IC50	nM	51.5
439264	17799008	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@@H](Cc1ccccc1)[C@H](O)CO		CHEMBL3896967	=	IC50	nM	15.4	CHEMBL3231	Homo sapiens	IC50	nM	15.4
439265	17799009	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(c1ccccc1F)C(C)(C)O		CHEMBL3965594	=	IC50	nM	24.7	CHEMBL3231	Homo sapiens	IC50	nM	24.7
439266	17799010	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(c1ccccc1F)C(C)(C)O		CHEMBL3965594	=	IC50	nM	585.0	CHEMBL3231	Homo sapiens	IC50	nM	585.0
439267	17799011	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Nc1cc(-c2cn[nH]c2)ccc1C(=O)NCCCc1ccccc1		CHEMBL3950431	=	IC50	nM	321.0	CHEMBL3231	Homo sapiens	IC50	nM	321.0
439268	17799012	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3926244	=	IC50	nM	16.7	CHEMBL3231	Homo sapiens	IC50	nM	16.7
439269	17799013	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC2(c3ccccc3)CCC2)ccc1-c1cn[nH]c1		CHEMBL3931254	=	IC50	nM	146.0	CHEMBL3231	Homo sapiens	IC50	nM	146.0
439270	17799014	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(C)c1c(F)cccc1Cl		CHEMBL3908187	=	IC50	nM	59.6	CHEMBL3231	Homo sapiens	IC50	nM	59.6
439271	17799015	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](c2ccccc2)[C@H](O)CO)ccc1-c1cn[nH]c1		CHEMBL4107687	=	IC50	nM	8.55	CHEMBL3231	Homo sapiens	IC50	nM	8.55
439272	17799016	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@@H](c1ccccc1)[C@H](O)CO		CHEMBL4107177	=	IC50	nM	7.59	CHEMBL3231	Homo sapiens	IC50	nM	7.59
439273	17799017	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(C)c1c(F)cccc1F		CHEMBL3894616	=	IC50	nM	26.5	CHEMBL3231	Homo sapiens	IC50	nM	26.5
439274	17799018	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(C)c1c(F)cccc1F		CHEMBL3894616	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439275	17799019	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3899661	=	IC50	nM	12.5	CHEMBL3231	Homo sapiens	IC50	nM	12.5
439276	17799020	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3899661	=	IC50	nM	182.0	CHEMBL3231	Homo sapiens	IC50	nM	182.0
439277	17799021	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1cccc(S(N)(=O)=O)c1		CHEMBL3985681	=	IC50	nM	11.2	CHEMBL3231	Homo sapiens	IC50	nM	11.2
439278	17799022	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(S(N)(=O)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3915928	=	IC50	nM	15.2	CHEMBL3231	Homo sapiens	IC50	nM	15.2
439279	17799023	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3964418	=	IC50	nM	1.04	CHEMBL3231	Homo sapiens	IC50	nM	1.04
439280	17799024	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(CN)Cc1ccccc1		CHEMBL3956875	=	IC50	nM	4.6	CHEMBL3231	Homo sapiens	IC50	nM	4.6
439281	17799025	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NCC(C)(C)O)c2)ccc1-c1cn[nH]c1		CHEMBL3961024	=	IC50	nM	3.24	CHEMBL3231	Homo sapiens	IC50	nM	3.24
439282	17799026	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)N(C)C)c2)ccc1-c1cn[nH]c1		CHEMBL3980770	=	IC50	nM	499.0	CHEMBL3231	Homo sapiens	IC50	nM	499.0
439283	17799027	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NCC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3910152	=	IC50	nM	1.79	CHEMBL3231	Homo sapiens	IC50	nM	1.79
439284	17799028	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3956238	=	IC50	nM	2.39	CHEMBL3231	Homo sapiens	IC50	nM	2.39
439285	17799029	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3947008	=	IC50	nM	2.44	CHEMBL3231	Homo sapiens	IC50	nM	2.44
439286	17799030	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)O)c2)ccc1-c1cn[nH]c1		CHEMBL3985261	=	IC50	nM	61.4	CHEMBL3231	Homo sapiens	IC50	nM	61.4
439287	17799031	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3986370	=	IC50	nM	11.8	CHEMBL3231	Homo sapiens	IC50	nM	11.8
439288	17799032	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCN1CCCC1CNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3957651	=	IC50	nM	1.54	CHEMBL3231	Homo sapiens	IC50	nM	1.54
439289	17799033	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)c(C(=O)O)c2)ccc1-c1cn[nH]c1		CHEMBL3964232	=	IC50	nM	39.2	CHEMBL3231	Homo sapiens	IC50	nM	39.2
439290	17799034	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)NCC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3977577	=	IC50	nM	3.38	CHEMBL3231	Homo sapiens	IC50	nM	3.38
439291	17799035	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)NC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3939581	=	IC50	nM	4.22	CHEMBL3231	Homo sapiens	IC50	nM	4.22
439292	17799036	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)NC[C@H]3CCCN3)c2)ccc1-c1cn[nH]c1		CHEMBL4107343	=	IC50	nM	2.46	CHEMBL3231	Homo sapiens	IC50	nM	2.46
439293	17799037	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CNCC4)c2)ccc1-c1cn[nH]c1		CHEMBL3902471	=	IC50	nM	0.26	CHEMBL3231	Homo sapiens	IC50	nM	0.26
439294	17799038	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)ccc1-c1cn[nH]c1		CHEMBL3961538	=	IC50	nM	0.39	CHEMBL3231	Homo sapiens	IC50	nM	0.39
439295	17799039	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NC3CCN(C)CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3949136	=	IC50	nM	0.43	CHEMBL3231	Homo sapiens	IC50	nM	0.43
439296	17799040	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1cccc(C(=O)NC2CCN(C)CC2)c1		CHEMBL3925017	=	IC50	nM	1.24	CHEMBL3231	Homo sapiens	IC50	nM	1.24
439297	17799041	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(N)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3985772	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
439298	17799042	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CC(=O)O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4113981	=	IC50	nM	45.7	CHEMBL3231	Homo sapiens	IC50	nM	45.7
439299	17799043	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CNC(=O)C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C)c1)c1ccccc1		CHEMBL4109757	=	IC50	nM	41.1	CHEMBL3231	Homo sapiens	IC50	nM	41.1
439300	17799044	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CC(=O)NCC(C)(C)O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4111334	=	IC50	nM	99.0	CHEMBL3231	Homo sapiens	IC50	nM	99.0
439301	17799045	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4114628	=	IC50	nM	0.77	CHEMBL3231	Homo sapiens	IC50	nM	0.77
439302	17799046	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(=O)NC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C)c1)c1ccccc1		CHEMBL4109115	=	IC50	nM	97.2	CHEMBL3231	Homo sapiens	IC50	nM	97.2
439303	17799047	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107839	=	IC50	nM	3.38	CHEMBL3231	Homo sapiens	IC50	nM	3.38
439304	17799048	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(C)(O)COc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107181	=	IC50	nM	85.1	CHEMBL3231	Homo sapiens	IC50	nM	85.1
439305	17799049	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	NC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OCCO)c1)c1ccccc1		CHEMBL4111527	=	IC50	nM	8.92	CHEMBL3231	Homo sapiens	IC50	nM	8.92
439306	17799050	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNC(C)=O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4110514	=	IC50	nM	23.6	CHEMBL3231	Homo sapiens	IC50	nM	23.6
439307	17799051	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNS(C)(=O)=O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107374	=	IC50	nM	6.62	CHEMBL3231	Homo sapiens	IC50	nM	6.62
439308	17799052	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNS(=O)(=O)C2CC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107417	=	IC50	nM	11.3	CHEMBL3231	Homo sapiens	IC50	nM	11.3
439309	17799053	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCS(=O)(=O)NC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1ccccc1		CHEMBL4113161	=	IC50	nM	55.2	CHEMBL3231	Homo sapiens	IC50	nM	55.2
439310	17799054	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4109081	=	IC50	nM	6.45	CHEMBL3231	Homo sapiens	IC50	nM	6.45
439311	17799055	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1c(F)cccc1F		CHEMBL4115593	=	IC50	nM	77.3	CHEMBL3231	Homo sapiens	IC50	nM	77.3
439312	17799056	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCNC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1c(F)cccc1F		CHEMBL4107997	=	IC50	nM	2.26	CHEMBL3231	Homo sapiens	IC50	nM	2.26
439313	17799057	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNC2CC2)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4110459	=	IC50	nM	4.62	CHEMBL3231	Homo sapiens	IC50	nM	4.62
439314	17799058	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2C(C)C)ccc1-c1cn[nH]c1		CHEMBL3983535	=	IC50	nM	204.0	CHEMBL3231	Homo sapiens	IC50	nM	204.0
439315	17799059	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4114269	=	IC50	nM	181.0	CHEMBL3231	Homo sapiens	IC50	nM	181.0
439316	17799060	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@H](O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4107581	=	IC50	nM	21.2	CHEMBL3231	Homo sapiens	IC50	nM	21.2
439317	17799061	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4111557	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439318	17799062	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(CO)c1)c1ccc(F)cc1		CHEMBL4113796	=	IC50	nM	3450.0	CHEMBL3231	Homo sapiens	IC50	nM	3450.0
439319	17799063	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(CO)c1)c1ccccc1		CHEMBL4114083	=	IC50	nM	284.0	CHEMBL3231	Homo sapiens	IC50	nM	284.0
439320	17799064	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112045	=	IC50	nM	50.0	CHEMBL3231	Homo sapiens	IC50	nM	50.0
439321	17799065	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(C)O)c1)c1ccccc1		CHEMBL4110038	=	IC50	nM	287.0	CHEMBL3231	Homo sapiens	IC50	nM	287.0
439322	17799066	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(NC(=O)c1ccc(-c2cn[nH]c2)c(C=O)c1)c1ccccc1F		CHEMBL3928424	=	IC50	nM	983.0	CHEMBL3231	Homo sapiens	IC50	nM	983.0
439323	17799067	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(NC(=O)c1ccc(-c2cn[nH]c2)c(C=O)c1)c1ccccc1F		CHEMBL3928424	=	IC50	nM	509.0	CHEMBL3231	Homo sapiens	IC50	nM	509.0
439324	17799068	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(C)O)c1)c1ccccc1		CHEMBL4110038	=	IC50	nM	156.0	CHEMBL3231	Homo sapiens	IC50	nM	156.0
439325	17799069	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3890248	=	IC50	nM	1780.0	CHEMBL3231	Homo sapiens	IC50	nM	1780.0
439326	17799070	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3890248	=	IC50	nM	52.9	CHEMBL3231	Homo sapiens	IC50	nM	52.9
439327	17799071	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112045	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439328	17799072	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112045	=	IC50	nM	26.8	CHEMBL3231	Homo sapiens	IC50	nM	26.8
439329	17799073	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL4113260	=	IC50	nM	242.0	CHEMBL3231	Homo sapiens	IC50	nM	242.0
439330	17799074	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL4113260	=	IC50	nM	50.6	CHEMBL3231	Homo sapiens	IC50	nM	50.6
439331	17799075	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCC(O)c1cc(C(=O)NC(C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3930519	=	IC50	nM	842.0	CHEMBL3231	Homo sapiens	IC50	nM	842.0
439332	17799076	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108515	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439333	17799077	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108515	=	IC50	nM	97.6	CHEMBL3231	Homo sapiens	IC50	nM	97.6
439334	17799078	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3893554	=	IC50	nM	111.0	CHEMBL3231	Homo sapiens	IC50	nM	111.0
439335	17799079	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3893554	=	IC50	nM	150.0	CHEMBL3231	Homo sapiens	IC50	nM	150.0
439336	17799080	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3936330	=	IC50	nM	275.0	CHEMBL3231	Homo sapiens	IC50	nM	275.0
439337	17799081	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3936330	=	IC50	nM	1950.0	CHEMBL3231	Homo sapiens	IC50	nM	1950.0
439338	17799082	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3936330	=	IC50	nM	138.0	CHEMBL3231	Homo sapiens	IC50	nM	138.0
439339	17799083	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4114494	=	IC50	nM	1140.0	CHEMBL3231	Homo sapiens	IC50	nM	1140.0
439340	17799084	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4114494	=	IC50	nM	98.2	CHEMBL3231	Homo sapiens	IC50	nM	98.2
439341	17799085	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107912	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439342	17799086	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4110398	=	IC50	nM	1700.0	CHEMBL3231	Homo sapiens	IC50	nM	1700.0
439343	17799087	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(N(C)C)c1)c1ccc(F)cc1		CHEMBL4111864	=	IC50	nM	145.0	CHEMBL3231	Homo sapiens	IC50	nM	145.0
439344	17799088	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CNc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4112708	=	IC50	nM	1760.0	CHEMBL3231	Homo sapiens	IC50	nM	1760.0
439345	17799089	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N(Cc2ccccc2F)CC(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3902850	=	IC50	nM	839.0	CHEMBL3231	Homo sapiens	IC50	nM	839.0
439346	17799090	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(NC(=O)c1ccc(-c2cn[nH]c2)c(C(F)F)c1)c1ccccc1F		CHEMBL3899293	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	nM	110.0
439347	17799091	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(F)F)c1)c1ccccc1F		CHEMBL4111492	=	IC50	nM	108.0	CHEMBL3231	Homo sapiens	IC50	nM	108.0
439348	17799092	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(F)F)c1)c1ccccc1F		CHEMBL3912987	=	IC50	nM	582.0	CHEMBL3231	Homo sapiens	IC50	nM	582.0
439349	17799093	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1n[nH]cc1-c1ccc(C(=O)N[C@H](C)c2cccc(OC)c2)c(OC)c1		CHEMBL4109268	=	IC50	nM	70.9	CHEMBL3231	Homo sapiens	IC50	nM	70.9
439350	17799094	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C#N)cc2OC)c1		CHEMBL4113511	=	IC50	nM	30.6	CHEMBL3231	Homo sapiens	IC50	nM	30.6
439351	17799095	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c(C)n[nH]c3C)cc2OC)c1		CHEMBL4107632	=	IC50	nM	133.0	CHEMBL3231	Homo sapiens	IC50	nM	133.0
439352	17799096	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL4115244	=	IC50	nM	2.15	CHEMBL3231	Homo sapiens	IC50	nM	2.15
439353	17799097	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3CO)cc2OC)c1		CHEMBL4110004	=	IC50	nM	63.8	CHEMBL3231	Homo sapiens	IC50	nM	63.8
439354	17799098	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C(C)O)cc2OC)c1		CHEMBL4111252	=	IC50	nM	544.0	CHEMBL3231	Homo sapiens	IC50	nM	544.0
439355	17799099	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OCCN(C)C)c1		CHEMBL4115302	=	IC50	nM	284.0	CHEMBL3231	Homo sapiens	IC50	nM	284.0
439356	17799100	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1n[nH]cc1-c1cc(OCCN(C)C)c(C(=O)N[C@H](C)c2ccccc2)cc1F		CHEMBL4107027	=	IC50	nM	0.2	CHEMBL3231	Homo sapiens	IC50	nM	0.2
439357	17799101	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@H](NC(=O)c1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C)c1ccccc1		CHEMBL3963276	=	IC50	nM	1110.0	CHEMBL3231	Homo sapiens	IC50	nM	1110.0
439358	17799102	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OCCN(C)C)c1		CHEMBL4114333	=	IC50	nM	22.3	CHEMBL3231	Homo sapiens	IC50	nM	22.3
439359	17799103	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)cc(F)c1C(=O)N[C@H](C)c1ccccc1		CHEMBL4112130	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
439360	17799104	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](C)c1cccc(OC)c1		CHEMBL4111653	=	IC50	nM	21.1	CHEMBL3231	Homo sapiens	IC50	nM	21.1
439361	17799105	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COCCOc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](C)c1cccc(OC)c1		CHEMBL4110456	=	IC50	nM	16.8	CHEMBL3231	Homo sapiens	IC50	nM	16.8
439362	17799106	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OCCO)c1		CHEMBL4114112	=	IC50	nM	7.19	CHEMBL3231	Homo sapiens	IC50	nM	7.19
439363	17799107	CHEMBL3889185	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 L assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 M ATP and 1.5 M peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(C(C)O)c2)c1		CHEMBL3950612	=	IC50	nM	82.2	CHEMBL3231	Homo sapiens	IC50	nM	82.2
Inactive	17935738	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935739	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935740	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935741	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935742	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935743	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935744	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935745	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935746	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935747	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935748	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935749	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935750	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935751	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935752	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935753	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935754	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935755	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	Kd	nM	1152.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	1152.0
Inactive	17935756	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935757	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935758	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935759	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935760	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935761	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935762	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935763	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935764	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935765	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935766	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935767	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935768	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935769	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935770	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935771	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935772	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935773	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935774	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935775	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935776	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935777	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935778	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935779	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	=	Kd	nM	1362.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	1362.0
Active	17935780	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	Kd	nM	8.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	8.0
Inactive	17935781	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935782	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935783	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935784	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935785	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935786	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935787	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	=	Kd	nM	482.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	482.0
Inactive	17935788	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935789	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935790	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935791	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935792	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935793	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935794	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935795	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935796	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935797	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935798	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935799	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935800	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935801	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935802	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935803	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935804	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935805	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935806	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935807	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935808	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935809	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935810	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935811	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935812	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935813	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935814	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935815	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935816	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935817	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935818	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	2676.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	2676.0
Inactive	17935819	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935820	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935821	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935822	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935823	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935824	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935825	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935826	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935827	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935828	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935829	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935830	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935831	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935832	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935833	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935834	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935835	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935836	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935837	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935838	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935839	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935840	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935841	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935842	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935843	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935844	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935845	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935846	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	=	Kd	nM	2816.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	2816.0
Inactive	17935847	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935848	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935849	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935850	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	819.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	819.0
Inactive	17935851	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935852	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935853	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935854	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935855	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935856	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935857	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935858	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935859	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935860	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17935861	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	Kd	nM	99233.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	99233.0
Inactive	17935862	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935863	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935864	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935865	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935866	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935867	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935868	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935869	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935870	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935871	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935872	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Kd	nM	706.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	706.0
Inactive	17935873	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935874	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935875	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935876	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935877	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935878	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935879	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935880	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935881	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935882	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935883	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935884	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935885	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935886	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935887	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935888	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935889	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935890	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935891	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935892	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935893	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935894	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	=	Kd	nM	13462.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	13462.0
Inactive	17935895	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935896	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935897	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935898	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935899	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935900	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935901	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935902	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935903	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935904	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935905	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935906	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935907	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935908	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935909	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	=	Kd	nM	27.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	27.0
Inactive	17935910	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935911	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935912	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935913	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935914	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	955.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	955.0
Inactive	17935915	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935916	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935917	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935918	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935919	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935920	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935921	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935922	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935923	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935924	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935925	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935926	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935927	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935928	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935929	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935930	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935931	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935932	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935933	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935934	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935935	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935936	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935937	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935938	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935939	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935940	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Kd	nM	906.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	906.0
Inactive	17935941	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935942	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935943	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	Kd	nM	2144.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	2144.0
Uncertain	17935944	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	2730.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	2730.0
Active	17935945	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	=	Kd	nM	17.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	17.0
Inactive	17935946	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935947	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935948	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935949	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935950	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935951	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935952	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935953	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	Kd	nM	532.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	532.0
Inactive	17935954	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935955	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935956	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935957	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Active	17935958	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	Kd	nM	33.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	33.0
Inactive	17935959	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935960	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935961	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935962	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935963	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935964	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935965	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935966	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935967	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935968	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935969	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935970	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935971	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935972	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935973	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935974	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935975	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935976	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935977	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935978	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935979	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935980	CHEMBL3991870	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL3231	Homo sapiens	Kd apparent	nM	30000.0
	17964949	CHEMBL3995059	Inhibition of human ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	88.0	CHEMBL3231	Homo sapiens	Activity	%	88.0
	17978440	CHEMBL3997626	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus infected sf21 cells at 200 nM using LIMKtide as substrate by electrophoretic mobility shift assay relative to control	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1c[nH]c3nc(F)ccc13)C2=O		CHEMBL4083975	=	Inhibition	%	94.0	CHEMBL3231	Homo sapiens	INH	%	94.0
	17978441	CHEMBL3997626	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus infected sf21 cells at 200 nM using LIMKtide as substrate by electrophoretic mobility shift assay relative to control	B	CCc1ccc2c(/C=C3\Oc4c(ccc(OC)c4CN4CCNCC4)C3=O)c[nH]c2n1		CHEMBL4074201	=	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	17978442	CHEMBL3997626	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus infected sf21 cells at 200 nM using LIMKtide as substrate by electrophoretic mobility shift assay relative to control	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1c[nH]c3nc(C)ccc13)C2=O		CHEMBL4060711	=	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	17978443	CHEMBL3997626	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus infected sf21 cells at 200 nM using LIMKtide as substrate by electrophoretic mobility shift assay relative to control	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1c[nH]c3ncccc13)C2=O		CHEMBL2147767	>	Inhibition	%	75.0	CHEMBL3231	Homo sapiens	INH	%	75.0
	17979271	CHEMBL3998075	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain (1 to 535 residues) expressed in baculovirus expression system at 10 uM relative to control	B	CC1=Nc2c(Sc3ccccc3)ncnc2Sc2ccccc21		CHEMBL4061152	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	INH	%	2.0
	18031852	CHEMBL4007742	Inhibition of ROCK1(unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	413.0	CHEMBL3231	Homo sapiens	IC50	uM	0.413
	18031853	CHEMBL4007742	Inhibition of ROCK1(unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	18031854	CHEMBL4007742	Inhibition of ROCK1(unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	=	IC50	nM	8610.0	CHEMBL3231	Homo sapiens	IC50	uM	8.61
	18031855	CHEMBL4007742	Inhibition of ROCK1(unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	5780.0	CHEMBL3231	Homo sapiens	IC50	uM	5.78
	18031856	CHEMBL4007742	Inhibition of ROCK1(unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	18048979	CHEMBL4011145	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system	B	CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1		CHEMBL1642655	=	IC50	nM	4897.79	CHEMBL3231	Homo sapiens	pIC50		5.31
	18048980	CHEMBL4011145	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system	B	COCCn1cc(NC(=O)c2csc(-c3nncn3C(C)C)n2)cn1		CHEMBL4073198	=	IC50	nM	5370.32	CHEMBL3231	Homo sapiens	pIC50		5.27
Not Active	18092346	CHEMBL4020202	Inhibition of ROCK1 (unknown origin)	B	Fc1cccc(Cl)c1CNc1nc(-c2ccco2)n[nH]1		CHEMBL1354522		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	18102171	CHEMBL4022200	Inhibition of ROCK1 (unknown origin) at 10 uM relative to control	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Inhibition	%	80.0	CHEMBL3231	Homo sapiens	INH	%	80.0
	18114835	CHEMBL4025365	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	18134450	CHEMBL4029525	Inhibition of ROCK1 (unknown origin) at 1 uM using long S6 peptide as substrate pretreated for 5 mins followed by substrate addition measured after 10 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	COCCNC(=O)c1ccc(Oc2sc(C(N)=O)c3c2-c2sncc2CC3)cn1		CHEMBL4066819	=	Inhibition	%	7.0	CHEMBL3231	Homo sapiens	INH	%	7.0
	18134481	CHEMBL4029525	Inhibition of ROCK1 (unknown origin) at 1 uM using long S6 peptide as substrate pretreated for 5 mins followed by substrate addition measured after 10 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CSc1sc(C(N)=O)c2c1-c1sncc1CC2		CHEMBL4082469	=	Inhibition	%	81.0	CHEMBL3231	Homo sapiens	INH	%	81.0
Not Active	18140418	CHEMBL4031017	Inhibition of human ROCK1 at 30 uM	B	CCN(CC)c1ccc(NC(=O)c2c(-c3ccccc3)noc2C)cc1		CHEMBL361366		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	18153038	CHEMBL4034477	Inhibition of ROCK1 protein kinase domain (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	-7.6	CHEMBL3231	Homo sapiens	INH	%	-7.6
	18153228	CHEMBL4034478	Inhibition of ROCK1 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	7.4	CHEMBL3231	Homo sapiens	INH	%	7.4
	18163925	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1nc2cc(-c3c[nH]nc3C)sc2c(=O)[nH]1		CHEMBL4063842	=	IC50	nM	1500.0	CHEMBL3231	Homo sapiens	IC50	nM	1500.0
	18163926	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(C3CCCCC3)[nH]c(=O)c2s1		CHEMBL4091279	=	IC50	nM	940.0	CHEMBL3231	Homo sapiens	IC50	nM	940.0
	18163927	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(-c3ccccc3)[nH]c(=O)c2s1		CHEMBL4061122	=	IC50	nM	1600.0	CHEMBL3231	Homo sapiens	IC50	nM	1600.0
	18163928	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(N3CCOCC3)[nH]c(=O)c2s1		CHEMBL4081417	=	IC50	nM	1700.0	CHEMBL3231	Homo sapiens	IC50	nM	1700.0
	18163929	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CCOCc1nc2cc(-c3c[nH]nc3C)sc2c(=O)[nH]1		CHEMBL4099435	=	IC50	nM	2100.0	CHEMBL3231	Homo sapiens	IC50	nM	2100.0
	18163930	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CNCc1nc2cc(-c3c[nH]nc3C)sc2c(=O)[nH]1.Cl.Cl		CHEMBL4070822	=	IC50	nM	360.0	CHEMBL3231	Homo sapiens	IC50	nM	360.0
	18163931	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CNCc3ccccc3)[nH]c(=O)c2s1.O=C(O)C(F)(F)F		CHEMBL4091694	=	IC50	nM	610.0	CHEMBL3231	Homo sapiens	IC50	nM	610.0
	18163932	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN(C)C)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4062209	=	IC50	nM	260.0	CHEMBL3231	Homo sapiens	IC50	nM	260.0
	18163933	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CCCC3)[nH]c(=O)c2s1		CHEMBL4083927	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
	18163934	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CCCCC3)[nH]c(=O)c2s1		CHEMBL4078031	=	IC50	nM	200.0	CHEMBL3231	Homo sapiens	IC50	nM	200.0
	18163935	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(Cn3cccc3)[nH]c(=O)c2s1		CHEMBL4096077	=	IC50	nM	370.0	CHEMBL3231	Homo sapiens	IC50	nM	370.0
	18163936	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CC3CCCC3)[nH]c(=O)c2s1		CHEMBL4080673	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	nM	400.0
	18163937	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CCN3CCCC3)[nH]c(=O)c2s1		CHEMBL4073971	=	IC50	nM	1600.0	CHEMBL3231	Homo sapiens	IC50	nM	1600.0
	18163938	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(C(C)N3CCCC3)[nH]c(=O)c2s1		CHEMBL4086790	=	IC50	nM	40.0	CHEMBL3231	Homo sapiens	IC50	nM	40.0
	18163939	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(C(c3ccccc3)N3CCCC3)[nH]c(=O)c2s1		CHEMBL4065361	=	IC50	nM	4.1	CHEMBL3231	Homo sapiens	IC50	nM	4.1
	18163940	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CCC[C@@H]3C)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4078941	=	IC50	nM	160.0	CHEMBL3231	Homo sapiens	IC50	nM	160.0
	18163941	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CCC[C@@H]3CO)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4103214	=	IC50	nM	1200.0	CHEMBL3231	Homo sapiens	IC50	nM	1200.0
	18163942	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CC[C@@H](C)C3)[nH]c(=O)c2s1		CHEMBL4068071	=	IC50	nM	540.0	CHEMBL3231	Homo sapiens	IC50	nM	540.0
	18163943	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CC[C@H](C)C3)[nH]c(=O)c2s1		CHEMBL4095460	=	IC50	nM	420.0	CHEMBL3231	Homo sapiens	IC50	nM	420.0
	18163944	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CCC(c4ccccc4)C3)[nH]c(=O)c2s1		CHEMBL4105646	=	IC50	nM	170.0	CHEMBL3231	Homo sapiens	IC50	nM	170.0
	18163945	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CC[C@H](F)C3)[nH]c(=O)c2s1		CHEMBL4087760	=	IC50	nM	770.0	CHEMBL3231	Homo sapiens	IC50	nM	770.0
	18163946	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	O=c1[nH]c(CN2CCCC2)nc2cc(-c3ccncc3)sc12		CHEMBL4080367	=	IC50	nM	180.0	CHEMBL3231	Homo sapiens	IC50	nM	180.0
	18163947	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	O=c1[nH]c(CN2CCCC2)nc2cc(-c3cn[nH]c3)sc12		CHEMBL4098392	=	IC50	nM	820.0	CHEMBL3231	Homo sapiens	IC50	nM	820.0
	18163948	CHEMBL4036257	Inhibition of recombinant human N-terminal GST-tagged ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using Biotin-STK2 as substrate pretreated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CCc1n[nH]cc1-c1cc2nc(CN3CCCC3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4084945	=	IC50	nM	830.0	CHEMBL3231	Homo sapiens	IC50	nM	830.0
Not Determined	18201996	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	CCCn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccncn1		CHEMBL1738878		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	18201997	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1		CHEMBL490	=	Inhibition	%	10.0	CHEMBL3231	Homo sapiens	INH	%	10.0
	18201998	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	65.0	CHEMBL3231	Homo sapiens	INH	%	65.0
Not Determined	18201999	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Cn1c(CNc2cccc(C(=O)NCc3ccccc3C(F)(F)F)c2)nnc1-c1ccncc1		CHEMBL1738877		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	18202000	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	COc1cccc(OC)c1CNC(=O)c1cc(C2NC(=O)NC(C)=C2C(=O)Nc2ccc3[nH]ncc3c2)ccc1F		CHEMBL3809020	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	18202001	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	CNC(=O)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4077133	=	Inhibition	%	11.0	CHEMBL3231	Homo sapiens	INH	%	11.0
	18202002	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1ccccc1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4099398	=	Inhibition	%	17.0	CHEMBL3231	Homo sapiens	INH	%	17.0
	18202003	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1ccccc1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4073639	=	Inhibition	%	22.0	CHEMBL3231	Homo sapiens	INH	%	22.0
	18202004	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1c(F)cccc1F)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4091281	=	Inhibition	%	34.0	CHEMBL3231	Homo sapiens	INH	%	34.0
	18202005	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1c(F)cccc1F)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4064274	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	18202006	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1ccccc1C(F)(F)F)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4071638	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	INH	%	5.0
	18202007	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Cc1cccc(C)c1CNC(=O)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4098656	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	18202008	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1c(Cl)cccc1Cl)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4063014	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	18202009	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	COc1cccc(OC)c1CNC(=O)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4090923	=	Inhibition	%	13.0	CHEMBL3231	Homo sapiens	INH	%	13.0
	18202010	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	COc1ccccc1CNC(=O)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4101136	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	INH	%	1.0
	18202011	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	COc1ccccc1CNC(=O)Cc1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4083142	=	Inhibition	%	18.0	CHEMBL3231	Homo sapiens	INH	%	18.0
	18202012	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1ccccn1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4070885	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	18202013	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1cccnc1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4077197	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	18202014	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1ccncc1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4072898	=	Inhibition	%	8.0	CHEMBL3231	Homo sapiens	INH	%	8.0
	18202015	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1ccccn1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4076131	=	Inhibition	%	15.0	CHEMBL3231	Homo sapiens	INH	%	15.0
	18202016	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1cccnc1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4074476	=	Inhibition	%	18.0	CHEMBL3231	Homo sapiens	INH	%	18.0
	18202017	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1ccncc1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4077459	=	Inhibition	%	21.0	CHEMBL3231	Homo sapiens	INH	%	21.0
	18202018	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(Cc1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F)NCc1ccccn1		CHEMBL4062790	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	18202019	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(Cc1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F)NCCc1ccccn1		CHEMBL4084465	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	18202020	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1ncc[nH]1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4075475	=	Inhibition	%	18.0	CHEMBL3231	Homo sapiens	INH	%	18.0
	18202021	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1c[nH]cn1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4075712	=	Inhibition	%	11.0	CHEMBL3231	Homo sapiens	INH	%	11.0
	18202022	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1ccn[nH]1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4090144	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	18202023	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1cc[nH]n1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4076529	=	Inhibition	%	18.0	CHEMBL3231	Homo sapiens	INH	%	18.0
	18202024	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Cc1cc(CNC(=O)c2cc([C@@H]3CCNC[C@H]3COc3ccc4c(c3)OCO4)ccc2F)n[nH]1		CHEMBL4097393	=	Inhibition	%	12.0	CHEMBL3231	Homo sapiens	INH	%	12.0
	18202025	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Cn1ccc(CNC(=O)c2cc([C@@H]3CCNC[C@H]3COc3ccc4c(c3)OCO4)ccc2F)n1		CHEMBL4079362	=	Inhibition	%	17.0	CHEMBL3231	Homo sapiens	INH	%	17.0
	18202026	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	Cn1nccc1CNC(=O)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4105100	=	Inhibition	%	14.0	CHEMBL3231	Homo sapiens	INH	%	14.0
	18202027	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCc1cn[nH]c1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4087244	=	Inhibition	%	19.0	CHEMBL3231	Homo sapiens	INH	%	19.0
	18202028	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(NCCc1cn[nH]c1)c1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F		CHEMBL4081802	=	Inhibition	%	13.0	CHEMBL3231	Homo sapiens	INH	%	13.0
	18202029	CHEMBL4043638	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	B	O=C(Cc1cc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)ccc1F)NCCc1cn[nH]c1		CHEMBL4070290	=	Inhibition	%	27.0	CHEMBL3231	Homo sapiens	INH	%	27.0
	18203889	CHEMBL4044176	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	18212135	CHEMBL4046153	Inhibition of ROCK1 (unknown origin) at 1 uM relative to control	B	Cc1c(-c2ccncc2)c[nH]c1C(N)=O		CHEMBL4100387	<	Inhibition	%	20.0	CHEMBL3231	Homo sapiens	INH	%	20.0
	18225278	CHEMBL4048659	Inhibition of ROCK1 (unknown origin) at 1 uM relative to control	B	N[C@H]1C[C@H](Oc2ccc3ncc(-c4ccc5cnccc5c4)n3n2)C1		CHEMBL4094080	=	Inhibition	%	17.0	CHEMBL3231	Homo sapiens	INH	%	17.0
	18253205	CHEMBL4054885	Inhibition of Rho-associated protein kinase 1 (unknown origin)	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	IC50	nM	95.0	CHEMBL3231	Homo sapiens	IC50	nM	95.0
	18253231	CHEMBL4054899	Inhibition of human ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by KINOMEscan assay relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	5.3	CHEMBL3231	Homo sapiens	Activity	%	5.3
	18253232	CHEMBL4054899	Inhibition of human ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by KINOMEscan assay relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	36.0	CHEMBL3231	Homo sapiens	Activity	%	36.0
	18265795	CHEMBL4057245	Inhibition of ROCK1 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	-2.0	CHEMBL3231	Homo sapiens	INH	%	-2.0
	18265993	CHEMBL4057443	Inhibition of ROCK1 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	INH	%	1.0
	18282206	CHEMBL4120161	Inhibition of recombinant N-terminal GST-tagged human ROCK1 catalytic domain (1 to 535 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	8.8	CHEMBL3231	Homo sapiens	INH	%	8.8
	18282525	CHEMBL4120161	Inhibition of recombinant N-terminal GST-tagged human ROCK1 catalytic domain (1 to 535 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	-7.4	CHEMBL3231	Homo sapiens	INH	%	-7.4
	18282827	CHEMBL4120412	Inhibition of ROCK1 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	-2.0	CHEMBL3231	Homo sapiens	INH	%	-2.0
	18282997	CHEMBL4120582	Inhibition of ROCK1 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	-7.3	CHEMBL3231	Homo sapiens	INH	%	-7.3
	18283221	CHEMBL4120806	Inhibition of ROCK1 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	-0.3	CHEMBL3231	Homo sapiens	INH	%	-0.3
	18286350	CHEMBL4121600	Inhibition of recombinant N-terminal GST-tagged human ROCK1 catalytic domain (1 to 535 residues) expressed in baculovirus expression system at 10 uM in presence of ATP relative to control	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12		CHEMBL4128926	=	Inhibition	%	-10.0	CHEMBL3231	Homo sapiens	INH	%	-10.0
	18379943	CHEMBL4145844	Inhibition of ROCK1 (unknown origin) at 10 uM relative to control	B	COc1cc(NC(=O)Nc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C)cc2OC)cc(OC)c1		CHEMBL4159506	=	Inhibition	%	-3.88	CHEMBL3231	Homo sapiens	INH	%	-3.88
	18379995	CHEMBL4145896	Inhibition of ROCK1 (unknown origin)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.64	CHEMBL3231	Homo sapiens	IC50	nM	0.64
	18434149	CHEMBL4156131	Inhibition of recombinant human GST-tagged ROCK1 cytoplasmic domain expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	4.0	CHEMBL3231	Homo sapiens	INH	%	4.0
	18434195	CHEMBL4156131	Inhibition of recombinant human GST-tagged ROCK1 cytoplasmic domain expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	3.0	CHEMBL3231	Homo sapiens	INH	%	3.0
	18434255	CHEMBL4156131	Inhibition of recombinant human GST-tagged ROCK1 cytoplasmic domain expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	17.0	CHEMBL3231	Homo sapiens	INH	%	17.0
	18434327	CHEMBL4156131	Inhibition of recombinant human GST-tagged ROCK1 cytoplasmic domain expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	-1.0	CHEMBL3231	Homo sapiens	INH	%	-1.0
	18440431	CHEMBL4157255	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	18450266	CHEMBL4178312	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf9 cells assessed as change in enzyme activity at 1 uM in presence of 1 uM ATP relative to control	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3967108	=	Activity	%	-4.0	CHEMBL3231	Homo sapiens	Activity	%	-4.0
	18450316	CHEMBL4178312	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf9 cells assessed as change in enzyme activity at 1 uM in presence of 1 uM ATP relative to control	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3966346	=	Activity	%	3.0	CHEMBL3231	Homo sapiens	Activity	%	3.0
	18450492	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CN1c2c(sc(-c3cn[nH]c3)c2Br)C(=O)NC1(C)C		CHEMBL4205039	=	IC50	nM	22.0	CHEMBL3231	Homo sapiens	IC50	nM	22.0
	18450493	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1c(-c2cn[nH]c2)sc2c1N(C)C(C)(C)NC2=O		CHEMBL4204540	=	IC50	nM	44.0	CHEMBL3231	Homo sapiens	IC50	nM	44.0
	18450494	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)N[C@]1(CC[C@](O)(C3CCCCC3)CC1)N2		CHEMBL4209416	=	IC50	nM	2900.0	CHEMBL3231	Homo sapiens	IC50	nM	2900.0
	18450495	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)N[C@]1(CC[C@@](O)(C3CCCCC3)CC1)N2		CHEMBL4208876	=	IC50	nM	350.0	CHEMBL3231	Homo sapiens	IC50	nM	350.0
	18450496	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)N[C@]1(CC[C@](O)(c3ccc(F)cc3)CC1)N2		CHEMBL4213805	=	IC50	nM	820.0	CHEMBL3231	Homo sapiens	IC50	nM	820.0
	18450497	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)N[C@]1(CC[C@@](O)(c3ccc(F)cc3)CC1)N2		CHEMBL4204333	=	IC50	nM	130.0	CHEMBL3231	Homo sapiens	IC50	nM	130.0
	18450498	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)NC1(CCCCC1)N2		CHEMBL4216005	=	IC50	nM	48.0	CHEMBL3231	Homo sapiens	IC50	nM	48.0
	18450499	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CCc1n[nH]cc1-c1cc2c(s1)C(=O)NC(C)(C)N2C		CHEMBL4218429	=	IC50	nM	350.0	CHEMBL3231	Homo sapiens	IC50	nM	350.0
	18450500	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]c(C)c1-c1cc2c(s1)C(=O)NC(C)(C)N2C		CHEMBL4213496	=	IC50	nM	2100.0	CHEMBL3231	Homo sapiens	IC50	nM	2100.0
	18450501	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)NC(C)(CC(F)(F)F)N2C		CHEMBL4214023	=	IC50	nM	22.0	CHEMBL3231	Homo sapiens	IC50	nM	22.0
	18450502	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2c(s1)C(=O)NC(C)(C)N2C		CHEMBL4209096	=	IC50	nM	54.0	CHEMBL3231	Homo sapiens	IC50	nM	54.0
	18450503	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CN1c2cc(-c3cn[nH]c3)sc2C(=O)NC1(C)C		CHEMBL4209617	=	IC50	nM	130.0	CHEMBL3231	Homo sapiens	IC50	nM	130.0
	18450504	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CC1(C)Nc2cc(-c3ccncc3)sc2C(=O)N1Cc1ccccc1		CHEMBL4204752	=	IC50	nM	1.5	CHEMBL3231	Homo sapiens	IC50	nM	1.5
	18450505	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CN1C(=O)c2sc(-c3ccncc3)cc2NC1(C)C		CHEMBL4205235	=	IC50	nM	240.0	CHEMBL3231	Homo sapiens	IC50	nM	240.0
	18450506	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	O=C1NC2(CCCCCC2)Nc2cc(-c3ccncc3)sc21		CHEMBL4216947	=	IC50	nM	37.0	CHEMBL3231	Homo sapiens	IC50	nM	37.0
	18450507	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	O=C1NC2(CCCCC2)Nc2cc(-c3ccncc3)sc21		CHEMBL4207094	=	IC50	nM	53.0	CHEMBL3231	Homo sapiens	IC50	nM	53.0
	18450508	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	O=C1NC2(CCCC2)Nc2cc(-c3ccncc3)sc21		CHEMBL4211971	=	IC50	nM	100.0	CHEMBL3231	Homo sapiens	IC50	nM	100.0
	18450509	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CC1(CC(F)(F)F)NC(=O)c2sc(-c3ccncc3)cc2N1		CHEMBL4202743	=	IC50	nM	31.0	CHEMBL3231	Homo sapiens	IC50	nM	31.0
	18450510	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CC(C)C1(C)NC(=O)c2sc(-c3ccncc3)cc2N1		CHEMBL4207608	=	IC50	nM	35.0	CHEMBL3231	Homo sapiens	IC50	nM	35.0
	18450511	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CCCC1(C)NC(=O)c2sc(-c3ccncc3)cc2N1		CHEMBL4214928	=	IC50	nM	33.0	CHEMBL3231	Homo sapiens	IC50	nM	33.0
	18450512	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CCC1(C)NC(=O)c2sc(-c3ccncc3)cc2N1		CHEMBL4203275	=	IC50	nM	36.0	CHEMBL3231	Homo sapiens	IC50	nM	36.0
	18450513	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CN1c2cc(-c3ccncc3)sc2C(=O)NC1(C)C		CHEMBL4210511	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
	18450514	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CC1(C)NC(=O)c2sc(-c3ccncc3)cc2N1		CHEMBL4215449	=	IC50	nM	90.0	CHEMBL3231	Homo sapiens	IC50	nM	90.0
	18450515	CHEMBL4178341	Inhibition of recombinant human N-terminal GST-tagged ROCK1 (1 to 477 residues) expressed in baculovirus expression system using biotin-STK substrate-2 as substrate preincubated for 5 mins followed by ATP addition after 2 hrs by TR-FRET assay	B	CC1(C)NC(=O)c2cc(-c3ccncc3)sc2N1		CHEMBL4206154	=	IC50	nM	100.0	CHEMBL3231	Homo sapiens	IC50	nM	100.0
	18463800	CHEMBL4181216	Inhibition of recombinant human N-terminal His6-tagged ROCK1 (17 to 535 residues) expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	-4.0	CHEMBL3231	Homo sapiens	INH	%	-4.0
	18470588	CHEMBL4182582	Inhibition of human ROCK1 at 10 uM by ADP-Glo kinase assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	85.0	CHEMBL3231	Homo sapiens	INH	%	85.0
	18470767	CHEMBL4182582	Inhibition of human ROCK1 at 10 uM by ADP-Glo kinase assay	B	Cc1nc(N)c2ccn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1		CHEMBL4206295	=	Inhibition	%	19.0	CHEMBL3231	Homo sapiens	INH	%	19.0
	18470768	CHEMBL4182582	Inhibition of human ROCK1 at 10 uM by ADP-Glo kinase assay	B	Nc1ncnc2c1ccn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1		CHEMBL4218073	=	Inhibition	%	6.0	CHEMBL3231	Homo sapiens	INH	%	6.0
	18484387	CHEMBL4186034	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	18484871	CHEMBL4186034	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	72.0	CHEMBL3231	Homo sapiens	Activity	%	72.0
	18507623	CHEMBL4191169	Inhibition of recombinant human ROCK1 (17 to 535 residues) at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-1.0	CHEMBL3231	Homo sapiens	INH	%	-1.0
	18568701	CHEMBL4220221	Inhibition of ROCK1 (unknown origin)	B	CN(C)[C@H]1C[C@@]23CC[C@@]4(O2)C(=CC[C@]2(C)[C@@H](c5ccc6ccncc6c5)CC[C@@H]42)C=C3[C@@H](O)[C@@H]1O		CHEMBL4080906	=	IC50	nM	250.0	CHEMBL3231	Homo sapiens	IC50	nM	250.0
	18653387	CHEMBL4230212	Inhibition of ROCK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	INH	%	5.0
	18653388	CHEMBL4230212	Inhibition of ROCK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	INH	%	1.0
	18655301	CHEMBL4230934	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	18665460	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	CN1CCC(CCCOc2cccc(CC(=O)Nc3nc(-c4ccncc4)cs3)c2)CC1		CHEMBL4237479	=	Ki	nM	10.0	CHEMBL3231	Homo sapiens	Ki	nM	10.0
	18665468	CHEMBL4233399	Inhibition of ROCK1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	=	IC50	nM	7.0	CHEMBL3231	Homo sapiens	IC50	nM	7.0
	18665499	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	=	Ki	nM	13.0	CHEMBL3231	Homo sapiens	Ki	nM	13.0
	18665502	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4ccncc4)cs3)c2)CC1		CHEMBL4241204	=	Ki	nM	45.0	CHEMBL3231	Homo sapiens	Ki	nM	45.0
	18665523	CHEMBL4233399	Inhibition of ROCK1 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	18665572	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	=	Ki	nM	51.0	CHEMBL3231	Homo sapiens	Ki	nM	51.0
	18665575	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCCN2CCOCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4241299	=	Ki	nM	240.0	CHEMBL3231	Homo sapiens	Ki	nM	240.0
	18665578	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCCN2CCCCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4249314	=	Ki	nM	220.0	CHEMBL3231	Homo sapiens	Ki	nM	220.0
	18665581	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4ccncc4)cs3)c2)CC1		CHEMBL4241689	=	Ki	nM	88.0	CHEMBL3231	Homo sapiens	Ki	nM	88.0
	18665584	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4240949	=	Ki	nM	47.0	CHEMBL3231	Homo sapiens	Ki	nM	47.0
	18665587	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCN2CCOCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4248852	=	Ki	nM	430.0	CHEMBL3231	Homo sapiens	Ki	nM	430.0
	18665590	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	O=C(Cc1cccc(OCCN2CCCCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4242549	=	Ki	nM	510.0	CHEMBL3231	Homo sapiens	Ki	nM	510.0
	18665593	CHEMBL4233278	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate by pyruvate kinase-lactate dehydrogenase coupled assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3581121	=	Ki	nM	83.0	CHEMBL3231	Homo sapiens	Ki	nM	83.0
	18674427	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1		CHEMBL3581140	=	Ki	nM	165.0	CHEMBL3231	Homo sapiens	Ki	nM	165.0
	18674428	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	COc1cccc(CC(=O)Nc2nc(-c3ccnc4[nH]ccc34)cs2)c1		CHEMBL4247780	=	Ki	nM	16.0	CHEMBL3231	Homo sapiens	Ki	nM	16.0
	18674429	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1ccccc1)Nc1nc(-c2ccnc3[nH]ccc23)cs1		CHEMBL4251448	=	Ki	nM	19.0	CHEMBL3231	Homo sapiens	Ki	nM	19.0
	18674430	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4240883	=	Ki	nM	5.0	CHEMBL3231	Homo sapiens	Ki	nM	5.0
	18674431	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1cccc(O)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245089	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	nM	3.0
	18674432	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	COc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4244623	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	nM	3.0
	18674433	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1ccc2c(c1)OCO2)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4248883	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	nM	6.0
	18674434	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	N#Cc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4239032	=	Ki	nM	14.0	CHEMBL3231	Homo sapiens	Ki	nM	14.0
	18674435	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4237255	=	Ki	nM	40.0	CHEMBL3231	Homo sapiens	Ki	nM	40.0
	18674436	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CN(C)S(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4240458	=	Ki	nM	11.0	CHEMBL3231	Homo sapiens	Ki	nM	11.0
	18674437	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4243123	=	Ki	nM	19.0	CHEMBL3231	Homo sapiens	Ki	nM	19.0
	18674438	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4240605	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	nM	3.0
	18674439	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CC(C)NS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249070	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	nM	6.0
	18674440	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	COCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4241959	=	Ki	nM	2.0	CHEMBL3231	Homo sapiens	Ki	nM	2.0
	18674441	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	=	Ki	nM	2.0	CHEMBL3231	Homo sapiens	Ki	nM	2.0
	18674442	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4250547	<	Ki	nM	1.0	CHEMBL3231	Homo sapiens	Ki	nM	1.0
	18674443	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4241305	=	Ki	nM	2.0	CHEMBL3231	Homo sapiens	Ki	nM	2.0
	18674444	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CC(C)S(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4244717	=	Ki	nM	2.0	CHEMBL3231	Homo sapiens	Ki	nM	2.0
	18674445	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CCCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4243658	=	Ki	nM	2.0	CHEMBL3231	Homo sapiens	Ki	nM	2.0
	18674446	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4238696	=	Ki	nM	8.0	CHEMBL3231	Homo sapiens	Ki	nM	8.0
	18674447	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4245197	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	nM	3.0
	18674448	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	<	Ki	nM	5.0	CHEMBL3231	Homo sapiens	Ki	nM	5.0
	18674449	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4242191	=	Ki	nM	10.0	CHEMBL3231	Homo sapiens	Ki	nM	10.0
	18674450	CHEMBL4235304	Inhibition of ROCK1 (6 to 553 residues) (unknown origin) using Lys-Lys-Arg-Asn-Arg-Thr-Leu-Ser-Val as substrate in presence of ATP by spectrophotometric assay	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	<	Ki	nM	1.0	CHEMBL3231	Homo sapiens	Ki	nM	1.0
	18697684	CHEMBL4254357	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	70.0	CHEMBL3231	Homo sapiens	Activity	%	70.0
	18702476	CHEMBL4255131	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4278211	=	Inhibition	%	7.0	CHEMBL3231	Homo sapiens	INH	%	7.0
	18702562	CHEMBL4255131	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4282644	=	Inhibition	%	11.0	CHEMBL3231	Homo sapiens	INH	%	11.0
	18702607	CHEMBL4255131	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4287097	=	Inhibition	%	1.0	CHEMBL3231	Homo sapiens	INH	%	1.0
	18702659	CHEMBL4255131	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4283739	=	Inhibition	%	-3.0	CHEMBL3231	Homo sapiens	INH	%	-3.0
	18702702	CHEMBL4255131	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4294318	=	Inhibition	%	5.0	CHEMBL3231	Homo sapiens	INH	%	5.0
	18702745	CHEMBL4255131	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4289040	=	Inhibition	%	11.0	CHEMBL3231	Homo sapiens	INH	%	11.0
Not Active	18728880	CHEMBL4259710	Inhibition of ROCK1 (unknown origin) at 1 uM after 40 mins by scintillation counting method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	18736440	CHEMBL4261163	Inhibition of ROCK1 (unknown origin) by ATP competition assay	B	c1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4284998	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	uM	1.0
	18736441	CHEMBL4261163	Inhibition of ROCK1 (unknown origin) by ATP competition assay	B	CN(C)CCOc1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4282551	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	uM	1.0
	18736442	CHEMBL4261163	Inhibition of ROCK1 (unknown origin) by ATP competition assay	B	c1cc(-c2cnco2)nc(-c2cnc(-c3cccc(-c4cccc(-c5ncc(-c6cccc(-c7cnco7)n6)o5)n4)n3)o2)c1		CHEMBL4284890	>	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	uM	1.0
	18751226	CHEMBL4263935	Inhibition of ROCK1 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	18752186	CHEMBL4264523	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	93.0	CHEMBL3231	Homo sapiens	Activity	%	93.0
	18761575	CHEMBL4266626	Inhibition of recombinant human N-terminal His6-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	-2.0	CHEMBL3231	Homo sapiens	INH	%	-2.0
	18761846	CHEMBL4266626	Inhibition of recombinant human N-terminal His6-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	18762009	CHEMBL4266626	Inhibition of recombinant human N-terminal His6-tagged ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	18789034	CHEMBL4272384	Inhibition of ROCK1 (unknown origin)	B	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	Ki	nM	40.0	CHEMBL3231	Homo sapiens	Ki	nM	40.0
	18858186	CHEMBL4308032	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	96.0	CHEMBL3231	Homo sapiens	Activity	%	96.0
	18892963	CHEMBL4314929	Inhibition of human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 120 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	109.5	CHEMBL3231	Homo sapiens	Activity	%	109.5
	18919523	CHEMBL4322879	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged ROCK1 (unknown origin) (1 to 477 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	35.0	CHEMBL3231	Homo sapiens	Kd	nM	35.0
	18919711	CHEMBL4322879	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged ROCK1 (unknown origin) (1 to 477 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	26.0	CHEMBL3231	Homo sapiens	Kd	nM	26.0
	18929710	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(CN3CCCC3)[nH]c(=O)c2s1		CHEMBL4083927	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
	18929711	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CCN3)[nH]c(=O)c2s1		CHEMBL4457256	=	IC50	nM	760.0	CHEMBL3231	Homo sapiens	IC50	nM	760.0
	18929712	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CCCN3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4440266	=	IC50	nM	360.0	CHEMBL3231	Homo sapiens	IC50	nM	360.0
	18929713	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CCCCN3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4439133	=	IC50	nM	420.0	CHEMBL3231	Homo sapiens	IC50	nM	420.0
	18929714	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@H]3CCCCN3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4587191	=	IC50	nM	370.0	CHEMBL3231	Homo sapiens	IC50	nM	370.0
	18929715	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CC=CCN3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4543158	=	IC50	nM	340.0	CHEMBL3231	Homo sapiens	IC50	nM	340.0
	18929716	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CCCCCN3)[nH]c(=O)c2s1		CHEMBL4529213	=	IC50	nM	450.0	CHEMBL3231	Homo sapiens	IC50	nM	450.0
	18929717	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cl.O=c1[nH]c([C@@H]2CCCCN2)nc2cc(-c3c[nH]nc3C(F)(F)F)sc12		CHEMBL4570191	=	IC50	nM	530.0	CHEMBL3231	Homo sapiens	IC50	nM	530.0
	18929718	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CCCN3C)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4589689	=	IC50	nM	160.0	CHEMBL3231	Homo sapiens	IC50	nM	160.0
	18929719	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@]3(C)CCCN3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4542797	=	IC50	nM	270.0	CHEMBL3231	Homo sapiens	IC50	nM	270.0
	18929720	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@H]3NCC[C@@H]3C)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4569914	=	IC50	nM	130.0	CHEMBL3231	Homo sapiens	IC50	nM	130.0
	18929721	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3C[C@H](C)CN3)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4462574	=	IC50	nM	630.0	CHEMBL3231	Homo sapiens	IC50	nM	630.0
	18929722	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CCC(C)(C)N3)[nH]c(=O)c2s1		CHEMBL4561384	=	IC50	nM	1500.0	CHEMBL3231	Homo sapiens	IC50	nM	1500.0
	18929723	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(C34CC(CN3)C4)[nH]c(=O)c2s1.Cl.Cl		CHEMBL4436649	=	IC50	nM	220.0	CHEMBL3231	Homo sapiens	IC50	nM	220.0
	18929724	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc(C34CCC(CC3)N4)[nH]c(=O)c2s1.Cl		CHEMBL4462898	=	IC50	nM	96.0	CHEMBL3231	Homo sapiens	IC50	nM	96.0
	18929725	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@@H]3CC4CCN3CC4)[nH]c(=O)c2s1		CHEMBL4297644	=	IC50	nM	430.0	CHEMBL3231	Homo sapiens	IC50	nM	430.0
	18929726	CHEMBL4325327	Inhibition of N-terminal GST-tagged human ROCK1 catalytic domain (1 to 477 residues) expressed in baculovirus expression system using biotin-STK-substrate 2 as substrate preincubated with enzyme for 5 mins followed by ATP addition and measured after 2 hrs by TR-FRET assay	B	Cc1n[nH]cc1-c1cc2nc([C@H]3CC4CCN3CC4)[nH]c(=O)c2s1		CHEMBL4572218	=	IC50	nM	460.0	CHEMBL3231	Homo sapiens	IC50	nM	460.0
	18934107	CHEMBL4326639	Inhibition of human ROCK1 at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(N4Cc5cccc(N(C)S(C)(=O)=O)c5C4)n3)cc2)CC1		CHEMBL4476226	=	Inhibition	%	6.9	CHEMBL3231	Homo sapiens	INH	%	6.9
	18938273	CHEMBL4327863	Inhibition of human ROCK1 assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	101.24	CHEMBL3231	Homo sapiens	Activity	%	101.24
	18938274	CHEMBL4327863	Inhibition of human ROCK1 assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	97.3	CHEMBL3231	Homo sapiens	Activity	%	97.3
	18938708	CHEMBL4328227	Inhibition of human ROCK1 assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL3231	Homo sapiens	Activity	%	65.0
	18939094	CHEMBL4328591	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.799	CHEMBL3231	Homo sapiens	IC50	10'-10M	7.99
	18939179	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	=	IC50	nM	550.0	CHEMBL3231	Homo sapiens	IC50	uM	0.55
	18939180	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	=	IC50	nM	160.0	CHEMBL3231	Homo sapiens	IC50	uM	0.16
	18939181	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4454552	=	IC50	nM	780.0	CHEMBL3231	Homo sapiens	IC50	uM	0.78
	18939182	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4476761	=	IC50	nM	520.0	CHEMBL3231	Homo sapiens	IC50	uM	0.52
	18939183	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc(O)c1)c1ccc(-c2ccncc2)cc1		CHEMBL4536833	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	uM	0.019
	18939184	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc(OC(F)(F)F)c1)c1ccc(-c2ccncc2)cc1		CHEMBL4475535	=	IC50	nM	4400.0	CHEMBL3231	Homo sapiens	IC50	uM	4.4
	18939185	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1OC		CHEMBL4447521	=	IC50	nM	16000.0	CHEMBL3231	Homo sapiens	IC50	uM	16.0
	18939186	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1		CHEMBL4522042	=	IC50	nM	280.0	CHEMBL3231	Homo sapiens	IC50	uM	0.28
	18939187	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc2c1OCCCO2)c1ccc(-c2ccncc2)cc1		CHEMBL4463301	=	IC50	nM	280.0	CHEMBL3231	Homo sapiens	IC50	uM	0.28
	18939188	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4436040	=	IC50	nM	340.0	CHEMBL3231	Homo sapiens	IC50	uM	0.34
	18939189	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc(OCCN2CCOCC2)c1)c1ccc(-c2ccncc2)cc1		CHEMBL4570150	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	IC50	uM	1.0
	18939190	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4448806	=	IC50	nM	17.0	CHEMBL3231	Homo sapiens	IC50	uM	0.017
	18939191	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4575880	=	IC50	nM	5100.0	CHEMBL3231	Homo sapiens	IC50	uM	5.1
	18939192	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(N)c3)cc2)c1		CHEMBL4474946	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	uM	0.11
	18939193	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4459800	=	IC50	nM	85.0	CHEMBL3231	Homo sapiens	IC50	uM	0.085
	18939194	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(Cl)c3)cc2)c1		CHEMBL4451899	=	IC50	nM	720.0	CHEMBL3231	Homo sapiens	IC50	uM	0.72
	18939195	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(C)c3)cc2)c1		CHEMBL4438453	=	IC50	nM	610.0	CHEMBL3231	Homo sapiens	IC50	uM	0.61
	18939196	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cc(C)nc(C)c3)cc2)c1		CHEMBL4540054	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	18939197	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL4472858	=	IC50	nM	11.0	CHEMBL3231	Homo sapiens	IC50	uM	0.011
	18939198	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL4460511	=	IC50	nM	210.0	CHEMBL3231	Homo sapiens	IC50	uM	0.21
	18939199	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1		CHEMBL4584824	=	IC50	nM	9400.0	CHEMBL3231	Homo sapiens	IC50	uM	9.4
	18939200	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCNc1cc(-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc2)ccn1		CHEMBL4445356	=	IC50	nM	650.0	CHEMBL3231	Homo sapiens	IC50	uM	0.65
	18939201	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCC4CC4)c3)cc2)c1		CHEMBL4556370	=	IC50	nM	400.0	CHEMBL3231	Homo sapiens	IC50	uM	0.4
	18939202	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCC(C)(C)O)c3)cc2)c1		CHEMBL4568447	=	IC50	nM	2400.0	CHEMBL3231	Homo sapiens	IC50	uM	2.4
	18939203	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCCO)c3)cc2)c1		CHEMBL4446212	=	IC50	nM	1500.0	CHEMBL3231	Homo sapiens	IC50	uM	1.5
	18939204	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCCCO)c3)cc2)c1		CHEMBL4588929	=	IC50	nM	580.0	CHEMBL3231	Homo sapiens	IC50	uM	0.58
	18939205	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(N[C@H](CCN1CCCC1)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL4459077	=	IC50	nM	46.0	CHEMBL3231	Homo sapiens	IC50	uM	0.046
	18939206	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](CCN2CCCC2)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4583341	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	uM	0.014
	18939207	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](CCO)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4469316	=	IC50	nM	39.0	CHEMBL3231	Homo sapiens	IC50	uM	0.039
	18939208	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](CCN2CCOCC2)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4436197	=	IC50	nM	139.0	CHEMBL3231	Homo sapiens	IC50	uM	0.139
	18939209	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](CCN2CCCCC2)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4471862	=	IC50	nM	550.0	CHEMBL3231	Homo sapiens	IC50	uM	0.55
	18939210	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	O=C(N[C@H](CCN1CCCC1)c1cccc(F)c1)c1ccc(-c2ccnc(F)c2)cc1		CHEMBL4521871	=	IC50	nM	240.0	CHEMBL3231	Homo sapiens	IC50	uM	0.24
	18939211	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](CCO)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4590232	=	IC50	nM	1600.0	CHEMBL3231	Homo sapiens	IC50	uM	1.6
	18939212	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](CCO)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL4577208	=	IC50	nM	720.0	CHEMBL3231	Homo sapiens	IC50	uM	0.72
	18939213	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4469434	=	IC50	nM	160.0	CHEMBL3231	Homo sapiens	IC50	uM	0.16
	18939214	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2N2CCC(CN)CC2)c1		CHEMBL4434688	=	IC50	nM	3.0	CHEMBL3231	Homo sapiens	IC50	uM	0.003
	18939215	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2NCCN)c1		CHEMBL4572198	=	IC50	nM	190.0	CHEMBL3231	Homo sapiens	IC50	uM	0.19
	18939216	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL4553926	=	IC50	nM	95.0	CHEMBL3231	Homo sapiens	IC50	uM	0.095
	18939217	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCCN)c1		CHEMBL4555093	=	IC50	nM	310.0	CHEMBL3231	Homo sapiens	IC50	uM	0.31
	18939218	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2NCCCCN)c1		CHEMBL4585481	=	IC50	nM	990.0	CHEMBL3231	Homo sapiens	IC50	uM	0.99
	18939219	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CC[C@@H](CN)C2)c1		CHEMBL4550282	=	IC50	nM	1900.0	CHEMBL3231	Homo sapiens	IC50	uM	1.9
	18939220	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CC[C@H](CN)C2)c1		CHEMBL4547725	=	IC50	nM	1700.0	CHEMBL3231	Homo sapiens	IC50	uM	1.7
	18939221	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CCC[C@H](CN)C2)c1		CHEMBL4557041	=	IC50	nM	160.0	CHEMBL3231	Homo sapiens	IC50	uM	0.16
	18939222	CHEMBL4328666	Inhibition of human GST-tagged catalytic ROCK1 expressed in baculovirus system using STK S2 peptide substrate and and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CCC[C@@H](CN)C2)c1		CHEMBL4465725	=	IC50	nM	120.0	CHEMBL3231	Homo sapiens	IC50	uM	0.12
	18939459	CHEMBL4328709	Inhibition of ROCK1 (unknown origin) incubated for 2 hrs by AbbVie kinase panel assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4448806	=	IC50	nM	1.0	CHEMBL3231	Homo sapiens	IC50	nM	1.0
	18950245	CHEMBL4331097	Inhibition of human ROCK1 assessed as residual activity at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	Activity	%	73.98	CHEMBL3231	Homo sapiens	Activity	%	73.98
	18958574	CHEMBL4333617	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	18964656	CHEMBL4335269	Inhibition of recombinant human ROCK1 (17 to 535 residues) assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 120 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	101.0	CHEMBL3231	Homo sapiens	Activity	%	101.0
	18964657	CHEMBL4335269	Inhibition of recombinant human ROCK1 (17 to 535 residues) assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 120 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	109.0	CHEMBL3231	Homo sapiens	Activity	%	109.0
	18972082	CHEMBL4337092	Inhibition of recombinant human ROCK1 (17 to 535 residues) assessed as residual activity at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 120 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	84.0	CHEMBL3231	Homo sapiens	Activity	%	84.0
	18989187	CHEMBL4340738	Inhibition of recombinant human ROCK1 measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method	B	CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12		CHEMBL4446681	=	IC50	nM	35000.0	CHEMBL3231	Homo sapiens	IC50	uM	35.0
Not Active	19040140	CHEMBL4352041	Inhibition of human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 120 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Active	19041269	CHEMBL4352530	Inhibition of human ROCK1 at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	19043777	CHEMBL4353243	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 0.1 uM in presence of 33P-gamma ATP by hotspot kinase assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4ccc5c(c4)OCO5)n[nH]3)cc2)CC1		CHEMBL4456471	=	Inhibition	%	104.49	CHEMBL3231	Homo sapiens	INH	%	104.49
	19059811	CHEMBL4358112	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	19072274	CHEMBL4361951	Inhibition of N-terminal His-tagged human ROCK1 (3 to 543 residues) expressed in baculovirus infected Sf9 cells using biotin-Ahx-AKRRRLSSLRA-CONH2 as substrate incubated for 90 mins in presence of [gamma33P]ATP by scintillation counting method	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	5.6	CHEMBL3231	Homo sapiens	IC50	nM	5.6
	19072275	CHEMBL4361951	Inhibition of N-terminal His-tagged human ROCK1 (3 to 543 residues) expressed in baculovirus infected Sf9 cells using biotin-Ahx-AKRRRLSSLRA-CONH2 as substrate incubated for 90 mins in presence of [gamma33P]ATP by scintillation counting method	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	IC50	nM	1.6	CHEMBL3231	Homo sapiens	IC50	nM	1.6
	19072277	CHEMBL4361949	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) using myelin basic protein as substrate incubated for 30 mins by ADP-Glo assay	B	COc1nc(N[C@H]2CC[C@H](N)CC2)c(F)cc1C(N)=O		CHEMBL4554795	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	19072284	CHEMBL4361943	Inhibition of human recombinant ROCK1 expressed in Baculovirus infected Sf9 cells assessed as inhibition of Ulight-RRRSLLE phosphorylation incubated for 20 mins by LANCE assay	B	CN(/N=C/c1ccccc1)S(=O)(=O)c1cccc2cnccc12		CHEMBL4471765	=	IC50	nM	3100.0	CHEMBL3231	Homo sapiens	IC50	uM	3.1
	19072295	CHEMBL4361940	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 20 mins in presence of [gamma33P]ATP by filter binding method	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4461288	=	IC50	nM	1.22	CHEMBL3231	Homo sapiens	IC50	nM	1.22
	19072296	CHEMBL4361940	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 20 mins in presence of [gamma33P]ATP by filter binding method	B	Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL4594250	=	IC50	nM	32.6	CHEMBL3231	Homo sapiens	IC50	nM	32.6
	19072297	CHEMBL4361941	Binding affinity to ROCK1 (unknown origin) incubated for 1 hrs by qPCR analysis	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4461288	=	Kd	nM	1.5	CHEMBL3231	Homo sapiens	Kd	nM	1.5
	19090375	CHEMBL4365949	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	54.0	CHEMBL3231	Homo sapiens	Activity	%	54.0
	19092102	CHEMBL4366576	Inhibition of human ROCK1 at 100 nM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	8.8	CHEMBL3231	Homo sapiens	INH	%	8.8
	19144829	CHEMBL4377845	Inhibition of recombinant human ROCK1 (17 to 535 residues) at 1 uM using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric assay relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	11.0	CHEMBL3231	Homo sapiens	INH	%	11.0
	19146966	CHEMBL4378826	Inhibition of human ROCK1 (17 to 535 residues) at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	9.0	CHEMBL3231	Homo sapiens	INH	%	9.0
	19147511	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)NC(=O)CC4)c2)cc1		CHEMBL4577999	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147512	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)CCC(=O)N4)c2)cc1		CHEMBL4476081	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147513	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1cccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)c1		CHEMBL4585524	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147514	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1cc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)ccc1C=O		CHEMBL4539818	=	IC50	nM	3741.0	CHEMBL3231	Homo sapiens	IC50	uM	3.741
	19147515	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1ccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)cc1OC		CHEMBL4514373	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147516	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1ccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)cc1F		CHEMBL4460696	=	IC50	nM	1820.0	CHEMBL3231	Homo sapiens	IC50	uM	1.82
	19147517	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(=O)c1ccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)cc1F		CHEMBL4447770	=	IC50	nM	445.0	CHEMBL3231	Homo sapiens	IC50	uM	0.445
	19147518	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)OCO4)c2)cc1		CHEMBL4569357	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147519	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)OCCO4)c2)cc1		CHEMBL4577880	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147520	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)OCCC4=O)c2)cc1		CHEMBL4558371	=	IC50	nM	144.0	CHEMBL3231	Homo sapiens	IC50	uM	0.144
	19147521	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	uM	0.014
	19147522	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4occc(=O)c4c3)c2)cc1		CHEMBL4463505	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147523	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1coc2cc(OCC(=O)Nc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)ccc2c1=O		CHEMBL4568022	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147524	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1c(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)ccc2c(=O)ccoc12		CHEMBL4458703	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147525	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(=O)Nc1cccc(NC(=O)COc2ccc3c(=O)ccoc3c2)c1		CHEMBL4473009	=	IC50	nM	2502.0	CHEMBL3231	Homo sapiens	IC50	uM	2.502
	19147526	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCCC(=O)Nc1cccc(NC(=O)COc2ccc3c(=O)ccoc3c2)c1		CHEMBL4452457	=	IC50	nM	1431.0	CHEMBL3231	Homo sapiens	IC50	uM	1.431
	19147527	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccccc2)c1		CHEMBL4586795	=	IC50	nM	120.0	CHEMBL3231	Homo sapiens	IC50	uM	0.12
	19147528	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4459655	=	IC50	nM	183.0	CHEMBL3231	Homo sapiens	IC50	uM	0.183
	19147529	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4458667	=	IC50	nM	235.0	CHEMBL3231	Homo sapiens	IC50	uM	0.235
	19147530	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCCc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4576394	=	IC50	nM	143.0	CHEMBL3231	Homo sapiens	IC50	uM	0.143
	19147531	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4556104	=	IC50	nM	165.0	CHEMBL3231	Homo sapiens	IC50	uM	0.165
	19147532	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(F)cc2)c1		CHEMBL4586827	=	IC50	nM	129.0	CHEMBL3231	Homo sapiens	IC50	uM	0.129
	19147533	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(Br)cc2)c1		CHEMBL4451407	=	IC50	nM	303.0	CHEMBL3231	Homo sapiens	IC50	uM	0.303
	19147534	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	N#Cc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4453948	=	IC50	nM	123.0	CHEMBL3231	Homo sapiens	IC50	uM	0.123
	19147535	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4446390	=	IC50	nM	18.0	CHEMBL3231	Homo sapiens	IC50	uM	0.018
	19147536	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCOc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4476505	=	IC50	nM	17.0	CHEMBL3231	Homo sapiens	IC50	uM	0.017
	19147537	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(OC(F)(F)F)cc2)c1		CHEMBL4555946	=	IC50	nM	869.0	CHEMBL3231	Homo sapiens	IC50	uM	0.869
	19147538	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc([N+](=O)[O-])cc2)c1		CHEMBL4467403	=	IC50	nM	67.0	CHEMBL3231	Homo sapiens	IC50	uM	0.067
	19147539	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COC(=O)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4533805	=	IC50	nM	72.0	CHEMBL3231	Homo sapiens	IC50	uM	0.072
	19147540	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2cccc([N+](=O)[O-])c2)c1		CHEMBL4437283	=	IC50	nM	528.0	CHEMBL3231	Homo sapiens	IC50	uM	0.528
	19147541	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)ccc1C(F)(F)F		CHEMBL4519471	=	IC50	nM	460.0	CHEMBL3231	Homo sapiens	IC50	uM	0.46
	19147542	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(C)(C)c1cc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)no1		CHEMBL4451007	=	IC50	nM	101.0	CHEMBL3231	Homo sapiens	IC50	uM	0.101
	19147543	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1nc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cs1		CHEMBL4470778	=	IC50	nM	473.0	CHEMBL3231	Homo sapiens	IC50	uM	0.473
	19147544	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2cnc(C(F)(F)F)s2)c1		CHEMBL4445974	=	IC50	nM	160.0	CHEMBL3231	Homo sapiens	IC50	uM	0.16
	19147545	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)no1		CHEMBL4562184	=	IC50	nM	68.0	CHEMBL3231	Homo sapiens	IC50	uM	0.068
	19147546	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	NCc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4472964	=	IC50	nM	532.0	CHEMBL3231	Homo sapiens	IC50	uM	0.532
	19147547	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Nc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4475912	=	IC50	nM	802.0	CHEMBL3231	Homo sapiens	IC50	uM	0.802
	19147548	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Nc1cccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)c1		CHEMBL4440876	=	IC50	nM	670.0	CHEMBL3231	Homo sapiens	IC50	uM	0.67
	19147549	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(C(=O)O)cc2)c1		CHEMBL4529033	=	IC50	nM	6892.0	CHEMBL3231	Homo sapiens	IC50	uM	6.892
	19147550	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cn1ccc(S(=O)(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)n1		CHEMBL4514074	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147551	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(S(=O)(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4474271	=	IC50	nM	803.0	CHEMBL3231	Homo sapiens	IC50	uM	0.803
	19147552	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(C)(C)c1ccc(S(=O)(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4467086	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147553	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1		CHEMBL4444893	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147554	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)c1		CHEMBL4474804	=	IC50	nM	6443.0	CHEMBL3231	Homo sapiens	IC50	uM	6.443
	19147555	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1ccc(NC(=O)COc2ccc3c(=O)ccoc3c2)cc1NC(=O)c1ccc(N(C)C)cc1		CHEMBL4551100	=	IC50	nM	1038.0	CHEMBL3231	Homo sapiens	IC50	uM	1.038
	19147556	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1ccc(NC(=O)c2ccc(N(C)C)cc2)cc1NC(=O)COc1ccc2c(=O)ccoc2c1		CHEMBL4454066	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147557	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1c(NC(=O)COc2ccc3c(=O)ccoc3c2)cccc1NC(=O)c1ccc(N(C)C)cc1		CHEMBL4587195	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147558	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(NC(=O)COc2ccc3c(=O)ccoc3c2)cc(NC(=O)c2ccc(N(C)C)cc2)c1		CHEMBL4588881	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147559	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cc(F)cc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4457201	=	IC50	nM	49.0	CHEMBL3231	Homo sapiens	IC50	uM	0.049
	19147560	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cc(Br)cc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4581933	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147561	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cc(NC(=O)COc3ccc4c(=O)ccoc4c3)cc(C(F)(F)F)c2)cc1		CHEMBL4529129	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147562	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(NC(=O)COc2ccc3c(=O)ccoc3c2)cc(NC(=O)c2ccc(N(C)C)cc2)c1C		CHEMBL4452238	=	IC50	nM	3951.0	CHEMBL3231	Homo sapiens	IC50	uM	3.951
	19147563	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2ccc(NC(=O)COc3ccc4c(=O)ccoc4c3)cc2)cc1		CHEMBL4526491	=	IC50	nM	1052.0	CHEMBL3231	Homo sapiens	IC50	uM	1.052
	19147564	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(NC(=O)COc2ccc3c(=O)ccoc3c2)ccc1NC(=O)c1ccc(N(C)C)cc1		CHEMBL4590957	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147565	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2ccc(NC(=O)COc3ccc4c(=O)ccoc4c3)cc2C(F)(F)F)cc1		CHEMBL4475590	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147566	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2ccc(CNC(=O)COc3ccc4c(=O)ccoc4c3)cc2)cc1		CHEMBL4444449	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	19147567	CHEMBL4379075	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NS(=O)(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4455163	=	IC50	nM	117.0	CHEMBL3231	Homo sapiens	IC50	uM	0.117
	19159639	CHEMBL4382743	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	46.0	CHEMBL3231	Homo sapiens	Activity	%	46.0
	19172309	CHEMBL4385133	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cc(-c2ccncc2)cnc1Cl		CHEMBL4474208	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	19181132	CHEMBL4387343	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain (1 to 535 amino acids) expressed in baculovirus expression system at 0.1 uM using serine/threonine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	18.5	CHEMBL3231	Homo sapiens	INH	%	18.5
	19181357	CHEMBL4387343	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain (1 to 535 amino acids) expressed in baculovirus expression system at 0.1 uM using serine/threonine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	2.0	CHEMBL3231	Homo sapiens	INH	%	2.0
	19191368	CHEMBL4389462	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	46.0	CHEMBL3231	Homo sapiens	INH	%	46.0
	19192125	CHEMBL4389939	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	71.0	CHEMBL3231	Homo sapiens	INH	%	71.0
	19200381	CHEMBL4391565	Binding affinity to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	36.0	CHEMBL3231	Homo sapiens	Activity	%	36.0
	19225487	CHEMBL4395907	Inhibition of human recombinant ROCK1 at 1 uM using Ulight-RRRSLLE as substrate measured after 20 mins in presence of ATP by LANCE assay relative to control	B	CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1		CHEMBL4536012	=	Inhibition	%	-8.13	CHEMBL3231	Homo sapiens	INH	%	-8.13
	19230935	CHEMBL4397173	Inhibition of ROCK1 (unknown origin) at 100 nM by [gamma-33P]ATP-based radiometric or Alphascreen assay relative to control	B	Cc1cc(-n2cc(C(=O)N3CCO[C@@H](C)C3)c3ccc(O[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL4440381	=	Inhibition	%	-5.0	CHEMBL3231	Homo sapiens	INH	%	-5.0
	19242750	CHEMBL4400085	Inhibition of recombinant human ROCK1 (17 to 535 residues) assessed as residual activity at 10 uM using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP at Km concentration by radiometric assay relative to control	B	COc1ccc2c(CCNc3nc(NCc4ccc(=O)[nH]c4)c4nc[nH]c4n3)c[nH]c2c1		CHEMBL4555782	=	Activity	%	91.0	CHEMBL3231	Homo sapiens	Activity	%	91.0
	19266597	CHEMBL4405547	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3231	Homo sapiens	INH	%	50.0
	19273858	CHEMBL4407368	Inhibition of human ROCK1 by mobile shift assay	B	CNC(=O)C[C@@H]1C[C@@H](c2ccc(F)c(F)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4440965	=	IC50	nM	64.0	CHEMBL3231	Homo sapiens	IC50	nM	64.0
	19273859	CHEMBL4407368	Inhibition of human ROCK1 by mobile shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCO)C[C@H]2c2ccc(F)c(F)c2)oc1Cl		CHEMBL4441825	=	IC50	nM	38.0	CHEMBL3231	Homo sapiens	IC50	nM	38.0
	19273860	CHEMBL4407368	Inhibition of human ROCK1 by mobile shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4457064	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	nM	20.0
	19273861	CHEMBL4407368	Inhibition of human ROCK1 by mobile shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	125.0	CHEMBL3231	Homo sapiens	IC50	nM	125.0
	19276113	CHEMBL4408116	Inhibition of recombinant human ROCK1 (17 to 535 residues) at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	33.0	CHEMBL3231	Homo sapiens	INH	%	33.0
	19298485	CHEMBL4413160	Binding affinity to wild-type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Kinomescan assay	B	CN(C)[C@H]1C[C@@]23CC[C@@]4(O2)C(=CC[C@]2(C)[C@@H](c5ccc6ccncc6c5)CC[C@@H]42)C=C3[C@@H](O)[C@@H]1O		CHEMBL4080906	=	Kd	nM	250.0	CHEMBL3231	Homo sapiens	Kd	nM	250.0
	19303788	CHEMBL4414240	Inhibition of ROCK1 (unknown origin) assessed as residual activity at 50 uM relative to control	B	O=C(O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4462082	=	Activity	%	100.0	CHEMBL3231	Homo sapiens	Activity	%	100.0
	19303830	CHEMBL4414240	Inhibition of ROCK1 (unknown origin) assessed as residual activity at 50 uM relative to control	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	Activity	%	107.0	CHEMBL3231	Homo sapiens	Activity	%	107.0
	19474685	CHEMBL4479374	Inhibition of ROCK1 (unknown origin)	B	COc1ncc(-c2cc3c(c(NC(=O)CN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O		CHEMBL4561692	<	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	pIC50		5.0
	19476626	CHEMBL4479774	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	360.0	CHEMBL3231	Homo sapiens	IC50	nM	360.0
	19476726	CHEMBL4479774	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	=	IC50	nM	780.0	CHEMBL3231	Homo sapiens	IC50	nM	780.0
	19476826	CHEMBL4479774	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	=	IC50	nM	17.0	CHEMBL3231	Homo sapiens	IC50	nM	17.0
	19476926	CHEMBL4479774	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	2300.0	CHEMBL3231	Homo sapiens	IC50	nM	2300.0
	19488170	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	CN(C)CCOc1cc(-c2ccncc2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL4483646	=	IC50	nM	104.0	CHEMBL3231	Homo sapiens	IC50	nM	104.0
	19488171	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	CN(C)CCOc1cc(-c2ccncc2)ccc1NC(=O)C1COc2ccc(Cl)cc2C1		CHEMBL4559633	=	IC50	nM	135.0	CHEMBL3231	Homo sapiens	IC50	nM	135.0
	19488172	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	CN(C)CCOc1cc(-c2ccncc2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL4521642	=	IC50	nM	30.0	CHEMBL3231	Homo sapiens	IC50	nM	30.0
	19488173	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	Cc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4513652	=	IC50	nM	169.0	CHEMBL3231	Homo sapiens	IC50	nM	169.0
	19488174	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4547623	=	IC50	nM	523.0	CHEMBL3231	Homo sapiens	IC50	nM	523.0
	19488175	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4552537	=	IC50	nM	68.0	CHEMBL3231	Homo sapiens	IC50	nM	68.0
	19488176	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4588109	=	IC50	nM	170.0	CHEMBL3231	Homo sapiens	IC50	nM	170.0
	19488177	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3c[nH]nc3C)cc1OCCN(C)C)CO2		CHEMBL4570327	=	IC50	nM	16.3	CHEMBL3231	Homo sapiens	IC50	nM	16.3
	19488178	CHEMBL4481804	Inhibition of ROCK1 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	A	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL482336	=	IC50	nM	3.4	CHEMBL3231	Homo sapiens	IC50	nM	3.4
	20600659	CHEMBL4603611	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system using serine/threonine-7 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL3231	Homo sapiens	IC50	uM	100.0
	20657212	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3cc(-c4ccc5[nH]ncc5c4)ccc3c2=O)c1		CHEMBL4641760	=	IC50	nM	3106.0	CHEMBL3231	Homo sapiens	IC50	uM	3.106
	20657213	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2ncc3cc(-c4ccc5[nH]ncc5c4)ccc3c2=O)c1		CHEMBL4645772	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657214	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2ccc3cc(-c4ccc5[nH]ncc5c4)ccc3c2=O)c1		CHEMBL4639886	=	IC50	nM	1877.0	CHEMBL3231	Homo sapiens	IC50	uM	1.877
	20657215	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(CN2CCc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4643620	=	IC50	nM	2062.0	CHEMBL3231	Homo sapiens	IC50	uM	2.062
	20657216	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccc5[nH]ncc5c4)cc3c2=O)c1		CHEMBL4636499	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	uM	0.02
	20657217	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccncc4)cc3c2=O)c1		CHEMBL4643315	=	IC50	nM	45.0	CHEMBL3231	Homo sapiens	IC50	uM	0.045
	20657218	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4cccnc4)cc3c2=O)c1		CHEMBL4633510	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657219	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccc(-c5ccncc5)cc4)cc3c2=O)c1		CHEMBL4635460	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657220	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(F)c4)cc3c2=O)c1		CHEMBL4649864	=	IC50	nM	1050.0	CHEMBL3231	Homo sapiens	IC50	uM	1.05
	20657221	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(Cl)c4)cc3c2=O)c1		CHEMBL4646435	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657222	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(C)c4)cc3c2=O)c1		CHEMBL4644231	=	IC50	nM	2515.0	CHEMBL3231	Homo sapiens	IC50	uM	2.515
	20657223	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(OC)c4)cc3c2=O)c1		CHEMBL4643565	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657224	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)c1		CHEMBL4649403	=	IC50	nM	18.0	CHEMBL3231	Homo sapiens	IC50	uM	0.018
	20657225	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccc(N)nc4)cc3c2=O)c1		CHEMBL4634527	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657226	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)c1		CHEMBL4638815	=	IC50	nM	4.0	CHEMBL3231	Homo sapiens	IC50	uM	0.004
	20657227	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4cccc5[nH]ccc45)cc3c2=O)c1		CHEMBL4639551	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657228	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	O=c1c2cc(-c3ccnc4[nH]ccc34)sc2ncn1Cc1cccc(F)c1		CHEMBL4645138	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	uM	0.013
	20657229	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	O=c1c2cc(-c3ccnc4[nH]ccc34)sc2ncn1Cc1cccc(C(F)(F)F)c1		CHEMBL4648713	=	IC50	nM	110.0	CHEMBL3231	Homo sapiens	IC50	uM	0.11
	20657230	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)cc1		CHEMBL4638636	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	uM	0.013
	20657231	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)cc1OC		CHEMBL4648698	=	IC50	nM	25.0	CHEMBL3231	Homo sapiens	IC50	uM	0.025
	20657232	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)cc(OC)c1		CHEMBL4634539	=	IC50	nM	74.0	CHEMBL3231	Homo sapiens	IC50	uM	0.074
	20657233	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	Nc1cc(-c2cc3c(=O)n(Cc4cccc(F)c4)cnc3s2)ccn1		CHEMBL4649693	=	IC50	nM	34.0	CHEMBL3231	Homo sapiens	IC50	uM	0.034
	20657234	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	Nc1cc(-c2cc3c(=O)n(Cc4cccc(C(F)(F)F)c4)cnc3s2)ccn1		CHEMBL4639553	=	IC50	nM	490.0	CHEMBL3231	Homo sapiens	IC50	uM	0.49
	20657235	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)cc1		CHEMBL4644637	=	IC50	nM	1445.0	CHEMBL3231	Homo sapiens	IC50	uM	1.445
	20657236	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)cc1OC		CHEMBL4637847	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20657237	CHEMBL4617454	Inhibition of recombinant human ROCK1 (17 to 535 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)cc(OC)c1		CHEMBL4649876	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	20669041	CHEMBL4620287	Inhibition of biotinylated ligand binding to wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system at 50 nM measured after 1 hr by kinomescan assay relative to control	B	CN(C)[C@@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC=C(c5cccc6cnccc56)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4637601	>	Inhibition	%	80.0	CHEMBL3231	Homo sapiens	INH	%	80.0
	20681611	CHEMBL4623292	Inhibition of ROCK1 (unknown origin)	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	51.0	CHEMBL3231	Homo sapiens	IC50	nM	51.0
	20683719	CHEMBL4623656	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 20 uM in presence of [gamma-33P]-ATP incubated for 2 hrs by hotspot kinase assay relative to control	B	CCOC(=O)c1cnc2cc(Cl)cc(Cl)c2c1Nc1cccc(S(N)(=O)=O)c1		CHEMBL4635411	=	Inhibition	%	0.785	CHEMBL3231	Homo sapiens	INH	%	0.785
	22392153	CHEMBL4667248	Inhibition of recombinant human GST-tagged ROCK1 (1 to 535 residues) expressed in baculovirus expression system using Ser/Thr 07 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	-8.5	CHEMBL3231	Homo sapiens	INH	%	-8.5
	22396434	CHEMBL4668588	Inhibition of human ROCK1 expressed in baculovirus expression system by Kinase-Glo luminescent Assay	B	NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL4753043	=	Ki	nM	0.2	CHEMBL3231	Homo sapiens	Ki	nM	0.2
	22396438	CHEMBL4668592	Inhibition of N-terminal GST-fused human ROCK1 catalytic domain ( 1 to 477 residues) expressed in baculovirus expression system using Long S6 Kinase as substrate incubated for 90 mins by Kinase-Glo luminescent assay	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	51.0	CHEMBL3231	Homo sapiens	IC50	nM	51.0
	22396440	CHEMBL4668594	Inhibition of ROCK1 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	260.0	CHEMBL3231	Homo sapiens	IC50	nM	260.0
	22401676	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3960736	=	IC50	nM	5.0	CHEMBL3231	Homo sapiens	IC50	nM	5.0
	22401677	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@@H](N)CCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4749675	=	IC50	nM	48.0	CHEMBL3231	Homo sapiens	IC50	nM	48.0
	22401678	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)Cc2ccc(Cl)c(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL4764401	=	IC50	nM	4.3	CHEMBL3231	Homo sapiens	IC50	nM	4.3
	22401679	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2F)c1		CHEMBL4111518	=	IC50	nM	6.0	CHEMBL3231	Homo sapiens	IC50	nM	6.0
	22401680	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C(F)(F)F)c2)c1		CHEMBL4114533	=	IC50	nM	7.1	CHEMBL3231	Homo sapiens	IC50	nM	7.1
	22401681	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL4111655	=	IC50	nM	8.7	CHEMBL3231	Homo sapiens	IC50	nM	8.7
	22401682	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4799704	=	IC50	nM	24.0	CHEMBL3231	Homo sapiens	IC50	nM	24.0
	22401683	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4746508	=	IC50	nM	5.4	CHEMBL3231	Homo sapiens	IC50	nM	5.4
	22401684	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3951271	=	IC50	nM	6.7	CHEMBL3231	Homo sapiens	IC50	nM	6.7
	22401685	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)Cc2ccccc2Cl)ccc1-c1cnco1		CHEMBL4799221	=	IC50	nM	15.0	CHEMBL3231	Homo sapiens	IC50	nM	15.0
	22401686	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4783577	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	22401687	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](O)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL4784425	=	IC50	nM	21.0	CHEMBL3231	Homo sapiens	IC50	nM	21.0
	22401688	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3907133	=	IC50	nM	5.4	CHEMBL3231	Homo sapiens	IC50	nM	5.4
	22401689	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(Cl)c2)c1		CHEMBL4109840	=	IC50	nM	10.0	CHEMBL3231	Homo sapiens	IC50	nM	10.0
	22401690	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@@H](c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL4757844	=	IC50	nM	16.0	CHEMBL3231	Homo sapiens	IC50	nM	16.0
	22401691	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4114628	=	IC50	nM	0.8	CHEMBL3231	Homo sapiens	IC50	nM	0.8
	22401692	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3913336	=	IC50	nM	0.9	CHEMBL3231	Homo sapiens	IC50	nM	0.9
	22401693	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)Cc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL4756156	=	IC50	nM	6.4	CHEMBL3231	Homo sapiens	IC50	nM	6.4
	22401694	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)CCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4741358	=	IC50	nM	7.2	CHEMBL3231	Homo sapiens	IC50	nM	7.2
	22401695	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL4780269	=	IC50	nM	14.0	CHEMBL3231	Homo sapiens	IC50	nM	14.0
	22401696	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2C)c1		CHEMBL4111347	=	IC50	nM	1170.0	CHEMBL3231	Homo sapiens	IC50	nM	1170.0
	22401697	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C#N)c2)c1		CHEMBL4740106	=	IC50	nM	56.0	CHEMBL3231	Homo sapiens	IC50	nM	56.0
	22401698	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	CCc1cc(C(=O)N[C@H](C)c2cccc(OC)c2)ccc1-c1cn[nH]c1		CHEMBL4791701	=	IC50	nM	0.8	CHEMBL3231	Homo sapiens	IC50	nM	0.8
	22401699	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3955445	=	IC50	nM	7.9	CHEMBL3231	Homo sapiens	IC50	nM	7.9
	22401700	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL4753754	=	IC50	nM	3.1	CHEMBL3231	Homo sapiens	IC50	nM	3.1
	22401701	CHEMBL4669818	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1ccccc1CNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3951573	=	IC50	nM	182.0	CHEMBL3231	Homo sapiens	IC50	nM	182.0
	22401830	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCN1CCC[C@H]1CNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)C(C)Oc2cnccc2-3)c1		CHEMBL4747999	=	IC50	nM	1.2	CHEMBL3231	Homo sapiens	IC50	nM	1.2
	22401831	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCNC(=O)c1cc(CNC(=O)c2ccc3c(c2)C(CC)Oc2cnccc2-3)ccc1F		CHEMBL4759713	=	IC50	nM	20.0	CHEMBL3231	Homo sapiens	IC50	nM	20.0
	22401832	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)C(C)Oc2cnccc2-3)c1		CHEMBL4758151	=	IC50	nM	3.2	CHEMBL3231	Homo sapiens	IC50	nM	3.2
	22401833	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CN1CC(NC(=O)c2cccc(CNC(=O)c3ccc4c(c3)COc3cnccc3-4)c2)C1		CHEMBL4749353	=	IC50	nM	8.9	CHEMBL3231	Homo sapiens	IC50	nM	8.9
	22401834	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)COc2cnccc2-3)c1		CHEMBL4790421	=	IC50	nM	7.0	CHEMBL3231	Homo sapiens	IC50	nM	7.0
	22401835	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)COc2cnccc2-3)c1		CHEMBL4746567	=	IC50	nM	8.0	CHEMBL3231	Homo sapiens	IC50	nM	8.0
	22401836	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)C(C2CC2)Oc2cnccc2-3)c1		CHEMBL4749267	=	IC50	nM	4.1	CHEMBL3231	Homo sapiens	IC50	nM	4.1
	22401837	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	0.67	CHEMBL3231	Homo sapiens	IC50	nM	0.67
	22401838	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	2.0	CHEMBL3231	Homo sapiens	IC50	nM	2.0
	22401839	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	0.63	CHEMBL3231	Homo sapiens	IC50	nM	0.63
	22401840	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)C(C)Oc2cnccc2-3)c1		CHEMBL4763198	=	IC50	nM	0.49	CHEMBL3231	Homo sapiens	IC50	nM	0.49
	22401841	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)OC(C)c2cnccc2-3)c1		CHEMBL4778671	=	IC50	nM	15.0	CHEMBL3231	Homo sapiens	IC50	nM	15.0
	22401842	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)COc2cnc(N)cc2-3)c1		CHEMBL4778588	=	IC50	nM	171.0	CHEMBL3231	Homo sapiens	IC50	nM	171.0
	22401843	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)COc2cncnc2-3)c1		CHEMBL4797403	=	IC50	nM	38.0	CHEMBL3231	Homo sapiens	IC50	nM	38.0
	22401844	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)c(=O)[nH]c2cnccc23)c1		CHEMBL4783882	>	IC50	nM	2000.0	CHEMBL3231	Homo sapiens	IC50	nM	2000.0
	22401845	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)[nH]c(=O)c2cnccc23)c1		CHEMBL4782709	=	IC50	nM	56.0	CHEMBL3231	Homo sapiens	IC50	nM	56.0
	22401846	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)COc2cnccc2-3)c1		CHEMBL4785041	=	IC50	nM	1.2	CHEMBL3231	Homo sapiens	IC50	nM	1.2
	22401847	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc(C(C)NC(=O)c2ccc3c(c2)OCc2cnccc2-3)n1		CHEMBL4749682	=	IC50	nM	27.0	CHEMBL3231	Homo sapiens	IC50	nM	27.0
	22401848	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)OCc2cnccc2-3)c1		CHEMBL3578250	=	IC50	nM	13.0	CHEMBL3231	Homo sapiens	IC50	nM	13.0
	22401849	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	C[C@@H](NC(=O)c1ccc2c(c1)OCc1cnccc1-2)c1ccccc1		CHEMBL4756660	=	IC50	nM	18.0	CHEMBL3231	Homo sapiens	IC50	nM	18.0
	22401850	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc(CNC(=O)c2ccc3c(c2)OCc2cnccc2-3)c1		CHEMBL4797055	=	IC50	nM	33.0	CHEMBL3231	Homo sapiens	IC50	nM	33.0
	22401851	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	O=C(NCc1ccccc1)c1ccc2c(c1)OCc1cnccc1-2		CHEMBL4748957	=	IC50	nM	81.0	CHEMBL3231	Homo sapiens	IC50	nM	81.0
	22401852	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	O=C(Cc1ccccc1)Nc1ccc2c(c1)OCc1cnccc1-2		CHEMBL4762662	=	IC50	nM	140.0	CHEMBL3231	Homo sapiens	IC50	nM	140.0
	22401853	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	N[C@@H](C(=O)Nc1ccc2c(c1)OCc1cnccc1-2)c1ccccc1		CHEMBL4748727	=	IC50	nM	16.0	CHEMBL3231	Homo sapiens	IC50	nM	16.0
	22401854	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	N[C@H](Cc1ccccc1)C(=O)Nc1ccc2c(c1)OCc1cnccc1-2		CHEMBL4746531	=	IC50	nM	19.0	CHEMBL3231	Homo sapiens	IC50	nM	19.0
	22401855	CHEMBL4669835	Inhibition of ROCK1 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	N[C@@H](COc1ccc2c(c1)OCc1cnccc1-2)Cc1ccccc1		CHEMBL4743809	=	IC50	nM	71.0	CHEMBL3231	Homo sapiens	IC50	nM	71.0
	22401860	CHEMBL4669837	Inhibition of ROCK1 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1.Cl.Cl		CHEMBL1605605	=	Ki	nM	140.0	CHEMBL3231	Homo sapiens	Ki	nM	140.0
	22401861	CHEMBL4669837	Inhibition of ROCK1 (unknown origin)	B	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	Ki	nM	24000.0	CHEMBL3231	Homo sapiens	Ki	nM	24000.0
	22401862	CHEMBL4669837	Inhibition of ROCK1 (unknown origin)	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	50.0	CHEMBL3231	Homo sapiens	IC50	nM	50.0
	22401863	CHEMBL4669837	Inhibition of ROCK1 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	940.0	CHEMBL3231	Homo sapiens	IC50	nM	940.0
	22401866	CHEMBL4669839	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system by Kinase-Glo luminescent kinase assay	B	NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL4753043	=	Ki	nM	0.2	CHEMBL3231	Homo sapiens	Ki	nM	0.2
	22401867	CHEMBL4669839	Inhibition of recombinant human GST-tagged ROCK1 catalytic domain expressed in baculovirus expression system by Kinase-Glo luminescent kinase assay	B	Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1.Cl.Cl		CHEMBL4796289	=	Ki	nM	1.0	CHEMBL3231	Homo sapiens	Ki	nM	1.0
	22423271	CHEMBL4674211	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	94.28	CHEMBL3231	Homo sapiens	Activity	%	94.28
	22423272	CHEMBL4674211	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	60.37	CHEMBL3231	Homo sapiens	Activity	%	60.37
	22440772	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncc(F)cc23)cs1		CHEMBL4777515	=	Ki	nM	1.0	CHEMBL3231	Homo sapiens	Ki	uM	0.001
	22440773	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3nccc(F)c23)cs1		CHEMBL4778806	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	uM	0.003
	22440774	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	=	Ki	nM	5.0	CHEMBL3231	Homo sapiens	Ki	uM	0.005
	22440775	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncc(F)cc45)cs3)c2)CC1		CHEMBL4742150	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	uM	0.003
	22440776	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4245197	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006
	22440777	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncc(F)cc45)cs3)c2)CC1		CHEMBL4788786	=	Ki	nM	5.0	CHEMBL3231	Homo sapiens	Ki	uM	0.005
	22440778	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5nccc(F)c45)cs3)c2)CC1		CHEMBL4748596	=	Ki	nM	10.0	CHEMBL3231	Homo sapiens	Ki	uM	0.01
	22440779	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006
	22440780	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Br)cc34)cs2)c1		CHEMBL4746642	=	Ki	nM	22.0	CHEMBL3231	Homo sapiens	Ki	uM	0.022000000000000002
	22440781	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Cl)cc34)cs2)c1		CHEMBL4793675	=	Ki	nM	11.0	CHEMBL3231	Homo sapiens	Ki	uM	0.011000000000000001
	22440782	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(Cl)c34)cs2)c1		CHEMBL4778609	=	Ki	nM	92.0	CHEMBL3231	Homo sapiens	Ki	uM	0.092
	22440783	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(O)cc34)cs2)c1		CHEMBL4751643	=	Ki	nM	7.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006999999999999999
	22440784	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(F)cc34)cs2)c1		CHEMBL4752045	=	Ki	nM	3.0	CHEMBL3231	Homo sapiens	Ki	uM	0.003
	22440785	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(F)c34)cs2)c1		CHEMBL4757625	=	Ki	nM	4.0	CHEMBL3231	Homo sapiens	Ki	uM	0.004
	22440786	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	Cc1sc(NC(=O)Cc2cccc(NS(C)(=O)=O)c2)nc1-c1c[nH]c2ncccc12		CHEMBL4763436	=	Ki	nM	52.0	CHEMBL3231	Homo sapiens	Ki	uM	0.052000000000000005
	22440787	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)ncn2)c1		CHEMBL4781437	=	Ki	nM	7.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006999999999999999
	22440788	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nccc(-c3c[nH]c4ncccc34)n2)c1		CHEMBL4752171	=	Ki	nM	48.0	CHEMBL3231	Homo sapiens	Ki	uM	0.048
	22440789	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nnc(-c3c[nH]c4ncccc34)s2)c1		CHEMBL4800244	=	Ki	nM	7.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006999999999999999
	22440790	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4794318	=	Ki	nM	100.0	CHEMBL3231	Homo sapiens	Ki	uM	0.1
	22440791	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2ccc(-c3c[nH]c4ncccc34)s2)c1		CHEMBL4754058	=	Ki	nM	8.0	CHEMBL3231	Homo sapiens	Ki	uM	0.008
	22440792	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cnc(-c3c[nH]c4ncccc34)s2)c1		CHEMBL4754398	=	Ki	nM	10.0	CHEMBL3231	Homo sapiens	Ki	uM	0.01
	22440793	CHEMBL4678429	Inhibition of ROCK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	=	Ki	nM	6.0	CHEMBL3231	Homo sapiens	Ki	uM	0.006
	22447008	CHEMBL4679718	Inhibition of ROCK1 (unknown origin)	B	Cc1nc(NC(=O)NCCc2cn(CC(F)F)cn2)sc1C#Cc1cccnc1		CHEMBL4795990	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	uM	4.0
	22447009	CHEMBL4679718	Inhibition of ROCK1 (unknown origin)	B	COc1cc(C#Cc2sc(NC(=O)NCCOCC3CC3)nc2C)cnc1OC		CHEMBL4759283	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	uM	4.0
	22447010	CHEMBL4679718	Inhibition of ROCK1 (unknown origin)	B	Cc1nc(NC(=O)NCCOCC2CC2)sc1C#Cc1ccc2cncn2c1		CHEMBL4764646	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	uM	4.0
	22447011	CHEMBL4679718	Inhibition of ROCK1 (unknown origin)	B	Cc1cncc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)c1		CHEMBL4784202	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	uM	4.0
	22447012	CHEMBL4679718	Inhibition of ROCK1 (unknown origin)	B	Cc1cc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)cnc1C		CHEMBL4756664	>	Ki	nM	4000.0	CHEMBL3231	Homo sapiens	Ki	uM	4.0
	22768264	CHEMBL4703625	Inhibition of human ROCK1	B	COc1cccc(Cn2cnc3ccc(-c4cn[nH]c4)cc3c2=O)c1		CHEMBL4742990	=	IC50	nM	246.0	CHEMBL3231	Homo sapiens	IC50	nM	246.0
	22768265	CHEMBL4703625	Inhibition of human ROCK1	B	COc1cccc(Cn2ncc3ccc(-c4cn[nH]c4)cc3c2=O)c1		CHEMBL4744858	=	IC50	nM	1271.0	CHEMBL3231	Homo sapiens	IC50	nM	1271.0
Not Active	22769886	CHEMBL4704193	Inhibition of human ROCK1 at 2 uM	B	CN(C)c1ccc(Nc2nc(-c3ccncc3)nc3c2CC(N)CC3)cc1		CHEMBL4758733		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	22809797	CHEMBL4713332	Inhibition of recombinant human ROCK1 (17 to 535 residues) assessed as residual activity at 1 uM using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of Km ATP by radiometric scintillation counting analysis relative to control	B	CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@H](C)C1		CHEMBL4761365	=	Activity	%	88.0	CHEMBL3231	Homo sapiens	Activity	%	88.0
	22820568	CHEMBL4716286	Inhibition of auto-activated recombinant N-terminal His6-tagged human ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM incubated in presence of Mg/ATP relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	123.0	CHEMBL3231	Homo sapiens	Activity	%	123.0
	22820569	CHEMBL4716286	Inhibition of auto-activated recombinant N-terminal His6-tagged human ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM incubated in presence of Mg/ATP relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	101.0	CHEMBL3231	Homo sapiens	Activity	%	101.0
	22826345	CHEMBL4717530	Inhibition of auto-activated recombinant N-terminal His6-tagged human ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells at 10 uM incubated in presence of Mg/ATP relative to control	B	CN1CCN(CCCOc2cccc3nc(Nc4ccc(Cl)c(C(F)(F)F)c4)ccc23)CC1		CHEMBL4797203	<	Inhibition	%	60.0	CHEMBL3231	Homo sapiens	INH	%	60.0
	22843582	CHEMBL4720568	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.444	CHEMBL3231	Homo sapiens	IC50	10^-10M	4.44
	22843925	CHEMBL4720911	Inhibition of human ROCK1 assessed as residual activity using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	97.24	CHEMBL3231	Homo sapiens	Activity	%	97.24
	22844853	CHEMBL4721528	Inhibition of wild-type human partial length ROCK1 (M1 to R415 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	94.22	CHEMBL3231	Homo sapiens	Activity	%	94.22
	22883458	CHEMBL4727549	Inhibition of ROCK1 (unknown origin)	B	CC(C)n1cnnc1-c1cccc(N2Cc3ccccc3C2=O)n1		CHEMBL3952214	=	IC50	nM	1000.0	CHEMBL3231	Homo sapiens	pIC50		6.0
	22883459	CHEMBL4727549	Inhibition of ROCK1 (unknown origin)	B	CC(C)n1cnnc1-c1cccc(NC(=O)C2CCCCO2)n1		CHEMBL4759397	<	IC50	nM	19952.62	CHEMBL3231	Homo sapiens	pIC50		4.7
Not Active	22909970	CHEMBL4734084	Inhibition of recombinant human GST-tagged ROCK1 expressed in baculovirus expression system using serine/threonine-07 peptide as substrate at 10 uM by Z'-LYTE assay	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	22909971	CHEMBL4734084	Inhibition of recombinant human GST-tagged ROCK1 expressed in baculovirus expression system using serine/threonine-07 peptide as substrate at 10 uM by Z'-LYTE assay	B	Clc1cccc(CSc2ncnc3[nH]cnc23)c1		CHEMBL4754930		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	22909972	CHEMBL4734084	Inhibition of recombinant human GST-tagged ROCK1 expressed in baculovirus expression system using serine/threonine-07 peptide as substrate at 10 uM by Z'-LYTE assay	B	Brc1ccccc1CSc1ncnc2[nH]cnc12		CHEMBL4776788		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	22936058	CHEMBL4739755	Inhibition of human ROCK1 at 1 uM using substrate peptide by off-chip mobility shift assay	B	CC(=O)c1ccc(C(N)=O)cc1Oc1ccc(OCCOC2CCOCC2)cc1		CHEMBL4749965		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	22952983	CHEMBL4766920	Inhibition of recombinant human ROCK1 (17 to 535 residues) assessed as residual activity at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 120 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	97.0	CHEMBL3231	Homo sapiens	Activity	%	97.0
	22955561	CHEMBL4767618	Inhibition of GST-tagged recombinant human ROCK1 catalytic domain (1-535) expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12		CHEMBL4785582	=	Inhibition	%	33.0	CHEMBL3231	Homo sapiens	INH	%	33.0
	22989365	CHEMBL4774945	Inhibition of ROCK1 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2cccc(C#Cc3cccc(NC(=O)c4ccc(N5CCOCC5)c(C(F)(F)F)c4)c3)c12		CHEMBL4793906	<	Inhibition	%	30.0	CHEMBL3231	Homo sapiens	INH	%	30.0
	23120992	CHEMBL4804484	Inhibition of ROCK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855542	=	IC50	nM	-11400.0	CHEMBL3231	Homo sapiens	IC50	uM	-11.4
	23120993	CHEMBL4804484	Inhibition of ROCK1 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	20800.0	CHEMBL3231	Homo sapiens	IC50	uM	20.8
	23120994	CHEMBL4804484	Inhibition of ROCK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4859660	=	IC50	nM	-55800.0	CHEMBL3231	Homo sapiens	IC50	uM	-55.8
	23122031	CHEMBL4804666	Inhibition of ROCK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	23122032	CHEMBL4804666	Inhibition of ROCK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	23122033	CHEMBL4804666	Inhibition of ROCK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL3231	Homo sapiens	INH	%	0.0
	23122796	CHEMBL4805147	Inhibition of human ROCK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	52.0	CHEMBL3231	Homo sapiens	Activity	%	52.0
	23123491	CHEMBL4805735	Inhibition of human ROCK1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	45.0	CHEMBL3231	Homo sapiens	Activity	%	45.0
	23123946	CHEMBL4806190	Inhibition of DNA-tagged human ROCK1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	87.0	CHEMBL3231	Homo sapiens	Activity	%	87.0
	23125072	CHEMBL4806752	Inhibition of human ROCK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	77.0	CHEMBL3231	Homo sapiens	Activity	%	77.0
	23125073	CHEMBL4806752	Inhibition of human ROCK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	67.0	CHEMBL3231	Homo sapiens	Activity	%	67.0
	23128530	CHEMBL4807985	Inhibition of ROCK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL3231	Homo sapiens	Activity	%	75.0
	23128531	CHEMBL4807985	Inhibition of ROCK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3231	Homo sapiens	Activity	%	75.0
	23128532	CHEMBL4807985	Inhibition of ROCK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3231	Homo sapiens	Activity	%	75.0
	23246347	CHEMBL4830039	Inhibition of ROCK1 (unknown origin)	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1		CHEMBL4556790	=	IC50	nM	354.0	CHEMBL3231	Homo sapiens	IC50	nM	354.0
	23250076	CHEMBL4830986	Inhibition of GST-tagged human recombinant ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM by Z'-LYTE assay	B	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(NCc3ccc(S(=O)(=O)F)cc3)cc2)n1		CHEMBL4866162	<	Inhibition	%	25.0	CHEMBL3231	Homo sapiens	INH	%	25.0
Not Active	23250077	CHEMBL4830986	Inhibition of GST-tagged human recombinant ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 1 uM by Z'-LYTE assay	B	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc(NC(C)=O)c2)n1		CHEMBL4856343		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
Not Active	23250124	CHEMBL4831013	Inhibition of GST-tagged human recombinant ROCK1 (1 to 535 residues) expressed in baculovirus expression system at 100 to 1000 nM by Z'-LYTE assay	B	C#CCNC(=O)c1cc(Nc2cc(C3CC3)[nH]n2)nc(N2CCN(Cc3ccc(S(=O)(=O)F)cc3)CC2)n1		CHEMBL4855850		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	23277338	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4643620	=	IC50	nM	2062.0	CHEMBL3231	Homo sapiens	IC50	uM	2.062
	23277339	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2COc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4864149	=	IC50	nM	1462.0	CHEMBL3231	Homo sapiens	IC50	uM	1.462
	23277340	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCCc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4877788	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	23277341	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4854297	=	IC50	nM	1080.0	CHEMBL3231	Homo sapiens	IC50	uM	1.08
	23277342	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CC(C)(C)Oc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4854400	=	IC50	nM	6012.0	CHEMBL3231	Homo sapiens	IC50	uM	6.0120000000000005
	23277343	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccc5c(c4)OCO5)ccc3C2=O)c1		CHEMBL4847282	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	23277344	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4877688	=	IC50	nM	93.0	CHEMBL3231	Homo sapiens	IC50	uM	0.09300000000000001
	23277345	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccnc(N)c4)ccc3C2=O)c1		CHEMBL4858407	=	IC50	nM	1145.0	CHEMBL3231	Homo sapiens	IC50	uM	1.145
	23277346	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccc(N)nc4)ccc3C2=O)c1		CHEMBL4868359	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	23277347	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4cncnc4)ccc3C2=O)c1		CHEMBL4859095	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	23277348	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccnc5[nH]ccc45)ccc3C2=O)c1		CHEMBL4865593	=	IC50	nM	103.0	CHEMBL3231	Homo sapiens	IC50	uM	0.10300000000000001
	23277349	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4cnc5[nH]ccc5c4)ccc3C2=O)c1		CHEMBL4879278	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	23277350	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3ccc(-c4ccncc4)cc3C2=O)c1		CHEMBL4846889	>	IC50	nM	10000.0	CHEMBL3231	Homo sapiens	IC50	uM	10.0
	23277351	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	O=C1c2ccc(-c3ccncc3)cc2OCCN1Cc1cccc(C(F)(F)F)c1		CHEMBL4867403	=	IC50	nM	1964.0	CHEMBL3231	Homo sapiens	IC50	uM	1.964
	23277352	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	O=C1c2ccc(-c3ccncc3)cc2OCCN1Cc1cccc(OC(F)(F)F)c1		CHEMBL4865566	=	IC50	nM	9242.0	CHEMBL3231	Homo sapiens	IC50	uM	9.242
	23277353	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	N#Cc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4857347	=	IC50	nM	3099.0	CHEMBL3231	Homo sapiens	IC50	uM	3.0989999999999998
	23277354	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COC(=O)c1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4876591	=	IC50	nM	208.0	CHEMBL3231	Homo sapiens	IC50	uM	0.20800000000000002
	23277355	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	O=Cc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4874825	=	IC50	nM	668.0	CHEMBL3231	Homo sapiens	IC50	uM	0.6679999999999999
	23277356	CHEMBL4836445	Inhibition of wild type partial length human ROCK1 (M1 to R415 residues) expressed in mammalian expression system by Euro-fins kinase profiler assay	B	COc1cc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)cc(OC)c1		CHEMBL4873381	=	IC50	nM	4493.0	CHEMBL3231	Homo sapiens	IC50	uM	4.493
Active	23277358	CHEMBL4836447	Inhibition of ROCK1 (unknown origin) at 10 uM	B	COc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4877688		Inhibition	%		CHEMBL3231	Homo sapiens	INH		
	23299290	CHEMBL4841745	Inhibition of ROCK1 (unknown origin) at 1000 nM relative to control	B	Nc1c(-c2nc3cc(N4CCN(C(=O)CCCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)ccc3[nH]2)c(=O)[nH]c2cccc(F)c12		CHEMBL4860038	=	Inhibition	%	4.0	CHEMBL3231	Homo sapiens	INH	%	4.0
	23299291	CHEMBL4841745	Inhibition of ROCK1 (unknown origin) at 1000 nM relative to control	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Inhibition	%	23.0	CHEMBL3231	Homo sapiens	INH	%	23.0
Not Active	23317632	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23318100	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23318766	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23319250	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23319887	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	90.4	CHEMBL3231	Homo sapiens	% Control	%	90.4
Not Active	23320362	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23321040	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23321508	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	93.0	CHEMBL3231	Homo sapiens	% Control	%	93.0
Not Active	23322138	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	65.0	CHEMBL3231	Homo sapiens	% Control	%	65.0
Not Active	23322606	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	81.0	CHEMBL3231	Homo sapiens	% Control	%	81.0
Not Active	23323295	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	89.0	CHEMBL3231	Homo sapiens	% Control	%	89.0
Not Active	23323763	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	84.0	CHEMBL3231	Homo sapiens	% Control	%	84.0
Not Active	23324120	CHEMBL4880739	ROCK-I (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	1.0	CHEMBL3231	Homo sapiens	% inhibition	%	1.0
Not Active	23324617	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	68.5	CHEMBL3231	Homo sapiens	% Control	%	68.5
Not Active	23325252	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	87.0	CHEMBL3231	Homo sapiens	% Control	%	87.0
Not Active	23325720	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	84.0	CHEMBL3231	Homo sapiens	% Control	%	84.0
Not Active	23326367	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	88.0	CHEMBL3231	Homo sapiens	% Control	%	88.0
Not Active	23326835	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23327535	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	94.0	CHEMBL3231	Homo sapiens	% Control	%	94.0
Not Active	23328003	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	82.0	CHEMBL3231	Homo sapiens	% Control	%	82.0
Not Active	23328590	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	97.0	CHEMBL3231	Homo sapiens	% Control	%	97.0
Not Active	23329058	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23329510	CHEMBL4881217	ROCK-I(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	112.0	CHEMBL3231	Homo sapiens	% residual kinase activity	%	112.0
Not Active	23330004	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23330472	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23331228	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	94.0	CHEMBL3231	Homo sapiens	% Control	%	94.0
Not Active	23331696	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23332283	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	74.9	CHEMBL3231	Homo sapiens	% Control	%	74.9
Not Active	23332749	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	74.8	CHEMBL3231	Homo sapiens	% Control	%	74.8
Not Active	23333467	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23334106	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	91.0	CHEMBL3231	Homo sapiens	% Control	%	91.0
Not Active	23334574	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	93.0	CHEMBL3231	Homo sapiens	% Control	%	93.0
Active	23335166	CHEMBL4881480	Biochemical ROCK1 assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		IC50	nM	0.6	CHEMBL3231	Homo sapiens	IC50	nM	0.6
Active	23335553	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	0.6	CHEMBL3231	Homo sapiens	% Control	%	0.6
Not Active	23336021	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	76.0	CHEMBL3231	Homo sapiens	% Control	%	76.0
Not Active	23336648	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	85.0	CHEMBL3231	Homo sapiens	% Control	%	85.0
Not Active	23337116	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	71.0	CHEMBL3231	Homo sapiens	% Control	%	71.0
Not Active	23337759	CHEMBL4882130	ROCK1 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	99.5	CHEMBL3231	Homo sapiens	% Ctrl	%	99.5
Not Active	23338197	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	97.0	CHEMBL3231	Homo sapiens	% Control	%	97.0
Not Active	23338665	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	83.0	CHEMBL3231	Homo sapiens	% Control	%	83.0
Not Active	23339277	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	84.0	CHEMBL3231	Homo sapiens	% Control	%	84.0
Not Active	23339745	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	69.0	CHEMBL3231	Homo sapiens	% Control	%	69.0
Not Active	23340382	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	79.0	CHEMBL3231	Homo sapiens	% Control	%	79.0
Not Active	23340850	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23341507	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	87.0	CHEMBL3231	Homo sapiens	% Control	%	87.0
Active	23341975	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	0.5	CHEMBL3231	Homo sapiens	% Control	%	0.5
Not Active	23342591	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23343059	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23343285	CHEMBL4882470	ROCK1 Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	97.0	CHEMBL3231	Homo sapiens	% Ctrl	%	97.0
Not Active	23343689	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	78.0	CHEMBL3231	Homo sapiens	% Control	%	78.0
Not Active	23344157	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	93.0	CHEMBL3231	Homo sapiens	% Control	%	93.0
Not Active	23344795	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	74.0	CHEMBL3231	Homo sapiens	% Control	%	74.0
Not Active	23345368	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	98.0	CHEMBL3231	Homo sapiens	% Control	%	98.0
Not Active	23345836	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23346413	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	70.7	CHEMBL3231	Homo sapiens	% Control	%	70.7
Not Active	23346881	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23347089	CHEMBL4882616	Invitrogen kinase screen (ROCK1)	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1	Non standard unit for type	CHEMBL4538174		IC50	M	1.2	CHEMBL3231	Homo sapiens	IC50	M	1.2
Not Active	23347582	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	64.7	CHEMBL3231	Homo sapiens	% Control	%	64.7
Not Active	23347583	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174	=	Kd	nM	98.0	CHEMBL3231	Homo sapiens	Kd	nM	98.0
Not Active	23347973	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	66.0	CHEMBL3231	Homo sapiens	% Control	%	66.0
Not Active	23348552	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23349020	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	85.0	CHEMBL3231	Homo sapiens	% Control	%	85.0
Not Active	23349607	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	84.0	CHEMBL3231	Homo sapiens	% Control	%	84.0
Not Active	23350225	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23350693	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Slightly Active	23351298	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	34.0	CHEMBL3231	Homo sapiens	% Control	%	34.0
Active	23351766	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	6.0	CHEMBL3231	Homo sapiens	% Control	%	6.0
Not Active	23352211	CHEMBL4882900	ROCK1 Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	-0.8991	CHEMBL3231	Homo sapiens	% Inhibition	%	-0.8991
Not Active	23352790	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	80.0	CHEMBL3231	Homo sapiens	% Control	%	80.0
Not Active	23353258	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23354140	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23354608	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23355340	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	93.0	CHEMBL3231	Homo sapiens	% Control	%	93.0
Not Active	23355808	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	78.0	CHEMBL3231	Homo sapiens	% Control	%	78.0
Not Active	23356444	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	99.0	CHEMBL3231	Homo sapiens	% Control	%	99.0
Not Active	23356912	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23357521	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23358168	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23358636	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	82.0	CHEMBL3231	Homo sapiens	% Control	%	82.0
Not Active	23359222	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23359820	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	71.0	CHEMBL3231	Homo sapiens	% Control	%	71.0
Not Active	23360288	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	71.0	CHEMBL3231	Homo sapiens	% Control	%	71.0
Not Active	23360873	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	89.0	CHEMBL3231	Homo sapiens	% Control	%	89.0
Not Active	23361341	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	96.0	CHEMBL3231	Homo sapiens	% Control	%	96.0
Not Active	23361914	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	91.0	CHEMBL3231	Homo sapiens	% Control	%	91.0
Not Active	23362450	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23362918	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	69.0	CHEMBL3231	Homo sapiens	% Control	%	69.0
Not Active	23363310	CHEMBL4883271	ROCK1 Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	9.368	CHEMBL3231	Homo sapiens	% inhibition	%	9.3679
Not Active	23363311	CHEMBL4883271	ROCK1 Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	5.173	CHEMBL3231	Homo sapiens	% inhibition	%	5.1733
Not Active	23364560	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	70.0	CHEMBL3231	Homo sapiens	% Control	%	70.0
Not Active	23365028	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23365767	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23366310	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23366900	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23367368	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23367729	CHEMBL4884082	ROCK1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	97.0	CHEMBL3231	Homo sapiens	% Residual activity with Skepinone-L	%	97.0
Not Active	23368246	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23368714	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23369313	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23369781	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23370224	CHEMBL4884466	ROCK-I(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	104.0	CHEMBL3231	Homo sapiens	% residual kinase activity	%	104.0
Not Active	23370749	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23371217	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23372026	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23372494	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	93.0	CHEMBL3231	Homo sapiens	% Control	%	93.0
	23372879	CHEMBL4884844	ROCK1(ROC1LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL3231	Homo sapiens	pIC50		6.0
	23373288	CHEMBL4885135	ROCK1(ROC1LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL3231	Homo sapiens	pIC50		6.0
	23373644	CHEMBL4885421	ROCK1(ROC1LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL3231	Homo sapiens	pIC50		6.0
Not Active	23375089	CHEMBL4886077	ROCK1 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	5.0	CHEMBL3231	Homo sapiens	% Inhibition	%	5.0
Not Active	23375366	CHEMBL4886348	Rho-associated, coiled-coil containing protein kinase 1 Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	-6.0	CHEMBL3231	Homo sapiens	% inhibition	%	-6.0
Not Active	23375921	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	80.0	CHEMBL3231	Homo sapiens	% Control	%	80.0
Not Active	23376389	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23376966	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23377434	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	82.0	CHEMBL3231	Homo sapiens	% Control	%	82.0
Not Active	23378294	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	72.0	CHEMBL3231	Homo sapiens	% Control	%	72.0
Not Active	23378762	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	81.0	CHEMBL3231	Homo sapiens	% Control	%	81.0
Not Active	23379929	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	86.0	CHEMBL3231	Homo sapiens	% Control	%	86.0
Not Active	23380397	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23381091	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23381739	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23382207	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23382429	CHEMBL4887144	ROCK1 Invitrogen kinase activity assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		Inhibition	%	20.0	CHEMBL3231	Homo sapiens	% inhibition	%	20.0
Not Active	23382831	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Slightly Active	23383299	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	49.0	CHEMBL3231	Homo sapiens	% Control	%	49.0
Not Active	23383971	CHEMBL4887576	ROCK1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	88.0	CHEMBL3231	Homo sapiens	% Ctrl	%	88.0
Slightly Active	23383972	CHEMBL4887576	ROCK1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	47.0	CHEMBL3231	Homo sapiens	% Ctrl	%	47.0
Not Active	23384447	CHEMBL4888042	ROCK-I(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-2.77	CHEMBL3231	Homo sapiens	% inhibition	%	-2.77
Not Active	23384706	CHEMBL4888232	ROCK1 SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	9.0	CHEMBL3231	Homo sapiens	% Inhibition	%	9.0
Not Active	23385214	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23385681	CHEMBL4879938	KinomeScan assay: inhibition of ROCK1	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL3231	Homo sapiens	% Control	%	100.0
Not Active	23385906	CHEMBL4888379	ROCK_I Invitrogen kinase panel	B	COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1		CHEMBL4802042		Inhibition	%	4.0	CHEMBL3231	Homo sapiens	% inhibition	%	4.0
